Metabolic biomarkers of colorectal cancer by Alfa-Wali, Maryam
METABOLIC	  BIOMARKERS	  OF	  
COLORECTAL	  CANCER	  	  
A	  Thesis	  submitted	  for	  the	  Degree	  of	  Doctor	  of	  Philosophy	  
	  
Maryam	  Alfa-­‐Wali	  
BSc	  (Honours)	  MB	  ChB	  MRCS	  	  	  	  
Imperial	  College	  London	  
Department	  of	  Surgery	  and	  Cancer	  
Faculty	  of	  Medicine	  	  	  	  	  	  	  
	  	   2	  
Statement	  of	  Originality	  
This	   thesis	   is	   my	   own	   work	   and	   where	   collaborations	   have	   been	   made	   with	   other	  individuals	  are	  clearly	  stated	  and	  appropriately	  referenced.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	   3	  
This thesis is protected by copyright and other intellectual property rights. Copyright 
in the material it contains belongs to the author unless stated otherwise. No 
information or quotation from the thesis may be published or re-used without proper 
acknowledgement.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	   4	  
Table	  of	  Contents	  	  
ABSTRACT	   8	  
ACKNOWLEDGEMENTS	   10	  
CONTRIBUTION	  OF	  OTHERS	   13	  
LIST	  OF	  FIGURES	   14	  
LIST	  OF	  TABLES	   17	  
LIST	  OF	  ABBREVIATIONS	   18	  
CHAPTER	  1	   23	  
INTRODUCTION	   23	  
1.1	  BACKGROUND	  OF	  COLORECTAL	  CANCER	   23	  
1.2	  PATHOGENESIS	  OF	  COLORECTAL	  CANCER	   26	  
1.3	  METABOLISM	  AND	  COLORECTAL	  CANCER	   27	  
1.3.1	  BACKGROUND	  OF	  METABONOMICS	   29	  
1.4	  METABONOMICS	  AND	  GASTROENTEROLOGY	   32	  
1.5	  PRINCIPLES	  OF	  NUCLEAR	  MAGNETIC	  RESONANCE	  SPECTROSCOPY	   34	  1.5.1	  RELAXATION	   37	  1.5.2	  HIGH	  RESOLUTION	  MAGIC	  ANGLE	  SPINNING	  NMR	  (HR-­‐MAS	  NMR)	   37	  
1.6	  NUCLEAR	  MAGNETIC	  RESONANCE	  SPECTROSCOPY	  AND	  COLORECTAL	  CANCER	   39	  1.6.1	  HYPOXIA,	  GROWTH	  AND	  COLORECTAL	  CANCER	  METABOLISM	   43	  1.6.2	  EARLY	  NUCLEAR	  MAGNETIC	  RESONANCE	  SPECTROSCOPY	  EXPERIMENTS	  USING	  COLORECTAL	  CANCER	  CELL	  LINES	   45	  
1.7	  COLORECTAL	  CANCER	  BIOMARKERS	   51	  
1.8	  METABOLIC	  PROFILING	  OF	  COLORECTAL	  CANCER	   53	  
1.9	  HYPOTHESIS	  AND	  AIMS	   63	  1.9.1	  HYPOTHESIS	   63	  1.9.2	  AIMS	   63	  
CHAPTER	  2	   66	  
MATERIALS	  AND	  METHODS	   66	  
2.1	  PATIENT	  RECRUITMENT	   66	  2.1.1	  INCLUSION	  CRITERIA:	   66	  2.1.2.EXCLUSION	  CRITERIA:	   67	  
2.2	  SAMPLE	  COLLECTION	  FOR	  HUMAN	  STUDIES	  (FOR	  CHAPTER	  5	  AND	  THE	  SUPPLEMENTARY	  CHAPTER)
	   68	  
2.3	  SAMPLE	  PREPARATION	  (FOR	  CHAPTERS	  4,	  5	  AND	  SUPPLEMENTARY)	   68	  
2.4	  1H	  NMR	  PROCESSING	  FOR	  ALL	  STUDIES	   69	  
2.5	  1H	  NMR	  EXPERIMENTS	   70	  2.5.1	  ONE-­‐DIMENSIONAL	  (1-­‐D)	  NOESY	   70	  2.5.2	  CPMG	  PULSE	  SEQUENCE	   71	  2.5.3	  TWO-­‐DIMENSIONAL	  (2-­‐D)	  1H	  NMR	   71	  
2.6	  METABOLITE	  PEAK	  ASSIGNMENTS	   71	  
2.7	  QUANTIFICATION	  OF	  METABOLITES	   72	  
2.8	  DATA	  ANALYSIS	   72	  2.8.1	  NORMALISATION	   73	  2.8.2	  CHEMOMETRIC	  METHODS	   73	  
2.9	  MULTIVARIATE	  STATISTICAL	  ANALYSES	   74	  
	  	   5	  
2.10	  STATISTICAL	  ANALYSIS	  FOR	  THE	  EXPERIMENTAL	  STUDIES	   78	  
CHAPTER	  3	   79	  
METABONOMIC	  PROFILING	  OF	  COLORECTAL	  CANCER	  (CRC)	  XENOGRAFT	  MODELS	   79	  
3.1	  ABSTRACT	   79	  
3.2	  INTRODUCTION	   80	  
3.3	  MATERIALS	  AND	  METHODS	   82	  3.3.1	  TUMOUR	  TISSUE	  COLLECTION	  AND	  PREPARATION	   82	  3.3.2	  SAMPLE	  PREPARATION	   83	  3.3.4	  1H	  NMR	  SPECTROSCOPY	  PROCESSING	   84	  3.3.5	  DATA	  ANALYSIS	   85	  
3.4	  RESULTS	   88	  3.4.1	  IDENTIFICATION	  OF	  METABOLIC	  DIFFERENCES	  BETWEEN	  THE	  CELL	  LINES	   88	  3.4.2	  NATIONAL	  CANCER	  INSTITUTE	  PANEL	  OF	  HUMAN	  CANCER	  CELL	  LINE	  MICROARRAY	  DATA	   99	  3.4.3	  METABOLITE	  SET	  ENRICHMENT	  ANALYSIS	  (MSEA)	   99	  3.4.4	  GENE	  EXPRESSIONS	  IN	  CELL	  LINES	  WITH	  HIGH	  PC:	  GPC	  RATIOS	  USING	  GENE	  SET	  ENRICHMENT	  ANALYSIS	  (GSEA)	   102	  
3.5	  DISCUSSION	   104	  
3.6	  CONCLUSIONS	   115	  
CHAPTER	  4	   116	  
CHEMOPREVENTION	  OF	  COLORECTAL	  ADENOMAS	   116	  
4.1	  ABSTRACT	   116	  
4.2	  INTRODUCTION	   117	  
4.3	  EFFECTS	  OF	  BILE	  ACIDS	  ON	  COLORECTAL	  CANCER	   119	  
4.4	  METABOLIC	  PROFILING	  USING	  FAECAL	  WATER	   122	  
4.5	  MATERIALS	  AND	  METHODS	   124	  4.4.1	  STUDY	  PARTICIPANTS	  AND	  SAMPLE	  COLLECTION	   124	  4.4.2	  FAECAL	  WATER	  AND	  URINE	  SAMPLE	  COLLECTION	   124	  4.4.3	  SAMPLE	  PREPARATION	   125	  4.4.4	  1H	  NMR	  PROCESSING	   127	  4.4.5	  DATA	  ANALYSIS	   128	  
4.6	  RESULTS	   130	  4.6.1	  PROFILE	  OF	  PARTICIPANTS	   130	  
4.7	  RESULTS	  OF	  FAECES	  SAMPLE	  TESTS	   132	  (I)	  ASSOCIATION	  BETWEEN	  GENDER	  AND	  CONCENTRATIONS	  OF	  METABOLITES	   135	  (II)	  EFFECT	  OF	  ADENOMA	  RECURRENCE	  AND	  UDCA	  TREATMENT	  ON	  METABOLITE	  CONCENTRATIONS	   136	  (III)	  EFFECTS	  OF	  PATIENT	  FACTORS	  ON	  METABOLITE	  CONCENTRATIONS	  AND	  ADENOMA	  RECURRENCE	   139	  (IV)	  ASSOCIATION	  BETWEEN	  AGE	  AND	  ADENOMA	  RECURRENCE	   140	  (V)	  ASSOCIATION	  BETWEEN	  AGE	  AND	  METABOLITE	  CONCENTRATIONS	   140	  (VI)	  ASSOCIATION	  BETWEEN	  ANATOMICAL	  LOCATION	  AND	  METABOLITE	  CONCENTRATIONS	   143	  (VII)	  TWO–DIMENSIONAL	  (2-­‐D)	  FAECAL	  WATER	  EXPERIMENTS	   143	  
4.8	  RESULTS	  OF	  URINE	  SAMPLE	  TESTS	   147	  (I)	  ASSOCIATION	  BETWEEN	  GENDER	  AND	  URINE	  METABOLITE	  CONCENTRATIONS	   147	  (II)	  ASSOCIATION	  BETWEEN	  ADENOMA	  RECURRENCE	  AND	  METABOLITE	  CONCENTRATIONS	   150	  (III)	  ASSOCIATION	  BETWEEN	  TREATMENT	  AND	  ADENOMA	  RECURRENCE	   153	  (IV)	  EFFECT	  OF	  BODY	  MASS	  INDEX	  (BMI)	  AND	  METABOLITE	  CONCENTRATIONS	   154	  (V)	  ASSOCIATION	  BETWEEN	  CLINICOPATHOLOGICAL	  DATA	  AND	  METABOLITE	  CONCENTRATIONS	   154	  
4.9	  DISCUSSION	   156	  
4.10	  CONCLUSION	   162	  
	  	   6	  
CHAPTER	  5	   163	  
EFFECTS	  OF	  NEO-­‐ADJUVANT	  CHEMOTHERAPY	  AND	  RADIOTHERAPY	  (CRT)	  ON	  THE	  
METABOLIC	  PROFILES	  OF	  RECTAL	  CANCER	  PATIENTS	   163	  
5.1	  ABSTRACT	   163	  
5.2	  INTRODUCTION	   164	  
5.3	  MATERIALS	  AND	  METHODS	   168	  5.3.1	  PATIENT	  RECRUITMENT	   168	  5.3.2	  SAMPLE	  COLLECTION	   168	  5.3.3	  1H	  NMR	  SPECTROSCOPY	   168	  5.3.4	  DATA	  ANALYSIS	   169	  
5.4	  RESULTS	   170	  5.4.1	  TREATMENT	  AND	  TOXICITY	   170	  5.4.2	  CHANGES	  IN	  METABOLITE	  LEVELS	  WITH	  TIMEFRAME	  OF	  RADIOTHERAPY	  TREATMENTS	   176	  5.4.3	  RESPONSE	  TO	  TREATMENT	   177	  5.4.4	  CLASSIFICATION	  ANALYSIS	   179	  
5.5	  DISCUSSION	   183	  
5.6	  CONCLUSION	   186	  
CHAPTER	  6	   187	  
METABOLIC	  SYNDROME	  (METS)	  AND	  COLORECTAL	  CANCER	   187	  
6.1	  ABSTRACT	   187	  
6.2	  INTRODUCTION	   188	  
6.3	  METHODS	   190	  
6.4	  RESULTS	   194	  
6.5	  DISCUSSION	   199	  
6.6	  CONCLUSION	   203	  
CHAPTER	  7	   204	  
DISCUSSION	   204	  
7.1	  CONCLUSION	   214	  
7.2	  LIMITATIONS	  OF	  METABOLIC	  PROFILING	  USING	  1H	  NMR	   216	  
7.3	  FUTURE	  WORK	   218	  
SUPPLEMENTARY	  CHAPTER	   221	  
METABONOMIC	  PROFILING	  OF	  COLONIC	  TISSUE	  USING	  HIGH-­‐RESOLUTION	  MAGIC	  ANGLE	  
SPINNING	  PROTON	  NMR	  (HR-­‐MAS1H	  NMR)	  SPECTROSCOPY	   221	  
S.1	  ABSTRACT	   221	  
S.2	  INTRODUCTION	   222	  
S.3	  MATERIALS	  AND	  METHODS	   225	  S.3.1	  PATIENT	  RECRUITMENT	   225	  S.3.2	  SAMPLE	  COLLECTION	   225	  S.3.3	  SAMPLE	  PREPARATION	   226	  S.3.4	  HR-­‐MAS	  1H	  NMR	  ANALYSIS	   227	  S.3.5	  DATA	  ANALYSIS	   228	  
S.4	  RESULTS	   229	  
S.5	  DISCUSSION	   231	  
S.6	  CONCLUSION	   233	  
	  	   7	  
APPENDICES	   234	  
APPENDIX	  I	  CELL	  LINES	   234	  
LOPES	  GENES	  FROM	  GENE	  ANALYSIS	  DATA	   236	  
MCGARVEY	  GENES	   237	  
GENE	  ENRICHMENT	  ANALYSIS	   238	  
APPENDIX	  II	  COLONIC	  ADENOMA	  CHEMOPREVENTION	  STUDY	   242	  
APPENDIX	  III	  RECIST	  CRITERIA	   245	  
PRESENTATIONS	  AND	  PUBLISHED	  ABSTRACTS	   246	  
REFERENCES	   247	  	  
	  
	   	  
	  	   8	  
ABSTRACT	  	  Colorectal	   cancer	   (CRC)	   remains	   a	   major	   public	   health	   problem	   with	   advanced	   and	  recurrent	  disease	  being	  a	  management	  challenge	  due	  to	  the	  lack	  of	  efficacy	  of	  currently	  available	  monitoring	  tools.	  Carcinoembryonic	  antigen	  is	  used	  as	  a	  marker	  for	  recurrent	  disease	   but	   has	   limited	   sensitivity.	   Early	   sensitive	   markers	   of	   disease	   severity	   and	  recurrence	   are	   required.	   The	   aim	   of	   this	   thesis	   was	   to	   identify	   potential	   metabolic	  biomarkers	   of	   CRC	  patients	   using	   ‘Metabonomics’	   based	  on	  proton	  nuclear	  magnetic	  resonance	   (1H	  NMR)	   spectroscopy.	   The	   breadth	   of	   1H	  NMR	  metabonomics	   exploring	  different	  aspects	  of	  CRC	  pathogenesis	  was	   investigated.	  A	  global	  approach	  profiling	  a	  large	  number	  of	  metabolites	  was	  undertaken	  in	  cell	  line	  and	  chemoprevention	  studies	  with	  subsequent	  targeted	  profiling	  experiments	  using	  human	  polypoid	  tissue	  samples.	  	  The	   studies	   primarily	   exhibited	   changes	   in	   choline	   and	   lipids	   to	   be	   associated	   with	  CRC.	  Although	  these	  metabolites	  are	  well	  reported,	  this	  thesis	  presents	  contemporary	  metabolic	   profiling	   using	   systems	   not	   previously	   reported.	   Tumour	   extracts	   of	   CRC	  xenografts	   showed	   higher	   levels	   in	   the	   ratio	   of	   phosphocholine	   and	  glycerophosphocholine	  between	  poorly	  and	  well-­‐differentiated	  cell	  lines.	  Human	  tissue	  and	   biofluids	   were	   used	   to	   define	   metabolic	   phenotypes.	   Normal	   and	   polypoid	  colorectal	   tissues	  were	   also	  metabolically	   characterised	   by	   changes	   in	   choline	   using	  magic	  angle	  spinning	  (MAS)	  1	  H	  NMR.	  	  	  Investigating	   chemoprevention	   strategies	   with	   bile	   acids	   in	   adenoma	   patients	  indicated	  alterations	  in	  short	  chain	  fatty	  acids,	  related	  to	  gut	  microflora	  metabolism.	  In	  clinical	   studies,	   higher	   levels	   of	   lactate	   and	   glycoproteins	   were	   identified	   in	   rectal	  cancer	  patients,	  as	  potential	  metabolic	  predictors	  of	  response	  to	  chemoradiotherapy.	  A	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metabolically	  translational	  feature	  of	  the	  thesis	  in	  a	  heterogeneous	  population	  confers	  a	   significant	   increase	   in	   the	   risk	   of	   CRC	   incidence	  with	  metabolic	   syndrome	   (MetS).	  Thus,	   inferring	   identification	   of	  MetS	   components	   as	   part	   of	   screening	  measures.	   In	  vivo	   studies	   provide	   a	   functional	   way	   of	   networking	   metabolic	   pathways	   to	  pathological	  states,	  thereby	  unifying	  perspectives	  post	  hoc.	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CHAPTER	  1	  
Introduction	  
1.1	  Background	  of	  Colorectal	  Cancer	  Colorectal	  cancer	  (CRC)	  is	  a	  pandemic	  disease	  being	  the	  second	  most	  common	  cancer	  in	  western	  societies	  (Davalos,	  2006,	  Austoker	  and	  Hewitson,	  2008),	  which	  continues	  to	  be	   a	   major	   health	   care	   issue.	   There	   are	   nearly	   40,000	   new	   cases	   diagnosed	   in	   the	  United	   Kingdom	   (UK)	   annually	   (Statistics,	   2005,	   Statistics,	   2008).	   It	   is	   a	   cause	   of	  significant	  morbidity	  and	  mortality	   in	   the	  developed	  world	  with	  a	   recurrence	  rate	  of	  nearly	   50	   per	   cent	   of	   treated	   patients	   (Kouji,	   2009).	   Moreover,	   its	   incidence	   is	  increasing,	   and	   consequently	   a	   national	   screening	   programme	   has	   been	   initiated	  throughout	   the	   National	   Health	   Service	   (NHS).	   In	   western	   societies,	   there	   are	  approximately	  half	  a	  million	  deaths	  from	  CRC	  annually	  due	  to	  the	  presence	  of	  distant	  metastases	   (Bhujwalla,	   1999,	   Alberts,	   2008,	   Parkin	   et	   al.,	   2005,	   Jemal,	   2006,	   Rajput,	  2008).	  While	  a	  few	  CRCs	  occur	  as	  familial	  cases,	  majority	  are	  sporadic,	  which	  may	  be	  due	  to	  the	  inter-­‐connections	  of	  genetic	  and	  environmental	  factors	  (Figure	  1.1).	  	  	  The	   adenomatous	   polyposis	   coli	   (APC)	   gene	   mutation,	   a	   tumour	   suppressor	   gene	  involved	  in	  apoptosis	  and	  cell	  cycle	  regulation	  (Smith	  et	  al.,	  2002)	  is	  a	  common	  cause	  of	   CRC.	   Hereditary	   non-­‐polyposis	   colorectal	   cancer	   (HNPCC)	   is	   another	   genetically	  based	   CRC	   that	   is	   due	   to	   the	   inactivation	   of	  mismatch	   repair	   genes	   (Markowitz	   and	  Bertagnolli,	  2009).	  The	  current	  National	  Bowel	  Cancer	  Screening	  Programme	  involves	  the	  detection	  of	  faecal	  occult	  blood	  (FOB),	  which	  can	  be	  caused	  by	  a	  number	  of	  benign	  or	  malignant	  diseases.	   It	   is	   targeted	  at	  men	  and	  women	  over	  the	  age	  of	  60	  years	  and	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has	  lead	  to	  a	  reduction	  in	  cancer	  mortality	  within	  the	  UK	  (Towler	  et	  al.,	  2000,	  Hewitson	  et	  al.,	  2007).	  Despite	   this,	  FOB	  testing	   lacks	  both	  sensitivity	  and	  specificity	  and	  many	  patients	   find	   providing	   stool	   samples	   unpleasant	   and	   are	   therefore	   unwilling	   to	  undergo	  such	  screening	  tests.	  This	  presence	  of	  such	  occult	  blood	  subsequently	  leads	  to	  a	   colonoscopy.	   Colonoscopy	   therefore,	   represents	   the	   current	   gold	   standard	   for	   CRC	  diagnosis	   (Austoker	   and	   Hewitson,	   2008).	   However,	   such	   invasive	   procedures	   also	  pose	   an	   associated	   morbidity	   and	   mortality.	   Therefore,	   there	   has	   been	   a	   concerted	  drive	  to	  deliver	  tumour	  markers	  that	  are	  able	  to	  non-­‐invasively	  describe	  the	  presence	  of	  CRC	  in	  a	  manner	  that	  is	  safe	  and	  acceptable	  to	  the	  patient.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
Figure	   1.1	  A	   simplified	   schematic	   of	   a	   complex	  multistep	   process	   of	   colorectal	   carcinogenesis.	  
Abbreviations:	   KRAS	   -­‐	   Kirsten	   rat	   sarcoma	   viral	   oncogene,	   APC	   –	   Adenomatous	   polyposis	   coli,	  
p53	  –	  protein	  53.	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Other	   non-­‐invasive	   diagnostic	   techniques	   such	   as	   double	   contrast	   barium	   enema,	  computed	  tomography	  (CT)	  pneumocolon	  examinations	  and	  CT	  faecal	  tagging	  are	  not	  without	   their	   limitations	   in	   terms	   of	   sensitivity.	   Despite	   the	   improved	   specificity	   of	  image-­‐based	   diagnostics	   such	   as	   CT	   colonography,	   the	   associated	   cost	   and	   radiation	  exposure	  mean	   it	   is	  not	  effective	  as	  a	   first-­‐line	  screening	   tool.	   	  Furthermore,	   it	   is	  not	  sensitive	   for	  malignant	   lesions	   less	   than	  a	   centimeter	   in	  diameter	   (Hermanek,	  1987)	  and	  it	  can	  be	  difficult	  to	  distinguish	  between	  benign	  and	  metastatic	  lesions	  (Neri	  et	  al.,	  2005).	  With	   these	   screening	  measures,	   70%	  of	   newly	   diagnosed	  CRC	  patients	   are	   at	  stage	  III	  or	  IV.	  The	  5-­‐year	  survival	  rate	  of	  stage	  III	  CRC	  being	  below	  70%	  after	  resection	  compared	   to	   stage	   I	   which	   has	   about	   a	   90%	   survival	   rate	   (O'Connell	   et	   al.,	   2004).	  Flexible	   sigmoidoscopy	   reduces	   CRC	   incidence	   by	   23%	   and	  mortality	   by	   up	   to	   31%	  (Atkin	  et	  al.,	  2010),	  while	  the	  effect	  of	  FOB	  and	  colonoscopy	  has	  not	  been	  evaluated	  yet.	  	  Hence,	  subsequent	  UK	  screening	  programmes	  may	   involve	   flexible	  sigmoidoscopy,	  as	  early	  detection	  is	  key	  to	  the	  management	  of	  CRC.	  	  
	  Most	   patients	   with	   CRC	   are	   treated	   by	   surgery	   with	   or	   without	   chemotherapy	   and	  radiotherapy.	  However	  significant	  proportions	  still	  relapse	  and	  die	   from	  recurrent	  or	  advanced	   disease.	   Progressive	   disease	   usually	   implies	   that	   patients	   have	   become	  resistant	   to	   the	  mechanisms	  of	  cytotoxic	  drug	  usually	   the	  result	  of	  genetic	   instability	  inherent	   in	   cancer	   that	   makes	   the	   transformed	   cells	   insensitive	   to	   chemotherapy	  agents	   (Grothey,	   2008).	   The	   management	   of	   advanced	   and	   recurrent	   CRC	   requires	  early	   diagnosis	   in	   order	   to	   improve	   survival	   outcomes.	   Metastasis	   is	   a	   multistep	  process	  that	  involves	  invasion	  and	  proliferation.	  The	  onset	  of	  metastatic	  disease	  in	  CRC	  makes	   the	   clinical	   outcome	   sub-­‐optimal	   with	   survival	   rates	   of	   between	   20	   and	   25	  months	  (Salz,	  2008).	  Unfortunately	  the	  recurrence	  of	  CRC	  is	  still	  high	  despite	  surgery	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and	   chemoradiotherapy.	   During	   the	   5-­‐year	   follow	   up	   period	   for	   CRC	   patients	   about	  50%	  can	  develop	  recurrent	  disease	  after	  “curative”	  treatment	  (Moller	  Sorensen	  et	  al.,	  2008).	  The	  recurrence	  of	  CRC	  depends	  on	  the	  characteristics	  of	  the	  cancer	  at	  the	  time	  of	  diagnosis	  (Manfredi,	  2001).	  	  	  Therefore,	  having	   the	  utmost	   information	  of	   the	   cancer	   characteristics	  at	   the	   time	  of	  initial	   diagnosis	   may	   aid	   in	   decreasing	   recurrence	   rates.	   Carcioembryonic	   antigen	  (CEA)	   is	   a	   cell	   surface	   glycoprotein	   (Goldenberg,	   1981)	   that	   is	   routinely	   used	   as	   a	  monitoring	   tool	   in	  CRC.	  However,	   the	   levels	  of	  CEA	  detected	  do	  not	  always	  correlate	  with	  the	  presence,	  extent	  of	  the	  tumour	  or	  recurrence	  (Tan,	  2009).	  It	  also	  suffers	  from	  a	  low	  specificity	  as	  it	  is	  raised	  in	  other	  disease	  states	  and	  smoking	  (Moertel	  et	  al.,	  1993,	  Gatenby,	  2004).	  A	  recent	  meta-­‐analysis	  has	  shown	  that	  CEA	  as	  a	  tumour	  marker	  has	  a	  high	  specificity	  for	  excluding	  colorectal	  cancer	  recurrence.	  	  However,	  it	  is	  not	  sensitive	  enough	   for	   diagnosing	   recurrence	   (Tan,	   2009).	   Consequently,	   there	   is	   need	   for	   the	  development	   and	   improvement	   of	   a	   biomarker	   for	   screening,	   diagnostic	   and	  prognostic	  purposes.	  	  	  
1.2	  Pathogenesis	  of	  Colorectal	  Cancer	  Tumorigenesis	   in	   CRC	   is	   known	   to	   be	   a	   multistep	   process	   (Foulds,	   1958)	   involving	  genetic	  and	  metabolic	  pathways.	  There	  are	  numerous	  genes	   involved	  such	  as	  Kirsten	  rat	   sarcoma	  viral	   oncogene	   (KRAS),	   p53	   and	  APC	   (Jass,	   2007).	   The	  well	  mapped	  out	  transition	  of	  normal	  colonic	  tissue	  to	  polypoid	  adenomas	  and	  subsequently	  carcinomas	  offers	   a	   useful	   sequence	   of	   studying	   the	  metabolic	   shift	   between	   these	   processes	   as	  depicted	  in	  Figure	  1.1.	  Diet	  and	  inflammation	  have	  been	  associated	  with	  the	  increased	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risk	   of	   CRC.	   Foods	   with	   high	   glycaemic	   index,	   red	   meat	   and	   fatty	   foods	   have	   been	  associated	  with	  the	  increased	  risk	  of	  CRC.	  The	  locations	  of	  the	  tumours	  within	  the	  large	  intestinal	   wall	   enable	   the	   staging	   for	   the	   tumour	   using	   the	   Tumour	   Node	   and	  Metastasis	   (TNM)	   classification	   (Edge	   and	   American	   Joint	   Committee	   on	   Cancer.,	  2010).	   Tumours	   that	   invade	   the	   submucosa	   are	   T1,	   T2	   invade	   the	   muscle,	   T3	   the	  subserosa	  and	  T4	  other	  nearby	  structures	  and	  organs	  (Figure	  1.2).	  Hence,	  CRC	  tumour	  markers	  have	  been	  developed	  for	  diagnostic	  and	  prognostic	  purposes.	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  1.2	  Locations	  of	  tumours	  in	  the	  different	  layers	  of	  the	  colon.	  The	  tumours	  are	  represented	  
by	  brown	  circles.	  	  
1.3	  Metabolism	  and	  Colorectal	  Cancer	  Metabolism	  is	  a	  dynamic	  process,	  and	  is	  subject	  to	  changes	  in	  connection	  with	  age,	  diet,	  gender	  and	  environment	  as	  well	  as	  disease.	  Tumour	  metabolism	  is	  considered	  the	  end	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point	  of	   the	  oncogenic	   activity	  of	   tumour	  development	   (Vizan	  et	   al.,	   2008).	  Tumours	  make	  use	  of	  enzymatic	  and	  signaling	  pathways	  to	  control	  metabolic	  changes.	  With	  this	  concept,	   antimetabolites	   in	   chemotherapy	   such	   as	   5	   fluorouracil	   (5-­‐FU)	   have	   been	  developed	  and	  are	  still	  in	  use	  today	  from	  the	  1940s	  (Tennant	  et	  al.,	  2010).	  The	  ability	  of	  tumour	  cells	  to	  alter	  their	  metabolism	  in	  order	  to	  proliferate	  makes	  it	  an	  appealing	  target	  for	  intervention.	  Presently,	  we	  are	  able	  to	  achieve	  and	  make	  use	  of	  the	  benefits	  of	   metabolic	   quantification	   non-­‐invasively	   with	   the	   use	   of	   positron	   emission	  tomography	  (PET)	  scanning	  in	  the	  clinical	  setting.	  	  Cancer	  cells	  have	  an	  altered	  metabolism	  compared	   to	  normal	  cells.	   In	   the	  1926,	  Otto	  Warburg,	   famously	  known	  for	   the	  Warburg	  Effect	  demonstrated	  that	  cancer	  cells	  did	  not	  metabolise	  glucose	  in	  the	  same	  way	  as	  normal	  cells	  (Warburg,	  1956).	  Cancer	  cells	  preferred	   to	  use	  glycolysis	   as	  a	  metabolic	  pathway	   rather	   than	   the	   tricarboxylic	   acid	  (TCA)	   cycle	   even	   in	   the	   presence	   of	   oxygen	   (aerobic	   glycolysis).	   This	   is	   energically	  inefficient	  as	  less	  energy	  in	  the	  form	  of	  adenosine	  triphosphate	  (ATP)	  is	  generated	  thus	  cancer	   cells	   combat	   this	   problem	   by	   using	   large	   amounts	   of	   glucose.	   This	   is	   the	  principle	   behind	   PET	   scanning	   where	   the	   glucose	   analogue	   radioactive	   tracer,	  Fluorodeoxyglucose	   (FDG)	   is	   used	   to	   show	   the	   location	   of	   cancerous	   cells	   (Gatenby,	  2004)(Levine	  and	  Puzio-­‐Kuter,	  2010).	  Oxygen	  concentrations	  are	  less	  in	  cancer	  tissue	  than	  normal	  tissue.	  This	  is	  facilitated	  by	  the	  regulation	  of	  the	  transcription	  of	  hypoxia-­‐inducible	   factor-­‐1	   (HIF)	   (Ashton	   et	   al.,	   1995)	  which	  may	   be	   in	   part	   the	   reason	  why	  cancer	   cells	   prefer	   to	   use	   a	   non	   oxygen	   dependent	   method	   of	   metabolism.	   This	  relationship	   of	   cancer	   and	   metabolism	   has	   allowed	   the	   application	   of	   science	  ‘Metabonomics’	  into	  its	  research.	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Systems	  biology	  is	  the	  understanding	  of	  biological	  systems	  at	  a	  molecular	  level	  (Gowda	  et	  al.,	  2008)	  incorporating	  genes,	  proteins	  and	  metabolites.	  The	  genetic	  basis	  of	  disease	  has	  been	  extensively	  explored	  and	  was	  a	  driving	  force	  of	  the	  Human	  Genome	  Project.	  Genomics	   and	   proteomics	   are	   the	   parent	   techniques	   before	   metabonomics.	   They	  represent	   the	   study	  of	  nucleotide	   sequences	  and	   identification	  of	  proteins	  with	   their	  pathological	  and	  physiological	  roles	  respectively	  (Baak	  et	  al.,	  2005,	  Lindon	  et	  al.,	  2003).	  Proteomics	   identifies	   signalling	   proteins	   and	   their	   interconnections	   with	   tumour	  growth	  (Bi	  et	  al.,	  2006).	  Hence	  a	  powerful	  tool	  to	  be	  used	  in	  connection	  with	  genomics	  and	  metabonomics,	  which	  involves	  the	  profiling	  of	  metabolites.	  Changes	  observed	  from	  proteomic	  studies	  of	  CRC	  revealed	  an	  improved	  glycolytic	  pathway	  as	  per	  the	  Warburg	  effect	  and	  impairment	  of	  the	  TCA	  cycle	  (Bi	  et	  al.,	  2006).	  
	  
1.3.1	  Background	  of	  metabonomics	  The	   resurrection	  of	  Otto	  Warburg’s	  phenomenon	  of	   cancer	   cells	   using	   the	   inefficient	  method	  of	  aerobic	  glycolysis	  to	  generate	  energy	  fueled	  the	  interest	  into	  metabonomics.	  The	   range	   of	   metabolites	   in	   a	   biological	   system	   are	   in	   the	   order	   of	   2000-­‐3000	   are	  amenable	   to	  being	   studied	   in	   contrast	   about	  100,000	  protein	  products	   (Di	  Leo	  et	   al.,	  2007).	  Metabonomics	  is	  formally	  defined	  as	  ‘the	  quantitative	  measurement	  of	  the	  time-­‐related	   multiparametric	   metabolic	   response	   of	   living	   systems	   to	   pathophysiological	  stimuli	   or	   genetic	   modification’	   (Nicholson,	   1999,	   Nicholson	   et	   al.,	   2002a).	   It	   is	   the	  study	   of	   the	   of	   metabolic	   changes	   in	   a	   biological	   system	   by	   high	   throughput	  spectroscopic	  analytical	  methods	  such	  as	  high-­‐resolution	  proton	  (1H)	  nuclear	  magnetic	  resonance	   (NMR)	   spectroscopy	   or	   mass	   spectrometry	   (MS)	   and	   combinations	   using	  chromatographic	  separation	  methods	  (Bjerrum	  et	  al.,	  2008).	   It	  generates	  a	  metabolic	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‘fingerprint’	  of	  biological	  fluids	  or	  tissues	  (Nicholson,	  1999).	  MS	  is	  more	  sensitive	  than	  NMR,	   is	   able	   to	   detect	   concentrations	   of	   metabolites	   that	   are	   much	   lower	   than	  detectable	   by	   NMR.	   It	   reflects	   phenotypic	   changes	   and	   thereby	   reflecting	   function	  (Spratlin	  et	  al.,	  2009).	  	  
	  
In	  this	  thesis	  the	  technique	  of	  1H	  NMR	  has	  been	  used	  for	  all	  experiments.	  The	  historical	  application	  of	  metabonomics	  using	  NMR	  dates	  back	  to	  the	  1970s,	  when	  the	  ‘malignant	  index’	  was	   thought	   to	  be	  used	   to	  discriminate	  between	  normal	  and	  cancerous	   tissue,	  based	  on	  NMR	  relaxation	  times	  using	  a	  mathematical	  equation	  (Herbert,	  1986).	  NMR	  has	   been	   used	   for	   several	   years	   to	   assess	   the	   tumour	   responses	   to	   drug	   therapy	  through	   the	   detection	   of	   metabolic	   changes	   (Griffin	   and	   Shockcor,	   2004).	   It	   gives	  enormous	  datasets	   of	   biological	   information	   and	   it	   is	   difficult	   to	   extract	   the	   relevant	  information	  manually.	  Therefore,	  multivariate	  statistical	  analyses	  of	  datasets	  are	  used	  to	  find	  patterns,	  which	  can	  give	  useful	  biological	  information.	  Metabonomic	  profiling	  is	  sensitive	  to	  the	  diurnal	  and	  physiological	  variation	  between	  humans.	  This	  is	  difficult	  to	  control	   in	   the	   clinical	   setting	   but	   can	   be	   accounted	   for	   in	   the	  multivariate	   statistical	  analysis	  using	  statistical	  and	  mathematical	  tools.	  	  
	  
Metabonomics	  enables	  the	  study	  of	  in	  vivo	  metabolic	  profiles	  by	  examining	  the	  changes	  that	   occur	   in	   metabolites	   in	   response	   to	   disease	   and	   the	   environment.	   Thereby	  enabling	  the	  metabolic	  changes	  that	  maintain	  homeostasis	  to	  be	  detected.	  It	  provides	  information	   about	   the	   dynamic	   cellular	   state	   of	   an	   organism	   by	   revealing	   the	  differences	   in	   metabolites	   in	   different	   health	   states.	   Metabonomics	   can	   be	   used	   to	  characterise	   biological	   endpoints	   of	   metabolic	   pathways,	   potentially	   allowing	   the	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prediction	  of	  clinical	  outcomes	  and	  monitoring	  of	  the	  progression	  of	  disease	  states.	  It	  has	  successfully	  been	  applied	  to	  various	  samples	  from	  animal	  models	  to	  human	  studies	  such	   as	   blood,	   urine,	   faeces	   and	   tissue	   (Nicholson,	   1995,	   Beckonert,	   2007).	   When	  metabolomics	  is	  applied	  to	  biofluids	  it	  is	  referred	  to	  as	  ‘metabonomics’	  (German	  et	  al.,	  2004).	   Biofluids	   allow	   disease	   states	   to	   be	   monitored	   and	   drug	   responses	   to	   be	  assessed	  (Ludwig	  et	  al.,	  2009).	  Urine	  for	  example	  is	  advantageous	  to	  use	  in	  analytical	  studies	   due	   to	   its	   wide	   array	   of	   metabolites	   present	   and	   these	   may	   be	   altered	   in	  disease	  states.	  
	  
Metabonomics	   is	   a	   top	   down	   systems	   biology	   approach	   to	   biomarker	   discovery.	  Metabolomics	   tends	   to	   be	   used	   interchangeably	  with	  metabonomics	   a	   times,	   though	  ‘metabolomics	  is	  tends	  to	  deal	  with	  the	  analysis	  of	  small	  molecular	  compounds	  that	  are	  found	  in	  samples	  such	  as	  cells,	  tissues	  and	  biological	  fluids	  as	  well	  (Fiehn,	  2002).	  Huge	  efforts	  have	  been	  made	  to	  establish	  metabolic	  databases	  of	  NMR	  spectra	  with	  projects	  such	  as	  the	  Consortium	  for	  Metabonomic	  Toxicity	  (COMET)	  (Lindon	  et	  al.,	  2005).	  The	  main	  steps	  involved	  in	  NMR	  based	  metabonomics	  are	  shown	  in	  Figure	  1.3.	  	  As	  the	  human	  genome	  project	  celebrates	  its	  tenth	  year,	  the	  Human	  Metabolome	  Project	  is	  still	  at	  its	  infancy	  aiming	  to	  identify	  and	  quantify	  human	  metabolites	  (Wishart	  et	  al.,	  2007).	  The	  Human	  Metabolome	  Database	  (HMDB)	  provides	  a	  comprehensive	  data	  on	  metabolites	   and	   metabolism	   thus	   providing	   a	   window	   of	   opportunity	   for	   future	  metabolite	   signatures	   to	   be	   discovered.	   The	   evolution	   of	   novel	   targets	   for	   therapy,	  early	   detection	   and	   preventative	   measures	   for	   CRC	   may	   rely	   in	   the	   future	   on	   a	  synergistic	   approach	   between	   genomics,	   proteomics	   and	  metabonomics.	   Specifically,	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Figure	  1.3	  Main	  steps	  involved	  in	  NMR	  metabonomics	  	  
1.4	  Metabonomics	  and	  Gastroenterology	  The	   application	   of	  metabonomics	   in	   gastrointestinal	   pathology	   includes	   both	   benign	  and	  neoplastic	   conditions.	  On	  an	  anatomical	  basis,	  metabonomic	  profiling	  using	  high	  resolution	  ‘magic	  angle	  spinning’	  HR-­‐MAS	  NMR	  has	  been	  successfully	  used	  to	  map	  out	  metabolic	   differences	   of	   different	   parts	   of	   the	   gastrointestinal	   tract	   (GIT),	   from	   the	  stomach	   to	   the	   colon	   (Wang,	   2007).	   Previous	   studies	   have	   demonstrated	   that	   high-­‐resolution	   nuclear	   magnetic	   resonance	   spectroscopy	   (HR-­‐NMR)	   can	   differentiate	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  proqile	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Blood/Uirne/Faeces/Saliva/Tissue	  NMR	  Analysis:	  Spectral	  acquisition,	  	  identiqication	  &	  assignment	  of	  peaks	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between	   benign	   and	   malignant	   colorectal	   cancers	   based	   on	   choline	   and	   lipid	  metabolites	   and	   it	   can	   identify	   abnormal	   colorectal	   mucosa,	   which	   is	   not	  morphologically	  manifested	   (Lean	   et	   al.,	   1992,	   Lean	   et	   al.,	   1993).	  Metabonomics	   has	  also	   been	   successfully	   used	   in	   the	   distinguishing	   the	   inflammatory	   bowel	   diseases	  (IBD),	   Crohn’s	   disease	   (CD)	   and	   ulcerative	   colitis	   (UC).	   Patients	  with	   IBD	   had	   lower	  levels	  of	  short	  chain	  fatty	  acids	  (such	  as	  acetate	  and	  butyrate)	  and	  increased	  levels	  of	  amino	   acids	   compared	   to	   control	   patients.	   In	   addition,	   the	   presence	   of	   glycerol	  differentiated	  CD	  from	  UC	  patients	  (Marchesi	  et	  al.,	  2007).	  Thus,	   illustrating	  the	  non-­‐invasive	  application	  of	  metabonomics	  in	  the	  diagnosis	  rather	  than	  invasive	  procedures	  such	  as	  a	  colonoscopy.	  	  	  
	  
Mass	   spectrometry	   using	   ultra-­‐high	   performance	   liquid	   chromatography	   (UPLC)	  revealed	  a	  significant	  increase	  in	  levels	  of	  low	  molecular	  weight	  compounds	  (LMC)	  MW	  283	   and	   234	   in	   the	   urine	   of	   pre-­‐operative	   patients	   with	   CRC	   compared	   to	   controls.	  	  Post	   operatively,	   the	   levels	   of	   these	   LMC	   decreased	   significantly	   (Ma	   et	   al.,	   2009).	  Hence,	  showing	  the	  potential	  of	  metabolic	  profiling	  as	  a	  perioperative	  tool	  for	  CRC.	  Gas	  chromatography	   studies	   have	   also	   shown	   decreases	   in	   valine,	   5-­‐oxo-­‐L-­‐proline,	   1-­‐deoxyglucose,	  D-­‐maltose,	  arachiodonic	  acid,	  D-­‐turanose	  and	  hexadecanoic	  acid	  as	  well	  as	   increases	   in	   tyrosine	   levels	   in	   post-­‐operative	   CRC	   patients	   compared	   to	   pre-­‐operative	   (Ma	   et	   al.,	   2010).	   This	   shows	   implications	   on	   post-­‐operative	   nutritional	  optimisation	   and	   also	   how	   using	   various	   separation	   techniques	   can	   give	   different	  information.	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1.5	  Principles	  of	  Nuclear	  Magnetic	  Resonance	  Spectroscopy	  NMR	   spectroscopy	   can	   be	   defined	   as	   ‘the	   study	   of	   molecular	   structure	   through	   the	  measurement	  of	  the	  interaction	  of	  an	  oscillating	  radiofrequency	  electromagnetic	  field	  with	  a	   collection	  of	  nuclei	   immersed	   in	  a	   strong	  external	  magnetic	   field’	   (Macomber,	  1998).	   The	  physical	  mechanism	  of	  NMR	   spectroscopy	   involves	   the	   effect	   an	   external	  magnetic	   filed	   has	   on	   certain	   nuclei.	   It	   makes	   use	   of	   superconducting	   magnets	   that	  produce	  great	  magnetic	  fields.	  A	  nucleus	  is	  a	  spinning	  charged	  particle	  which	  generates	  a	  magnetic	   field.	  When	  this	   is	  exposed	   to	  an	  external	  magnetic	   field	   the	  nuclei	  of	   the	  atoms	   within	   these	   molecules	   tend	   to	   orientate	   themselves	   with	   respect	   to	   the	  magnetic	  field.	  
	  
	  The	   atomic	   nuclei	   in	   a	  magnetic	   field	   absorb	   electromagnetic	   radiation	   at	   a	   certain	  frequency.	   An	   electromagnetic	   energy	   pulse	   (radiofrequency)	   is	   used	   to	   disturb	   the	  equilibrium	   distribution	   of	   the	   orientations	   of	   the	   nuclear	  magnetisation	   and	   create	  coherence	  in	  this	  distribution	  such	  that	  after	  the	  removal	  of	  this	  energy	  an	  oscillating	  magnetic	   field	   (a	   ‘resonance’)	   is	   generated	   by	   the	   nuclei.	   This	   can	   be	   detected	   as	   an	  induced	  current	  in	  a	  coil	  around	  the	  sample	  until	  the	  nuclear	  magnetization	  returns	  to	  equilibrium.	  The	  exact	   frequencies	  detected	  depend	  on	  the	  chemical	  environments	  of	  the	  atoms	   (nuclei).	  A	   radiofrequency	   receiver	  detects	   the	  emitted	   frequencies,	  which	  are	  then	  represented	  as	  a	  frequency	  spectrum	  after	  Fourier	  transformation.	  The	  NMR	  spectrum	  is	  thus	  a	  plot	  of	  intensity	  versus	  frequency	  and	  the	  different	  peaks	  arise	  due	  to	   the	   different	   chemical	   environments	   of	   the	   nuclei.	   (Claridge,	   1999,	   Spratlin	   et	   al.,	  2009).	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Figure	  1.4	  Schematic	  representation	  of	  the	  multiplicity	  of	  metabolites.	  	  	  This	   in	   turn	   provides	   structural	   information	   on	   the	   chemicals	   or	  metabolites	   in	   the	  sample	   (Clarke	   and	  Haselden,	   2008).	   The	   concentration	   of	   a	  metabolite	   can	   then	   be	  calculated	  from	  the	  area	  of	  the	  individual	  resonance	  peaks	  (Shulman	  et	  al.,	  1984).	  One	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of	   the	   advantages	   of	  NMR	   is	   the	   ability	   to	   detect	   and	   characterise	   several	  molecules	  simultaneously,	   therefore	   enabling	  multiple	  metabolites	   to	   be	   identified	   in	   biological	  samples.	  NMR	  based	  studies	  can	  detect	  20-­‐40	  metabolites	  in	  tissue	  samples	  and	  100-­‐200	   from	  urine	   samples	   (Griffin	   and	   Shockcor,	   2004).	   The	   structural	   nature	   of	  NMR	  based	  metabonomics	  is	  used	  in	  the	  confirmation	  of	  identified	  metabolites	  (Kaddurah-­‐Daouk	  et	  al.,	  2008).	  The	  data	  acquired	  from	  1H	  NMR	  is	  immensely	  complex	  with	  a	  large	  number	   of	   signal	   intensities	   that	   relate	   to	   individual	   metabolites	   and	   their	   spectral	  integrals	   signifying	   the	   concentrations	   of	   the	   metabolites.	   So,	   the	   combination	   of	  bioinformatics	  and	  statistical	  analysis	  is	  applied	  to	  the	  data	  in	  order	  to	  make	  it	  easier	  to	  interpret	  and	  be	  more	  understandable.	  NMR	  spectroscopy	  is	  a	  minimally	  destructive	  method	   in	   which	   blood,	   urine	   or	   tissue	   samples	   used	   can	   be	   re-­‐analysed	   for	   future	  studies.	  It	  has	  the	  advantage	  of	  requiring	  minimal	  sample	  preparation.	  Thus,	  it	  is	  used	  in	   the	   identification	   of	   chemical	   compounds	   and	   the	   determination	   of	   bimolecular	  structures.	  
	  
A	   number	   of	   nuclides	   are	  NMR	   active	   and	   are	   used.	   These	   include	  Hydrogen-­‐1	   (1H),	  Deuterium-­‐2	   (2H	   or	   D),	   Carbon-­‐13	   (13C)	   and	   Phosphorus-­‐31	   (31P)	   (Simpson,	   2008).	  Both	   31P	   and	   1H	   NMR	   spectroscopy	   have	   been	   shown	   to	   provide	   diagnostic	   and	  prognostic	  information	  in	  a	  number	  of	  malignant	  tumours	  such	  as	  breast	  and	  prostate	  (Mueller-­‐Lisse,	  2001,	  Claudino	  and	  et	  al.,	  2007).	  1H	  NMR	  is	  mostly	  used	  due	  to	  its	  high	  sensitivity	   on	   account	   of	   its	   large	   abundance	   (>99.9%)	   and	   high	   gyromagnetic	   ratio	  (Keun,	  2010).	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1.5.1	  Relaxation	  	  The	   relaxation	   is	   the	   process	   by	   which	   the	   nuclear	   spins	   return	   to	   the	   state	   of	  equilibrium.	  The	  two	  components	  for	  relaxation	  are	  the	  longitudinal	  or	  spin-­‐lattice	  (T1)	  and	  the	  transverse	  or	  spin-­‐spin	  (T2).	  The	  spin-­‐lattice	  relaxation	  involves	  the	  exchange	  of	  energy	  with	  the	  lattice	  (the	  surroundings,	  the	  sample	  in	  which	  the	  nuclei	  exist).	  The	  spin-­‐spin	   relaxation	   characterises	   the	   evolution	   of	   the	   nuclei	   perpendicular	   to	   the	  magnetic	  field,	   it	  does	  not	  change	  the	  energy	  of	  the	  spin	  system	  compared	  with	  spin-­‐lattice	  relaxation.	  The	  T2	  relaxation	   involves	   the	   interaction	  of	   two	  spin	  states	   (Hore,	  1995,	  Claridge,	  1999).	  
	  	  
1.5.2	  High	  Resolution	  Magic	  Angle	  Spinning	  NMR	  (HR-­‐MAS	  NMR)	  The	   term	   ‘magic-­‐angle	   spinning’	   (MAS)	  NMR	  was	   coined	   in	   1960	  by	  Gorter	   (Hennel,	  2004).	  MAS-­‐NMR	   closed	   the	   gap	   of	   the	   limitations	   of	   liquid	   state	  NMR	   in	  metabolite	  analysis.	   Tissues	   are	   by	   nature	   heterogeneously	   complex	   compounds	   thus	   the	  movement	  of	  molecules	  within	  tissue	  is	  not	  uniform	  i.e.	   isotropic.	  The	  effect	  of	  this	  is	  the	   line	   broadening	   of	   the	   NMR	   spectra	   by	   dipolar	   coupling	   and	   chemical	   shift	  anisotropy	   (CSA)	  when	  conventional	   solution	  state	  NMR	  methods	  are	  used	  on	  whole	  tissue	  (Wang,	  2003).	  HR-­‐MAS	  NMR	  is	  able	  to	  combat	  this	  problem	  through	  narrowing	  line	   widths	   with	   sample	   spinning	   at	   high	   speeds	   and	   producing	   well-­‐resolved	   NMR	  spectra	   (Andrew	   et	   al.,	   1959,	   Beckonert	   et	   al.,	   2010).	   The	   technique	   is	   based	   on	   the	  spinning	  of	  a	  tissue	  sample	  at	  the	  magic	  angle	  of	  54.7°	  relative	  to	  the	  magnetic	  field	  at	  a	  frequency	   typically	   5000Hz,	   which	   produces	   high-­‐resolution	   spectra	   (Figure	   1.5)	  (Griffin	  and	  Shockcor,	  2004).	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In	   addition	   to	   removing	   dipolar	   coupling,	   MAS	   reduces	   the	   inhomogeneity	   of	   the	  magnet	   and	   allows	   better	   resolution	   of	   spectra	   (Keun,	   2006).	   It	   thus	   provides	   a	  technique	   for	   obtaining	   metabolite	   information	   from	   tissue	   and	   provide	   metabolic	  maps	   of	   intact	   tissue	   samples	   (Righi,	   2009).	   Furthermore,	   MAS	   NMR	   is	   a	   non-­‐destructive	  analytic	  tool	  that	  utilizes	  only	  a	  small	  amount	  of	  tissue	  ranging	  from	  10	  to	  20	  milligrams	  (mg)	  (Coen,	  2008,	  Chen	  et	  al.,	  2001).	  The	  study	  of	   tumour	  tissue	   in	  an	  unaltered	  state	  provides	  the	  descriptions	  of	  the	  molecules	  as	  they	  exist	  in	  the	  context	  of	  their	  surroundings	  (Veenstra,	  2009).	  	  	  The	   abundance	   and	   complexity	   of	   data	   obtained	   from	   HR-­‐MAS	   NMR	   of	   biological	  samples	   also	   requires	   the	   use	   of	   multivariate	   statistics	   such	   as	   pattern	   recognition	  methods	  to	  extract	  metabonomic	  information	  (Righi,	  2009).	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  1.5	  Schematic	  showing	  the	  ‘magic	  angle’,	  location	  of	  the	  rotor	  containing	  the	  specimen	  in	  
relation	  to	  the	  magnetic	  field.	  
Rotor	  
Magnetic	  field	  
Direction	  of	  spin	  θ=54.7° 	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The	  value	  of	  the	  angle	  is	  derived	  from	  the	  mathematical	  equation,	  	   D	  α	  r-­‐3	  (3cos2θ-­‐1)	  The	  ‘D’	  in	  the	  equation	  is	  the	  dipolar	  coupling,	  which	  is	  the	  direct	  interaction	  between	  two	  magnetic	  nuclei	   in	  a	   solid	  state	  and	   ‘r’	   is	   the	  separation	  between	   the	  nuclei.	  The	  angle	   between	   the	   applied	  magnetic	   field	   and	   the	   vector	   that	   is	   responsible	   for	   the	  interaction	  is	  θ.	  	  	  The	   sample	  needs	   to	  be	   spun	  at	   an	   angle	  where	   ‘3cos2θ-­‐1’	   is	   zero,	   thus	   the	   angle	  of	  54.7°	  (Duer,	  2004).	  This	  reduces	  the	  dipolar	  coupling	  that	  causes	  the	  line	  broadening	  effects	   in	   the	   spectra,	   to	  produce	  highly	   resolved	   spectra	   (Coen,	  2008).	  The	   spinning	  frequency	  of	  4-­‐6kHz	  is	  required	  to	  relocate	  the	  spinning	  side	  bands	  that	  can	  occur	  with	  solid-­‐state	   NMR	   experiments	   so	   that	   they	   occur	   outside	   the	   range	   of	   the	   spectra	   of	  interest.	  Nevertheless,	  this	  is	  done	  at	  the	  slight	  cost	  of	  the	  tissue	  integrity	  (Beckonert	  et	  al.,	  2010).	  The	  metabolism	  and	  physiology	  of	  tumour	  tissues	  are	  altered	  in	  comparison	  to	  normal	  tissue	  (Moreno	  et	  al.,	  1993).	  So,	  HR-­‐MAS	  NMR	  is	  a	  vehicle	  for	  investigating	  the	  changes	  in	  CRC	  tissue	  metabolites.	  	  	  
1.6	  Nuclear	  Magnetic	  Resonance	  Spectroscopy	  and	  Colorectal	  Cancer	  	  NMR	   has	   been	   used	   to	   apply	   numerous	   experimental	   models	   into	   the	   research	   of	  cancer.	   The	   application	   of	   NMR	   technology	   to	   CRC	   in	   particular	   is	   discussed	   in	   this	  section,	  with	   the	  other	  cancers	  considered	   later.	  Tissue	  studies	  have	  been	  performed	  using	   1H,	   31P	   and	   13C	   NMR	   spectroscopy	   (Table	   1.1).	   Varied	   biofluids	   from	   animal	  models	  have	  also	  been	  used	  including	  cell	  lines	  (and	  extracts);	  blood,	  urine	  and	  faeces	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for	   CRC	   related	   NMR	   studies.	   Research	   into	   the	   use	   of	   faecal	   water	   extracts	   in	  particular	  for	  the	  diagnosis	  of	  CRC	  (Monleon,	  2008)	  offers	  potential	  to	  augment	  current	  screening	   techniques.	   Recent	   advances	   in	   NMR	   technology	   permit	   cellular	  compartments	   in	   whole	   histological	   specimens	   to	   be	   analysed	   by	   HR-­‐MAS	   NMR.	  Additionally,	   the	   multiple	   number	   of	   samples	   that	   can	   be	   collected	   over	   time	   with	  automation,	   its	   reproducibility	   and	   lack	   of	   harmful	   radiation	   (West-­‐Jordan,	   1987)	  make	  it	  a	  potential	  candidate	  as	  a	  biomarker	  tool	  in	  clinical	  practice.	  It	  has	  successfully	  been	  used	   to	   identify	  metabolic	   signatures	   that	  distinguish	   small	   and	   large	   intestinal	  tissue	   and	   to	   characterise	  malignant	   and	   normal	   human	   breast	   and	   prostate	   tissues	  (Wang,	  2007,	  Cheng	  et	  al.,	  1998,	  Cheng	  et	  al.,	  2001).	  	  Earlier	  NMR	  studies	  made	  use	  of	  relaxation	  times,	  T1	  and	  T2	  to	  differentiate	  malignant	  from	   non-­‐malignant	   tissues	   (Medina	   et	   al.,	   1975,	   Loar	   et	   al.,	   1988)	   using	   the	  ‘malignancy	   index’,	   stating	   “no	   cancer	   had	   a	   malignancy	   index	   within	   two	   standard	  deviations	   of	   the	   average	  malignancy	   index	   of	   normal	   colon	   tissue”	   (Koutcher	   et	   al.,	  1978).	   This	   was	   however	   later	   disputed	   as	   errors	   in	   the	   statistical	   analysis	   were	  identified	  (Herbert,	  1986).	  Other	  studies	  using	  rat	  and	  human	  GI	  cancers	  demonstrated	  that	   normal	   tissue	   had	   shorter	   relaxation	   times	   than	   tumours	   (Beall,	   1982).	   This	  suggestion	   that	  relaxation	   times	   for	  cancer	   tissue	  were	  generally	   longer	   than	  healthy	  tissue	  brought	  about	   the	   interest	   into	   the	  use	  of	  NMR	  as	  a	  diagnostic	   tool	   (Kowalski,	  1997,	   Koutcher,	   1978).	   Multiple	   variations	   subsequently	   occurred	   between	   studies,	  which	   did	   not	   produce	   consistent	   results	   to	   allow	   the	   application	   of	   differences	   in	  relaxation	  times	  alone	  to	  be	  used	  as	  a	  diagnostic	  tool.	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Both	  rats	  and	  mice	  have	  been	  used	  and	  are	  still	  being	  used	  as	  animal	  models	  for	  CRC.	  	  Xenograft	   models	   using	   human	   CRC	   are	   also	   being	   used	   for	   NMR	   studies.	   Previous	  studies	   using	   rat	   animal	  models	   for	   colonic	   tumours	  were	   found	   to	   have	   significant	  intensities	  at	  3.2	  and	  3.4	  ppm,	  which	  were	  assigned	  as	  choline-­‐containing	  compounds	  and	   taurine	   respectively.	   Taurine	   at	   3.4	   ppm	  was	   found	   in	   5%	   and	   20%	   of	   rat	   and	  human	  tumours	  respectively	  (Bezabeh,	  1996).	  The	  results	  indicated	  that	  rats	  might	  be	  useful	  models	  for	  CRC	  giving	  the	  same	  metabolite	  changes	  as	  in	  human	  specimens	  but	  with	  different	  percentages.	  	  	   	  
	  	   42	  
Table	  1.1	  Early	  studies	  that	  used	  CRC	  tissue	  in	  NMR	  experiments	  only,	  including	  1H	  NMR	  MAS	  
experiments	  (highlighted	  in	  green).	  
Study	  (Year)	   Species	   Tissue	   NMR	  Koutcher	  et	  al	  (1978)	   Human	   T	   biopsy	   &	   non	   involved	  mucosa	   13C	  Evanochko	  et	  al	  (1982)	   Athymic	  mice	   Colon	   cancer	   implanted	  subcutaneously	   31P	  Mountford	  et	  al	  (1986)	   Human	   Colon	  T	  biopsy	   1H	  Chen	  et	  al	  (1987)	   Human	   Colon	  Ts	   1H	  Halliday	  et	  al	  (1988)	   Human	   T	  biopsy	   13C	  Kasimos	  et	  al	  (1990)	   Human	   N	  &	  T	  mucosa	   31P	  Merchant	  et	  al	  (1991)	   Human	   T	  biopsy	   31P	  Lean	  et	  al	  (1992)	   Human	   Colectomy	  specimens	   1H	  Merchant	  et	  al	  (1992)	   Human	   Saponification	   of	   chloroform	  –methanol	  extracts	   31P	  Lean	  et	  al	  (1993)	   Human	   T	  biopsy	   1H	  Moreno	  et	  al	  (1993)	   Human	   T	  biopsy	   1H	  Su	  et	  al	  (1993)	   Human	   T	  biopsy,	  chloroform	  extracts	  &	   Glycerol-­‐3-­‐phosphodiesterase	  extraction	  	   31P	  13C	  1H	  Briere	  et	  al	  (1995)	   S-­‐D	  rats	   Mucosa,	   submucosa	   &	  muscularis	  of	  T	   1H	  Merchant	  et	  al	  (1995)	   Human	   Adenocarcinoma	   &	  chloroform	  extracts	   31P	  PCA	  Bezabeh	  et	  al	  (1996)	   Human,	  S-­‐D	  rats	   T	  biopsy	   1H	  Ende	  et	  al	  (1996)	   Human	   N	  &	  T	   1H	  Fantazzini	  et	  al	  (1996)	   Human	   Resected	  T	   1H	  Fluge	  et	  al	  (1996)	   Human	   N	  serum	  &	  colon	  cancer	   1H	  Kowalski	  et	  al	  (1997)	   Human	   T	  center	   1H	  Kristensen	  et	  al	  (1999)	   Nude	  mice	   Intradermal	   injection	   of	  tumour	   31P	  1H	  Krupnik	  et	  al	  (1999)	   S-­‐D	  rats	   Colonic	  mucosa	   1H	  Chan	  et	  al	  (2009)	   Human	   Mucosa	  T	  &	  N	   1H	  Jordan	  et	  al	  (2009)	  	   Human	   Rectal	  mucosa	  	   1H	  Righi	  et	  al	  (2009)	  	   Human	   N	  &	  T	   1H	  Piotto	  et	  al	  (2009)	  	   Human	   N	  &	  T	   1H	  Tessem	  et	  al	  (2010)	  	   Human	   N	  &	  T	   1H	  	  T-­‐tumour,	   N-­‐	   Normal,	   S-­‐D	   rats-­‐	   Sprague-­‐Dawley	   rats,	   PCA-­‐Perchloric	   acid,	   H-­‐Hydrogen,	   C-­‐	   Carbon,	   P-­‐	  Phosphorus	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1.6.1	  Hypoxia,	  growth	  and	  colorectal	  cancer	  metabolism	  The	  metabolism	   of	   glucose	   to	   lactate	   even	   in	   aerobic	   conditions	   is	   an	   adaptation	   to	  intermittent	   hypoxia	   in	   pre-­‐malignant	   conditions	   (Gatenby,	   2004).	   Neoplastic	   cells	  themselves	   are	   subjected	   to	  hypoxia	   as	   the	   tumour	  grows	  beyond	   its	   inherent	  blood	  supply	   (Kasimos	   J.N	   and	  Glonek,	   1990).	   Changes	   in	   the	  metabolites	   phosphocreatine	  (PCr),	   nucleotide	   triphosphates	   (NTP),	   inorganic	   phosphates	   (Pi)	   and	  phosphomonoesters	   (PME)	  have	  been	  noted	   in	   tumours	   (West-­‐Jordan,	  1987).	  This	   is	  thought	   to	   be	   secondary	   to	   hypoxia	   as	   the	   tumour	   outgrows	   its	   vascular	   supply	   and	  these	   findings	  have	  been	  corroborated	   in	  HT-­‐29	  cells.	   Separate	   resonances	   for	  DPDE	  and	   α-­‐NTP	   have	   also	   been	   observed	   during	   hypoxia,	   with	   separate	   peaks	   for	  glycerophosphoryethanolamine	  (GPE)	  and	  glycerophosphocholine	  (GPC).	  	  The	   NTP	   peaks	   fell	   with	   increasing	   hypoxia,	   as	   did	   the	   GPC	   peak,	   and	   the	   Pi	  concentrations	  increased	  as	  expected.	  The	  rise	  in	  PME	  concentrations	  was	  suspected	  to	  be	  the	  result	  of	  reduced	  levels	  of	  PC	  as	  seen	  in	  interferon	  treated	  tumours.	  There	  was	  also	  an	  associated	  pH	  drop,	  as	  indicated	  by	  the	  shift	   in	  the	  Pi	  peak.	  However,	  this	  did	  not	  represent	  necrosis	  as	  the	  cells	  were	  able	  to	  recover	  after	  a	  period	  of	  48	  hours	  when	  re-­‐suspended	  in	  McCoy’s	  growth	  medium.	  These	  changes	  were	  also	  oxygen	  dependent	  and	   therefore	   suggested	   they	   could	   be	   used	   to	  monitor	   response	   to	   therapy	   (West-­‐Jordan,	  1987).	  	  	  Rapidly	  growing	  cells	  such	  as	  cancer	  cells	  therefore	  have	  the	  capacity	  for	  altering	  their	  metabolic	  pathways	  to	  meet	  the	  homeostatic	  demands	  of	  their	  changing	  environment.	  This	   property	   can	   be	   utilised	   to	   determine	   the	   extent	   of	   cell	   differentiation.	   Such	  studies	  were	  done	  in	  HT-­‐29	  clones	  where	  differentiation	  was	  achieved	  by	  altering	  the	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carbon	  source	  of	  the	  culture	  medium.	  The	  undifferentiated	  HT-­‐29	  cells	  possessed	  a	  PCr	  store,	   indicating	   the	   activity	   of	   creatine	   kinase,	   while	   adenosine	   triphosphate	   (ATP)	  utilisation	   was	   higher	   in	   differentiating	   cells,	   as	   indicated	   by	   their	   consumption	   of	  glucose	   and	   acetate.	   	   Levels	   of	   phosphocholine	   (PC)	   provided	   the	   greatest	   variation	  between	   the	   two	   cell	   types,	   being	   nearly	   twice	   as	   high	   in	   the	   differentiated	   group	  (Galons,	   1989).	   This	  was	   consistent	  with	   the	   cell	   being	   forced	   into	   a	   ‘starved	   state,’	  which	   induces	   the	   utilisation	   of	   fatty	   acids	   as	   energy	   substrates.	   	   However,	   several	  other	   theories	   have	   been	   suggested	   for	   this	   finding,	   such	   as	   an	   increased	   rate	   of	  phospholipids	  synthesis,	  an	  enhancement	  of	  phosphokinase	  activity	  and	   inhibition	  of	  cytidyltransferase	   activity	   resulting	   in	   the	   accumulation	   of	   the	   substrate.	   The	   same	  study	  also	  used	  1H	  NMR	  and	  recorded	  the	  presence	  of	  myoinositol	  in	  non-­‐differentiated	  HT-­‐29	   cells,	   as	   myoinositol	   1,4,5-­‐triphosphate	   has	   been	   suggested	   as	   a	   second	  messenger	  of	  intracellular	  calcium	  mobilising	  hormones.	  High	  levels	  of	  lactic	  acid	  were	  also	  demonstrated	  in	  the	  differentiating	  cells	  extract	  which	  demonstrated	  that	  both	  the	  glycolytic	  activity	  and	  the	  glycogen	  synthesis	  were	  both	  raised	  (Carpinelli,	  1984).	  	  Membranes	   of	   tumour	   cells	   show	   significant	   modifications	   from	   normal	   cells,	   with	  observed	   differences	   in	  membrane	   fluidity	   and	   lipid	   head	   group	   arrangement	  which	  are	   related	   to	   the	   growth	   necessities	   of	   the	   tumour	   (Guidoni,	   1987).	   HCT-­‐8R	   colon	  adenocarcinoma	   cells	   used	   to	   investigate	   this	   further	   concluded	   that	   membrane	  phospholipids	   might	   undergo	   isotropic	   motion	   in	   tumour	   cells.	   31P	   NMR	   spectra	   of	  HCT-­‐8R	  cells	  demonstrated	  an	  intense	  phosphodiester	  peak	  at	  -­‐0.5	  ppm	  that	  was	  not	  related	   to	   cellular	   metabolism	   and	   was	   positioned	   at	   a	   frequency	   typical	   of	   a	  phosphodiester	   position	   from	   lipids	   (Guidoni,	   1987).	   This	   peak	  was	   not	   due	   to	   GPC,	  glycerophosphorylserine	   (GPS)	   or	   GPE	   as	   was	   confirmed	   also	   by	   RNA	   and	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phospholipase	   C	   studies.	   The	   presence	   of	   a	   peak	   at	   the	   same	   position	   from	   total	  membrane	  samples	  indicated	  that	  this	  arose	  from	  a	  membrane	  structure.	  By	  using	  1H	  NMR,	  peaks	  of	  typical	  lipids	  in	  small	  vesicles	  were	  characterised	  by	  very	  high	  mobility,	  notably	   fatty	   acid	   methyl	   and	   methylene	   groups	   at	   +0.85	   and	   +1.25	   ppm	   (Guidoni,	  1987).	   The	   alterations	   in	   relaxation	   times	   and	   line	  widths	   of	   the	   (-­‐CH2)n	   proteolipid	  complex	  at	  1.25	  ppm	  indicated	  a	  reduced	  membrane	  lipid	  mobility	  in	  HCT-­‐8R	  and	  LS-­‐174T	   cell	   lines	   treated	   with	   trans-­‐retinol	   which	   was	   used	   as	   a	   potential	   anti	  carcinogenic	  agent	   (Rosi,	  1987).	  The	  area	  of	   the	  phosphodiester	  peak	   increased	  with	  retinol	  concentration,	  which	  the	  authors	  concluded	  occurred	  due	  to	  growth	  inhibition.	  	  	  
1H	  NMR	  has	  more	  recently	  been	  used	  to	  investigate	  the	  metabolic	  changes	  associated	  with	   the	   deletion	   of	   the	   p300	   gene,	   which	   is	   a	   transcriptional	   co-­‐activator	   that	   has	  acetyltransferase	   activity.	   This	   may	   have	   an	   effect	   on	   cell	   cycle	   control,	   apoptosis,	  differentiation	   and	   proliferation	   in	   human	   colon	   cancer	   cell	   line	   HCT-­‐116.	   This	  revealed	   an	   increase	   in	   peak	   intensity	   of	   choline-­‐containing	   compounds	  which	   have	  been	  shown	  in	  previous	  studies	  to	  play	  an	  important	  role	  in	  cancer	  cells	  (Bundy	  et	  al.,	  2006).	  This	  provides	  an	  example	  of	  how	  NMR	  may	  be	  used	  as	  an	  indirect	  measure	  of	  single	  gene	  deletions.	  	  
1.6.2	  Early	  nuclear	  magnetic	  resonance	  spectroscopy	  experiments	  using	  colorectal	  cancer	  
cell	  lines	  The	  common	  cell	  lines	  used	  for	  NMR	  CRC	  studies	  are	  HT-­‐29,	  SW-­‐620,	  COLO-­‐205,	  HCT-­‐116	  and	  HCT-­‐8R	  (Table	  1.2).	  Studying	  cell	  lines	  in	  vitro	  for	  preliminary	  studies	  allows	  high	  quality	   spectra	   to	  be	  obtained	  under	  optimal	   spectroscopic	   conditions	   for	  more	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detailed	  assignment	  and	  characterisation	  of	  metabolites.	  There	  has	  been	  criticism	  that	  biopsy	   samples	   possess	   a	   large	   amount	   of	   heterogeneity,	   therefore	   in	   vitro	   studies	  enable	   greater	   sample	   consistency	   (Loar,	   1988).	   They	   also	   provide	   a	   starting	   point	  prior	  to	  human	  sample	  studies.	  Various	  cell	  lines;	  tumour	  tissue	  cell	  cultures,	  extracts,	  supernatants;	  membrane	  fragments	  and	  intact	  membranes	  have	  all	  been	  used	  in	  CRC	  studies.	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Table	  1.2	  Cell	  line	  studies	  using	  NMR	  with	  the	  culture	  medium	  and	  type	  of	  NMR	  used	  
Study	  (Year)	   Cell	  line	   Culture	  medium	   Intra/Extra
-­‐cellular	  
NMR	  Beall	   et	   al	  (1982)	  	  	  	  	  	  	  	  	  	  	   	  
LS180	  LS174T	  (with	   clones	  3-­‐5,	  6-­‐6)	  	  	  	  	  	  	  	  HT29	  SW480	  SW1345	  	  Normal	  (NB-­‐V,	  NB-­‐M)	  Hs	  0074Int	  Hs	  0677Int	  
	  	  MEM/F-­‐12	   +	   20%	   FBS,	   10μg/ml	  insulin,	   2mM	   l-­‐glutamine,	   1mM	  Na	  pyruvate,	  20mM	  Hepes	  buffer,	  pH	  7.4	  	  	  	  	  	  MEM	  +10%	  FBS	  L-­‐15	  +10%	  FBS	  	  	  DMEM	  +10%	  FBS	  +10ng/ml	  EGF	  
Cells	   1H	  
Desmoulin	   et	   al	  (1986)	  	   HT29	   10%	  DMEM	  +	  25mM	  glucose	   Cell	  extracts	  Cell	  extracts	  Cell	  extracts	  Perfused	  cells	  
31P	  13C	  1H	  31P	  Fantini	   et	   al	  (1987)	  	   HT29	   DMEM+10%	  FBS	   Perfused	  cells	  PCA	  extracts	   31P	  Guidoni	   et	   al	  (1987)	  	   HCT8R	   RPMI1640	   +	   10%FBS,	   100u/ml	  penicillin,	   100μg/ml	  streptomycin	   PCA	  extracts	  Total	   cell	  membrane	  PCA	  extracts	  Total	   cell	  membrane	  
31P	  31P	  	  1H	  1H	  Rosi	   et	   al	  (1987)	  	   HCT8R	  LS174T	   RPMI	   1640	   +	   10%	   FBS,	   2mM	  glutamine,	   90mg/l	   Na	   pyruvate,	  100u/ml	   penicillin,	   100μg/ml	  streptomycin	  
Cell	  extract	   1H	  31P	  
West-­‐Jordan	   et	  al	  (1987)	  	   HT29/5	   McCoys	  5A	   Cells	   31P	  Loar	   et	   al	  (1988)	  	   COLO201	  COLO205	   RPMI	   1640	   +10%	   FBS	  +gentamicin	  sulphate	  5µg/ml	   Cells	   1H	  Rosi	   et	   al	  (1988)	  	   HCT8R	   RPMI	   1640	   +	   Hepes,	   100	   iu/ml	  penicillin	   +	   100µg/ml	  streptomycin,	  10%	  FBS	   Total	   cell	  membrane	   1H	  31P	  Ceccarini	   et	   al	  (1989)	  	  	  	  
HCT8R	   RPMI	  1640	  +	  20mM	  Hepes,	  100iu	  penicillin,	   100μM	  streptomycin	  +	  10%	  FBS	   Cells	  Supernatant	  Cells	   31P	  31P	  1H	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Galons	   et	   al	  	  (1989)	  	   HT29-­‐D4UD	  HT29-­‐D4D	   DMEM,	   4.5g/dl	   glucose	   +	   10%	  FBS	   Cells	   31P	  	  1H	  13C	  Masella	   et	   al	  (1989)	  	   HCT8R	   RPMI	   1640	   +10%	   FBS,	   2mM	  glutamine,	   90mg/l	   Na	   pyruvate,	  100µg/ml	   penicillin	   &	  streptomycin	  
Cytoplasm	  deprived	  cells	  Plasma	  membrane	  fragments	  Chloroform-­‐methanol	  lipid	  extracts	  	  
1H	  
Galons	   et	   al	  (1990)	  	   HT29	   Grown	  in	  DMEM	  +10%	  FBS,	   then	  DMEM/FBS	   +F12	   +5μg/ml	  transferrin,	   10ng/ml	   EGF,	  10ng/ml	   selenous	   acid,	   15mM	  Hepes	  	  
Perfused	  cells	  PCA	  extracts	  	  
31P	  13C	  
Lean	   et	   al	  (1991)	  	   LIM	  1215	   RPMI	  1640	  +5%	  FBS	   Plasma	  membrane	  fragments	   1H	  Lean	   et	   al	  (1992)	  	   LIM	  1215	  LIM	  1863	   RPMI	   1640	   +5%	   FBS,	   0.5%	  Hepes,	   0.03%-­‐glutamine,	   0.1%	  NaHCO3	   Cells	  Plasma	  membrane	  fragments	  
1H	  
Mackinnon	  et	  al	  (1994)	  	   Human	  adenoma	  derived,	  non-­‐tumorigenic	  PC/AA	  PC/AAC1	  	  Carcinoma	  derived	  PC/JW	  SW1222	  SW480	  SW620	  
DMEM,	   20%	   FBS,	   4.5g/l	   glucose,	  Iμg/ml	   hydrocortisone	  hemisuccinate,	  2u/ml	  insulin	  	  	  DMEM	  +	  10%FBS	  	  	  	  	  	  	  	  
Cells	   1H	  
Ronen	   et	   al	  (1999)	  	   SW620	   DMEM	   +	   10%	   FBS,	   2mM	   l-­‐glutamine,	   50U/ml	   penicillin,	  50μg/ml	  streptomycin	  	  
Cell	  extracts	   31P	  
Mori	   et	   al	  (2004)	  	   HCT116	   McCoys	   5A	   +	   10%	   FBS,	   2mM	  glutamine,	   5iu	   penicillin,	   5µg/ml	  streptomycin	   Cell	  extracts	   1H	  31P	  	  MEM	  -­‐	  Eagle’s	  Minimum	  Essential	  Medium,	  FBS	  -­‐	  Foetal	  bovine	  serum,	  Int	  -­‐	  intestinal.	  EGF	  -­‐	  Epidermal	  growth	   factor,	   DMEM	   -­‐	  Dulbecco’s	  modified	  MEM,	   PCA	   -­‐	   Perchloric	   acid,	  Hepes	   -­‐	   4(2-­‐hydroxyethyl-­‐1-­‐piperazine)	  ethanesulfonic	  acid	  buffer,	  D	  -­‐	  differentiated,	  UD	  -­‐	  undifferentiated.	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As	  described	   earlier	   normal	   and	  neoplastic	   tissues	  demonstrate	  dissimilar	  T1	   and	  T2	  relaxation	   times,	   (Loar,	   1988)	  which	   also	   vary	   between	   neoplastic	   tissues.	   They	   are	  difficult	   to	   interpret	   in	  whole	  tissue	  samples	  of	   the	  GIT	  as	   it	   is	  covered	  in	  mucus	  and	  consists	   of	   several	   anatomical	   layers.	   Therefore,	   an	   in	   vitro	   approach	  was	   preferred	  and	  the	   first	  study	  to	  examine	  this	  phenomenon	  was	   in	  normal	  colon	  cell	   lines,	  NB-­‐V	  and	  NB-­‐M	  and	  CRC	  clones	  of	   the	  LS-­‐174T,	  LS-­‐180,	   SW-­‐480,	   SW-­‐1345	  and	  HT-­‐29	   cell	  lines	   (Beall,	   1982).	   However,	   contrary	   to	   findings	   in	   tissues,	   normal	   cell	   lines	   had	  longer	  T1	  and	  T2	  values	  than	  all	  of	  the	  cancer	  cell	  lines.	  It	  was	  thought	  that	  this	  was	  due	  to	  the	  fact	  that	  normal	  human	  cell	  populations	  have	  a	  shorter	   life	  span	  in	  culture.	   	   In	  addition	  these	  cells	  had	  limited	  reproduction	  numbers	  and	  therefore	  early	  passage	  cell	  populations	  compared	  to	  cancer	  cells.	  Thereafter,	  primary	  cultures	  and	  early	  passages	  were	  felt	  to	  be	  inappropriate	  controls	  for	  these	  experiments	  (Beall,	  1982).	  	  	  A	  later	  study	  used	  COLO-­‐201	  and	  205	  adenocarcinoma	  cell	  lines,	  which	  were	  disrupted	  into	  a	  solute	  and	  a	  pellet	  phase.	  The	  NMR	  relaxation	  times	  were	  analysed	  and	  showed	  a	  significant	   difference	   (p	  <	  0.01)	   in	   the	  disparity	   of	   relaxation	   times	  between	   the	   cell	  lines	  in	  the	  intact,	  lysis	  and	  fragmentation	  states.	  The	  pellet	  fraction	  yielded	  differences	  for	   T1	   pairs	   but	   not	   for	   T2.	   The	   disparity	   in	   relaxation	   times	   was	   suggested	   to	   be	  tracked	  through	  the	  various	  stages	  of	  disruption	  and	  the	  dissimilarity	  explained	  by	  the	  biophysical	   properties	   of	   the	  water	  macro	  molecular	   interaction	   (Loar,	   1988).	   These	  early	   studies	   started	   to	   indicate	   the	   differences	   in	   relaxation	   times	   obtained	   with	  samples	   in	  different	  states.	  The	  differences	  in	  serum	  type	  and	  culture	  conditions	  also	  alter	   metabolite	   concentrations	   and	   cell	   differentiation	   significantly.	   For	   early	   NMR	  spectroscopy	  studies	   to	  be	  effective,	   the	  cell	   suspension	  had	   to	  be	  densely	  packed	   to	  increase	   the	  signal	   to	  noise	   ratio.	  As	  a	   result,	   various	  perfusion	   techniques	  have	  also	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been	   described	   to	   maintain	   metabolic	   integrity	   during	   spectral	   acquisition.	   One	  modified	  attempt	  was	  able	  to	  perform	  31P	  NMR	  studies	  on	  HT-­‐29	  CRC	  cells	  grown	  as	  a	  monolayer	   on	   micro	   carrier	   beads.	   However,	   this	   did	   not	   prove	   to	   be	   universally	  adopted.	  
	  The	   31P	   NMR	   spectra	   of	   the	   human	   colon	   adenocarcinoma	   HCT-­‐8R	   cell	   lines	   have	  shown	   mobile	   lipids	   for	   fatty	   acid	   chains	   and	   lipid	   head	   groups.	   Similarly,	   1H	   NMR	  studies	  of	  the	  same	  cell	   lines	  demonstrated	  peaks	  typical	  of	  lipids	  in	  small	  vesicles	  as	  indicated	   earlier	   that	   were	   indicative	   of	   the	   high	   motility	   of	   fatty	   acid	   methyl	   and	  methylene	  groups	  (Guidoni,	  1987).	  Thus	  both	  31P	  and	  1H	  NMR	  experiments	  have	  and	  can	  be	  used	  for	  similar	  observations.	  The	  interest	  behind	  the	  lipids	  in	  these	  studies	  is	  that	   the	   metabolism	   of	   lipoproteins	   is	   known	   to	   be	   abnormal	   in	   patients	   with	  malignant	   disease	   with	   an	   increase	   in	   very	   low	   density	   lipoprotein	   (VLDL)	   and	  decrease	   in	   high	   density	   lipoprotein	   (HDL)	   (Fluge	   et	   al.,	   1996).	   Additional	  investigations	  into	  these	  differences	   in	   lipids	  may	  aid	   in	  the	  further	  understanding	  of	  cancer	  pathology.	  	  	  Morphological	   changes	   in	   CRC	   cell	   lines	   have	   been	   correlated	   with	   carbohydrate	  metabolism,	   as	   this	   is	   the	   major	   source	   of	   energy	   for	   cultured	   cells.	   31P	   NMR	  spectroscopy	   has	   therefore	   been	   used	   with	   particular	   reference	   to	   non-­‐invasive	  monitoring	  of	  cell	  energetics	  (Rosi,	  1987,	  Kristensen,	  1999,	  Krupnik,	  1999).	  HT-­‐29	  cells	  have	   high	   concentrations	   of	   PC,	   glucose	   6-­‐phosphate	   (G-­‐6-­‐P)	   and	   UDP	   hexose	  derivatives.	  These	  have	  been	  linked	  to	  the	  activity	  of	  glycogen	  metabolising	  enzymes.	  The	  G-­‐6-­‐P	  concentrations	  were	  found	  to	  be	  nearly	  ten	  times	  that	  of	  normal	  epithelial	  cells	  and	  the	  elevated	  levels	  of	  glycogen	  were	  explained	  in	  these	  cells	  by	  an	  increased	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flux	  through	  the	  glycogen	  biosynthesis	  breakdown	  cycle	  (Paris,	  1983).	  Likewise,	  it	  was	  proposed	   that	   the	   high	   concentration	   of	   G-­‐6-­‐P	   in	   these	   cell	   lines	   is	   due	   to	   a	   large	  increase	   in	   glucose	   utilisation	   through	   the	   glycolytic	   pathway	   in	   tumour	   cells	  (Desmoulin,	  1986).	  In	  addition,	  HT-­‐29	  cells	  demonstrated	  a	  rapid	  decline	  in	  ATP	  only	  two	  hours	  after	  glucose	  deprivation.	  	  	  The	   tumour	   suppressor	   gene,	   p53	   is	   widely	   associated	   with	   human	   cancers	   (Ryan,	  2001).	   It	   is	   the	  most	   common	  molecular	   abnormality	   in	   cancer	   and	  alterations	   in	   its	  function	   induce	  metabolic	   changes	   (Michelakis	   et	   al.,	   2008).	   NMR	   studies	   have	   been	  used	   to	   show	   clear	   differences	   in	   the	   choline	   metabolism	   of	   cancer	   cells	   with	   and	  without	  p53	  using	   the	  human	  colon	  cancer	  cell	   line	  HCT-­‐116,	  which	  could	  serve	  as	  a	  surrogate	  marker	  of	   its	  activity.	  They	  exhibited	  high	  PC	  and	   low	  GPC	   levels,	  however	  no	  significant	  differences	  in	  the	  GPC	  or	  PC/GPC	  levels	  were	  seen	  in	  the	  p53	  wild	  type	  (p53	  +	  )	  and	  non-­‐wild	  type	  (p53	  -­‐	  )	  HCT-­‐116	  cell	  lines.	  	  Interestingly,	  the	  p53	  -­‐	  had	  an	  increase	   in	   PC	   and	   total	   choline	   compared	  with	   p53	   +	   cell	   lines	   (Mori,	   2004).	   Thus,	  demonstrating	  the	  application	  of	  NMR	  in	  the	  study	  of	  colorectal	  and	  other	  cancers	  to	  be	  used	  in	  synergy	  with	  genetic	  studies.	  	  
1.7	  Colorectal	  Cancer	  Biomarkers	  Risk	   prediction	   tools	   based	   on	   clinical	   history,	   examination	   and	   investigations	   are	  useful.	  However	  tumour	  markers,	   that	  are	  present	   in	   tissue	  or	  biofluids	   in	  cancers	   in	  unusually	   high	   concentrations	   are	   beneficial	   as	   diagnostic,	  monitoring	   or	   prognostic	  markers.	  The	  search	  for	  the	  ultimate	  tumour	  marker	  has	  continued	  for	  decades.	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For	   a	   tumour	   marker	   to	   be	   useful	   it	   also	   has	   to	   be	   sensitive,	   specific	   and	   reliable	  (Chmurny	  et	  al.,	  1988).	  The	  molecular	  profiles	  of	  cancer	  tissue	  can	  be	  used	  to	  identify	  prognostic	  or	  predicative	  markers	  (Yamashita	  and	  Watanabe,	  2009).	  The	  use	  of	  CEA	  in	  CRC	  is	  for	  mainly	  prognostic	  and	  recurrence	  detection	  purposes	  (Sturgeon	  et	  al.,	  2009,	  O'Connell	  et	  al.,	  2004),	  as	  the	  proportion	  of	  Stage	  I	  cancers	  detected	  with	  CEA	  levels	  of	  >5μg/l	  is	  only	  3%	  compared	  to	  Stage	  III	  at	  65%	  (Wanebo	  et	  al.,	  1978).	  The	  impetus	  is	  now	  on	  the	  metabolic	  state	  of	  an	  individual	  as	  it	  represents	  the	  physiological	  state.	  So	  a	  two-­‐way	   process	   whereby	   the	   presence	   of	   a	   tumour	   or	   cancer	   affects	   the	   body’s	  metabolism	  and	  also	  the	  effects	  of	  haemostatic	  mechanisms	  affect	  the	  metabolism.	  	  	  This	  global	  metabolic	  profiling	  approach	  can	  provide	  a	  systems	  approach	  for	  studying	  in	  vivo	  metabolic	  profiles,	  allowing	  latent	  biological	  data	  of	  prognostic	  and	  diagnostic	  use	   to	   be	   extracted	   (Nicholson,	   2008).	   The	   identification	   of	   defined	   sets	   of	   spectral	  features	  allows	  the	  characterization	  of	  physiological	  status	  and	  metabolic	  dysfunction	  in	  organisms	  (Gatenby,	  2004,	  Fluge	  et	  al.,	  1996,	  West-­‐Jordan,	  1987)	  and	  the	  potential	  to	  highlight	  panels	  of	  biomarkers	  associated	  with	  specific	  pathologies.	  This	  science	  has	  been	   widely	   applied	   to	   disease	   states	   outside	   oncology	   including	   cardiovascular	  diseases	  (Holmes,	  2008,	  Holmes	  et	  al.,	  2006,	  Marchesi	  et	  al.,	  2007,	  Brindle	  et	  al.,	  2002)	  and	  a	   large	  amount	  of	  data	  supports	   the	  theory	  that	   this	   technique	   is	  robust	  and	  has	  significant	  potential	  to	  generate	  non	  invasive	  biomarkers	  for	  routine	  use	  in	  colorectal	  oncology	  (Chan	  et	  al.,	  2009,	  Seierstad	  et	  al.,	  2008).	  	  	  
Both	   adjuvant	   and	   neo-­‐adjuvant	   chemotherapy	   and	   radiotherapy	   are	   used	   for	   the	  management	  of	  CRC.	  In	  spite	  of	  this,	  some	  patients	  do	  not	  respond	  to	  such	  treatments	  and	  others	  find	  the	  toxicities	  associated	  with	  these	  treatments	  intolerable.	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The	  ability	  to	  be	  able	  to	  specifically	  tailor	  chemotherapy	  and	  or	  radiotherapy	  regimes	  for	  a	  patient	  in	  order	  to	  decrease	  the	  side	  effects	  and	  increase	  the	  treatment	  potential	  will	  enhance	  the	  management	  of	  CRC	  as	  well	  as	  patient	  safety.	  Metabonomics	  offers	  a	  novel	   approach	   to	   the	   management	   of	   CRC	   by	   identifying	   a	   new	  minimally	   or	   non-­‐invasive	   biomarker	   from	   blood,	   urine	   or	   stool	   which	   would	   be	   a	   more	   acceptable	  screening	  tool	  as	  part	  of	  a	  national	  screening	  program.	  
	  
1.8	  Metabolic	  Profiling	  of	  Colorectal	  Cancer	  A	  number	  of	  reproducible	  metabolic	  biomarkers	  have	  been	  associated	  with	  CRC	  (Table	  1.3).	   Tumours	   have	   been	   found	   to	   have	   higher	   amounts	   of	   phosphatidylcholine	   and	  hence	   it	   has	   been	   suggested	   as	   a	   potential	   target	   for	   monitoring	   the	   response	   to	  chemotherapy.	  Malignant	   tissues	   from	   breast	   and	   colon	   cancers	   have	   been	   found	   to	  produce	  more	  glycerol	  2-­‐phosphoglycerol	  which	   is	  derived	   from	  phosphatidylcholine	  than	  non-­‐malignant	  tissue	  (Su,	  1993).	  Such	  results	  have	  led	  the	  interests	  in	  NMR	  to	  be	  used	  in	  monitoring	  tumour	  growth.	  	  	  	  Perchloric	   acid	   extracts	   of	   HT-­‐29	   cell	   lines	   using	   high-­‐performance	   liquid	  chromatography	   (HPLC)	   gave	   clear	   diphosphodiesters	   (DPDE)	   resonances	   that	  were	  not	  visible	  in	  the	  in	  vivo	  model	  (Wice,	  1985).	  A	  theory	  for	  this	  observation	  is	  that	  DPDE	  is	  not	  freely	  mobile	  within	  the	  cell,	  thus	  giving	  resonances	  that	  are	  too	  broad	  to	  be	  seen	  by	  NMR.	  It	  was	  postulated	  that	  DPDE	  is	  sequestered	  into	  a	  membrane	  system	  in	  which	  glycosylation	   is	   initiated.	   It	   has	  previously	   been	   reported	   that	  DPDE	  accumulation	   is	  correlated	   with	   the	   inability	   of	   HT-­‐29	   cells	   to	   differentiate,	   suggesting	   that	   its	  expression	   is	   associated	   with	   a	   modification	   of	   protein	   glycosylation	   (Wice,	   1985).	  
	  	   54	  
However,	  these	  were	  not	  the	  findings	  were	  not	  universal	  as	  no	  significant	  change	  was	  seen	   in	   DPDE	   levels	   between	   differentiated	   and	   non-­‐differentiated	   HT-­‐29	   cell	   lines	  (Galons,	  1989).	  	  	  	  The	   31P	   NMR	   studies	   in	   human	   colon	   specimens	   using	   perchloric	   acid	   extraction	  techniques	  identified	  31P	  containing	  metabolite	  intermediates.	  	  Elevations	  were	  seen	  in	  relative	  concentrations	  of	  phosphorylethanolamine	  (PE),	  nicotine	  adenine	  dinucleotide	  phosphate	   2-­‐	   phosphate	   (NADP	  2’-­‐	   P),	   glycerol	   3-­‐phosphorylcholine,	   phosphorylated	  glycans	   and	   nucleoside	   diphosphosugars	   in	   malignant	   tissue.	   However,	   this	   was	  associated	  with	  a	  reduction	  in	  PC,	  PCr	  and	  ATP.	  Statistically	  significant	  decreases	  were	  seen	   in	   PC	   (p<0.05)	   in	  malignant	   tissues	   compared	   to	   normal	   tissues.	   These	   studies	  showed	  that	  PE	  is	  elevated	  in	  malignant	  disease	  and	  the	  ratio	  of	  PE/PC	  is	  significantly	  elevated	  in	  malignant	  tissue	  (Kasimos	  J.N	  and	  Glonek,	  1990).	  	  	  Studies	   using	   HR	   MAS	   NMR	   have	   been	   able	   to	   characterise	   metabolic	   patterns	   of	  macroscopically	   or	   histologically	   normal	   tissue	   collected	   away	   from	   the	  adenocarcinoma	  site	   to	  have	   features	   typical	  of	   tumour	   lesions	   (Righi,	  2009).	  Recent	  studies	  using	  the	  ApcMin/+	  mouse	  model	  of	  early	  GI	  tumorigenesis	  through	  HR	  MAS	  and	  
1H	  NMR	   spectroscopy	   has	   revealed	  metabolic	   differences	   between	   the	   normal	   tissue	  and	  wide	  type	  (Backshall,	  2009).	  There	  was	  an	  increase	  in	  lactate	  and	  myo-­‐inositol	  as	  well	   as	  PC/GPC	  as	  previously	   reported	   in	  malignant	   cells.	   Interestingly,	   studies	   from	  human	  colon	  biopsies	  using	  HR	  MAS	  also	  revealed	  elevated	  levels	  of	  taurine,	  glutamate,	  aspartate	  and	  lactate	  in	  tumour	  tissue.	  This	  was	  associated	  with	  high	  amounts	  of	  myo-­‐inositol	  and	  glucose	   from	  adjacent	  normal	   tissue	   from	  the	  same	  patient	  (Piotto	  et	  al.,	  2009).	   These	   differences	   in	   pattern	   of	   metabolite	   change	   may	   be	   due	   to	   a	   species	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difference	  or	  due	  to	  myoinositol	  increases	  seen	  in	  macroscopically	  healthy	  tissue	  being	  in	  a	  pre-­‐malignant	  state.	  	  HR-­‐MAS	  and	  gas	  chromatography	  MS	  (GC/MS)	  have	  also	  been	  used	   with	   success	   recently	   to	   analyse	   CRC	   metabolites	   in	   order	   to	   distinguish	  malignant	   from	   normal	   tissue	   (Chan,	   2009).	   HR	  MAS	   has	   the	   potential	   advantage	   of	  allowing	   direct	   comparison	  with	  magnetic	   resonance	   imaging	   (MRI)	   data	   (Backshall,	  2009).	   Another	  metabolite	   evident	   in	  NMR	   studies	   of	   CRC	   has	   been	   taurine	   and	   has	  been	   suggested	   as	   a	   potential	   tumour	  marker	   for	   CRC	   (Bezabeh,	   1996,	   Piotto	   et	   al.,	  2009,	   Righi	   et	   al.,	   2009).	   Earlier	   studies	   showed	   significant	   differences	   between	   the	  taurine:	  creatine	  ratio	  in	  colonic	  tumours	  compared	  to	  normal	  colonic	  tissue	  (Moreno	  et	  al.,	  1993).	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Table	  1.3	  Metabolites	  associated	  with	  colorectal	  cancer	  by	  1H,	  31P	  and	  13C	  NMR	  and	  their	  
associated	  chemical	  shifts	  
Study	  
(Year)	  




Evanochko	  et	  al	  (1982)	  	   31P	   PCr	  ATP	  Pi	  Sugar	  phosphates	  
	   15.9	   }-­‐Decreased	   as	  tumour	   size	  increases	  }	  Increased	  with	  tumour	  size	  Desmoulin	  et	  al	  (1986)	   31P	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1H	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  13C	  
Pi	  NTP∝	  NTPβ	  NTPγ	  Diphosphodiesters	  -­‐UDP-­‐glucose	  -­‐UDP-­‐galactose	  -­‐UDP-­‐N-­‐acetyl-­‐glucosamine	  -­‐UDP-­‐N-­‐acetyl-­‐galactosamine	  	  Phosphomonoesters	  -­‐PC	  -­‐G-­‐6-­‐P	  	  	  PCr	  	  Aliphatic	  region	  Lactic	  acid	  Leucine	  Proline	  Glycine	  Glutamic	  acid	  Glutamine	  Taurine	  PCr	  Creatine	  	  Aromatic	  region	  Glucose	  G-­‐6-­‐P	  Nucleotides/nucleosides	  	  Lactic	  acid	  Amino	  acids	  Taurine	  PCr	  Creatine	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  -­‐CH3	  	  	  	  	  	  	  	  	  	  	  	  	  H-­‐1	   of	  ribose	  
2.9	  -­‐10	  to-­‐12	  -­‐21	  -­‐7	  -­‐12.5,	  	  -­‐11.1	  	  	  	  	  	  	  	  4-­‐6	  4.1	  5.4	  	  -­‐2.45	  	  	  1.28	  	  	  	  	  	  	  	  	  	  	  5.2	  5.35	  6-­‐6.3	  	  	  70-­‐75	  0-­‐80	  0-­‐80	  0-­‐80	  0-­‐80	  45.2,	  65.1	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Guidoni	   et	   al	  (1987)	  	   1H,	  31P	   Unidentified	  Unidentified	  GPC	  GPS	  PDE	  PC	  AMP	  Fatty	  acids	  
	  	  	  	  	  	  	  Methylene	  -­‐CH3	  
-­‐0.5	  -­‐0.46	  0.48,	  0.54	  1.4	  -­‐0.3	  3.61	  4.02	  1.25	  0.85	  
Used	  the	  HCT8R	  cell	  line	  
Chen	   et	   al	  (1987)	  	   1H	   Arginine	  Urea	  Purines	  	  Simple	   &	   compound	  lipids,	  sialic	  acid	  	  N-­‐acetyl	   neuraminic	  acid,	   mucin,	   heparin,	  chrondroitin	  sulphate	  	  Aromatic	   amino	  acids,	   adenine	  nucleotide	  
Ureidyl	  proton	   }	  6.7-­‐6.87	  	  	  	  1.4-­‐1.47	  	  	  2.0-­‐2.33	  	  	  	  	  8.3-­‐8.6	  
	  	  	  	  	  	  	  Increased	  frequency	   in	  metastases	   not	  significant	  
Rosi	   et	   al	  (1987)	  	   1H	  	  	  	  	  	  	  31P	  	  	  
GPC	  	  	  	  	  	  	  PDE	  
	  -­‐CH3	  	  	  	  	  	  (-­‐CH2)n	  	  	  
	  0.9	  1.25	  	  	  	  	  -­‐0.5	  
Both	   T1/T2	  times	   decreased	  following	  treatment	   with	  retinol	  	  	  Peaks	   increased	  with	   high	  concentrations	  of	  retinol	  Halliday	  et	  al	  (1988)	  	   13C	   Triacylglycerol	  carbonyls	  Phospholipid	  carbonyl	  	  Lipid	  head	  group	  Lactate	  	  	  Lipid	   methylene:	  Choline	  	  Colloid	   tumour	  (mucin-­‐producing)	  	  	  	  
β-­‐galactose	   &	  galactosamine	  
	  	  	  	  	  C3	  	  	  	  	  	  	  	  	  	  	  	  	  
172.5	  	  174.5	  	  	  61.8	  21.0	  	  30.5:54.8	  	  	  	  	  	  	  	  103.0	  	  
	  	  -­‐Increases	   0.3x	  in	  tumours	  	  -­‐Increases	   2.4x	  in	  tumours	  	  -­‐Significantly	  decreased	   in	  tumours	  	  Dominated	   by	  glycoprotein	  rather	   than	  lipids	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α-­‐sialic	  acid	  moieties	  Lipid	  Isoleucine	  Glutamine	  Proline	  Tryptophan	  Phenylalanine	  	  	  
	  Methylene	   	  99.7	  30.4	  11.5	  34.1	  48.2	  121.6	  129.1	  
	  	  Therefore,	   13C	  can	   be	   used	   to	  distinguish	  normal,	  adenocarcinoma	  and	   mucin	  producing	  tumours	  Rosi	   et	   al	  (1988)	  	   1H	   PDE	  PC	  PEt	   	   -­‐0.5	  4.0	  4.7	   -­‐Mainly	   from	  RNA	  }-­‐	   not	   affected	  by	   digestion	  with	  RNAase	  Galons	   et	   al	  (1989,	  1990)	  	   31P	  	  1H	  	  	  	  	  13C	  
Choline	  PC	  	  	  	  	  PCr	  Myoinositol	  	  	  	  Hexose	  phosphates	  Pyrophosphates	  	  	  Glycogen	  	  Glucose	  Alanine	  Fatty	  acyl	  chains	  Glutamine	  Glutamate	  Lactate	  
-­‐CH3	  	  	  	  	  	  H5	  H1,	  H3	  H4,	  H6	  	  	  	  	  	  	  C3	  (CH2)n	  C4	  C4	  
3.20	  3.80	  	  	  	  	  -­‐2.75	  3.30	  3.55	  3.60	  	  4.30,4.60	  -­‐7.50	  	  	  100.5	  96.8,	  93.7	  17.3	  30.5	  34	  32	  20.8	  
}-­‐4x	   &	   2x	  increase	  respectively	   in	  differentiated	  cell	  lines	  	  	  
Kasimos	  et	  al	  (1990)	  	   31P	   IMP	  NADP-­‐2’P	  GPE	  PME	  	  G-­‐1-­‐P	  GPS	  PG	  PC	  PCr	  
	   3.78	  3.63	  0.85	  8-­‐12	  	  2.05	  0.66	  -­‐0.7	  3.32	  -­‐3.10	  
-­‐all	   raised	   in	  tumours	  	  	  	  	  	  
Lean	   et	   al	  (1991)	  	   1H	   Lactate	  Threonine	  Alanine	  
β-­‐anomers	  (fucose)	  
	   1.33-­‐4.12	  1.33-­‐4.27	  1.49-­‐3.79	  1.26-­‐3.81	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Merchant	   et	  al	   (1991,	  1992)	  	   31P	   LPC	  PC	  plas	  	  PE	  plas	  Sphingolipid	  	  	  	  GPG	  	  	  GPS	  
	   -­‐0.27	  -­‐0.78	  	  0.09	  -­‐0.07	  	  	  	  0.92	  	  	  0.10	  
}-­‐significantly	  raised	   in	  tumours	  	  }-­‐decreased	   in	  tumours	  	  	  	  -­‐increased	   in	  tumours	  	  -­‐decreased	   in	  tumours	  Lean	   et	   al	  (1992,	  1993)	  	   1H/1D	  	  	  	  	  	  	  	  1H/2D	  
Lipid	  	  	  Sialic	  acid	  Choline	  Unidentified	  	  	  	  Choline	  PC	  	  Methyl-­‐methine	  coupling	  Lactate	  Alanine	  
Methyl	  Methylene	  Olefinic	  Acetyl	  group	  +N	  (CH3)3	  	  	  	  	  -­‐CH2-­‐CH2	  
0.9	  1.33	  5.26	  2.18	  3.2	  4.01	  	  	  	  3.50-­‐4.07	  3.61-­‐4.25	  	  	  	  1.33-­‐1.42	  1.49-­‐3.79	  
Cell	   lines	   LIM	  1215	   &	   LIM	  1863:	   high	   &	  low	  tumorigenicity	  respectively	  	  	  	  	  -­‐more	  prominent	   in	  LIM1215	  	  
Moreno	   et	   al	  (1993,	  1996)	  	   1H	   Taurine	  	  	  	  	  Choline	   containing	  compounds	  	  Lactate	  Glutamate	  Glutathione	  	  	  	  Myoinositol	  
	  	  	  	  	  -­‐CH3	  -­‐CH3	  
3.4	  	  	  	  	  3.2	  0.9	  	  1.33,	  4.11	  2.35	  2.17-­‐2.55	  	  	  	  4.06,	   3.4-­‐3.6	  
-­‐statistically	  significant	  increase	   in	  tumours	  	  	  	  	  }-­‐statistically	  significant	  increase	   in	  malignant	  tissue	  	  	  -­‐statistically	  significant	  decrease	   in	  malignant	  tissue	  Mackinnon	  et	  al	  (1994)	  	   1H	   Fatty	   acyl	   lipid	  chains	  	  	  Choline,	  PC,	  GPC	  
-­‐CH3	  -­‐CH2	  -­‐CH=	  -­‐N+	  (CH3)3	  	  
0.9	  1.3,	  1.6,2.0,2.3	  5.3	  3.20	  
	  	  	  -­‐20x	   increased	  in	  SW620	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  Creatine,	  PC	  	  UDP	  hexose	  
	  -­‐CH3	  -­‐CH2	   	  	  3.0	  3.9	  6.0	  
	  	  }-­‐increase	   with	  increased	  tumorigenicity	  Merchant	   et	  al	  (1995)	  	   31P	   α-­‐glycerol	  phosphate	  Pi	  	  	  	  	  PME	  PC	  	  PEt	  
	   4.29	  2.63	  	  	  	  	  3.39	  3.32	  	  3.85	  
-­‐raised	   with	  tumours	   with	  blood	   vessel	  invasion	  	  	  }-­‐decrease	   with	  LNI	  	  -­‐increases	   with	  LNI	  Briere	   et	   al	  (1995)	  	   1H	   Mucosa	  	  	  Submucosa	  Fatty	   acyl	   chains	   in	  mobile	  lipids	  
-­‐CH3	  	  	  -­‐CH3-­‐	  -­‐(CH2)n	  -­‐CH2COO-­‐	  -­‐CH=CH-­‐	  
1.3	  	  	  1.3	  1.5	  5.3	  5.5	  
-­‐Narrow	   lipid	  resonances	  	  
Bezabeh	  et	  al	  (1996)	  	   1H	   Choline	   containing	  compounds	  Glutamic	  acid	  Lactic	  acid	  Amino	  acids	  Taurine	  
	   3.2	  	  2.0	  1.3	  0.9	  3.4	  
	  
Ende	   et	   al	  (1996)	  	   1H	   Submucosa	  Lipid	  methyl	  Methylene	  Olefinic	  	  Mucosa	  Choline	  Creatine	  PC,	  GPC	  Leucine	  Valine	  Threonine	  Lysine	  
	   	  0.9,1.3	  2.0	  5.3	  	  	  3.5-­‐4.07	  3.0	  3.61-­‐4.25	  0.97-­‐1.78	  1.03-­‐2.34	  1.33-­‐4.27	  1.72-­‐3.05	  
	  
Kristensen	  et	  al	  (1999)	  	   1H	  	  	  31P	  
Creatine	  Lactate	  	  Pi	  
	   -­‐3.1	  -­‐1.3	  	  0-­‐3	  
	  
Mori	   et	   al	  (2004)	  	   1H	  	  	  	  	  	  31P	  
PC	  	  	  GPC	  Choline	  	  PC	  
	   3.23	  	  	  ~3.24	  ~3.21	  	  ~4	  
-­‐Significantly	  increased	   in	  p53-­‐ve	  compared	   to	  p53+ve	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Monleón	   et	  al	  (2008)	  	   1H	   Butyrate	  Leucine	  Acetate	  Proline	  	  Cysteine	  
	   0.90,	  2.16	  0.97	  1.92	  2.05,	   3.35,	  4.14	  3.04,	  3.99	  
Faecal	   water	  extract	  study	  
Piotto	   et	   al	  (2009)	  	  	  	  
1H	   Taurine	  	  Glutamate	  	  Aspartate	  	  	  Lactate	  	  
-­‐CH2-­‐NH3+	  -­‐CH2-­‐SO3-­‐	  βCH2	  γCH2	  βCH2(u)	  γCH2(d)	  αCH	  CH3	  CH	  
3.26	  3.42	  2.06	  2.34	  2.70	  2.80	  3.90	  1.33	  4.12	  
Higher	   amounts	  of	   myo-­‐inositol	  and	   β-­‐glucose	  were	   found	   in	  macroscopically	  normal	   colonic	  tissue	   from	  patients	   with	  primary	  CRC	  Tessem	   et	   al	  (2010)	  	   1H	   Lactate	  Glycine	  Taurine	  	  	  Myo-­‐inositol	  GPC	  
	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Increased	  	  	  	  Decreased	  	  PCr	   -­‐	   Phosphocreatine,	   Pi	   -­‐	   inorganic	   phosphate,	   NTP	   -­‐	   Nucleoside	   triphosphate,	   UDP	   -­‐	   Uridine	  diphosphohexose,	  PC	  -­‐	  phosphorylcholine,	  G-­‐6-­‐P	  -­‐	  Glucose-­‐6-­‐phosphate,	  ppm	  -­‐	  parts	  per	  million,	  GPC	  -­‐	  Glycerophosphorylcholine,	   GPS	   -­‐	   Glycerophosphorylserine,	   PDE	   -­‐	   Phosphodiester,	   AMP	   -­‐	   Adenosine	  monophosphate,	  PEt	  -­‐	  Phosphorylethanolamine,	  H	  -­‐	  proton	  resonances,	  PME	  -­‐	  Phosphomonester,	  IMP	  -­‐	  Inosine	   monophosphate,	   NADP	   -­‐	   Nicotine	   adenine	   dinucleotide	   phosphate,	   GPE	   -­‐	   glycerol	   3-­‐phosphorylethanolamine,	   PG	   -­‐	   Phosphorylated	   glycans,	   Plas	   -­‐	   Plasmalogen,	   LPC	   -­‐	  Lysophosphatidylcholine,	  GPG	  -­‐	  Glycerol	  3-­‐phosphorylglycerol,	  LNI	  -­‐	  Lymph	  node	  invasion.	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NMR	  technology	  has	  now	  evolved	  from	  using	  relaxation	  times	  and	  line	  widths	  and	  now	  uses	  sophisticated	  statistical	  methods	  in	  order	  to	  make	  inferences.	  The	  efficacy	  of	  NMR	  as	  an	  investigative	  tool	  has	  been	  challenged	  for	  some	  time.	  Being	  thought	  of	  not	  useful	  in	  the	  diagnosis	  of	  CRC	  or	  polyps	  due	  to	  low	  sensitivity	  rates	  of	  cancer	  detection	  of	  only	  20	  per	   cent	   (Fluge	  et	   al.,	   1996).	  Furthermore,	   earlier	   studies	  did	  not	  have	   successful	  results	  with	  water-­‐suppressed	  1H	  NMR	  spectrum	  of	  plasma	  lipoprotein	  in	  the	  detection	  of	   cancer	   (Dowd,	   1987).	   The	   average	   line	   width	   measured	   using	   water-­‐suppressed	  proton	   spectra	   at	   400Hz	   for	   controls	   and	   untreated	   cancer	   patients	   were	   not	  significant	  between	  the	  two	  groups.	  Hence,	  that	  these	  measurements	  could	  not	  be	  used	  to	  detect	  cancer,	  in	  addition	  to	  the	  day	  to	  day	  variations	  found	  (Dowd,	  1987).	  This	  may	  be	  in	  part	  with	  the	  methodology	  of	  involving	  patients	  with	  different	  types	  of	  cancers	  at	  the	   same	   time	   such	   as	   colon,	   lung,	   gallbladder	   and	   malignant	   melanomas.	   Today,	  consistency	  in	  the	  timings	  of	  collection	  and	  processing	  of	  samples	  (Beckonert,	  2007)	  as	  well	   as	   taking	   into	   account	   daily	   variations	   are	   factors	   that	   are	   considered	   when	  interpreting	  NMR	   results.	   This	   is	   necessary	   in	   order	   to	   allow	   for	   the	   reproducibility,	  potential	  screening	  and	  diagnostic	  applications	  of	  NMR	  (Keun	  et	  al.,	  2002,	  Bjerrum	  et	  al.,	  2008).	  The	  use	  of	  the	  differences	  in	  T1	  and	  T2	  relaxation	  times	  had	  been	  purposed	  as	  a	  method	  of	  distinguishing	  normal	  and	  cancerous	  samples.	  However,	  this	  perhaps	  was	  useful	  only	  for	  initial	  tissue	  sampling	  for	  possible	  cancer	  changes	  (Kowalski,	  1997).	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1.9	  Hypothesis	  and	  Aims	  
1.9.1	  Hypothesis	  The	   hypothesis	   for	   this	   research	   project	   is	   that	   there	   is	   a	   detectable	   metabonomic	  profile	   in	   the	   tissue	   and	   biofluids	   of	   patients	   with	   colonic	   adenomas	   and	   CRC	  undergoing	   chemopreventive	   treatment	   and	   chemoradiotherapy	   respectively.	   The	  hypothetical	   focus	   was	   on	   the	   metabolite	   changes	   in	   tissue,	   urine	   and	   faecal	   water	  extracts	  associated	  with	  colorectal	  adenomas	  and	  blood	  for	  the	  CRC	  patients.	  	  	  
1.9.2	  Aims	  The	   primary	   endpoint	   of	   the	   study	   is	   to	   identify	   potential	   biomarkers	   or	   biomarker	  complexes	  in	  patients	  with	  CRC	  and	  colorectal	  adenomas	  as	  well	  as	  markers	  to	  identify	  response	  to	  neo-­‐adjuvant	  chemotherapy	  and	  radiotherapy	  in	  rectal	  cancer	  patients.	  	  	  
The	  aims	  of	  this	  project	  are	  to:	  -­‐	  
1. To	   use	   CRC	   cell	   lines	   for	   exploratory	   studies	   to	   investigate	   the	  metabonomic	  profiles	  of	  different	  cancer	  grades.	  
2. To	   characterize	   the	   metabonomic	   profiles	   of	   patients	   with	   benign	   colorectal	  tumours	  using	  solid	  state	  1H	  NMR.	  
3. To	   establish	   metabolic	   changes	   in	   patients	   colorectal	   adenomas	   in	   a	   trial	  treatment	  with	  a	  chemopreventive	  agent.	  
4. To	  study	  the	  change	  in	  the	  metabolic	  profiles	  of	  patients	  diagnosed	  with	  CRC	  as	  they	   travel	   through	   the	   ‘cancer	   pathway’	   during	   neo-­‐adjuvant	   chemotherapy	  and	  radiotherapy.	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5. To	   meta-­‐analyze	   the	   association	   between	   metabolic	   syndrome	   and	   CRC	   as	   a	  translational	   aspect	   of	   the	   project	   to	   investigate	   potential	   CRC	   screening	  adjuncts.	  	  
	  
An	  untargeted	  approach	   to	  metabolic	  profiling	  was	   initially	  undertaken	  using	  animal	  models	   in	   this	   thesis	   to	   broadly	   identify	   as	   many	   metabolites	   involved	   in	   the	  biochemistry	   of	   CRC.	   Following	   these	   metabolite	   identifications	   a	   more	   focused	  approach	   was	   undertaken	   for	   the	   human	   samples.	   Currently,	   there	   is	   no	   accurate	  distinguishable	  marker	  for	  patients	  with	  a	  good	  or	  poor	  prognosis	  and	  hence	  a	  need	  for	  one.	   This	   relates	   to	   primary	   disease	   and	   also	   patients	   that	   are	   treated	   with	  chemotherapy	   or	   radiotherapy	   in	   order	   to	   be	   able	   to	   decipher	   good	   and	   poor	  responders	  of	  treatment.	  1H	  NMR	  used	  in	  this	  research	  project	  allows	  non-­‐invasive	  in	  vivo	  measurements	  of	  metabolites	  giving	  insight	  into	  the	  characteristic	  biochemistry	  of	  tumours	  at	  a	  cellular	  level	  (Seierstad	  et	  al.,	  2007).	  The	  information	  generated	  will	  aid	  in	   the	   further	   understanding	   of	   CRC	   biology	   at	   a	   metabolic	   level.	   This	   will	   identify	  potential	  biomarkers	  for	  CRC	  and	  adenomas	  as	  well	  as	  generating	  bespoke	  response-­‐monitoring	   regimes	   to	   chemotherapy	   and	   radiotherapy.	   The	   ability	   to	   be	   able	   to	  quantify	   metabolites	   can	   open	   a	   gateway	   of	   opportunities	   into	   cancer	   pathology	  mechanisms.	  	  
	  
CRC	  induces	  a	  number	  of	  metabolite	  disturbances	  (Ma	  et	  al.,	  2009),	  hence	  looking	  for	  potential	  biomarkers	  through	  the	  changes	  in	  metabolites	  seem	  a	  reasonable	  approach.	  The	  aim	  of	   this	   study	   therefore	  will	  be	   to	  develop	  metabolic	  phenotypes	   for	  patients	  with	   CRC	   and	   adenomas	   with	   the	   aim	   of	   producing	   novel	   biomarkers	   and	   further	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understanding	   the	   cancer	   biology.	   Preliminary	   studies	   identifying	   metabonomic	  profiles	   of	   colorectal	   pathology	   were	   carried	   out	   using	   CRC	   xenografts	   and	   human	  colonic	  tissue.	  	  	  
	  
Malignant	   tumours	   posses	   an	   altered	  metabolic	   phenotype	   (Kasimos	   J.N	   and	  Glonek,	  1990).	  Primary	  and	  metastatic	  cancers	  up-­‐regulate	  the	  process	  of	  glycolysis	  and	  they	  are	   reliant	   on	   the	   Warburg	   effect	   for	   meeting	   their	   cellular	   energy	   requirements	  (Masella	   et	   al.,	   1989,	   Gatenby,	   2004).	   Therefore,	   the	   analysis	   of	   complex	   metabolic	  systems	  by	  high	  throughput	  spectral	  techniques	  such	  as	  NMR	  is	  a	  potentially	  valuable	  method	  to	  further	  understand	  the	  biology	  of	  CRC	  and	  develop	  more	  effective	  therapies.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
	  	   66	  
CHAPTER	  2	  
Materials	  and	  Methods	  The	  exact	  methodology	  used	  for	  each	  study	  is	  specified	  within	  the	  individual	  chapter.	  	  
2.1	  Patient	  Recruitment	  	  This	   study	   was	   reviewed	   and	   approved	   by	   the	   Royal	   Marsden	   Ethics	   Committee	  (08/H0801/180).	  Written	  informed	  consent	  was	  obtained	  from	  patients	  recruited	  for	  the	   study.	  Demographic	  data	   and	  medical	   history	   including	   tumour	   location,	   and	   the	  histological	  stage	  of	  the	  cancer	  were	  collected	  in	  addition	  to	  the	  samples	  of	  blood,	  urine	  and	  tissue.	  	  	  The	   samples	   collected	   from	   these	   individuals	   have	   been	   used	   for	   the	   studies	   in	   the	  supplementary	   chapter	   and	   chapter	   5.	   The	   inclusion	   and	   exclusion	   criteria	   for	   the	  study	  are	  listed	  below:	  	  
2.1.1	  Inclusion	  criteria:	  • Patients	  who	  are	  undergoing	  a	  colonoscopy.	  • Patients	  who	  have	  a	  new	  diagnosis	  of	  CRC.	  	  • Patients	  attending	  for	  a	  follow-­‐up	  colonoscopy	  after	  treatment	  for	  CRC.	  • Patients	  undergoing	  chemotherapy	  and	  radiotherapy	  for	  rectal	  cancer.	  • Newly	  diagnosed	  patients	  with	  recurrent	  CRC.	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2.1.2.Exclusion	  criteria:	  • Pregnancy,	  patients	  who	  have	   recently	  given	  birth	  over	  a	  12-­‐month	  period	  or	  lactating	  women.	  • Individuals	  under	  the	  age	  of	  18	  years.	  • Previous	  CRC	  patients	  with	  a	  new	  diagnosis	  of	  a	  non-­‐colorectal	  primary	  cancer.	  • Patients	  who	  have	  Familial	  Adenomatous	  Polyposis	  (FAP)	  or	  a	  family	  history	  of	  Hereditary	  Non-­‐Polyposis	  Colon	  Cancer	  (HNPCC).	  • Patients	  who	  have	  Ulcerative	  colitis	  (UC)	  or	  Crohn’s	  Disease	  (CD).	  • Patients	  who	  have	  had	  a	  blood	  transfusion	  in	  the	  last	  two	  months.	  • Patients	  requiring	   total	  parenteral	  nutrition	  (TPN)	  or	  any	   form	  of	   intravenous	  nutrition.	  • Professional	  athletes	  as	  these	  patients	  have	  a	  high	  creatinine	  in	  their	  biofluids.	  
• Patients	  with	  a	  urinary	  tract	  infection	  or	  macroscopic	  haematuria. 	  The	  samples	  were	  collected	  at	   the	   time	  of	  colonoscopy,	  which	  was	  performed	  at	   two	  study	  sites	   (The	  Royal	  Marsden	  NHS	  Foundation	  Trust	  and	  Chelsea	  and	  Westminster	  NHS	  Foundation	  Hospital,	  London).	  The	  indications	  for	  colonoscopy	  are	  listed	  below:	  	   • Bleeding	  per	  rectum	  (occult	  or	  fresh)	  • Change	  in	  bowel	  habit	  • Anaemia	  • Follow	  up	  for	  previous	  CRC	  • Follow	  up	  for	  previous	  polypectomy	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Blood	   samples	   for	   patients	   undergoing	   chemotherapy	   and	   radiotherapy	   used	   in	   the	  chapter	   5	   study	   were	   obtained	   in	   the	   clinic	   setting	   (at	   The	   Royal	   Marsden	   NHS	  Foundation	   Trust)	   at	   the	   beginning,	   in	   between	   and	   at	   the	   end	   of	   their	   treatment	  sessions.	  	  
2.2	   Sample	   Collection	   for	   Human	   Studies	   (for	   chapter	   5	   and	   the	   supplementary	  
chapter)	  In	   order	   to	   minimise	   factors	   that	   could	   affect	   metabolic	   effects	   such	   as	   diurnal	  variation	  (Bollard	  et	  al.,	  2001),	  samples	  of	  blood	  and	  colorectal	  tissue	  were	  taken	  in	  the	  morning.	  	  	  
2.2.1	  Blood	  sample	  collection	  Eight	  millilitres	  (ml)	  of	  venous	  blood	  were	  collected	  from	  each	  patient	   in	  a	  green-­‐top	  lithium	   bottle	   (BD	   Vacutainer®,	   USA)	   for	   plasma	   samples	   and	   an	   untreated	   red	   top	  bottle	   (BD	   Vacutainer®	   USA)	   for	   the	   serum	   samples.	   Samples	   were	   stored	   on	   ice	  immediately	   after	   collection	   and	   allowed	   to	   clot	   for	   30-­‐40	  minutes.	   The	   two	   sample	  bottles	  were	  then	  centrifuged	  at	  1500g	  for	  15	  minutes.	  Aliquots	  of	  250	  microliters	  (μl)	  of	   both	   plasma	   and	   serum	   were	   placed	   into	   cryotube	   vials	   (Nunc,	   Thermo	   Fisher	  Scientific,	  Denmark)	  and	  stored	  at	  -­‐80°C	  until	  NMR	  sample	  preparation.	  	  
2.3	  Sample	  Preparation	  (for	  chapters	  4,	  5	  and	  supplementary)	  All	  sample	  preparation	  was	  performed	  in	  a	  class	  II	  laboratory.	  Tissue,	  urine	  and	  blood	  samples	  were	  prepared	  according	  to	  standard	  protocols	  (Beckonert,	  2007),	  which	  are	  described	  in	  the	  individual	  chapters.	  Faecal	  water	  samples	  were	  prepared	  as	  per	  urine	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samples.	   Frozen	   samples	   were	   defrosted	   at	   room	   temperature	   prior	   to	   preparation.	  Following	  preparation,	  samples	  were	  transferred	  into	  five	  millimetre	  (mm)	  NMR	  tubes	  (Wilmad,	   CortecNet,	   France)	   and	   subjected	   to	   experiments	   with	   each	   NMR	   tube	  containing	  550μl	  of	  sample.	  	  	  
2.3.1	  Plasma	  and	  serum	  sample	  preparation	  Following	  vortexing,	  200μl	  of	  the	  plasma	  or	  serum	  supernatant	  was	  added	  to	  400μl	  of	  saline	  (0.9%	  w/v	  sodium	  chloride	  (NaCl)	  in	  90:10	  H20/D20)	  in	  a	  1.5	  ml	  Eppendorf	  tube	  (Fisher	  Scientific).	  This	  was	  then	  centrifuged	  at	  12000g	  for	  5	  minutes	  before	  transfer	  to	  the	  NMR	  tube	  prior	  to	  NMR	  analysis.	  	  	  	  
2.3.2	  Urine	  and	  faecal	  water	  sample	  preparation	  A	   0.2M	   concentration	   of	   phosphate	   buffer	   (200μl)	   made	   of	   sodium	   biphosphate	  (Na2HPO4)	   and	   NaH2PO4	   (monosodium	   phosphate)	   (Sigma-­‐Aldrich,	   Poole,	   UK)	  (containing	   20%	   D2O,	   trimethylsilyl	   propanoic	   acid	   or	   trimethylsilyl-­‐2,2,3,3-­‐tetradeuteropropionic	   acid	   (TSP)	   as	   an	   internal	   reference,	   and	   NaN3)	   was	   added	   to	  400μl	  of	  urine	   in	  Eppendorf	   tubes	   (Fisher	  Scientific).	  The	  mixture	  was	   then	   inverted	  and	   centrifuged	   at	   12000g	   for	   5	   minutes.	   Prior	   to	   analysis	   on	   the	   1H	   NMR	  spectrometer,	  550μl	  of	  sample	  were	  transferred	  into	  a	  standard	  5mm	  NMR	  tube.	  	  	  
2.4	  1H	  NMR	  Processing	  for	  All	  Studies	  The	  NMR	  experiments	  were	  performed	  on	  a	  Bruker	  Avance	  600MHz	  (14.1	  Tesla)	  NMR	  system,	  using	  a	  TXI	  (triple	  resonance)	  probe	  tuned	  to	  the	  frequency	  of	  the	  1H	  nucleus.	  A	   B-­‐ACS	   60	   tube	  NMR	   autosampler	  was	   used	   for	   automated	  NMR	   analysis	   of	   blood,	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urine	  and	  faecal	  water	  samples.	  Experiments	  were	  performed	  at	  a	  temperature	  of	  300	  Kelvin	   (K)	  using	   standard	  metabolic	  profiling	  NMR	  protocols	   (Beckonert,	   2007).	  The	  sample	  order	  was	  randomised	  prior	  to	  automated	  1H	  NMR	  analysis.	  Automatic	  locking	  to	  D2O	  and	  gradient	  shimming	  was	  carried	  out	  on	  every	  sample	  in	  order	  to	  improve	  the	  homogeneity	  of	  the	  magnetic	  field	  and	  hence	  enable	  high	  and	  consistent	  resolution	  of	  the	   spectra.	   Depending	   on	   sample	  matrix,	   different	   spectral	   editing	   techniques	  were	  selected	   (Beckonert,	   2007).	   The	   NMR	   spectra	   obtained	   were	   Fourier-­‐transformed,	  phased,	   baseline	   corrected	   and	   calibrated	   to	   the	   appropriate	   signal	   of	   the	   reference	  compound	   for	   each	   experiment	   using	   in-­‐house	   programmes	   created	   in	   MATLAB	  (MathWorks,	  R2011a,	  Natwick,	  MA).	  	  
2.5	  1H	  NMR	  Experiments	  	  The	  main	  1H	  NMR	  experiments	  used	  in	  this	  thesis	  were	  the	  Nuclear	  Overhauser	  Effect	  Spectroscopy	   (NOESY)	   and	   the	   Carr-­‐Purcell-­‐Meiboom-­‐Gill	   (CPMG)	   sequences	   of	  analysis.	  These	  were	  chosen	  in	  order	  to	  allow	  better	  distinction	  of	  different	  groups	  of	  metabolites.	   Both	   one	   and	   two-­‐dimensional	   experiments	   (1-­‐D	   and	   2-­‐D	   respectively)	  were	  undertaken	  for	  profiling	  and	  assignment	  purposes.	  	  	  
2.5.1	  One-­‐dimensional	  (1-­‐D)	  NOESY	  As	  part	  of	  the	  1-­‐D	  NOESY	  set-­‐up,	  a	  pulse	  sequence	  of	  RD-­‐90°-­‐t-­‐90°-­‐tm-­‐90°-­‐AQ	  was	  used,	  where	  RD	   is	   the	   relaxation	  delay,	   t	   the	   short	  delay	  of	   approximately	  3	  microseconds	  (μs)	   with	   a	   mixing	   time	   (tm)	   of	   100-­‐150μs.	   The	   acquisition	   period	   of	   the	   data	   is	  represented	   as	   ‘AQ’	   (Nicholson,	   1995).	   Irradiation	   of	   the	   large	   water	   signal	   ('water	  suppression')	  was	  performed	  during	  the	  RD	  and	  mixing	  time.	  The	  parameter	  settings	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for	  the	  number	  of	  time	  domain	  data	  points	  =	  32,	  768,	  the	  RD	  =	  2.0	  seconds	  and	  number	  of	  scans	  =	  64	  or	  128	  transients	  for	  urine	  and	  plasma	  respectively	  (Beckonert,	  2007).	  	  	  
2.5.2	  CPMG	  pulse	  Sequence	  The	   CPMG	   pulse	   sequence	   (RD-­‐90°-­‐(τ-­‐180°-­‐τ)n-­‐AQ)	   is	   used	   for	   the	   suppression	   of	  macromolecular	   signals,	  where	   τ	   =	   400μs	   and	   n	   =	   300.	   It	   is	   used	   to	   suppress	   broad	  signals	  in	  tissue	  and	  serum	  samples	  to	  highlight	  the	  resonances	  of	  small	  biomolecules	  (Beckonert,	  2007,	  Gowda	  et	  al.,	  2008).	  	  	  
2.5.3	  Two-­‐dimensional	  (2-­‐D)	  1H	  NMR	  This	   technique	   of	   NMR	   analysis	   is	   used	   to	   study	   the	   connectivity	   between	   different	  nuclei	  (e.g.	  1H-­‐1H	  couplings,	  or	  1H-­‐13C)	  and	  hence	  links	  different	  signal	  groups	  to	  their	  structural	   moieties	   (Lindon	   et	   al.,	   2007).	   The	   2-­‐D	   J-­‐resolved	   spectroscopy	   (JRES)	  experiments	   were	   introduced	   by	   Ernst	   and	   colleagues	   in	   the	   late1970s	   using	   the	  separated	   effects	   of	   chemical	   shift	   and	   J	   –	   coupling	   to	   create	   two	   independent	  dimensions	   (Ludwig	  and	  Viant,	  2010,	  Aue	  et	  al.,	   1976).	  They	  are	  applied	   to	  decipher	  complex	  regions	  of	  overlapping	  signals	   into	  the	  respective	  multiplicities	  of	   individual	  signal	  groups	  for	  metabolite	  identification.	  The	  2-­‐D	  experiments	  usually	  require	  longer	  acquisition	  times	  of	  several	  hours	  and	  are	  performed	  on	  selected	  samples.	  	  
2.6	  Metabolite	  Peak	  Assignments	  The	   web-­‐based	   Human	   Metabolome	   Database	   (HMDB),	   which	   contains	   reference	  libraries	   of	   NMR	   spectra	   of	   metabolites,	   was	   used	   for	   metabolite	   peak	   assignments	  (Wishart	  et	  al.,	  2007).	  Furthermore,	   spectral	  assignments	  were	  also	  made	  using	  data	  
	  	   72	  
from	   literature	   and	   from	   commercial	   databases	   such	   as	   Chenomx	   NMR	   Suite	  (Chemomx	   Inc,	   Edmonton,	   Canada)	   and	   from	   performing	   2-­‐D	   experiments.	   For	  Chenomx,	   the	   Chemical	   Shape	   Indicator	   (CSI)	   is	   adjusted	   for	   the	   software	   to	   have	   a	  basis	   for	   fitting	   and	   profiling.	   Chenomx	   allows	   the	   quantification	   of	   individual	  metabolites	   by	   using	   the	   known	   concentration	   of	   a	   reference	   signal	   (TSP)	   in	   all	   the	  experiments	  on	  urines	  and	   faecal	  water	  samples)	  using	  a	  600MHz	   library.	   	  Statistical	  correlation	   spectroscopy	   (STOCSY)	  was	   also	   used	   for	   assignments.	   This	   involves	   the	  correlation	   statistics	   between	   sets	   of	   1D	   NMR	   spectra.	   It	   generates	   connections	  between	   signals	   from	   molecules	   of	   varying	   concentrations,	   hence	   allows	   molecular	  structural	  assignments	  and	  peak	  identification	  (Cloarec	  et	  al.,	  2005).	  	  	  
2.7	  Quantification	  of	  Metabolites	  Relative	   concentrations	   of	   compounds	   in	   the	   biological	   samples	   were	   calculated	   by	  direct	   integration	   of	   the	   spectral	   regions	   using	   in-­‐house	   programmes	   developed	   in	  MATLAB	   (MathWorks,	   Natick,	   MA).	   As	   the	   peak	   intensity	   is	   proportional	   to	   the	  concentration	   of	   the	   metabolites,	   and	   as	   known	   amounts	   of	   sample	   and	   buffer	  (including	   the	   reference	   compound,	   TSP)	   are	   used,	   concentrations	   were	   estimated	  under	  certain	  assumptions	  and	  calculation	  of	  reference	  factors.	  	  
2.8	  Data	  Analysis	  Metabonomics	  uses	  chemometric	  as	  well	  as	  quantitative	  methods	  for	  sample	  analysis,	  involving	  parametric	  and	  non-­‐parametric	  techniques.	  The	  complexity	  of	  1H	  NMR	  data	  makes	   it	   necessary	   for	   data	   to	   be	   processed	   and	   normalised	   to	   a	   more	   meaningful	  format	  that	  is	  robust	  and	  reflects	  the	  complex	  metabolic	  processes	  under	  investigation.	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Multivariate	   analyses	  were	   employed	   to	   aid	   in	   describing	   sample	   variation	   between	  groups	  and	  within	  the	  respective	  groups	  and	  also	  in	  reducing	  the	  dimensionality	  of	  the	  data.	  	  	  
2.8.1	  Normalisation	  Normalisation	   is	   an	   integral	   part	   of	   NMR	   data	   processing	   as	   it	   scales	   the	   spectra	   to	  fundamentally	   the	   same	   overall	   concentration	   thus	   accounting	   for	   the	   different	  dilution	  of	   the	  samples	   (Dieterle	  et	  al.,	  2006).	  Normalisation	  of	   the	  data	  removes	   the	  sample-­‐to-­‐sample	  variability.	  Mean	  fold	  change	  (mfc)	  normalisation	  was	  chosen	  for	  the	  experiments	   in	   this	   thesis,	  which	   is	   a	  mathematical	   correction	   that	   employs	   the	   fold	  change	   relative	   to	   the	  average	   spectra	  assuming	   that	  all	   the	   spectra	  are,	   the	   same.	   It	  has	   the	  benefit	  of	  accounting	   for	  errors	   in	  sample	  dilutions.	   It	  makes	   the	  assumption	  that	   measured	   peak	   intensities	   are	   directly	   proportional	   to	   concentrations	   of	  metabolites	   in	   solution.	   Hence,	   the	   change	   in	   intensity	   of	   a	   profile	   due	   to	   variable	  sample	  dilution	  and/or	  inconsistency	  of	  NMR	  acquisition	  parameters	  is	  expected	  to	  be	  uniform	   across	   all	   peaks	   (Veselkov	   et	   al.,	   2011).	   Binning	   of	   1H	   NMR	   data	   was	  performed	  in	  order	  to	  prepare	  the	  data	  for	  multivariate	  modeling.	  This	  involves	  peak	  extraction	  within	  defined	  spectral	  regions	  (Coen,	  2008).	  	  
2.8.2	  Chemometric	  methods	  Chemometric	  methods	  involve	  pattern	  recognition	  techniques	  that	  are	  supervised	  and	  unsupervised.	  Chemometrics	   involves	  methods	  that	  either	  enable	  the	  classification	  of	  samples	   (supervised	   methods)	   or	   employs	   untargeted	   methods	   that	   rely	   on	  multivariate	   statistics	   such	   as	   principal	   component	   analysis	   (PCA)	   to	   identify	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differences	   between	   or	   within	   groups.	   In	   NMR,	   using	   the	   chemical	   shifts	   of	   various	  metabolites	  enables	  this	  analysis.	  The	  chemical	  shift	  allows	  the	  study	  of	  the	  molecular	  structure	  as	  well	  as	  the	  assignment	  to	  a	  certain	  metabolite	  to	  be	  made.	  It	  expresses	  the	  transition	   frequency	  of	   the	  nuclear	   transitions	   in	  parts	  per	  million	  (ppm)	  and	  can	  be	  derived	  from	  the	  formula	  below:	  	  	  Chemical	  Shift,	  δ	  	   δ	  =	  [v	  (solute	  in	  Hz	  –	  v	  (reference	  in	  Hz)]	  x	  106	  	   	   	   [Spectrometer	  frequency	  in	  Hz]	  	  where	  v	  is	  a	  frequency	  and	  the	  chemical	  shift	  is	  essentially	  the	  difference	  between	  the	  resonance	   frequency	   and	   that	   of	   the	   reference	   substance	   divided	   by	   the	   operating	  frequency	  of	  the	  spectrometer.	  	  Quantitative	   methods	   then	   compare	   the	   absolute	   or	   relative	   concentrations	   of	   the	  identified	   discriminatory	   compounds,	   and	   univariate	   analysis	   such	   as	   ANOVA	   and	  multivariate	   analyses	   are	   applied	   as	   means	   of	   determining	   the	   significance	   of	   the	  findings	  (Xia	  and	  Wishart,	  2011).	  	  	  
2.9	  Multivariate	  Statistical	  Analyses	  Pattern	  recognition	  techniques	  have	  been	  part	  of	  the	  revolution	  of	  metabonomics	  data	  analysis.	   Supervised	   techniques	   are	   used	   for	   classification	   purposes	   and	   involve	   the	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use	  of	  orthogonal	  partial	  least	  squares	  (O-­‐PLS)	  and	  discriminant	  analysis	  such	  as	  PLS-­‐DA	  and	  unsupervised	  methods	  include	  techniques	  such	  as	  PCA.	  	  
2.9.1	  Principal	  component	  analysis	  (PCA)	  Principal	  component	  analyses	  were	  performed	  using	  SIMCA	  P+	  Version	  12	  (Umetrics,	  Umeå,	   Sweden)	   and	   MATLAB	   (MathWorks,	   R2011a,	   Natick,	   MA).	   PCA	   facilitates	   the	  analysis	  and	  visualisation	  of	  sample	  clusters	  in	  datasets	  by	  visualising	  the	  variations	  in	  datasets.	   It	  allows	   intrinsic	  clustering	  behaviour	  between	  groups	  or	   individuals	   to	  be	  observed	  (Coen,	  2008),	  without	  any	  prior	  knowledge	  of	  their	  group.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  2.1	  Diagram	  representing	  a	  scores	  plot	  of	  a	  principal	  component	  analysis.	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PCA	  results	  are	  characterised	  as	  ‘scores’	  and	  ‘loadings’	  plots	  that	  represent	  the	  original	  data.	  The	  clustering	   in	  a	  PCA	  scores	  plot	  determines	   the	  similarity	  between	  the	  data.	  Each	  point	  on	  a	  scores	  plot	  represents	  an	   individual	  sample	  whereas	  each	  point	  on	  a	  loadings	  plot	   is	  a	  spectral	   region	  (Wang,	  2003).	  The	  relationship	  between	  groups	   ‘A’,	  ‘B’,	   ‘C’	   and	   ‘D’	   in	  Figure	  2.1	   is	   an	  example	  of	   the	  distinct	   separation	  between	  groups,	  assuming	   each	   group	   contained	   multiple	   samples	   within	   the	   four	   quadrants	   of	   the	  circle.	   The	   close	   proximity	   of	   the	   groups	   between	   each	   other	   gives	   an	   indication	   of	  their	  similarities	  or	  differences.	  	  PCA	   involves	   the	   projection	   of	   data	   points	   into	   directions	   that	   maximise	   the	   data	  variance	   into	   ‘principal	   components’	   (PCs).	   Each	   PC	   is	   a	   linear	   combination	   of	   the	  original	   dataset	   and	   each	   of	   the	   subsequent	   PCs	   describe	   the	   full	   variance	   not	  accounted	  for	  by	  the	  previous	  PCs	  (Lindon	  et	  al.,	  2006).	  The	  scores	  plot	  provides	  the	  2-­‐D	   representation	   of	   the	   first	   two	   PCs	   and	   the	   corresponding	   loading	   plot	   provides	  further	   information	   into	   the	   variables	   that	   influence	   the	   observed	   clusters	   in	   the	  sample	  sets.	  	  	  The	  quality	  of	  the	  models	  is	  assessed	  by	  the	  cumulative	  R2	  and	  the	  predictive	  value	  of	  the	  Q2.	   The	  R2	  represents	   the	   goodness	   of	   fit	   parameter	   and	  Q2,	   the	   goodness	   of	   the	  prediction	   parameter.	   A	   value	   of	   1	   for	   both	   variables	   provides	   complete	   data	  correlation	  and	  the	  prediction	  of	  the	  dataset	  being	  100%.	  Values	  of	  above	  0.5	  denote	  good	  models.	   A	   negative	   Q2	  means	   that	   the	   model	   created	   is	   not	   predictive.	   The	   Q2	  represents	   the	  percentage	   in	  variation	   in	   the	  dataset;	   it	   signifies	  how	  well	   the	  model	  predicts	  new	  data	  (Weljie	  et	  al.,	  2006)(Kinross	  et	  al.,	  2011).	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In	   this	   work,	   data	   were	   processed	   using	   mean	   centering,	   unit	   variance	   or	   Pareto	  scaling.	   Mathematically,	   the	   unit	   variance	   divides	   the	   ‘x’	   variables	   by	   the	   standard	  deviation	   (SD)	   and	  Pareto	   scaling	   divides	   the	   variables	   by	   the	   square	   root	   of	   the	   SD	  (Weljie	   et	   al.,	   2006).	   The	   scaling	  methods	   involved	   in	   PCA	   analysis	   are	   described	   as	  follows:	  
(i)	  Unit	  variance	  or	  Auto-­‐scaling	  It	  uses	  the	  SD	  as	  the	  scaling	  factor.	  Auto-­‐scaling	  relies	  on	  each	  spectral	  variable	  having	  the	  same	  weight.	  The	  loadings	  plots	  created	  with	  auto-­‐scaling	  show	  the	  variables	  that	  categorically	  have	  an	  effect	  on	  the	  differences	  between	  sample	  groups	  (Cloarec	  et	  al.,	  2005).	  Auto-­‐scaling	  allows	  for	  all	  metabolites	  to	  have	  a	  SD	  of	  1,	  therefore,	  the	  data	  can	  be	  analysed	  as	  correlations	  rather	  than	  co-­‐variances.	  This	  places	  equal	   importance	  to	  all	  metabolites	  (van	  den	  Berg	  et	  al.,	  2006).	  	  	  
(ii)	  Pareto	  scaling	  This	  method	   has	   less	   distortion	   of	   the	   data	   than	   the	   auto-­‐scaling;	   it	   uses	   the	   square	  root	  of	  the	  SD	  as	  the	  scaling	  factor	  (van	  den	  Berg	  et	  al.,	  2006).	  However,	  it	  also	  has	  the	  disadvantage	  of	  giving	  the	  variables	  with	  higher	  variance	  more	  weight	  in	  the	  modeling	  (Cloarec	  et	  al.,	  2005).	  	  
(iii)	  Mean-­‐centered	  Mean-­‐centering	  involves	  the	  mean	  of	  each	  variable	  within	  the	  data	  set	  being	  subtracted	  from	  its	  value	  for	  each	  sample	  in	  the	  group	  (Cloarec	  et	  al.,	  2005).	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2.9.2	  Orthogonal	  -­‐	  projection	  to	  latent	  structures	  discriminant	  analysis	  (O-­‐PLS-­‐DA)	  This	  form	  of	  analysis	  is	  used	  to	  remove	  the	  variation	  in	  the	  spectra	  that	  are	  not	  related	  i.e.	   orthogonal	   to	   the	   class	   separation	   (Beckonert,	   2007).	   It	   removes	   systematic	  variation	  from	  an	  inputted	  data	  set	  ‘X’	  that	  is	  not	  correlated	  to	  the	  response	  set	  ‘Y’,	  i.e.	  ‘X’	  that	  is	  orthogonal	  (independent)	  to	  ‘Y’.	  It	  relates	  to	  a	  predictor	  set	  of	  variables	  (X)	  to	  one	  or	  more	  responses	  (Y)	  (Trygg	  and	  Wold,	  2002).	  The	  R2	  value	  explains	  how	  much	  the	   total	   variance	   is	   explained	   by	   the	   model	   and	   the	   Q2	   is	   how	   much	   variance	   is	  predictable	  by	  the	  model	  and	  how	  robust	  the	  model	  is.	  The	  value	  of	  Q2	  is	  always	  less	  than	  R2.	  A	  7-­‐fold	  cross-­‐validation	  was	  used	  to	  evaluate	  the	  models	  ability	  to	  predict	  the	  response	  variation	  (Q2)	  (Stone,	  1974).	  	  
2.9.3	  Partial	  least	  square	  -­‐	  discriminate	  analysis	  (PLS-­‐DA)	  PLS-­‐DA	   is	   a	   classification	   tool	   based	   on	   the	   dependent	   variable	   representing	   the	  membership	  of	  the	  class.	  It	  explores	  the	  differences	  between	  groups	  by	  explaining	  the	  maximum	   separation	   between	   samples	   defined	   by	   class	   in	   a	   dataset	   (Brindle	   et	   al.,	  2002).	  The	  cross-­‐validation	  is	  revealed	  by	  the	  Q2	  value	  (Westerhuis	  et	  al.,	  2008).	  	  	  
2.10	  Statistical	  Analysis	  for	  the	  Experimental	  Studies	  Statistical	  analysis	  was	  carried	  out	  using	  the	  Statistical	  Package	  for	  the	  Social	  Sciences	  (SPSS)	  version	  18	  (SPSS	   Inc.,	  Chicago,	   IL,	  USA)	  and	  Microsoft	  Excel.	  Data	  distribution	  was	  tested	  and	  comparisons	  made	  using	  Kruskal-­‐Wallis	  and	  Mann	  Whitney	  U	  tests	  as	  univariate	  forms	  of	  analysis.	  The	  median	  was	  reported	  in	  most	  cases	  as	  a	  more	  robust	  measure	   than	   the	   mean.	   A	   p-­‐value	   of	   <0.05	   was	   considered	   to	   indicate	   statistical	  significance.	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CHAPTER	  3	  
Metabonomic	  profiling	  of	  colorectal	  cancer	  (CRC)	  xenograft	  models	  
3.1	  Abstract	  Cancer	   xenografts	   are	   useful	   tools	   for	   research	   into	   the	   mechanism	   of	   disease	   and	  potential	   treatments.	  A	  number	  of	  different	  cell	   lines	  have	  been	  used	  for	  the	  study	  of	  colorectal	   cancer	   (CRC),	  but	   few	  studies	  have	  compared	   the	  metabolic	  profiles	  of	   the	  commonly	  used	  cell	  lines.	  The	  aim	  of	  this	  study	  was	  to	  elucidate	  the	  differences	  and/or	  similarities	   between	   four	   commonly	   used	   CRC	   cell	   lines:	   namely,	   SW-­‐620,	   HT-­‐29,	  COLO-­‐205	  and	  HCT-­‐116,	  using	  1H	  NMR	  spectroscopy.	  Data	  analyses	  included	  gene	  and	  metabolite	   enrichment.	   A	   number	   of	   metabolites	   were	   identified	   including	   choline,	  phosphocholine	   (PC)	   and	   glycerphosphocholine	   (GPC).	   Principal	   component	   analysis	  (PCA)	   showed	   clustering	  between	   the	  different	   cell	   lines.	   There	  was	   a	   lower	   level	   of	  GPC	   in	   the	   SW-­‐620	   and	   the	   HCT-­‐116	   cell	   lines.	   This	   was	   also	   associated	   with	   a	  significant	   difference	   between	   the	   levels	   of	   GPC	   and	   the	   PC	   to	   GPC	   ratio	   (p<0.05)	  between	   the	   different	   cell	   lines.	   Additionally,	   gene	   enrichment	   analysis	   showed	   high	  expressions	   in	   tumour	   suppressor	   genes	   and	   genes	   involved	   in	   apoptosis.	   Protein	  biosynthetic	  pathways	  were	  also	  enriched	   in	   the	   cell	   lines	  with	  a	  high	  PC:	  GPC	  ratio.	  Tumour	  cells	  have	  a	  high	  turnover	  rate	  and	  membrane	  phospholipid	  metabolism	  plays	  a	  significant	  role	  in	  cancer	  pathogenesis.	  SW-­‐620	  and	  HCT-­‐116	  are	  highly	  tumorigenic	  cell	  lines	  that	  could	  be	  used	  for	  the	  study	  of	  choline	  metabolism	  inhibitors	  as	  they	  show	  significant	   differences	   in	   the	   membrane	   synthesizing	   metabolites	   as	   well	   as	  enrichment	  in	  genes	  involved	  with	  CRC	  pathogenesis	  and	  protein	  metabolism.	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3.2	  Introduction	  	  The	   processes	   by	   which	   tumours	   metastasise	   are	   multi-­‐factorial	   and	   have	   not	   been	  individually	   identified.	   The	   risk	   of	   recurrence	   and	   metastases	   is	   also	   substantially	  higher	   in	   advanced	   disease.	   Despite	   the	   surgical	   treatment	   of	   CRC,	   invasion	   and	  metastases	  still	  play	  major	  roles	   in	  poor	  outcomes.	  Animal	  models	  have	  been	  used	  in	  the	   study	   of	   human	   disease	   for	   many	   years.	   In	   researching	   cancer	   states,	   animal	  models	  have	  proved	  to	  be	  invaluable	  in	  elucidating	  host	  and	  tumour	  factors	  involved	  in	  cancer	  metastasis	  (Fidler,	  1978).	  Nevertheless,	  the	  outputs	  in	  terms	  of	  translation	  from	  the	  laboratory	  bench	  studies	  of	  animal	  models	  to	  clinical	  settings	  have	  been	  variable.	  Animal	  studies	  using	  xenografts	  can	  aid	  biomedical	  research	  significantly	  by	  enabling	  pilot	   studies	   to	   be	   carried	   out	   especially	   in	   the	   field	   of	   pharmacology.	   The	   current	  application	  of	  1H	  NMR	  based	  metabonomics	  offers	  a	  new	  insight	  into	  the	  use	  of	  animal	  models	  in	  the	  study	  of	  the	  pathogenesis	  and	  mechanism	  of	  cancer	  and	  other	  diseases.	  	  	  Xenograft	  CRC	  models	  offer	   the	  potential	   for	  obtaining	   further	  biological	   information	  about	   cancer	  and	   the	  application	  of	   interventions.	  The	   slow	  progression	  of	  CRC	  over	  time	   makes	   it	   difficult	   to	   adequately	   study	   different	   tumour	   stages	   in	   real	   time.	  Xenografts	   therefore	   offer	   excellent	  means	   in	   the	   facilitation	   of	   the	   study	   of	   tumour	  progression	  that	  otherwise	  would	  be	  difficult	  as	  time	  has	  to	  elapse	  in	  order	  to	  obtain	  specimens	   from	   patients.	   Furthermore,	   the	   variability	   of	   humans	   with	   regards	   to	  uncontrollable	  factors	  such	  as	  stress,	  genetics	  makes	  single	  studies	  in	  human	  samples	  much	  more	  challenging.	  	  	  In	   addition,	   there	   has	   been	   criticism	   that	   biopsy	   samples	   possess	   a	   large	   amount	   of	  heterogeneity	  and	  the	  in	  vitro	  studies	  ensure	  greater	  sample	  consistency	  (Loar,	  1988).	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Thus,	   cell	   lines	   provide	   a	   more	   robust	   starting	   point	   prior	   to	   the	   analysis	   of	   tissue	  samples	   that	   can	   also	   sometimes	   be	   limited	   for	   experimental	   purposes.	   Established	  CRC	  cell	  lines	  provide	  the	  perfect	  opportunity	  to	  be	  used	  in	  investigating	  cell	  behaviour	  at	   a	   metabolic	   level	   from	   the	   analysis	   of	   carcinogenesis	   to	   cellular	   differentiation.	  Studying	   cell	   lines	   in	   vitro	   to	   obtain	   NMR	   spectra	   would	   also	   permit	   more	   detailed	  assignment	  and	  characterisation	  of	  metabolites.	  	  	  	  The	  cell	  lines	  HT-­‐29,	  COLO-­‐205,	  HCT-­‐116	  and	  SW-­‐620	  used	  in	  the	  experiments	  in	  this	  chapter	  are	  among	  the	  most	  commonly	  used	  cell	  lines	  for	  the	  study	  of	  CRC	  as	  seen	  from	  the	  previous	   1H	  NMR	  studies	   (discussed	   in	  chapter	  1).	  These	  cell	   lines	  with	  different	  characteristics	  allow	  the	  study	  of	  different	  CRC	  grades.	  The	  optimum	  management	  of	  metastatic	   and	   advanced	   colorectal	   cancer	   is	   still	   a	   problematic	   clinical	   task	   and	  research	   into	   this	   is	  presently	  on	  going.	  The	  studies	  of	  metastatic	  and	  advanced	  CRC	  cell	   lines	   have	   the	   potential	   to	   provide	   knowledge	   for	   further	   understanding	   of	   the	  pathogenesis	   of	   the	   disease.	   Hence,	   the	   study	   of	   the	   metabolic	   profile	   of	   xenograft	  models	  has	  the	  potential	  to	  assist	  in	  the	  application	  of	  their	  use	  in	  laboratory	  studies.	  	  	  The	  use	  of	  1H	  NMR	  to	  decipher	  the	  metabolic	  profiles	  of	  these	  cell	   lines	  will	  generate	  novel	   information	   on	   the	   biochemical	   nature	   of	   CRC.	  Making	   sense	   of	   this	  metabolic	  profiling	   data	   of	   xenograft	   animal	   models	   may	   help	   in	   providing	   a	   framework	   for	  human	   studies	   and	   interventions.	   This	   chapter	   investigates	   the	   differences	   and	  similarities	  between	   the	  xenograft	  models	  of	   the	  CRC	  cell	   lines	  SW-­‐620,	  HT-­‐29,	  HCT-­‐116	   and	   COLO-­‐205	   using	   1H	   NMR	   spectroscopy	   with	   the	   hypothesis	   that	   metabolic	  changes	  specific	  to	  each	  cell	  can	  be	  identified.	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3.3	  Materials	  and	  Methods	  
3.3.1	  Tumour	  tissue	  collection	  and	  preparation	  The	   tumour	  extract	   samples	  were	  kindly	   received	   from	  AstraZeneca	  UK	   (through	  the	  
collaboration	   with	   Professor	   Ian	   Wilson).	   Forty-­‐seven	   tumour	   tissue	   samples	   were	  collected	   from	   cell	   lines	   grown	   in	   vivo	   as	   subcutaneous	   xenografts	   in	   athymic	  mice.	  Aqueous	   tumour	   tissue	  extracts	  of	   the	  cell	   lines	  SW-­‐620,	  HT-­‐29,	  COLO-­‐205	  and	  HCT-­‐116	   were	   used	   (American	   Type	   Culture	   Collection,	   ATCC®,	   Rockville,	   MD).	   The	  different	  cell	  lines	  were	  harvested	  (day	  of	  sampling	  from	  day	  of	  implant)	  after	  different	  time	  period	  (Table	  3.1).	  	  
	  
The	   tumour	   samples	   were	   prepared	   using	   100mg	   of	   tumour	   tissue	  which	  was	   then	  manually	  desegregated	  and	  extracted	  with	  1ml	  acetonitrile:	  water	  at	  a	  ratio	  of	  1:1	  then	  placed	   in	  an	  ultrasonic	  bath	  and	  centrifuged	  at	  17,900	  rcf	   (relative	  centrifugal	   force)	  for	  10	  minutes.	  The	  aqueous	  supernatants	  were	  then	  extracted	  as	  the	  aqueous	  tissue	  extract	   samples.	   These	   samples	   were	   then	   freeze-­‐dried.	   All	   samples	   were	   stored	   in	  eppendorf	  tubes	  at	  -­‐40°C	  until	  the	  time	  of	  NMR	  sample	  preparation	  and	  analysis.	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Table	  3.1:	  Characteristics	  and	  number	  of	  colorectal	  cancer	  cell	  lines	  samples	  
Cell	  line	   Characteristics	   Number	   of	  
animals	   per	  
cell	  line	  (n)	   Days	  of	  Harvest	  	  HT-­‐29	   Well-­‐differentiated	   primary	  tumour	   10	   7	  &	  14	  days	  	  	  COLO-­‐205	   Colon	   adenocarcinoma	   from	  metastatic	   site,	   ascites	   (adjuvant	  therapy	   with	   5-­‐fluorouracil	  (Dukes	  D)	  
18	   13	  days	  	  	  
SW-­‐620	   Lymph	   node	   metastasis,	   poorly	  differentiated	  (Dukes	  C)	   10	   35	  days	  	  	  HCT-­‐116	   Poorly	  differentiated	  colon	  cancer	  	   9	   33	  days	  	  
	  	  
3.3.2	  Sample	  preparation	  The	   samples	   were	   defrosted	   at	   room	   temperature	   prior	   to	   1H	   NMR	   preparation.	  	  Phosphate	   buffer	   composed	   of	   2.885g	   of	   disodium	   hydrogen	   phosphate	   (Na2HPO4),	  0.525g	   of	   monosodium	   phosphate	   (NaH2PO4,),	   0.173g	   of	   TSP	   and	   0.195g	   of	   sodium	  azide	  (NaN3),	  in	  addition	  to	  90mls	  of	  D2O	  was	  used.	  The	  phosphate	  buffer	  (600μl)	  was	  used	  to	  reconstitute	  the	  dry	  frozen	  tumour	  tissue	  extracts.	  A	  sample	  of	  the	  phosphate	  buffer	   solution	  was	   run	  as	  a	   ‘blank’	  on	   the	   spectrometer	  prior	   to	   reconstituting	  with	  the	  aqueous	  extracts	  to	  ensure	  no	  impurities	  were	  present.	  The	  reconstituted	  samples	  were	  then	  mixed,	  using	  a	  whirl	  mixer	  for	  one	  minute	  and	  subsequently	  centrifuged	  for	  five	  minutes	  at	  16000g.	  A	  550μl	  of	  each	  sample	  was	  placed	   in	  a	  standard	  5mm	  glass	  NMR	   tube	   and	   frozen	   at	   -­‐40°C	   for	   24	   hours	   before	   being	   analysed	   in	   the	   1H	   NMR	  spectrometer.	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3.3.4	  1H	  NMR	  spectroscopy	  processing	  All	   the	   high-­‐resolution	   one-­‐dimensional	   (1D)	   1H	   NMR	   spectra	   were	   acquired	   on	   a	  Bruker	  DRX	  600	  spectrometer	  (Bruker	  Biospin,	  Rheinstetten,	  Germany)	  operating	  at	  a	  frequency	  of	  600.13MHz	  with	  a	   field	  strength	  of	  14.1Telsa.	  The	  temperature	  of	  300K	  was	  set	  as	  the	  optimum	  temperature	  setting	  for	  the	  spectrometer.	  A	  random	  run	  order	  was	  used	  when	  placing	  the	  samples	  in	  the	  spectrometer	  to	  minimise	  sequential	  errors	  if	  there	  were	  problems	  with	  instrumentation.	  A	  BACS	  60	  automated	  sample	  exchanger	  was	  used	  to	  place	  the	  samples	  into	  the	  spectrometer	  using	  the	  software	  Xwin-­‐NMR	  and	  Icon-­‐NMR	  (Bruker	  Biospin,	  Rheinstetten,	  Germany).	  	  Prior	   to	   the	  acquisitions	  of	   the	  NMR	  spectra,	  manual	  gradient	  shimming	  was	  used	   to	  improve	  the	  homogeneity	  of	  the	  magnetic	  field	  in	  order	  to	  obtain	  high-­‐resolution	  NMR	  spectra.	   The	   pulse	   sequence	   of	   RD-­‐90°-­‐t1-­‐90°-­‐tm-­‐90°-­‐AQ	   was	   used.	   The	   relaxation	  delay	   (RD)	   defines	   the	   repetition	   rate	   of	   the	   experiment.	   The	   ‘AQ’	   is	   the	   acquisition	  period	  of	  2.73	  seconds.	  The	  mixing	  time	  (TM)	  was	  set	  to	  10ms	  and	  t1	  was	  4μs.	  The	  free	  induction	   decay	   (FID)	  was	   recorded	   into	   64k	   data	   points	   in	   the	   time	   domain	  with	   a	  spectral	   width	   of	   20ppm.	   The	   spectra	   were	   recorded	   as	   the	   sum	   of	   64	   transients	  following	   eight	   dummy	   scans	   (ds).	   All	   spectra	  were	   acquired	   using	   the	   standard	   1D	  NMR	   experiment,	   CPMG	   with	   specific	   settings	   on	   the	   spectrometer	   as	   subsequently	  described.	  This	  had	  a	  pulse	  sequence	  of	  (RD	  -­‐	  90°-­‐{τ-­‐180°-­‐τ}	  n	  -­‐	  AQ)	  where	  the	   fixed	  echo	  time	  τ	  is	  the	  time	  for	  change	  in	  direction	  of	  the	  nuclear	  spin	  set	  at	  400μs	  giving	  a	  total	   spin-­‐echo	   time	   of	   64ms.	   This	   pulse	   sequence	   refers	   to	   the	   series	   of	   radio	  frequency	   pulses	   applied	   to	   the	   sample.	   Spectra	   were	   recorded	   as	   the	   sum	   of	   128	  transients	  following	  16	  ds.	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The	  NMR	   spectra	   produced	   include	   a	  water	   peak	   at	   a	   certain	   resonance	   that	   comes	  from	  the	  samples.	  This	  was	  suppressed	   in	  order	   to	   interpret	   the	  obtained	  data	  more	  precisely.	   The	   water	   suppression	   resonances	   were	   centred	   at	   4.7ppm	   by	   the	  application	  of	  a	  pre-­‐saturation	  pulse	  during	   the	  RD	  of	  3s.	  The	  obtained	  spectra	  were	  phased	  to	  ensure	  all	  spectra	  where	  upright.	  They	  were	  then	  baseline	  corrected	  to	  the	  internal	   standard	  of	  TSP	  at	   δ0	  ppm	   to	   ensure	   the	   same	  baseline	   for	   all	   spectra.	  This	  minimises	   the	   errors	   during	   data	   analyses.	   The	   1H	  NMR	   spectra	   obtained	  were	   then	  imported	   into	  the	  MATLAB®	  (R2010b,	  MathWorks,	  USA).	  The	  resonance	  assignments	  of	  the	  spectra	  were	  made	  from	  previous	  studies	  in	  the	  literature	  (Seierstad	  et	  al.,	  2008,	  Wishart	  et	  al.,	  2009).	  
	  
3.3.5	  Data	  analysis	  All	  processing	  of	  data	  was	  done	   in	  MATLAB	   (R2010b,	  Mathworks,	  USA).	  The	   spectra	  were	   phased,	   baseline	   corrected	   and	   normalised	   using	  median	   fold	   change	   (mfc)	   in	  MATLAB	   with	   an	   in-­‐house	   code	   (written	   by	   Dr	   Tim	   Ebbels,	   Dr	   Jake	   Pearce	   and	   Dr	  Rachel	  Cavill).	  Full	  resolution	  data	  was	  used	  for	  analysis.	  Multivariate	  analyses	   in	  the	  form	  of	  unsupervised	  PCA	  were	   carried	  out	  using	   the	   Soft	   Independent	  Modelling	  of	  Class	   Analogy	   Software,	   SIMCA-­‐P	   (Umetrics,	   Sweden)	   to	   identify	   outliers	   and	   innate	  clustering	  trends.	  The	  water	  signal	  between	  4.5-­‐5ppm	  was	  removed	  prior	  to	  the	  data	  analysis	   in	   SIMCA.	   The	   supervised	   technique	   of	   O-­‐PLS	   was	   used	   after	   PCA	   to	  investigate	   the	  metabolic	   class	   separation	   by	   identifying	   the	  metabolites	   responsible	  for	   the	   discrimination.	   A	   7-­‐fold	   cross	   validation	   method	   was	   used	   to	   assess	   the	  robustness	  of	  the	  models	  used	  in	  the	  analysis	  (Cloarec	  et	  al.,	  2005).	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The	  metabolite	  integrals	  were	  calculated	  using	  an	  in-­‐house	  code	  (written	  by	  Dr	  Hector	  Keun,	  Dr	  Tim	  Ebbels,	  Dr	  Jake	  Pearce,	  Dr	  Rachel	  Cavill)	  in	  MATLAB.	  The	  mean,	  standard	  deviation	   (SD)	   and	   standard	  errors	   (SEs)	  of	   the	  metabolite	   integrals	  were	   calculated	  using	  Microsoft	   Office	   Excel	   (2007).	   The	   differences	   between	   the	  metabolites	   in	   the	  various	   cell	   lines	   were	   compared	   using	   the	   mean	   values	   of	   the	   intensities	   of	   the	  metabolites	  detected.	  The	  unpaired	  student	  t-­‐test	  and	  the	  one-­‐way	  analysis	  of	  variance	  (ANOVA)	   tests	   were	   performed	   to	   evaluate	   the	   statistical	   significance	   between	   the	  different	   cell	   lines.	   Tests	  were	   considered	   to	  be	   statistically	   significant	  when	   the	  p	   –	  value	  was	  ≤	  0.05.	  
	  
3.3.6	  The	  NCI	  60	  panel	  The	  United	  States	  (U.S.)	  National	  Cancer	  Institute	  panel	  of	  60	  human	  cancer	  cell	   lines	  (NCI60)	  which	  is	  used	  to	  screen	  anticancer	  agents	  in	  order	  to	  assess	  chemotherapeutic	  responses	   was	   used	   to	   correlate	   the	   changes	   in	   ratios	   of	   certain	   metabolites	  (http://www.sanger.ac.uk/genetics/CGP/NCI60/).	  This	  cell	  line	  panel	  of	  over	  100,000	  chemical	  compounds	  offers	  an	  extensive	  database	  in	  which	  four	  of	  the	  cell	  lines	  used	  in	  this	  study	  were	  analysed	  (Lee	  et	  al.,	  2007,	  Shoemaker,	  2006).	  	  
3.3.7	  MetaboAnalyst	  and	  Metabolite	  Set	  Enrichment	  Analysis	  (MSEA)	  The	  metabolic	  data	  obtained	  from	  the	  1H	  NMR	  experiments	  were	  also	  analysed	  using	  MetaboAnalyst,	   which	   is	   a	   web-­‐based	   service	   for	   the	   analysis	   of	   metabolomic	   data	  (http://www.metaboanalyst.ca/MetaboAnalyst/faces/Home.jsp)	   (Xia	   et	   al.,	   2009,	   Xia	  and	   Wishart,	   2011).	   Additionally,	   metabolite	   set	   enrichment	   analysis	   (MSEA)	  (http://www.msea.ca/MSEA/)	   was	   performed	   in	   order	   to	   identify	   biologically	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meaningful	   information	   patterns	   or	   pathways	   that	   are	   augmented	   in	   the	   identified	  metabolites	   from	   the	   cell	   line	   NMR	   experiments.	   This	   has	   the	   potential	   benefit	   of	  identifying	  subtle	  changes	  among	  related	  metabolites.	  The	  enrichment	  algorithm	  used	  for	  the	  MSEA	  was	  the	  Over	  Representation	  Analysis	  (ORA),	  which	  entails	  the	  inputting	  of	  metabolite	  lists.	  The	  ORA	  tests	  if	  a	  certain	  group	  of	  metabolites	  are	  represented	  more	  than	  expected	  by	  chance	   from	  the	   list	  of	  metabolites	   that	  are	   inputted.	  This	  pathway	  analysis	  uses	  information	  from	  the	  Kyoto	  Encyclopaedia	  of	  Genes	  and	  Genomes	  (KEGG)	  database	  (Xia	  and	  Wishart,	  2011).	  	  
3.3.8	  Gene	  Set	  Enrichment	  Analysis	  (GSEA)	  The	   gene	   set	   enrichment	   analysis	   (GSEA)	   is	   a	   computational	   process	   that	   allows	   the	  determination	  of	  gene	  enrichment	  profiles	  from	  data,	  which	  is	  widely	  used	  in	  genomics	  with	  some	  insights	  into	  cancer	  related	  data	  sets	  (Subramanian	  et	  al.,	  2005).	  It	  is	  freely	  available	  on	  the	  World	  Wide	  Web	  at	  http://www.broadinstitute.org/gsea/index.jsp.	  It	  is	  used	  to	  identify	  if	  statistically	  significant	  differences	  between	  biological	  states	  occur.	  	  The	   gene	   sets	   used	   in	   the	   gene	   enrichment	   analysis	   are	   from	   previously	   published	  material	   or	   from	   experimental	   data	   (Subramanian	   et	   al.,	   2005).	   A	   molecular	   profile	  data	  set	  and	  a	  gene	  set	  database	  are	  used	  to	  run	  the	  GSEA	  software	  in	  order	  to	  detect	  enriched	  gene	  sets.	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3.4	  Results	  
3.4.1	  Identification	  of	  metabolic	  differences	  between	  the	  cell	  lines	  A	   total	  of	   forty-­‐seven	   tumour	   tissue	  extract	   samples	   from	   the	  CRC	  cell	   lines	  SW-­‐620,	  HCT-­‐116,	   HT-­‐29	   and	   COLO-­‐205	   were	   analysed.	   A	   representative	   median	   spectrum	  form	  the	  SW-­‐620	  cell	  line	  is	  shown	  in	  Figure	  3.1.	  The	  PCA	  scores	  plot	  showed	  distinct	  clustering	  of	   the	   individual	  samples	  within	  the	  same	  cell	   lines,	  suggesting	  similarities	  within	  each	  group	  of	  cell	  lines	  as	  well	  as	  distinct	  separation	  between	  the	  different	  cell	  lines	  (Figure	  3.2).	  	  
	  
	  
Figure	  3.1	  Representative	  1H	  NMR	  median	  spectra	  of	  the	  SW-­‐620	  aqueous	  tumour	  extract.	  The	  
water	  peak	  region	  has	  been	  removed	  from	  δ	  4.6-­‐5.	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Figure	  3.2	  1H	  NMR	  Principal	  component	  analysis	  (PCA)	  univariant	  (uv)	  scores	  plot	  of	  all	  samples.	  
Each	  point	  on	  the	  scores	  plot	  represents	  a	  single	  sample.	  The	  number	  of	  days	  within	  which	  each	  
tumour	  was	  harvested	  from	  the	  time	  of	  implant	  is	  used	  to	  represent	  each	  cell	  line	  group:	  35	  days	  
=	  SW-­‐620,	  33	  days	  =	  HCT-­‐116,	  14	  &	  7	  days	  =	  HT-­‐29	  and	  13	  days	  =	  COLO-­‐205.	  	  
	  
Twenty-­‐eight	  metabolites	  were	   identified.	  Visual	   inspection	  of	   the	  spectra	   revealed	  a	  number	  of	  metabolites	  within	  the	  different	  cell	  lines	  were	  obtained	  as	  shown	  in	  Table	  3.2.	  The	  highest	  levels	  of	  metabolites	  observed	  were	  taurine	  (δ	  3.42)	  and	  myoinositol	  (δ3.27).	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Although	  there	  were	  higher	  levels	  of	  myoinositol	  in	  the	  HCT-­‐116	  cell	  line	  compared	  to	  the	   HT-­‐29	   cell	   line,	   this	   was	   not	   statistically	   significant	   (p	   =	   0.06)	   but	   had	   a	   trend	  towards	   significance	  with	   higher	   levels	   also	   being	   present	   in	   COLO-­‐205	   and	   SW620	  compared	   with	   HT29.	   So	   also,	   the	   taurine	   levels	   were	   not	   statistically	   significant	  between	  the	  different	  cell	  line	  groups	  (p	  =	  0.19).	  	  	  The	  lowest	  metabolite	  levels	  were	  imidazole	  (δ8.35),	  uracil	  (δ5.8),	  formate	  (δ8.46)	  and	  fumarate	   (δ6.52).	   Specific	   changes	   that	   were	   statistically	   significant	   in	   the	   1H	   NMR	  spectra	   were	   seen	   in	   the	   choline	   metabolites,	   which	   resonate	   at	   δ3.2	   ppm.	   These	  consist	  of	  choline,	  phosphocholine	  (PC)	  and	  glycerophosphocholine	  (GPC)	  (Figure	  3.3).	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Table	   3.2	   The	   identified	   metabolites	   from	   the	   different	   colorectal	   cancer	   cell	   lines	   with	   the	  
chemical	  shift	  regions	  of	  the	  integral	  values,	  showing	  the	  mean	  integral	  values	  for	  each	  cell	  line	  
and	  the	  p-­‐value	  of	  the	  ANOVA	  tests.	  
Metabolites	   Regions	  
integrated	  
Mean	   Mean	  values	  for	  each	  cell	  line	   ANOVA	   p	   -­‐
value	  
	   SW620	   HCT116	   HT29	   COLO205	   	  Choline	   3.2-­‐3.215	   5.02	   6.28	   3.16	   3.89	   5.78	   <0.05	  PC	   3.22-­‐3.23	   6.96	   9.51	   6.17	   7.97	   5.53	   <0.05	  GPC	   3.23-­‐3.24	   4.78	   2.75	   1.67	   9.61	   4.77	   <0.05	  Lactate	   1.33-­‐1.35	   0.36	  	   0.39	   0.35	   0.31	   0.38	   >0.05	  Myoinositol	   3.26-­‐3.29	   13.90	   14.20	   16.10	   11.20	   14.20	   0.06	  Tyrosine	   7.19-­‐7.22	   0.85	   0.84	   0.86	   0.76	   0.88	   0.67	  Formate	   8.456-­‐8.47	   0.11	   0.24	   0.40	   0.17	   0.05	   0.44	  Citrate	   2.79-­‐2.81	   0.57	   0.54	   0.63	   0.53	   0.58	   0.35	  Glucose	   5.23-­‐5.26	   0.35	   0.38	   0.51	   0.07	   0.40	   0.25	  Valine	   1.04-­‐1.05	   1.97	   1.88	   1.95	   2.03	   2.01	   0.57	  Fumarate	   6.52-­‐6.53	   0.09	   0.09	   0.08	   0.10	   0.08	   0.18	  Glutamate	   2.33-­‐2.375	   4.58	   4.51	   4.54	   4.50	   4.67	   0.95	  Alanine	   1.47-­‐1.5	   5.78	  	   5.75	   5.80	   5.51	   5.92	   0.82	  Taurine	  	   3.40-­‐3.44	   30.60	   31.37	   35.37	   24.95	   31.00	   0.19	  Asparagine	   2.96-­‐2.98	   0.34	   0.33	   0.35	   0.34	   0.34	   0.99	  Imidazole	   8.34-­‐8.35	   0.02	   0.02	   0.02	   0.03	   0.02	   0.19	  Scyllo-­‐inositol	   3.355-­‐3.36	   0.54	   0.57	   0.57	   0.48	   0.54	   0.26	  Histidine	   7.09-­‐7.11	   0.23	   0.21	   0.23	   0.20	   0.23	   0.42	  Glycine	   3.56-­‐3.57	   4.66	   4.81	   4.86	   4.23	   4.72	   0.33	  Succinate	   2.4-­‐2.415	   0.70	   0.65	   0.38	   1.31	   0.57	   0.16	  Creatine	   3.92-­‐3.94	   2.68	   2.75	   2.35	   2.54	   2.86	   0.79	  Acetate	   1.90-­‐1.93	   2.09	   2.30	   1.47	   2.94	   1.83	   0.35	  Lysine	   1.68-­‐1.76	   4.84	   4.52	   4.74	   4.95	   4.99	   0.52	  Phenylalanine	   7.32-­‐7.34	   0.50	   0.48	   0.52	   0.42	   0.54	   0.35	  Glutamine	   2.44-­‐2.45	   0.73	   0.69	   0.71	   0.79	   0.73	   0.38	  Aspartate	   2.68-­‐2.72	   0.35	   0.36	   0.37	   0.32	   0.35	   0.15	  Uracil	   5.81-­‐5.82	   0.15	   0.22	   0.17	   0.05	   0.16	   0.42	  Isoleucine	   2.33-­‐2.37	   6.01	   5.64	   6.03	   5.84	   6.28	   0.63	  
 If	  P-­‐value	  <	  0.05,	  this	   indicates	  there	  is	  a	  significant	  difference	  between	  the	  groups	  on	  that	  metabolite.	  Values	   divided	   by	   108.	   The	   rows	   highlighted	   in	   blue	   show	   statistically	   significance	   and	   the	   ones	   in	  highlighted	  in	  orange	  are	  close	  to	  significance.	  	  
	  
	   	  









Figure	  3.3	  1H	  NMR	  mean	  spectra	  of	  all	  the	  cell	  lines	  showing	  the	  region	  of	  the	  choline	  metabolites	  
(δ	  3.22-­‐3.24).	  	  	  There	  was	  a	  significant	  statistical	  difference	  between	  the	  groups	  in	  choline,	  PC	  and	  GPC	  with	  a	  p-­‐value	  of	  <	  0.05.	  There	  were	  higher	  levels	  of	  PC	  and	  lower	  levels	  in	  GPC	  in	  the	  SW-­‐620,	  HCT-­‐116	   and	   the	  COLO-­‐205	   cell	   lines.	   The	   levels	   of	   PC	  were	   three	   and	  half	  times	  higher	  compared	  with	  GPC	  in	  the	  SW-­‐620	  and	  the	  HCT-­‐116	  cell	  lines.	  The	  HT-­‐29	  cell	  lines	  on	  the	  other	  hand	  had	  higher	  levels	  of	  GPC	  compared	  with	  PC.	  There	  was	  also	  a	   significant	  difference	  with	   the	  PC:	  GPC	  ratio	   (p	  <	  0.05)	  between	   the	  cell	   lines,	  with	  higher	   levels	   in	   the	  SW-­‐620	  and	  the	  HCT-­‐116	  cell	   lines	  (Figure	  3.4).	  When	  PCA	  were	  carried	  out	  to	  correlate	  group	  distinctions	  of	  cell	  lines	  based	  on	  high	  and	  low	  levels	  of	  PC:	   GPC	   ratios,	   the	   SW-­‐620	   and	   the	   HCT-­‐116	   cell	   lines	   clustered	   together	  while	   the	  COLO-­‐205	  and	  the	  HT-­‐29	  cell	  lines	  also	  clustered	  together	  (Figure	  3.5).	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(c)	  	  	  	  	  	  	  	  	  
Figure	   3.4	   The	   chemical	   structures	   of	   the	   choline	   metabolites	   from	   ChemSpider.	   The	   graphs	  
represent	   the	  differences	   in	   the	  relative	  concentrations	  of	   (a)	  choline,	   (b)	  phosphocholine	  (PC)	  
and	  glycerophosphocholine	  (GPC)	  levels	  between	  the	  different	  cell	   lines	  and	  (c)	  the	  ratio	  of	  PC:	  
GPC	  in	  the	  different	  cell	  lines.	  The	  values	  represent	  the	  peak	  integrations	  of	  each	  metabolite.	  The	  









Figure	  3.5	  PCA	  3-­‐D	  scores	  plot	  showing	  the	  distribution	  of	  the	  cell	  lines	  according	  to	  high	  and	  low	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The	  visual	   1H	  NMR	  spectral	  changes	   in	  choline	  metabolites	  between	   the	  SW-­‐620	  and	  the	  HCT-­‐116	  cell	  lines	  are	  shown	  in	  Figure	  3.6.	  These	  cell	  lines	  (SW-­‐620	  and	  HCT-­‐116)	  are	   the	   poorly	   differentiated	   adenocarcinoma	   cell	   lines	   and	   the	   COLO-­‐205	   being	  derived	  from	  a	  Dukes	  D	  tumour.	  Hence,	  the	  higher	  levels	  of	  choline,	   lactate	  and	  PC	  in	  these	  cell	  lines	  may	  be	  due	  to	  their	  tumourgenicity.	  	  	  	  
	  	  	  	  	  	  	  	  
Figure	  3.6	  The	  expanded	  1H	  NMR	  region	  of	  the	  choline	  metabolites	  showing	  PC,	  GPC	  and	  choline	  
levels	  in	  the	  SW-­‐620	  (blue)	  and	  HCT-­‐116	  (red)	  cell	  lines.	  	  	  Interestingly,	  changes	   in	   the	   levels	  acetate	  (δ1.92)	  (Figure	  3.7)	  and	  succinate	  (δ2.41)	  were	   highest	   in	   the	   HT-­‐29	   cell	   line,	   which	   is	   a	   well-­‐differentiated	   tumour	   cell	   line.	  Creatine	  and	  glutamine	  on	   the	  other	  hand	  had	  higher	   levels	   in	  COLO205	  and	  SW620	  than	  in	  HCT116	  and	  HT29.	  There	  were	  no	  other	  statistically	  significant	  differences	  in	  the	   levels	   of	   any	   other	  metabolites	   between	   the	   cell	   line	   groups.	   The	   findings	   of	   the	  changes	   between	   the	   cell	   lines	   from	   these	   metabolites	   also	   shown	   above	   are	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Figure	  3.7	  The	  changes	  in	  acetate	  (δ1.92)	  between	  the	  different	  cell	  lines.	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  (a)	  	  	  	  	  (b)	  	  	  	  	  	  (c)	  	  	  	  	  
(d)	  	  
	  
Figure	  3.8	  Loadings	  plot	   from	   the	  O-­‐PLS-­‐DA	  models	  with	  colour	  correlations	  between	  different	  
call	   lines	   (a	   –	   d).	   The	   red	   colour	   indicates	   a	   high	   correlation	   whereas	   blue	   indicates	   no	  
correlation	  in	  the	  sample	  sets.	  The	  horizontal	  axis	  represents	  the	  chemical	  shift	  (ppm).	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Normal	   cells	   are	   known	   to	   consume	   glucose	   and	   produce	   lactate	   as	   a	   by-­‐product.	  Tumour	  cells	  as	  in	  these	  cell	  lines	  tend	  to	  consume	  glucose	  rapidly	  and	  produce	  large	  amounts	   of	   lactate	   as	   shown	   in	   the	   levels	   of	   these	   metabolites	   in	   the	   1HNMR	  experiments	  here	  (Figure	  3.9).	  	  	  (a)	  	  	  	  	  	  	  	  (b)	  	  	  	  	  	  	  	  	  
Figure	  3.9	  The	   levels	   of	   lactate	   and	   glucose	  produced	   (a)	  within	   the	  panel	   of	   cell	   lines,	   (b)	   for	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3.4.2	  National	  cancer	  institute	  panel	  of	  human	  cancer	  cell	  line	  microarray	  data	  	  The	  NCI	  60	  panel	  was	  used	  to	  evaluate	  the	  correlation	  of	  metabolites	  with	  the	  cell	  lines	  according	  to	  their	  PC:	  GPC	  ratio	  as	  displayed	  in	  Table	  3.3.	  A	  negative	  correlation	  was	  seen	   in	   most	   of	   the	   metabolites	   in	   the	   NCI	   60	   metabolite	   list.	   This	   represented	   a	  decrease	  in	  the	  metabolite	  levels	  between	  the	  cell	  lines	  with	  high	  PC:	  GPC	  ratios	  (SW-­‐620	  and	  HCT-­‐116)	   compared	  with	   the	   cell	   lines	  with	   low	  PC:	  GPC	   ratios	   (HT-­‐29	  and	  COLO-­‐205).	   These	   were	   mostly	   in	   sugars	   and	   amino	   acid	   metabolites.	   There	   was	  however	   a	   strong	   positive	   correlation	   between	   the	   cell	   lines	   and	   the	   metabolites	  ornithine,	  5'-­‐s-­‐methyl-­‐5'-­‐thioadenosine	  and	  the	  pentose	  phosphate	  pathway.	  	  
3.4.3	  Metabolite	  Set	  Enrichment	  Analysis	  (MSEA)	  To	  detect	  biologically	  significant	  metabolic	  pathways	  from	  the	  identified	  metabolites	  of	  the	   NMR	   analysis,	   metabolite	   set	   enrichment	   analysis	   (MSEA)	   was	   carried	   from	  publically	   available	   data.	   For	   the	   data	   processing	   of	   the	  MSEA,	   28	  metabolites	  were	  selected	  from	  the	  NCI	  60	  panel	  (see	  Appendix	  I).	  The	  metabolites	  that	  were	  enriched	  were	   notably	   from	   protein	   biosynthesis,	   phenylacetate	   metabolism	   and	   the	  metabolism	   of	   methionine,	   phenylalanine,	   tyrosine,	   and	   glycerol	   phosphate	   (Figure	  3.10).	   However,	   only	   the	   protein	   biosynthesis	   metabolites	   were	   significantly	   over	  represented	   with	   a	   p-­‐value	   of	   0.01.	   Additionally,	   the	   analysis	   of	   the	   metabolic	  pathways	  showed	  that	  the	  top	  five	  pathways	  were	  again	  amino	  acid	  pathways.	  These	  included	   important	   pathways	   that	   are	   indicated	   in	   cancer	   metabolism	   such	   as	  aminoacyl	  biosynthesis,	   the	  pentose	  phosphate	  pathway,	  phenylalanine,	   tyrosine	  and	  tryptophan	  biosynthesis	  as	  well	  as	  nitrogen	  and	  methionine	  metabolism.	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Table	  3.3	  Showing	  the	  normalized	  values	  of	  metabolites	  from	  the	  NCI	  60	  panel.	  The	  SW-­‐620	  and	  
HCT-­‐116	  have	  a	  high	  PC:	  GPC	  ratio	  and	  COLO-­‐205	  and	  HT-­‐29	  have	  a	  low	  PC:	  GPC	  ratio.	   	  The	  log2	  
fold	   change	   represents	   the	   changes	   in	   the	   cell	   lines	   based	   on	   their	   PC:	   GPC	   ratios.	   	   Negative	  
(green)	  log2	  fold	  change	  represents	  a	  decrease	  (low	  correlation)	  in	  metabolite	  changes	  between	  
the	  two	  PC:	  GPC	  cell	  line	  groups	  and	  a	  positive	  value	  (orange)	  represents	  a	  high	  correlation.	  The	  
isobars	   represent	   peaks	   that	   have	   the	   same	  mass,	   therefore	   difficult	   to	   distinguish	   from	   each	  
other.	  
Metabolite	   SW-­‐620	   HCT-­‐116	   HT-­‐29	   COLO-­‐205	   Log2foldchange	  
Gulono-­‐1,4-­‐lactone	   0.03	   0.03	   2.68	   0.43	   -­‐5.65	  
Mannose-­‐6-­‐phosphate	   0.22	   0.05	   6.20	   0.46	   -­‐4.62	  
N	  ('6)-­‐trimethyl-­‐l-­‐lysine	   0.05	   0.05	   0.65	   1.11	   -­‐4.17	  
6-­‐phosphogluconic	  acid	   0.11	   0.34	   6.40	   0.75	   -­‐3.99	  
Ribulose-­‐5-­‐phosphate	   0.26	   0.083	   4.97	   0.27	   -­‐3.94	  
Octopamine	   0.11	   0.11	   1.53	   0.24	   -­‐2.97	  
(P-­‐Hydroxyphenyl)lactic	  acid	   0.07	   0.17	   1.24	   0.37	   -­‐2.73	  
Uracil	   0.01	   0.30	   1.25	   0.76	   -­‐2.68	  
Xanthosine	   0.10	   0.10	   0.62	   0.62	   -­‐2.53	  
Isobar	   3:	   inositol	   1-­‐phosphate,	  
mannose	   6-­‐phosphate,	   glucose	  
6-­‐phosphate,	   D-­‐mannose	   1-­‐
phosphate,	   alpha-­‐D-­‐glucose	   1-­‐
phosphate,	   alpha-­‐D-­‐galactose	  1	  
phosphate	  
0.34	   0.72	   4.63	   0.85	   -­‐2.36	  
D-­‐ribose	   0.14	   0.33	   0.64	   0.99	   -­‐1.79	  
Gluconic	  acid	   0.11	   0.26	   0.34	   0.82	   -­‐1.65	  
Methionine	   0.12	   0.63	   0.96	   1.26	   -­‐1.57	  
Inositol	  1-­‐phosphate	   0.23	   0.46	   1.00	   0.92	   -­‐1.48	  
Phenylalanine	   0.20	   0.69	   1.22	   1.13	   -­‐1.40	  
Leucine	   0.14	   0.63	   0.85	   1.13	   -­‐1.36	  
Serine	   0.29	   0.96	   1.49	   1.59	   -­‐1.30	  
Anthranilic	  acid	   0.14	   0.69	   1.12	   0.91	   -­‐1.30	  
N-­‐acetylneuraminic	  acid	   0.25	   0.70	   1.11	   1.24	   -­‐1.30	  
Valine	   0.16	   0.66	   1.08	   0.93	   -­‐1.29	  
2'-­‐deoxyuridine	   0.10	   0.10	   0.23	   0.26	   -­‐1.26	  
Tyramine	   0.11	   0.78	   0.88	   1.22	   -­‐1.22	  
Sn-­‐Glycerol	  3-­‐phosphate	   0.35	   0.44	   0.91	   0.94	   -­‐1.21	  
Isobar	  6:	  valine,	  betaine	   0.19	   0.82	   1.05	   1.06	   -­‐1.06	  
Tyrosine	   0.23	   0.87	   1.096	   1.18	   -­‐1.04	  
Isobar	   35:	   D-­‐arabinose	   5-­‐
phosphate,	   D-­‐ribulose	   5-­‐
phosphate,	   alpha-­‐D-­‐ribose-­‐5-­‐
phosphate	  
0.77	   1.27	   1.91	   2.21	   -­‐1.02	  
Ornithine	   2.13	   1.23	   0.65	   0.93	   1.09	  
5'-­‐s-­‐methyl-­‐5'-­‐thioadenosine	   0.66	   1.27	   0.42	   0.38	   1.28	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Figure	  3.10	  The	  summary	  plot	  of	  the	  over	  representation	  analysis	  using	  the	  MetaboAnalyst.	  The	  
red	  colour	  represents	  values	  closer	  to	  significance	  and	  the	  yellow	  colour	  less	  significant.	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3.4.4	  Gene	  expressions	   in	  cell	   lines	  with	  high	  PC:	  GPC	  ratios	  using	  gene	  set	  enrichment	  
analysis	  (GSEA)	  The	  GSEA	  identified	  two	  genesets,	  McGarvey	  and	  Lopes	  that	  are	  methylated	  in	  CRC.	  In	  essence	  the	  GSEA	  data	  showed	  that	  the	  cell	  lines	  that	  were	  high	  in	  PC:	  GPC	  had	  higher	  expressions	   of	   the	   genes	   involved	   in	   the	   DNA	  methylation-­‐dependent	   silencing	   that	  relates	  to	  the	  protein,	  Kaiso.	  Kaiso	  is	  a	  protein	  that	  is	  a	  transcriptional	  repressor	  in	  CRC	  that	   can	   bind	   to	   methylated	   clusters	   of	   CpG	   dinucloetides,	   where	   the	   cytosine	  nucleotide	  is	  next	  to	  guanine	  (Lopes	  et	  al.,	  2008)	  (Figure	  3.11).	  	  	  This	  process	  of	  methylation	  and	  binding	  is	  a	  way	  of	  silencing	  DNA	  (Prokhortchouk	  and	  Hendrich,	  2002).	  The	  genes	  involved	  in	  tumour	  suppression	  are	  over	  expressed	  when	  the	  Kaiso	  gene	  is	  absent	  as	  in	  two	  of	  the	  cell	  lines	  that	  were	  used	  in	  this	  1	  H	  NMR	  study,	  which	   have	   a	   high	   PC:	   GPC	   ratio	   (HCT-­‐116	   and	   SW-­‐620).	   Some	   of	   the	   identified	  enriched	  genes	  from	  the	  McGarvey	  geneset	  (McGarvey	  et	  al.,	  2008)	  are	  involved	  with	  processes	   such	   as	   apoptosis,	   Wnt	   signalling	   pathways	   and	   transcription	   roles	   (see	  Appendix	  I).	  These	  processes	  are	  all	  attributed	  to	  cancer	  pathophysiology.	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  (a)	  	  	  	  	  	  	  	  	  	  	  	  	  (b)	  	  	  	  	  	  	  	  	  
Figure	   3.11	   The	   heat	   maps	   of	   the	   gene	   expression	   from	   the	   (a)	   Lopes	   and	   the	   (b)	   McGarvey	  
genesets	  involved	  in	  the	  enrichment	  of	  the	  gene	  dataset	  with	  high	  PC:	  GPC.	  	   	  
SW620	   	  	  	  	  	  	  HCT116	   HT29	   	  	  	  COLO205	  
gene	  expression	  from	  McGarvey	  geneset	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3.5	  Discussion	  The	  cell	   lines	  used	  in	  this	  chapter	  gave	  distinct	  phenotypes	  using	  metabolic	  profiling.	  Cell	  lines	  offer	  a	  good	  exploratory	  route	  into	  establishing	  metabolic	  profiles	  of	  disease	  that	  otherwise	  take	  time	  to	  become	  apparent	  in	  humans.	  It	  is	  well	  known	  that	  tumour	  cells	  have	  a	  high	  turnover	  rate.	  Hence,	  the	  membrane	  phospholipid	  metabolism	  plays	  a	  crucial	  role	  in	  cancer	  pathogenesis.	  The	  metabolic	  profiling	  studies	  carried	  out	  in	  this	  chapter	   depict	   changes	   in	   choline	   metabolites,	   which	   are	   associated	   with	   cell	  membrane	   synthesis.	   Choline	   is	   present	   in	   all	   tissues,	   mostly	   in	   the	   form	   of	  phospholipids	   (Dieterle	   et	   al.,	   2006).	   Cells	   must	   be	   able	   to	   produce	   additional	  phospholipids	  prior	   to	  cell	  division	   in	  order	   to	  be	  able	   to	  provide	  enough	  membrane	  surface	  for	  subsequent	  cell	  formation	  (Jackowski,	  1994).	  This	  may	  explain	  the	  increase	  in	   phospholipids	   seen	   in	   all	   the	   cell	   lines	   used	   here.	   Phospholipid	   turnover	   is	   high	  during	  the	  G1	  phase	  when	  cells	  increase	  in	  size	  and	  the	  accumulation	  of	  phospholipid	  in	  the	  S	  phase	  (during	  DNA	  replication)	  is	  associated	  with	  the	  cessation	  of	  phospholipid	  turnover	  at	  the	  G1-­‐S	  boundary	  (Figure	  3.12)	  (Jackowski,	  1994).	  	  	  	  	  	  	  	  	  
Figure	  3.12	  Schematic	  diagram	  of	  the	  cell	  cycle.	  Abbreviations:	  	  G0	  –	  Gap	  zero	  (resting	  phase	  of	  
cell	  cycle),	  G1	  –	  Gap	  1,	  G2	  –	  Gap	  2,	  S	  –	  Synthesis,	  M	  –	  Mitosis.	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Magnetic	  resonance	  studies	  have	  identified	  choline	  phospholipid	  as	  a	  metabolite	  with	  increased	  levels	  in	  malignancy	  (Mori,	  2004).	  Choline	  is	  an	  essential	  component	  for	  the	  synthesis	   of	   phosphatidylcholine	   (PtC),	   which	   is	   a	   major	   structural	   phospholipid	  component	   of	   cell	   membranes.	   Hence,	   choline	   is	   an	   essential	   component	   to	   the	  function	  of	  cell	  membranes	  (Al-­‐Saffar	  et	  al.,	  2006,	  Kouji,	  2009).	  PC	  is	  a	  precursor	  and	  a	  breakdown	   product	   of	   PtC,	   which	   is	   a	   major	   cell	   membrane	   component.	   This	   is	   in	  comparison	  with	  GPC	  which	  is	  only	  a	  breakdown	  product	  of	  cell	  membranes	  (Glunde,	  2006).	   The	   enzyme	   choline	   kinase	   catalyses	   the	   reaction	   for	   the	   phosphorylation	   of	  choline	  by	  ATP	  to	  produce	  PC	  in	  the	  Kennedy	  pathway	  (Kouji,	  2009).	  Choline,	  PC	  and	  GPC	  are	  essential	  substrates	  in	  lipid	  metabolism	  and	  the	  levels	  of	  choline	  increase	  with	  tumour	  proliferation	  (Seierstad	  et	  al.,	  2007).	  	  	  Recent	  studies	  using	  MAS	  1H	  NMR	  on	  rectal	   tissue	  has	  shown	  significant	  elevation	   in	  choline	  metabolites	   in	  malignant	   compared	   to	   normal	   tissue	   (Jordan,	   2009).	   Human	  prostatic	  epithelial	  cells	  also	  display	  an	   increase	   in	  total	  choline	  compounds	  with	  the	  progression	   to	   a	   malignant	   phenotype.	   Metastatic	   prostate	   cancer	   cells	   have	   been	  shown	  to	  have	  significantly	  higher	  choline	   levels	  compared	  to	  normal	  prostate	   tissue	  (Ackerstaff,	  2001,	  Glunde,	  2006).	  	  The	   increase	   in	   PC	   and	   PC:	   GPC	   ratio	   is	   associated	   with	   malignant	   transformation	  (Podo,	  1999).	  High	  PC:	  GPC	  ratios	  were	  observed	  here	  in	  the	  SW-­‐620	  and	  the	  HCT-­‐116	  cell	  lines.	  	  PC	  in	  this	  study	  was	  shown	  to	  be	  highest	  in	  the	  SW-­‐620	  cell	  line,	  which	  was	  originally	  derived	  from	  a	  poorly	  differentiated	  metastatic	  cancer	  lymph	  node.	  Both	  the	  SW-­‐620	  and	  the	  HCT-­‐116	  cell	  lines	  had	  high	  PC	  levels	  with	  low	  GPC	  levels	  which	  are	  in	  keeping	  with	  the	  other	  tumour	  studies	  and	  these	  cell	  lines	  being	  worse	  tumour	  grade.	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Treatment	   of	   HCT-­‐116	   with	   mitogen-­‐activated	   protein	   kinase	   (MAPK)	   signalling	  inhibitors	  has	  been	  shown	  to	  decrease	   the	   levels	  of	  PC,	   thus	  prompting	   the	  potential	  application	  of	  PC	  as	  a	  biomarker	  (Beloueche-­‐Babari	  et	  al.,	  2005).	  High	  levels	  of	  GPC	  and	  PC	   were	   found	   in	   the	   HT-­‐29	   xenografts	   suggesting	   that	   there	   is	   increased	   tumour	  proliferation	   and	   cell	   membrane	   turnover	   through	   the	   PtC	   pathway	   in	   xenografts	  (Podo,	   1999).	   The	   increase	   in	   PC	   may	   be	   due	   to	   the	   increased	   choline	   uptake	   and	  increased	  choline	  kinase	  activity	  (Assfalg	  et	  al.,	  2008).	  The	  over-­‐expression	  of	  choline	  kinase,	  which	  is	  the	  first	  enzyme	  in	  the	  Kennedy	  pathway	  for	  the	  synthesis	  of	  PtC,	  was	  found	  to	  be	  47	  per	  cent	  higher	  in	  HT-­‐29	  colon	  cell	  lines	  compared	  to	  normal	  cells.	  This	  has	   also	   been	   demonstrated	   in	   human	   mammary	   cells,	   prostate	   and	   lung	   tumour	  samples	  (Ramirez	  de	  Molina,	  2002).	  	  	  Consequently,	   affecting	   the	   function	   of	   choline	   kinase	   had	   an	   impact	   on	   the	  proliferation	   and	   invasion	   of	   metastatic	   breast	   cancer	   cells	   (Glunde,	   2006).	   Thus,	  changes	   in	   choline	   kinase	   expression	   associated	   with	   PC	   levels	   are	   linked	   to	  invasiveness	  of	  the	  tumour	  (Shah	  et	  al.,	  2010).	  This	  further	  suggests	  a	  potential	  role	  for	  choline	  kinase	  inhibitors	  in	  cancer	  treatment.	  It	  may	  however	  be	  that	  multiple	  targets	  in	  the	  choline	  metabolism	  pathway	  and	  other	  metabolic	  pathways	  may	  be	  important	  in	  the	  treatment	  of	  cancer.	  	  	  	  The	   pathogenesis	   of	  most	   cancers	   is	   associated	  with	   the	   loss	   of	   function	   of	   the	   p53	  gene	   (Vogelstein	  and	  Kinzler,	  1992).	  The	  analysis	  of	   the	  mutations	   in	  oncogenes	  and	  tumour	  suppressor	  genes	  in	  human	  cell	  lines	  reflects	  the	  situation	  in	  primary	  tumours	  (Berglind,	  2008).	  The	  p53	  protein	  is	  a	  regulator	  of	  transcription	  that	  contributes	  to	  the	  development	  of	  human	  cancers	  when	  there	  is	  a	  loss	  of	  its	  tumour	  suppressor	  pathway	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(Ryan,	  2001).	  It	  is	  the	  most	  common	  molecular	  abnormality	  in	  cancer	  and	  alterations	  in	   its	   function	   induce	   metabolic	   change	   and	   also	   acts	   to	   prevent	   the	   growth	   and	  development	  of	  malignancy	  through	  apoptosis	  (Ryan,	  2001,	  Kaeser,	  2004,	  Oren,	  2003,	  Michelakis	   et	   al.,	   2008).	   In	   essence,	   p53	   plays	   an	   essential	   role	   in	   gene	   expression	  regulation	   that	  mediates	   cell	   cycle	   progression	   and	   apoptosis	   that	   is	   regulated	   by	   a	  negative	  feedback	  loop	  (Amaral	  et	  al.,	  2007).	  Human	  cancers	  with	  a	  p53	  mutation	  are	  more	   aggressive,	   more	   likely	   to	   metastasize	   and	   are	   considered	   to	   be	   more	   fatal	  (Glunde,	  2006,	  Mori,	  2004,	  Raman,	  2007).	  Mutations	  in	  p53	  have	  been	  associated	  with	  an	  increase	  in	  PC	  and	  total	  choline	  (Mori,	  2004).	  The	  sources	  of	  the	  cell	   lines	  used	  in	  these	   1H	  NMR	  experiments	  here	  have	  mutated	  p53,	  as	   the	   increase	   in	  PC	  seen	   in	   the	  increased	  malignancy.	  	  The	   changes	   seen	   in	   HCT-­‐116	   at	   a	   genetic	   level	   may	   also	   be	   associated	   with	   the	  microsatellite	   instability	   (MSI)	   of	   the	   cell	   line	   (Bhattacharyya	   et	   al.,	   1994).	   This	  phenotype	  in	  the	  HCT-­‐116	  which	  is	  known	  to	  be	  a	  highly	  tumorigenic	  and	  aggressive	  (Sawhney,	  2002)	  cell	  line,	  with	  mutated	  p53,	  also	  had	  an	  increased	  PC:	  GPC	  ratio.	  As	  a	  potent	  inhibitor	  of	  cell	  growth,	  the	  mutation	  of	  p53	  has	  a	  potential	  effect	  on	  the	  control	  of	   growth	   as	   seen	   in	   the	   HCT-­‐116	   cell	   lines	   in	   this	   study	   with	   regards	   to	   choline	  metabolism.	  	  	  Additionally,	   the	   effect	   on	   tumour	   suppressor	   may	   also	   allow	   the	   proliferation	   of	  tumour	   cells.	   NMR	   studies	   have	   been	   used	   to	   show	   clear	   differences	   in	   the	   choline	  metabolism	  of	   cancer	   cells	  with	   and	  without	   p53	  using	   the	   cell	   line	  HCT-­‐116,	  which	  could	  serve	  as	  a	  surrogate	  marker	  of	  its	  activity.	  These	  cell	  lines	  exhibited	  high	  PC	  and	  low	  GPC	  levels,	  but	  no	  significant	  differences	  between	  the	  GPC	  or	  PC:	  GPC	  levels	  were	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seen	  in	  the	  p53	  wild	  type	  (p53	  +	  )	  and	  without	  p53	  (p53	  -­‐	  )	  (Mori,	  2004).	  Interestingly,	  the	  p53-­‐	  had	  an	  increase	  in	  PC	  and	  total	  choline	  compared	  with	  p53	  +.	  Thus,	  the	  loss	  of	  p53	   function	   in	   colon	   cancer	   cells	   results	   in	   the	   increase	   in	   PC	   and	   total	   choline.	   In	  relation	   to	  other	   cancers,	   extracts	   from	  breast	   cancer	   cells	   also	   show	   the	   increase	   in	  PC:	  GPC	  ratio	  when	  compared	  with	  normal	  mammary	  cells	  (Aboagye,	  1999,	  Bogin	  et	  al.,	  1998)	   with	   malignant	   transformations	   of	   brain	   tumours	   also	   eliciting	   the	   same	  metabolic	  change	  (Bhakoo	  et	  al.,	  1996).	  	  Fatty	   acid	   metabolism	   plays	   an	   important	   role	   in	   the	   carcinogenesis	   of	   CRC	   and	  malignant	   cells	  have	   typically	  been	   found	   to	  have	  high	  PC	  and	   low	  GPC	   levels	   (Mori,	  2004,	  Raman,	  2007,	  Yeh,	  2008).	  A	  number	  of	  studies	  have	  shown	  high	  levels	  of	  PC	  or	  phosphoethanolamine	  (PE)	  or	  both	  in	  various	  cancers	  such	  as	  prostate,	  leukaemia	  and	  brain	   (Podo,	   1999,	   Ackerstaff,	   2003,	   Ackerstaff,	   2001,	   Carpinelli	   et	   al.,	   1984,	   Glunde,	  2006).	  These	  changes	  in	  metabolites	  in	  breast	  cancer	  cells	  MCF-­‐10T	  and	  MCF-­‐231	  that	  are	  ras	  oncogene	   transformed	  and	  metastatic	   cells	   respectively	  have	  been	  associated	  with	  high	  tumorigenicity	  (Podo,	  1999).	  	  Previously	   observed	   changes	   of	   choline	  metabolism	   that	  were	   associated	  with	  more	  aggressive	   breast	   cancer	   phenotypes	   in	   response	   to	   chemotherapy	   showed	   a	  significant	   reduction	   in	   total	   choline	   (Glunde,	   2006).	   Hence,	   there	   is	   a	   relationship	  between	   choline	  metabolism	   and	   invasion	   and	  metastasis	   of	   cancer.	   In	   vitro	   studies	  with	  magnetic	  resonance	  spectroscopy	  (MRS)	  using	  a	  choline	  kinase	  inhibitor	  MN58b	  showed	   that	   levels	   of	   PC	   were	   significantly	   decreased	   (p	   ≤	   0.05)	   in	   treated	   HT-­‐29	  tumour	   extracts	   (Al-­‐Saffar	   et	   al.,	   2006).	   Aqueous	   extracts	   from	   ovarian	   cancer	   and	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normal	  cell	  lines	  have	  also	  revealed	  intense	  choline	  resonances	  in	  the	  cancer	  cell	  lines	  (Ricci,	  2008).	  	  SW-­‐620	  is	  considered	  the	  most	  malignant	  of	  the	  cell	  lines	  used	  here,	  which	  is	  a	  poorly	  differentiated	  carcinoma.	  In	  comparison	  with	  adenomatous	  cell	  lines,	  SW-­‐620	  has	  been	  shown	  to	  have	  at	  least	  20	  times	  more	  intense	  choline	  (Mackinnon	  et	  al.,	  1994).	  The	  use	  of	   new	   cell	   microinjection	   designs	   and	   techniques,	   mice	   models	   using	   SW-­‐620	   and	  HCT-­‐116	   had	   successfully	   generated	   advanced	   stages	   of	   CRC	   (Cespedes,	   2007).	   The	  HCT-­‐116	   cell	   line,	   as	   an	   orthotropic	   model	   of	   CRC,	   provides	   a	   tool	   to	   dissect	   the	  mechanisms	   involved	   in	   cancer	  metastasis.	   These	   animals	   showed	   evidence	   of	   liver,	  lung	   and	   peritoneal	   dissemination	   following	   protein	   imaging	   and	   histological	  examination	   (Rajput,	   2008).	   The	  HCT-­‐116	   cell	   line	   in	   orthotopic	   nude	  mice	   has	   also	  been	   shown	   to	   have	   the	   greatest	   growth	   rate	   and	   have	   significantly	   higher	   mean	  tumour	  volume	  (p	  <	  0.05)	  compared	   to	  SW-­‐620.	  The	  HCT-­‐116	  and	  SW-­‐620	  had	  high	  frequencies	   of	   mesenteric	   lymphatic	   foci	   following	   orthotopic	   tumour	   cell	  microinjection	  between	   the	  mucosa	  and	  muscularis	   layers	  of	   the	   caecal	  wall	   of	  nude	  mice.	  The	  HCT-­‐116	  lines	  yielded	  stage	  IV	  disease	  and	  the	  SW-­‐620	  stage	  III	  disease.	  	  	  With	  correlations	  of	  survival	  time,	  the	  HCT-­‐116	  cell	  lines	  had	  the	  shortest	  with	  39	  ±	  4	  days	   and	   producing	   highly	   aggressive	   and	   disseminated	   tumours	   while	   the	   SW-­‐620	  survived	  for	  73	  ±	  10	  days	  (Cespedes,	  2007).	  	  Hence,	  their	  feasibility	  in	  being	  applied	  as	  animal	  models	   for	  metastatic	  disease.	  This	   further	  supports	   the	  metabolic	  changes	   in	  cell	  membrane	   synthesising	  metabolites	   seen	   in	   the	   SW-­‐620	   and	   HCT-­‐116	   cell	   lines	  associated	  with	  their	  aggressive	  nature	  that	  has	  been	  observed	  in	  the	  experiments	  of	  this	  chapter.	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Even	   though	   the	   COLO-­‐205	   cell	   line	   was	   from	   a	  metastatic	   site,	   it	   did	   not	   correlate	  exactly	  with	  the	  other	  metastatic	  cell	  line	  SW-­‐620	  in	  this	  study.	  The	  reason	  may	  be	  due	  to	  the	  previous	  treatment	  with	  5-­‐FU	  that	  the	  original	  patient	  from	  whom	  the	  cell	   line	  was	  derived	  had,	  thereby	  making	  it	  less	  aggressive	  or	  the	  fact	  that	  the	  tumour	  extracts	  are	   from	   ascitic	   fluid	   rather	   than	   solid	   tumour.	   The	   COLO-­‐205	   cell	   line	   has	   been	  thought	   of	   closely	   resembling	   the	   SW-­‐620	   cell	   line	   due	   to	   bipolar	   cells	   and	   some	  loosely	   attached	  epithelial	   colonies	   (Semple,	  1978).	  Hence,	   the	   similar	   changes	   in	  PC	  and	  GPC	  levels	  (higher	  levels	  of	  PC	  compared	  with	  GPC).	  	  	  The	   clustering	   of	   the	   cell	   lines	   observed	   in	   this	   experiment	   may	   be	   due	   to	   the	  phenotypes	  of	   the	  different	   cell	   lines.	  This	  metabolic	  phenotype	   is	   referred	   to	   as	   the	  ‘metabotype’	  (Griffin,	  2006).	  Aggressive	  phenotypic	  traits	  of	  tumorigenic	  cell	  lines	  such	  as	  invasion	  and	  metastasis	  can	  be	  observed	  in	  this	  study	  as	  the	  aggressive	  cell	  lines	  are	  closer	   to	   each	   other	   in	   the	   PCA	   plot.	   Similar	   studies	   with	   HR-­‐MAS	   NMR	   showed	  clustering	   in	   the	   PCA	   scores	   plots	   between	   SW-­‐620,	  HCT-­‐116	   and	  HT-­‐29	   xenografts.	  The	   differences	   however	   detected	  were	  mainly	   due	   to	   the	   lipids,	   lactate	   and	   choline	  containing	  compounds.	  These	  studies	  showed	  that	  HT-­‐29	  cell	   lines	  were	  most	  similar	  to	  human	  rectal	  cancer	  tissue.	  Although	  the	  rectal	  cancer	  samples	  had	  higher	  levels	  of	  lactate,	   taurine	   and	   choline	   and	   interestingly	   lower	   levels	   of	   PC,	   creatine	   and	   GPC	  (Seierstad	  et	  al.,	  2008).	  	  The	   highest	   levels	   of	   metabolites	   present	   within	   these	   malignant	   cell	   lines	   were	  myoinositol	  and	   taurine,	  which	  have	  been	  noted	   from	  other	  studies	   including	  human	  sample	  studies	  (Chan	  et	  al.,	  2009,	  Piotto	  et	  al.,	  2009).	   In	  previous	  metabolic	  research	  using	  1H	  NMR	  (as	  discussed	  in	  chapter	  1),	  rat	  and	  human	  colon	  cancer	  mucosa	  showed	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a	   dominance	   in	   choline-­‐containing	   metabolites,	   creatine,	   lysine	   and	   lactic	   acid	  (Backshall,	   2009,	   Bezabeh,	   1996).	   HR-­‐MAS	   NMR	   studies	   have	   also	   shown	   that	   CRC	  tissue	  has	  higher	  levels	  of	  taurine,	  glycine	  and	  lactate	  when	  compared	  to	  normal	  tissue	  (Seierstad	   et	   al.,	   2008,	   Chan,	   2009).	   Taurine	   in	   particular	   has	   been	   noted	   to	   be	  increased	  in	  human	  colon	  cancer	  and	  may	  be	  related	  to	  tumour	  aggressiveness	  and	  has	  been	  suggested	  as	  a	  possible	  tumour	  marker	  (Moreno,	  1993,	  Bezabeh,	  1996).	  	  	  Although	  this	  study	  did	  not	  reveal	  statistically	  significant	  changes	  in	  these	  metabolites	  despite	   different	   tumour	   grades,	   perhaps	  with	   their	   inherent	  malignant	   nature,	   it	   is	  difficult	  to	  distinguish	  subtle	  changes	  in	  such	  metabolite	  levels.	  In	  this	  study,	  the	  HT-­‐29	  cell	  line,	  which	  is	  well	  differentiated,	  had	  the	  highest	  level	  of	  acetate	  in	  comparison	  to	  the	  poorly	  differentiated	  ones.	  Faecal	  water	  extracts	  1H	  NMR	  studies	  have	  shown	  that	  patients	   with	   CRC	   have	   a	   significant	   decrease	   in	   acetate	   (p<0.001)	   compared	   to	  controls.	  This	  has	  been	  hypothesised	  to	  have	  a	  protective	  role	  against	  colorectal	  cancer	  (Monleon,	  2008),	  though	  tumour	  cell	  extract	  levels	  may	  not	  correspond	  to	  levels	  from	  faecal	   water	   extracts.	   This	   may	   explain	   the	   high	   levels	   of	   acetate	   in	   a	   well-­‐differentiated	  cell	  line.	  	  	  In	  keeping	  with	  Otto	  Warburg’s	  observation	  about	  aerobic	  glycolysis,	   the	  cell	   lines	   in	  this	  study	  showed	  a	  higher	  concentration	  of	  lactate	  and	  minimal	  glucose	  despite	  being	  normoxic	  conditions.	  Here,	   the	  more	  tumourigenic	  cell	   lines	  SW620	  and	  HCT116	  had	  higher	   levels	  of	   lactate	   than	  COLO205	  and	  HT29,	   as	  well	   as	   the	   former	  having	   lower	  levels	  of	  glucose.	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The	  use	  of	  fluorinde-­‐18	  (18F)	  labelled	  choline	  as	  PET	  scan	  tracers	  in	  brain	  and	  prostate	  tumours	   has	   evolved	   from	   metabolic	   studies	   (DeGrado	   et	   al.,	   2001).	   Recently,	   [11C]	  choline	  PET	  scanning	  has	  been	  used	  to	  assess	  and	  reproduce	  the	  effects	  of	  trastuzumab	  uptake,	  a	  drug	  used	  in	  breast	  cancer	  treatment,	  which	  was	  used	  as	  a	  marker	  of	  choline	  kinase	  activity,	  which	  is	  increased	  in	  tumorigensis	  (Kenny	  et	  al.,	  2010).	  	  The	  phenotypical	  changes	  in	  CRC	  like	  other	  cancers	  are	  based	  on	  the	  interplay	  between	  changes	  in	  genetic	  material,	  metabolites	  and	  protein	  levels.	  Thus,	  the	  use	  of	  data	  panel	  sets	   to	   link	   such	   information	   such	   as	   the	   NCI	   60	   panel	   and	   gene	   and	   metabolism	  enrichment	  analyses	  databases.	  Using	  platforms	  with	  genetic	  data,	  the	  gene	  signatures	  associated	  with	  CRC	  and	  certain	  metabolites	  were	  elucidated	  in	  this	  chapter.	  From	  the	  gene	  enrichment	  analysis,	   the	  Kaiso	  protein	  was	   identified	  as	  being	  expressed	   in	  cell	  lines	   with	   higher	   PC:	   GPC	   ratio.	   It	   is	   known	   to	   repress	   the	   methylated	   tumour	  suppressor	  genes	   that	  can	  bind	   in	   the	  methylation-­‐dependent	  region	  of	  human	  colon	  cancer	  cell	  lines	  (Lopes	  et	  al.,	  2008).	  	  	  The	  absence	  of	  the	  Kaiso	  gene	  induces	  the	  genes	  involved	  in	  tumour	  suppression.	  It	  is	  able	   to	  do	   this	  without	  affecting	  DNA	  methylation	  processes	   that	  are	  associated	  with	  gene	   silencing	  which	   involves	   the	   switching	   off	   of	   a	   gene,	   thereby	   altering	   function.	  This	  plays	  a	  significant	   function	   in	  tumour	  progression	  (Jones	  and	  Baylin,	  2007).	  The	  cytosine	   (CpG)	   methylation	   of	   tumour	   suppressor	   genes	   is	   associated	   with	  transcriptional	   silencing	   which	   subsequently	   impacts	   on	   malignant	   transformation	  (Baylin	  and	  Ohm,	  2006)	  as	  can	  occur	  with	  the	  Kaiso	  protein.	  	  The	  result	  of	  the	  GESA	  in	  relation	  to	  the	  cell	  lines	  with	  high	  PC:	  GPC	  translates	  to	  CRC	  cells	  becoming	  susceptible	  to	  cell	  cycle	  arrest	  and	  cell	  death	  that	  occurs	  with	  the	  use	  of	  chemotherapeutic	  agents	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(Lopes	   et	   al.,	   2008).	   Thus,	   offering	   the	   possibility	   of	   further	   exploration	   of	  chemotherapeutic	  targets	  towards	  the	  Kaiso	  protein.	  	  The	  Lopes	  genes	  that	  were	  over	  expressed	  in	  the	  SW-­‐620	  and	  HCT-­‐116	  cell	  lines	  were	  those	   involved	   in	   tumour	   suppression	   (RUNX3,	   FHIT)	   and	   anti-­‐proliferative	   activity	  
(RBP1,	  CDKN1C).	  The	  McGarvey	  genesets	  on	  the	  other	  hand	  were	  those	  involved	  in	  MSI	  
(SFRP5,	   RAB32,	   CHFR),	   polymorphisms	   in	   glutathione-­‐S-­‐transferase	   which	   are	  associated	   in	   tumour	   progression	   and	   hence	   patient	   outcome	   in	   CRC.	   Epigenetics,	  which	  studies	  the	  modifications	  that	  occur	  in	  gene	  expression	  through	  changes	  in	  DNA	  sequencing	   when	   silenced,	   has	   been	   described	   as	   a	   contributory	   factor	   in	   the	  pathogenesis	  of	  CRC	   (Laird	  et	   al.,	   1995).	  This	   involves	   the	   silencing	  of	   genes	   such	  as	  
CDKN2A,	  a	  tumour	  suppressor	  inactivating	  cyclin	  D-­‐cdk4/6	  complexes	  and	  causing	  cell	  arrest	  and	  HIC1a	   transcriptional	  repressor	   from	  the	  same	   family	  of	  proteins	  as	  Kaiso	  that	  modulates	  p53	  damage	  and	  is	  associated	  with	  multiple	  tumours	  in	  mice	  (Esteller,	  2002,	  Chen	  et	  al.,	  2003).	  	  Interestingly,	   metabolite	   enrichment	   data,	   showed	   a	   high	   correlation	   with	   protein	  synthesis	  but	  not	  so	  much	  with	  the	  glycerol	  phosphate	  pathway.	  This	  could	  possibly	  be	  due	  the	  high	  replication	  rate	  of	  these	  tumour	  cells	  and	  hence	  the	  protein	  production	  as	  they	  are	  all	  malignant.	  Five	  hits	  were	  identified	  from	  the	  protein	  synthesis	  metabolites	  from	  a	  total	  of	  19,	  compared	  to	  only	  one	  out	  of	  19	  in	  the	  phospholipid	  metabolism.	  This	  exemplifies	  the	  added	  information	  that	  can	  be	  obtained	  using	  computational	  methods.	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From	  the	  NCI	  60	  data	  panel	  there	  was	  a	  high	  correlation	  in	  the	  levels	  of	  ornithine	  and	  5'-­‐s-­‐methyl-­‐5'-­‐thioadenosine	   (MTA),	   which	   is	   involved	   in	   methionine	   metabolism	  (Figure	  3.13).	  	  	  	  
	  
Figure	   3.13	  Modified	   synthesis	   and	  metabolism	   of	  MTA.	  Decarboxylated	   s-­‐adenosylmethionine	  
partakes	   in	   polyamine	   synthesis,	   which	   starts	   with	   the	   conversion	   of	   ornithine	   to	   putrescine	  
(steps	   not	   shown).	   MTA	   itself	   is	   an	   enzyme	   substrate	   which	   catalyses	   the	   first	   step	   of	   the	  
methionine	  pathway	  (Avila	  et	  al.,	  2004).	  	  	  MTA	   plays	   a	   role	   in	   gene	   expression	   regulation,	   proliferation,	   differentiation	   and	  apoptosis	  (Avila	  et	  al.,	  2004).	  As	  ornithine	  and	  methionine	  are	  connected	   in	  the	  MTA	  metabolic	  pathway,	  it	   is	  not	  surprising	  that	  they	  are	  both	  elevated	  with	  high	  levels	  of	  PC:	   GPC	   in	   the	   SW-­‐620	   and	   HCT-­‐116	   cell	   lines	   together.	   The	   role	   of	   MTA	   in	  tumorigensis	   may	   be	   due	   to	   the	   enzymatic	   role	   of	   5’-­‐methythioadenosine	  phosphorylase	   (MTAP),	   which	   yields	   adenine	   and	   is	   subsequently	   involved	   in	   the	  methionine	   salvage	   pathway.	   MTAP	   is	   thought	   to	   be	   a	   tumour	   suppressor	   gene	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(Christopher	  et	  al.,	  2002).	  Enzymatic	  studies	  in	  both	  pancreatic	  and	  breast	  cancer	  have	  shown	  alterations	  in	  MTAP	  and	  ornithine	  decarboxylase	  (Subhi	  et	  al.,	  2004,	  Subhi	  et	  al.,	  2003).	   These	   could	   be	   future	   potential	   chemotherapeutic	   targets.	   This	   is	   also	   in	  accordance	  with	   the	  MESA	   data	  where	   strong	   correlations	  were	   seen	   in	   the	   protein	  biosynthesis	  and	  methionine	  metabolism.	  The	  findings	  of	  the	  metabolic	  changes	  in	  this	  study	   provide	   further	   metabolic	   evidence	   of	   the	   role	   of	   choline	   metabolites	   in	   CRC	  carcinogenesis.	  Therefore,	  the	  rapid	  division	  of	  cancer	  cells	  makes	  choline	  metabolism	  a	  logical	  molecular	  target	  for	  intervention.	  	  
3.6	  Conclusions	  Cancer	   xenografts	   in	   mice	   such	   as	   the	   ones	   used	   in	   this	   study	   allow	   for	   the	  reproducibility	   and	   comparative	   studies	   with	   human	   samples.	   They	   offer	   the	  possibility	  to	  compare	  changes	  detected	  in	  vivo	  to	  histological	  observations.	  Knowing	  the	   metabolic	   profiles	   of	   xenograft	   animal	   models	   provides	   the	   opportunity	   for	   the	  targeting	  of	  specific	  metabolites	  for	  future	  cancer	  therapy	  and	  also	  as	  biomarkers.	  This	  GPC	   to	   PC	   switch	   observed	   in	   this	   study	   and	   other	   studies	   has	   been	   observed	   in	   a	  number	  of	  cancers	  from	  metabonomic	  studies	  and	  thus	  suggests	  a	  major	  role	  to	  play	  in	  the	   pathogenesis	   of	   cancers.	   Here,	   strong	   correlations	   between	   tumour	   grade	   and	  choline	  metabolite	   levels,	   which	   are	   related	   to	   cell	   proliferation	   in	   terms	   of	   tumour	  aggression,	   were	   observed.	   Furthermore,	   the	   knowledge	   of	   more	   aggressive	   or	  tumorigenic	   cell	   lines	   may	   enable	   the	   appropriate	   use	   of	   xenograft	   models	   in	   drug	  targeting	   approaches.	   This	  metabolic	   profiling	   investigation	  using	   tumour	   xenografts	  with	  NMR	  provides	  an	  insight	  into	  the	  use	  of	  different	  CRC	  cell	  lines	  and	  how	  they	  can	  be	  used	  to	  further	  understand	  the	  biology	  of	  CRC	  from	  its	  metabolic	  profile.	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CHAPTER	  4	  
Chemoprevention	  of	  colorectal	  adenomas	  
4.1	  Abstract	  Colorectal	   adenomas	   are	   the	   precursor	   lesions	   for	   CRC.	   Therefore	   inhibiting	   the	  progression	  of	  adenomas	  to	  carcinomas	  is	  beneficial	  in	  the	  early	  management	  of	  CRC.	  Chemoprevention	   strategies	   in	   the	   form	   of	   bile	   acids	   have	   been	   evaluated	   in	  randomized	  clinical	  trials.	  In	  this	  chapter,	  the	  metabolic	  profiles	  of	  colorectal	  adenoma	  recurrence	  following	  treatment	  with	  Ursodeoxycholic	  acid	  (UDCA)	  were	  demonstrated.	  Urine	  and	  faecal	  water	  extracts	  of	  patients	  with	  colorectal	  adenomas	  with	  and	  without	  recurrence	  after	  treatment	  with	  UDCA	  were	  investigated	  for	  metabolic	  changes	  using	  
1H	  NMR.	  In	  the	  faecal	  water	  samples,	  significant	  differences	  were	  seen	  in	  the	  levels	  of	  propionate	   and	   succinate	   between	   individuals	   that	   had	   recurrent	   and	   non-­‐recurrent	  adenomas.	   The	   levels	   of	   propionate	   were	   higher	   in	   patients	   that	   had	   adenoma	  recurrence	  and	  UDCA	  treatment.	  In	  urine	  analysis,	  both	  citrate	  and	  formate	  levels	  were	  higher	  in	  the	  non-­‐recurrent	  adenoma	  group	  compared	  with	  the	  recurrent	  group.	  This	  relationship	   between	   the	   levels	   of	   short	   chain	   fatty	   acids	   and	   metabolites	   from	   the	  tricarboxylic	   acid	   cycle	   indicate	   the	   interaction	   between	   the	   metabolism	   of	   gut	  microflora	  and	  colorectal	  adenoma	  metabolic	  pathogenesis.	  	  	  	   	  
	  	   117	  
4.2	  Introduction	  The	   roles	   of	   colorectal	   adenomas	   as	   pathogenic	   precursors	   to	   carcinoma	   are	   well	  mapped	  out.	  Colonoscopy	  screening	  programmes	  aim	  to	  prevent	  the	  progression	  of	  the	  adenoma-­‐carcinoma	   sequence	   (Vogelstein	   et	   al.,	   1988).	   However,	   these	   programmes	  are	   not	   without	   the	   potential	   risks	   of	   bleeding	   and	   perforation,	   which	   can	   cause	  significant	   morbidity	   and	   mortality.	   The	   challenge	   still	   remains	   as	   to	   ways	   of	  identifying	   colorectal	   adenomas	   non-­‐invasively	   with	   high	   sensitivity	   and	   preventing	  the	  progression	  to	  carcinoma.	  Metabonomic	  profiling	  of	  colonic	  polyps	  using	  HR-­‐MAS	  NMR	   interestingly	   identifies	   similar	   metabolites	   as	   CRC	   studies	   (see	   supplementary	  chapter).	   The	   concept	   of	   chemoprevention	   in	   CRC	   is	   to	   prevent	   the	   progression	   of	  adenomas	   to	   carcinomas.	   Oral	   chemopreventive	   agents	   that	   have	   the	   potential	   of	  reducing	   the	   recurrence	   of	   colorectal	   adenomas	  would	   have	   a	   significant	   impact	   on	  CRC	   prevention	   (Lance,	   2008).	   These	   agents	   have	   the	   prospect	   of	   preventing	   or	  delaying	   the	   development	   of	   cancer	   in	   high	   risk	   individuals	   or	   individuals	   with	  premalignant	  lesions	  (Haller	  et	  al.,	  2000,	  Stan	  et	  al.,	  2010).	  Despite	  several	  efforts	  over	  the	  past	  two	  decades,	  no	  chemopreventive	  drug	  is	  being	  used	  in	  clinical	  practice	  today.	  	  Chronic	   inflammation	   through	   complex	   immunological	   and	   genetic	   mechanisms	   is	  associated	  with	   cancer	  development	  by	  promoting	  vascular	  growth	  and	  extracellular	  matrix	  redesign	  (Westbrook	  et	  al.,	  2010,	  Gravitz,	  2011).	  On	  the	  quest	  to	  find	  drugs	  for	  chemoprevention	   of	   colonic	   adenomas,	   commonly	   used	   drugs	   such	   as	   non-­‐steroidal	  anti-­‐inflammatory	  drugs	  (NSAIDs)	  such	  as	  aspirin	  and	  other	  cyclooxygenase-­‐2	  (COX-­‐2)	  inhibitors	   have	   been	   used.	   COX-­‐2	   is	   the	   rate-­‐limiting	   enzyme	   in	   synthesis	   of	  prostaglandins	   (Serfaty	   et	   al.,	   2003a).	   The	   chemopreventive	   actions	   of	   NSAIDs	   are	  thought	   to	   be	   mediated	   through	   their	   inhibition	   of	   COX	   and	   thereby	   platelet	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aggregation	   and	   thus	   prevention	   of	   inflammation	   (Westbrook	   et	   al.,	   2010).	   In	   trials	  these	  drugs	  have	  revealed	  a	  reduction	  in	  adenoma	  formation.	  A	  randomised	  controlled	  trial	   (RCT)	   was	   carried	   out	   using	   325mg	   of	   aspirin	   versus	   placebo	   in	   patients	   with	  previous	   colorectal	   cancer	   to	   investigate	   adenoma	   incidence.	   A	   relative	   risk	   (RR)	   of	  0.65	  [95%	  Confidence	  Interval	  (CI)	  0.46-­‐0.91]	  of	  adenoma	  recurrence	  was	  found	  in	  the	  aspirin	  group	  compared	  to	  placebo,	  with	  a	  longer	  duration	  to	  the	  first	  adenoma	  in	  the	  aspirin	  group	  [hazard	  ratio	  (HR)	  0.64,	  p	  =	  0.022]	  (Sandler	  et	  al.,	  2003).	  	  	  Several	  RCTs	  have	  shown	  that	  aspirin	  reduced	  the	  20	  year	  risk	  of	  mortality	  (p	  =	  0.02)	  and	  morbidity	  (p	  =	  0.005)	  of	  colon	  but	  not	  rectal	  cancer	  (Rothwell	  et	  al.,	  2010).	  Hence,	  the	  prospects	  of	  using	  aspirin	  to	  reduce	  the	  development	  of	  adenomas	  in	  patients	  with	  a	   previous	   history	   of	   CRC	   and	   thereby	   preventing	   CRC	   are	   still	   being	   explored.	  However,	  there	  are	  still	  concerns	  about	  the	  side	  effects	  of	  NSAIDs	  (Wang	  et	  al.,	  2010),	  such	  as	  bleeding	  and	  their	  effect	  on	  renal	  function.	  	  	  A	  polyamine	  synthesis	  inhibitor,	  Difluoromethylornithine	  (DFMO),	  from	  animal	  studies	  has	   been	   identified	   as	   a	   potent	   inhibitor	   of	   colonic	   carcinogenesis.	   A	   randomised	  double-­‐blind	  controlled	  trial	  based	  on	  this	  rationale	  used	  oral	  DFMO	  and	  sulindac	  (an	  NSAID)	   on	   patients	   with	   a	   history	   of	   adenomas	   and	   matched	   controls.	   It	   revealed	  12.3%	  (risk	  ratio	  0.30,	  95%	  CI	  0.18-­‐0.49,	  p	  <	  0.001)	  recurrence	  rate	  in	  the	  intervention	  group	   compared	   to	   41.1%	   in	   the	   control	   group.	   Patients	   in	   the	   interventional	   group	  were	  also	  less	  likely	  to	  have	  advanced	  adenomas	  (Meyskens	  et	  al.,	  2008).	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4.3	  Effects	  of	  Bile	  Acids	  on	  Colorectal	  Cancer	  The	   involvement	  of	  bile	  acids	   in	   the	  development	  of	  CRC	  has	  been	   investigated	  since	  the	  early	  1970s	  with	  alterations	  in	  bile	  acids	  such	  as	  deoxycholic	  acid,	  which	  has	  more	  receptors	   in	   CRC	   patients	   compared	   to	   controls	   (Serfaty	   et	   al.,	   2003a,	   Tocchi	   et	   al.,	  1996).	   Bile	   acids	   are	   synthesized	   from	   cholesterol	   in	   the	   liver	   through	   multiple	  enzymatic	  reactions.	  They	  are	  required	  in	  the	  body	  for	  the	  digestion	  and	  absorption	  of	  lipids	  by	  being	  released	  into	  the	  intestinal	   lumen	  (Lefebvre	  et	  al.,	  2009,	  Palmeira	  and	  Rolo,	  2004).	  Primary	  bile	  acids	  such	  as	  cholic	  and	  chenodeoxycholic	  acids	  are	  the	  first	  products	  of	  bile	  acid	  synthesis.	  Secondary	  bile	  acids	  (deoxycholic	  and	  lithocholic	  acids)	  are	  the	  result	  of	  gut	  microbial	  activity.	  Gut	  microbes	  are	  increasingly	  becoming	  points	  of	  interest	  in	  research	  due	  to	  certain	  implications	  in	  colonic	  disease	  pathogenesis.	  Most	  bile	  acids	  are	  reabsorbed	   in	   the	   intestine	  via	   the	  enterohepatic	  cycle	   (Lefebvre	  et	  al.,	  2009).	  	  Research	   into	   the	   link	   between	   the	   pathogenesis	   of	   CRC	   and	   secondary	   bile	   acids	   in	  faeces	   has	   been	   going	   on	   for	   decades.	   Deoxycholic	   acid	   (DCA)	   and	   lithocholic	   acids,	  both	   secondary	   bile	   acids,	   have	   been	   found	   to	   be	   higher	   in	   patients	   with	   colorectal	  adenomas	  than	  controls	  (Bayerdorffer	  et	  al.,	  1995,	  Bayerdorffer	  et	  al.,	  1993,	   Imray	  et	  al.,	  1992).	  They	  are	  thought	  to	  be	  tumour	  promoters	  and	  are	  increased	  in	  the	  patients	  with	  colonic	  tumours	  (Cohen	  et	  al.,	  1980,	  Hori	  et	  al.,	  1998).	  DCA,	  a	  tumour	  promoter,	  stimulates	   oncogenic	   activity	   as	   well	   as	   the	   proliferation	   of	   tumour	   cells	   in	   human	  colon	   cancer	   cells	   (Wu	  and	  Makuch,	  2010).	  This	  was	   thought	   to	  be	   correlated	   to	   the	  high	  fat	  diets	  of	  patients,	  as	  increased	  intake	  of	  dietary	  fat	  promotes	  the	  build	  up	  of	  bile	  acid	  in	  faeces,	  which	  are	  then	  subsequently	  metabolised	  to	  secondary	  bile	  acids	  such	  as	  DCA	   (Hill	   et	   al.,	   1975,	   Reddy	   et	   al.,	   1977).	   The	   alternative	   hypothesis	   about	   the	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modality	  of	   the	  pathogenic	  activity	  of	  bile	  acids	   in	   colorectal	   tumours	   is	   through	  cell	  apoptosis	  (Martinez	  et	  al.,	  1998).	  Other	  bile	  acids	  found	  to	  be	  higher	   in	  patients	  with	  adenomas	  include	  iso-­‐deoxycholic	  acid,	  unconjugated	  cholic	  acid,	  iso-­‐chenodeoxycholic	  acid	   and	   lithocholic	   acid	   (Bayerdorffer	   et	   al.,	   1995).	   Correlations	   between	   colonic	  proliferation	  rates	  and	  the	  serum	  levels	  of	  DCA	  have	  been	  found	  without	  correlations	  to	  other	  bile	  acids	  such	  as	  cholic	  acid,	  lithocholic	  acid	  and	  Ursodeoxycholic	  acid	  (UDCA)	  (Ochsenkuhn	  et	  al.,	  1999).	  	  Animal	   studies	   using	   rats	   showed	   that	   supplementing	   UDCA	   (Figure	   4.1)	   into	   their	  diets	  did	  not	  promote	  colonic	  tumour	  formation	  or	  progression	  once	  the	  tumours	  were	  present;	   thus,	   emphasizing	   the	   modulatory	   role	   of	   bile	   acid	   in	   colonic	   tumour	  development	  and	  their	  potential	  application	  in	  chemopreventive	  strategies.	  UDCA	  is	  a	  hydrophilic	  tertiary	  bile	  acid	  used	  in	  the	  treatment	  of	  cholestatic	  liver	  disease	  (Earnest	  et	  al.,	  1994,	  Poupon	  et	  al.,	  1991).	  Interestingly,	  UDCA	  interacts	  with	  p53	  in	  regulating	  apoptosis,	   thereby	   preventing	   cell	   proliferation	   (Amaral	   et	   al.,	   2007,	  Martinez	   et	   al.,	  1998).	  Studies	  have	  reported	  that	  the	  administration	  of	  UDCA	  for	  a	  period	  of	  12	  years	  in	  patients	  with	  UC	  and	  primary	  sclerosing	  cholangitis	  (PSC)	  reduced	  the	  incidence	  of	  CRC	  in	  these	  patients	  (Pardi	  et	  al.,	  2003).	  A	  median	  intervention	  period	  of	  over	  three	  years	  was	  reported	  to	  decrease	  the	  recurrence	  of	  colorectal	  adenomas	  in	  patients	  with	  primary	  biliary	  sclerosis	  (Serfaty	  et	  al.,	  2003a).	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Figure	  4.1	  Chemical	  structure	  of	  Ursodeoxycholic	  Acid	  (C24H4004)(Liu	  et	  al.,	  2011).	  
	  
The	   rational	   of	   using	   UDCA	   in	   the	   treatment	   of	   CRC	   is	   due	   to	   its	   ability	   to	   reduce	  apoptosis	   in	  mitochondrial	   pathways	   and	   p53	   transcriptional	   activity	   (Amaral	   et	   al.,	  2007).	  UDCA	  has	  been	  described	  as	  being	  a	   cytoprotective	   agent	   through	  potentially	  regulating	  cellular	  proliferative	  signalling	  (Wu	  and	  Makuch,	  2010)	  and	  has	  thus	  been	  tested	   as	   a	   potential	   CRC	   prevention	   drug.	   However,	   it	   was	   not	   efficacious	   in	   the	  prevention	   of	   colorectal	   adenomas,	   although	   some	   groups	   have	   observed	   UDCA	   to	  decrease	  the	  rates	  of	  colonic	  adenoma	  recurrence	  (Serfaty	  et	  al.,	  2003b).	  UDCA	  has	  also	  been	  evaluated	  based	  on	  gender	  differences	  and	  bile	  acid	  metabolism	  in	  patients	  with	  colorectal	   adenomas,	   which	   showed	   a	   decrease	   in	   lesions	   in	   men	   but	   not	   women	  (Thompson	  et	  al.,	  2009).	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4.4	  Metabolic	  Profiling	  using	  Faecal	  Water	  	  The	  use	  of	  faeces	  in	  NMR	  studies	  offers	  the	  advantage	  of	  the	  intimate	  contact	  of	  faeces	  with	   the	   colon	   and	   thereby	   benefiting	   from	   the	   study	   of	   unique	   biology.	   As	   a	   non-­‐invasive	  test,	  faecal	  extracts	  were	  able	  to	  distinguish	  UC	  and	  CD	  patients	  from	  controls	  using	  metabolic	   profiling.	   Inflammatory	   bowel	   disease	   (IBD)	   patients	  were	   found	   to	  have	   lower	   levels	   of	   butyrate,	   acetate,	   methylamine	   and	   trimethylamine	   with	   high	  amino	   acid	   levels	   compared	   to	   controls.	   	   Additionally,	   glycerol	   was	   lower	   in	   CD	  compared	   to	   UC	   (Marchesi	   et	   al.,	   2007).	   Studies	   on	   faecal	   water	   extracts	   from	   CRC	  patients	  have	  revealed	  lower	  concentrations	  of	  short-­‐chain	  fatty	  acids	  such	  as	  butyrate	  (δ	  2.16)	  and	  acetate	  (δ	  1.92)	  (Monleon	  et	  al.,	  2009).	  	  Significantly	   higher	   levels	   of	   deoxycholic	   acid	   (p	   =	   0.01)	   and	   lithocholic	   acid	   were	  found	  in	  aqueous	  faecal	  extracts	  in	  patients	  with	  colonic	  tumours	  compared	  to	  controls	  without	  colonic	  pathology.	  Colonic	  cell	  proliferation	  is	  linked	  with	  the	  concentration	  of	  bile	  acids	   in	   faecal	  water	  (Stadler	  et	  al.,	  1988).	  Therefore,	  colonic	  polyps	  and	  cancers	  were	  thought	  to	  have	  higher	  proliferation	  rates	  and	  thus	  hypothesised	  to	  have	  higher	  concentrations	  of	  bile	  acids.	  The	  amount	  of	  bile	  acids	  in	  faecal	  water	  is	  also	  related	  to	  the	   amount	   of	   fatty	   food	   ingested,	  with	   higher	   fat	   intake	   relating	   to	   higher	   bile	   acid	  concentrations	  and	  also	  increased	  rectal	  mucosa	  proliferation	  (Stadler	  et	  al.,	  1988).	  	  The	   use	   of	   bile	   acids	   in	   chemopreventive	   trial	   involving	   patients	   with	   colorectal	  adenomas	   has	   been	   evaluated.	   The	   phase	   III	   double-­‐blind	   placebo-­‐controlled	   trial	  explored	  the	  use	  of	  UDCA	  in	  preventing	  colorectal	  adenoma	  recurrence.	  It	  showed	  that	  treatment	   with	   UDCA	   was	   associated	   in	   a	   non-­‐statistically	   significant	   way	   to	   the	  reduction	   of	   adenoma	   recurrence	   (Alberts	   et	   al.,	   2005).	   The	   samples	   of	   the	   1H	  NMR	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metabonomics	  experiments	  in	  this	  chapter	  are	  based	  on	  the	  hypothesis	  that	  metabolic	  profile	  changes	  can	  be	  identified	  in	  this	  patient	  cohort.	  The	  main	  aims	  of	  this	  chapter	  were	   to	   identify	   the	   metabonomic	   profiles	   of	   patients	   with	   colonic	   adenomas	   using	  faecal	  water	  extracts	  and	  urine	  samples	  from	  the	  chemoprevention	  trial	  performed	  by	  Alberts	  and	  colleagues	  (Alberts	  et	  al.,	  2005).	  This	  study	  observed	  the	  metabolic	  profile	  differences,	  in	  the	  unusual	  sample	  type	  of	  human	  faecal	  water	  extracts.	  The	  association	  between	   treated	   and	   untreated	   group	   of	   patients	   with	   UDCA	   were	   made	   with	  colorectal	  adenoma	  recurrence.	  The	  relationship	  between	  the	  patient	  groups	  and	  their	  demographics	  were	  also	  explored	  using	  1	  H	  NMR	  metabonomics.	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4.5	  Materials	  and	  Methods	  
4.4.1	  Study	  participants	  and	  sample	  collection	  The	  samples	  used	   in	  this	  study	  were	  based	  on	  prospectively	  collected	  samples	  at	   the	  time	  of	  a	  phase	  III	  clinical	  trial	  to	  prevent	  colonic	  adenomas	  using	  UDCA	  at	  the	  Arizona	  Cancer	   Centre	   as	   per	   study	   protocol	   (Alberts	   et	   al.,	   2005).	   This	   was	   a	   randomised	  double-­‐blinded	   placebo-­‐controlled	   study.	   The	   study	   participants	   were	   recruited	  between	   1995	   and	   1999.	   Individuals	  were	   eligible	   following	   removal	   of	   a	   colorectal	  adenoma	   within	   the	   prior	   6	   months	   of	   the	   trial	   starting.	   The	   follow-­‐up	   period	   was	  three	  years.	  Demographic	  and	  clinicopathological	  data	  including	  location	  of	  adenomas	  was	   collected.	   Tumours	   were	   defined	   as	   ‘distal’	   if	   they	   were	   present	   in	   the	   rectum,	  sigmoid,	  descending	  and	  left	  transverse	  colon.	  	  
4.4.2	  Faecal	  water	  and	  urine	  sample	  collection	  	  The	  faeces	  and	  urine	  samples	  were	  collected	  as	  per	  the	  study	  protocol	  of	  the	  phase	  III	  trial	   (Kindly	   provided	   by	   Professor	   Peter	   Lance	   and	   colleagues).	   Pooled	   stool	   samples	  were	  collected	  over	  a	  72-­‐hour	  period	  from	  552	  consented	  participants	  (Figure	  4.2),	  of	  whom	   261	   were	   in	   the	   placebo	   group	   and	   291	   in	   the	   UDCA	   group.	   The	   median	  treatment	   time	   for	   the	   UDCA	   participants	   was	   31.8	   months	   and	   32	   months	   for	   the	  placebo	  group.	  The	  baseline	  characteristics	  of	  the	  treated	  and	  the	  placebo	  groups	  were	  matched	   except	   for	   the	   carbohydrate	   intake,	   which	   was	   higher	   in	   the	   UDCA	   group	  (287.8g/day	  in	  the	  UDCA	  group	  compared	  to	  268.6g/day	  in	  the	  placebo	  group).	  Once	  collected	  the	  samples	  were	  put	  on	  dry	  ice	  and	  subsequently	  frozen	  at	  -­‐80°C.	  The	  urine	  samples	   were	   collected	   at	   the	   timed	   interval	   periods	   from	   participants.	   Out	   of	   this	  patient	   group,	   26	   samples	   were	   analysed	   using	   1H	   NMR	   spectroscopy.	   The	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concentrations	  of	  identified	  metabolites	  were	  evaluated	  based	  on	  the	  characteristics	  of	  patients	  and	  clinicopathological	  data.	  	  	  
	  	  
Figure	   4.2	   Flow	   diagram	   of	   the	   number	   of	   participants	   in	   the	   trial	   showing	   distribution	   of	  
treatment	   and	   recurrence.	   Recurrence	   is	   defined	   as	   the	   recurrence	   of	   one	   or	  more	   colorectal	  
adenomas	  within	  six	  months	  or	  more	  of	  the	  qualifying	  colonoscopy.	  	  	  
4.4.3	  Sample	  Preparation	  	  
(i)	  Preparation	  of	  faecal	  water	  extracts	  The	   extraction	   of	   the	   faeces	  was	   performed	  with	  water.	   This	   is	   the	   optimal	  method	  described	  thus	  far	  for	  short-­‐chain	  fatty	  acids	  and	  organic	  acids	  (Bezabeh	  et	  al.,	  2009).	  The	   samples	   were	   then	   homogenized	   for	   15	   minutes	   with	   equal	   water	   weight.	  Duplicates	   of	   10mls	   of	   each	   sample	  was	   aliquoted	   and	   ultracentrifuged	   at	   4°C	   for	   1	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hour	  at	  38,500	  revolutions	  per	  minute	  (rpm).	  The	  supernatant	  was	  removed,	  weighed	  and	  stored	  at	  -­‐80°C	  until	  1H	  NMR	  analysis.	  	  
(ii)	  Urine	  and	  faecal	  water	  extract	  NMR	  sample	  preparation	  The	  400μl	  of	  faecal	  water	  extract	  and	  urine	  placed	  in	  eppendorf	  tubes	  of	  the	  defrosted	  samples	  were	  used.	  These	  were	  kept	  on	  dry	  ice	  prior	  to	  preparation.	  Phosphate	  buffer	  (200μl)	  at	  a	  pH	  7.4	  was	   then	  added	   to	  each	  sample.	  The	  phosphate	  buffer	  was	  made	  from	  28.85g	  (0.2M)	  of	  Na2HPO4,	  5.25g	  (0.043m)	  NaH2PO4,	  0.173g	  (1mM)	  TSP,	  0.195g	  (3mM)	   sodium	   azide	   (NaN3),	   200ml	  D2O	   and	   800ml	  H2O.	   The	   buffer	   sample	   (550μl)	  was	   placed	   in	   a	   standard	   5mm	   glass	   NMR	   tube	   and	   then	   analysed	   on	   the	   1H	   NMR	  spectrometer	   to	   ensure	   no	   impurities	   were	   present	   prior	   to	   using	   it	   for	   sample	  preparation.	  The	  eppendorf	   tubes	  were	   firstly	   inverted	  manually	   to	  mix	   the	  contents	  and	  then	  centrifuged	  at	  13000	  rpm	  for	  5	  minutes.	  An	  aliquot	  of	  550μl	  of	  the	  resulting	  supernatant	  was	  pipetted	  into	  a	  pre-­‐labelled	  5mm	  NMR	  tube.	  The	  samples	  were	  stored	  in	  a	  -­‐80°C	  freezer	  prior	  to	  NMR	  analysis.	  	  	  A	   random	   run	   order	   was	   used	   when	   placing	   the	   samples	   in	   the	   spectrometer	   to	  minimise	   sequential	   errors	   if	   there	   were	   problems	   with	   instrumentation.	   D2O	   was	  added	   to	   the	   samples	   to	   act	   as	   a	   signal	   lock	   for	   the	   spectrometer	   and	   the	   TSP	   was	  added	  to	  be	  a	  chemical	  shift	  reference	  at	  0	  ppm	  and	  for	  alignment	  of	  the	  NMR	  spectra	  (Bezabeh	  et	  al.,	  2009).	  Samples	  were	  then	  placed	  in	  a1H	  NMR	  auto-­‐sampler.	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4.4.4	  1H	  NMR	  processing	  The	   NMR	   spectra	   were	   acquired	   using	   a	   600MHz	   1H	   NMR	   spectrometer	   with	   an	  automatic	   sample	   delivery	   system	   (Bruker	   Biospin,	   Rheinstetten,	   Germany).	   The	  temperature	  was	  set	  at	  300K	  (27°C).	  One	  dimensional	  (1-­‐D)	  NOSEY	  experiments	  and	  two-­‐dimensional	   (2-­‐D)	   J-­‐resolved	  spectroscopy	   (JRES)	  experiments	  were	  carried	  out.	  	  Gradient	   shimming	   of	   the	  magnet	  was	   carried	   out	  manually	   prior	   to	   obtaining	  NMR	  spectral	   data.	   The	   acquisition	   parameters	   for	   the	   1-­‐D	   experiments	   were	   as	   follows:	  number	  of	  scans,	  ns	  =	  8	  with	  a	  ds	  number	  of	  2.	  The	  pulse	  width,	  P1	  was	  set	  at	  11.81	  microseconds	   (μs),	   presaturation	   power,	   PL1	   at	   3	   dB	   and	   PL9	   at	   55dB.	   The	   time	  domain	  size	  (TD)	  was	  32768	  with	  an	  AQ	  of	  2.04	  seconds;	  a	  receiver	  gain,	  RG	  of	  128	  and	  the	  RD	  of	  2	  seconds.	  The	  suppression	  of	  the	  water	  signal	  in	  the	  1H	  NMR	  spectra	  which	  can	  distort	  the	  spectrum,	  if	  present	  in	  large	  amounts	  and	  therefore	  potential	  interfere	  with	  signal	  identification,	  was	  set	  at	  O1	  =	  1889	  Hz.	  The	  O1	  is	  a	  pulse	  frequency	  that	  can	  be	  altered	  to	  the	  frequency	  at	  which	  the	  water	  protons	  resonate.	  	  	  Standard	  2-­‐D	  experiments	  were	  carried	  out	  on	  the	  400MHz	  Bruker	  NMR	  spectrometer	  (Bruker	   Biospin,	   Rheinstetten,	   Germany).	   The	   NMR	   spectra	   obtained	  were	  manually	  baseline	   corrected,	   phased	   and	   calibrated	   to	   TSP	   at	   a	   chemical	   shift	   of	   δ0ppm	  using	  TOPSPIN	  version	  2.0	  (Bruker	  Biospin	  Rheinstetten,	  Germany).	  The	  parameters	  for	  the	  JRES	  experiments	  at	  a	  set	  temperature	  of	  300K	  were	  as	  follows:	  TD	  =	  16384,	  NS	  =	  16,	  DS	   =	   16,	   PL1	   =	   3dB,	   PL9	   =	   55dB,	   AQ	   =	   1.02	   seconds,	   P1	   =	   11.81μs	   and	   a	   RD	   of	   2	  seconds.	  	  
	  	   128	  
4.4.5	  Data	  analysis	  
(i)	  Metabolite	  identification	  and	  quantification	  Metabolites	   were	   identified	   using	   previous	   chemical	   shift	   identifications	   in	   the	  literature	  (Saric,	  2008,	  Martinez-­‐Bisbal	  et	  al.,	  2004,	  Jacobs	  et	  al.,	  2008,	  Wu	  et	  al.,	  2010,	  Bales	   et	   al.,	   1984,	   Claus	   et	   al.,	   2008)	   as	   well	   as	   the	   software	   Chenomx	   NMR	   Suite	  (Version	   6.0,	   Alberta,	   Canada).	   Metabolite	   concentrations	   were	   obtained	   from	   the	  Chenomx	  based	  on	  the	  known	  concentration	  of	  TSP	  added	  to	  each	  sample.	  The	  stored	  Chenomx	  library	  was	  used	  to	  profile	  the	  NMR	  spectra.	  	  
(ii)	  Spiking	  experiments	  Spiking	   experiments	   were	   carried	   out	   in	   order	   to	   confirm	   the	   identification	   of	  metabolites.	   Authentic	   standards	   of	   the	   identified	   metabolite	   of	   interest	   were	   used.	  Spike	  solution	  of	  10uL	  of	  a	  pre-­‐made	  mixture	  containing	  buffer	  and	  the	  standard	  were	  incrementally	  added	  to	  the	  identified	  sample	  containing	  the	  metabolite	  of	  interest.	  1H	  NMR	   spectra	   were	   obtained	   with	   each	   incremental	   concentration	   to	   assess	   the	  differences	   in	   intensity	   of	   the	   metabolite	   peak	   of	   interest.	   The	   calculations	   of	   the	  solutions	  that	  needed	  to	  be	  added	  to	  make	  up	  concentrations	  were	  performed	  using	  in-­‐house	  applications	  on	  Excel	  (Dr	  T.	  Athersuch,	  Imperial	  College	  London).	  	  
	  
(iii)	  Statistical	  Analysis	  Raw	   NMR	   spectra	   were	   imported,	   phased,	   baseline	   corrected	   and	   calibrated	  automatically	  using	  an	  in-­‐house	  code	  developed	  by	  Dr	  Rachel	  Cavill	  (Imperial	  College	  London)	   in	  MATLAB	   (MathWorks	   Inc,	  MA).	  The	  data	  was	  normalised	   to	  median	   fold	  change	   (mfc)	   and	   integral	   values	   calculated	   using	   in-­‐house	   MATLAB	   codes.	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Multivariate	   data	   analysis	   was	   applied	   to	   the	   urine	   samples	   using	   PCA	   in	   order	   to	  reveal	   any	   inherent	   treatment	   related	   patterns	   within	   the	   data	   using	   SIMCA-­‐P+	  (version	   12,	   Umetrics,	   Umeå,	   Sweden).	   The	  water	   region	   at	   the	   4.7	   -­‐	   4.92	   ppm	  was	  excluded.	  	  Data	  collected	  was	  entered	  into	  SPSS	  Version	  18	  (SPSS	  Inc,	  Chicago,	  USA)	  for	  univariate	  analysis	   using	   descriptive	   and	   inferential	   statistics.	   Tests	   of	   normality	   and	   abnormal	  skewness	  were	  conducted	  within	  the	  metabolite	  variables.	  Descriptive	  statistics	  were	  then	   performed,	   including	   frequencies,	   means	   and	   medians.	   As	   the	   data	   did	   not	  conform	  to	  the	  assumptions	  of	  normality,	  appropriate	  non-­‐parametric	  tests	  were	  used:	  Mann-­‐Whitney	   U	   tests,	   Kruskal-­‐Wallis	   tests	   and	   Chi-­‐Square	   tests.	   The	   median	   is	  reported	   in	  most	   cases	   due	   to	   being	  more	   appropriate	   for	   non-­‐parametric	   tests.	   All	  statistical	   tests	   were	   two-­‐sided.	   Post	   hoc	   Mann-­‐Whitney	   U	   tests	   with	   a	   Bonferroni	  correction	  set	  at	  a	  significance	  level	  of	  0.0125	  (i.e.,	  p	  	  <	  0.05/4	  comparisons)	  were	  used	  to	  identify	  where	  significant	  difference	  existed	  between	  groups.	  A	  p-­‐value	  of	  less	  than	  0.05	  was	  considered	  to	  be	  statistically	  significant.	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4.6	  Results	  
4.6.1	  Profile	  of	  participants	  	  From	  the	  cohort	  of	  patients	  from	  the	  RCT	  (Alberts	  et	  al.,	  2005)	  using	  UDCA	  to	  prevent	  colorectal	   adenoma	   recurrence,	   26	   patients	  were	   recruited	   for	   the	   1HNMR	   study,	   17	  male	  and	  nine	  female	  patients.	  The	  mean	  age	  of	  the	  participants	  was	  63.8	  years	  (range	  40-­‐77	  years).	  	  	  The	  average	  BMI	  of	  all	  the	  participants	  was	  26.85	  (range	  17-­‐37).	  The	  demographic	  and	  clinical	   history	   characteristics	   of	   the	   26	   participants	   are	   shown	   in	   Table	   4.1.	   Nine	  patients	  were	  treated	  with	  the	  chemo-­‐preventative	  drug,	  UDCA	  of	  whom	  four	  recurred.	  Nine	  patients	  in	  total	  ended	  up	  recurrent	  adenomas	  in	  the	  NMR	  study	  group.	  The	  urine	  and	  faecal	  water	  extract	  samples	  from	  these	  patients	  were	  analysed.	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Table	  4.1	  Patient	  characteristics	  of	  the	  subgroup	  of	  patients	  used	  in	  the	  study:	  demographic	  and	  
clinicopathological	  characteristics	  of	  the	  sample	  (n	  =	  26).	  	  




	   	  Male	   17	   65	  Female	   9	   35	  	  	  Age	  (Years)	   	   	  40-­‐49	  	   2	   8	  50-­‐59	  	   4	   15	  60-­‐69	  	   12	   46	  70-­‐79	   8	   31	  
Anatomical	  Location	  of	  Adenoma	   	   	  Distal	  Colon	   10	   39	  Proximal	  Colon	   16	   62	  
Body	  Mass	  Index	  (BMI)	   	   	  Underweight	  [16.5-­‐18.4]	   1	   4	  Normal	  [18.5-­‐24.9]	   6	   24	  Overweight	  [25-­‐29.9]	   13	   52	  Obese	  [30-­‐40]	   5	   20	  
Smoking	  History	   	   	  Former	   13	   54	  Never	   11	   46	  
Treatment	   	   	  Not	  Treated	  (Placebo)	   16	   64	  Treated	  (UDCA)	   9	   36	  
Adenoma	  Recurrence	   	   	  No	  Recurrence	   16	   64	  Recurrence	   9	   36	  
Treatment	  with	  UCDA	  and	  Adenoma	  Recurrence	   	   	  Treatment,	  Recurrence	   4	   16	  Treatment,	  No	  Recurrence	   5	   20	  No	  Treatment,	  Recurrence	   5	   20	  No	  Treatment,	  No	  Recurrence	   11	   44	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4.7	  Results	  of	  Faeces	  Sample	  Tests	  Fifty-­‐five	   metabolites	   were	   identified	   from	   the	   faecal	   water	   1H	   NMR	   spectra.	   A	  representative	   spectrum	   of	   the	   samples	   is	   shown	   in	   Figure	   4.3.	   The	   metabolites	  present	   in	   more	   than	   50	   per	   cent	   of	   the	   samples	   are	   shown	   in	   Table	   4.2.	   The	  resonances	  were	  assigned	  based	  on	  Chenomx	  data	  and	  metabolites	  identified	  from	  the	  literature	   (Saric,	   2008,	   Martinez-­‐Bisbal	   et	   al.,	   2004,	   Nicholson	   et	   al.,	   1995).	   Spiking	  experiments	   were	   carried	   out	   to	   confirm	   the	   identifications	   of	   metabolites	   such	   as	  propionic	  acid	  and	  succinic	  acid.	  	  A	  variety	  of	  metabolites	  were	  identified	  from	  short	  fatty	  acids	  (SCFA)	  such	  as	  formate,	  acetate,	   propionate	   and	   butyrate	   to	   amino	   acids,	   TCA	   intermediates	   and	   purine	   and	  pyrimidine	   metabolites.	   The	   six	   highest	   concentrations	   of	   metabolites	   in	   the	   faecal	  water	   samples	  were	   acetate	   (mean	   =	   13.72,	   SD	   =	   6.3),	   butyrate	   (mean	   =	   5.14,	   SD	   =	  2.70),	  propionate	  (mean	  =	  4.49,	  SD	  =	  1.6),	  glutamate	  (mean	  =	  2.76,	  SD	  =	  0.91),	  alanine	  (mean	   =	   2.26,	   SD	   =	   1.5)	   and	   glucose	   (Mean	   =	   2.04,	   SD	   =	   1.82).	   Quantitatively,	   this	  metabonomic	  study	  has	  shown	  the	  3:1	  ratio	  of	  the	  presence	  of	  acetate	  and	  propionate	  in	  human	  colonic	  content.	  The	  metabolites	  that	  showed	  significant	  differences	  between	  patient	  characteristics	  are	  shown	  in	  Table	  4.3.	  	  .	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   Chemical	  shift	  (ppm)	  	  
Figure	  4.3	  A	   representative	   1H	  NMR	  NOESY	   spectrum	  of	   a	   faecal	  water	   extract	   sample.	   Spectra	  
were	   labelled	  using	  Chenomx	  and	  sources	   identified	   from	  the	   literature	  (Saric,	  2008,	  Martinez-­‐
Bisbal	  et	  al.,	  2004,	  Nicholson	  et	  al.,	  1995,	  Jacobs	  et	  al.,	  2008,	  Wu	  et	  al.,	  2010).	  Key:	  1	  –	  Formate,	  2	  –	  
Uracil,	  3-­‐	  Phenylalanine,	  4	  –	  Tyrosine,	  5	  –	  Fumarate,	  6	  –	  Glucose	  and	  amino	  acids,	  7	  –	  Lysine,	  8	  –	  
Propionate,	  9	  –	  Methionine,	  10	  –	  Acetate,	  11	  –	  Butyrate,	  12	  –	  Lactate.	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Table	   4.2	   Descriptive	   statistics	   of	   the	   35	   metabolites	   (mM)	   identified	   from	   the	   faecal	   water	  
samples.	   SD	   -­‐	   Standard	  Deviation.	  The	  multiplicity	   is	   shown	   in	  brackets:	   s-­‐singlet,	   d-­‐doublet,	   t-­‐
triplet,	  m-­‐multiplet,	  dd-­‐doublet	  of	  doublets,	  q-­‐quartet,	  and	  td-­‐triplet	  of	  doublet.	  
Metabolite	   Chemical	  Shift	  (ppm)	  and	  Multiplicity	  
Mean	  ±	  SD	  
(mM)	  
Median	  Acetate	   1.92(s)	   13.72±	  6.30	   14.53	  Butyrate	   0.90(t),	  2.16(t),	  1.56(m)	   5.14±	  2.75	   4.35	  Propionate	   2.19(q),	  1.06(t)	   4.49±	  1.61	   4.47	  Glutamate	   2.06(m),	  2.34(m),	  3.76(m)	   2.76±	  0.91	   2.71	  Alanine	   1.47(d),	  3.78(q)	   2.26±	  1.53	   1.75	  Glucose	   3.42(t),	   3.54(dd),	   3.71(t),	   3.83(dd),	  3.84(m),	  5.23(d)	   2.04±	  1.82	   1.61	  Glycerol	   3.56(dd),	  3.65(dd),	  3.78(m)	   1.87±	  0.86	   1.74	  Valerate	   0.88(t),	  1.30(m),	  2.19(t)	   1.42±	  0.63	   1.43	  Isobutyrate	   1.13(d)	   1.22±	  0.36	   1.23	  Valine	   0.98(d),	  1.04(d),	  2.27(m),	  3.59(d)	   1.17±	  0.71	   1.05	  Leucine	   0.94(d),	  0.96(d),	  1.71(m),	  3.73(t)	   1.14±	  0.65	   0.97	  Proline	   2.00(m),	   2.05(m),	   2.35(m),	   3.33(m),	  3.41(m),	  4.13(m)	   1.12±	  0.41	   0.92	  Glycine	   3.56(s)	   1.07±	  0.45	   0.95	  Aspartate	   2.70,	  2.80,	  3.90	   0.96±	  0.42	   0.84	  Glucose-­‐6-­‐Phosphate	  (G-­‐6-­‐P)	   	   0.89±	  0.55	   0.68	  Isoleucine	   0.93(t),	   1.0(d),	   1.28(m)	   1.48(m),	  3.67(d)	   0.85±	  0.49	   0.68	  Galactose	   5.2 ( ),	  3.81(dd),	  3.97(m)	   0.77	  ±	  0.32	   0.73	  Lysine	   1.46(m),	   1.71(m),	   1.90(m),	   3.05(t),	  3.77(t)	   0.77±	  0.36	   0.71	  Threonine	   3.59(d),	  4.26(m),	  1.33(d)	   0.75±	  0.36	   0.65	  Succinate	   2.41(s)	   0.74±	  1.05	   0.33	  Lactate	   1.33(d),	  4.12(q)	   0.67±	  0.36	   0.60	  Isovalerate	  	   0.91(d),	  2.06(d)	   0.55±	  0.18	   0.54	  Acetone	   2.24(s)	   0.54±	  0.28	   0.53	  Taurine	   3.26,	  3.42	   0.48±	  0.32	   0.39	  Methionine	   2.12(s),	  2.16(m),	  2.65(dd),	  3.87(m)	   0.47±	  0.15	   0.44	  Phenylalanine	   3.17(dd),	  3.99(dd),	  7.32(m),	  7.40(m),	  7.44(m)	   0.45±	  0.17	   0.43	  1,3-­‐Dihydroxyacetone	   4.43(s)	   0.44	  ±	  0.19	   0.43	  Malonate	   3.13(s)	   0.40±	  0.36	   0.27	  Fumarate	   6.53(s)	   0.38±	  0.30	   0.19	  Phenylacetate	   3.52(s),	  7.29(t),	  7.36(t)	   0.35±	  0.10	   0.34	  Tyrosine	   6.88(d),	  7.18(d)	   0.34±	  0.12	   0.33	  Formate	   8.46(s)	   0.32±	  0.29	   0.20	  Uracil	   5.81(d),	  7.59(d)	   0.32±	  0.14	   0.27	  Nicotinate	   7.51(dd),	   8.24(td),	   8.60(dd),	   8.92-­‐8.94(m)	   0.31±	  0.13	   0.27	  Methanol	   3.36(s)	   0.26±	  0.13	   0.21	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Table	   4.3	   Changes	   in	   metabolites	   with	   clinicopathological	   states	   that	   show	   significant	  
differences.	  	  	  




Mean	  ±	  SD	  
(mM)	  
Gender	  Male	  Female	   Malonate	   	  0.54	  ±	  0.51	  0.25	  ±	  0.04	  
Anatomical	  Location	  of	  Adenoma	  Distal	  colon	  Proximal	  colon	   1,	  3-­‐dihydroxyacetone	  	   	  0.33	  ±	  0.06	  0.52	  ±	  0.21	  
Adenoma	  Recurrence	  Recurrence	  
	  
	  No	  recurrence	  
	  
	  Propionate	  Succinate	  	  Propionate	  Succinate	  
	  6.75	  ±	  1.25	  0.25	  ±	  0.89	  	  3.98	  ±	  1.19	  1.09	  ±	  1.38	  
Treatment	   with	   UCDA	   and	   Adenoma	  
Recurrence	  Treated	  and	  recurrence	  Not	  treated	  and	  no	  recurrence	  
	  
	  Propionate	  	   	  	  6.50	  ±	  1.5	  3.98	  ±	  1.4	  	  SD	  -­‐	  standard	  deviation	  and	  the	  mean	  concentrations	  of	  the	  metabolites.	  Distal	  adenomas	  are	  present	  in	  the	  rectum,	  sigmoid,	  descending	  and	  left	  transverse	  colon.	  	  	  
(i)	  Association	  between	  gender	  and	  concentrations	  of	  metabolites	  A	  Mann-­‐Whitney	  U	  test	  was	  performed	  to	  evaluate	  if	  male	  and	  female	  patients	  would	  have	   different	   levels	   of	   metabolites	   in	   faecal	   water	   samples.	   All	   metabolites	   were	  analysed	   to	   test	   for	   statistical	   significance.	   There	   was	   a	   significant	   difference	   in	  malonate	  between	  the	  groups	  (U	  =	  24,	  p	  <	  0.05).	  Male	  patients	  had	  significantly	  higher	  levels	  of	  malonate	  (median	  =	  0.43,	  SD	  =	  0.51)	  than	  females	  (median	  =	  0.25,	  SD	  =	  0.04)	  (Figure	  4.4).	  All	  the	  other	  comparisons	  were	  not	  significant.	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Figure	  4.4	  Box	  plot	  illustrating	  the	  significantly	  higher	  levels	  of	  malonate	  (mM)	  in	  males	  (n	  =	  17)	  
than	  females	  (n	  =	  9)	  in	  faecal	  water	  samples.	  The	  median	  is	  indicated	  by	  the	  horizontal	  line.	  The	  
male	  median	  and	  range	  for	  malonate	  are	  higher	  than	  the	  female	  median.	  	  	  	  	  
(ii)	  Effect	  of	  adenoma	  recurrence	  and	  UDCA	  treatment	  on	  metabolite	  concentrations	  Propionate	  levels	  were	  found	  to	  be	  significantly	  higher	  in	  patients	  that	  had	  recurrent	  adenomas	   (median	   =	   5.19,	   SD	   =	   1.40)	   compared	   to	   the	   patients	  without	   recurrence	  (median	  =	  4.10,	  SD	  =	  1.30),	  with	  a	  p	  value	  of	  <	  0.05	  (Figure	  4.5).	  All	  other	  comparisons	  were	  not	  significant.	  The	  association	  between	  treatment	  and	  recurrence	  of	  adenomas	  showed	  no	  significant	  association	  between	  treatment	  and	  recurrence	  (χ2	  =	  0.435,	  p	  =	  0.51).	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Figure	  4.5	  Box	  plot	  illustrating	  the	  significant	  difference	  in	  propionate	  (mM)	  levels	  for	  colorectal	  
adenomas	  in	  patients	  with	  and	  without	  recurrence.	  The	  median	  and	  range	  of	  values	  is	  higher	  in	  
the	  recurrence	  group.	  	  
	  Nevertheless,	   the	   participants	   samples	   used	   in	   this	   1H	  NMR	   study	  who	  were	   treated	  with	  UDCA	  had	   lower	   recurrence	   than	   those	   in	   the	  placebo	   group.	   Propionate	   levels	  differed	   significantly	  as	   a	   function	  of	   treatment	  and	   recurrence	   status	   (χ2	   =	  7.71,	  p	  <	  0.05).	  Individuals	  who	  had	  been	  treated	  and	  had	  adenoma	  recurrence	  had	  significantly	  higher	  propionate	  levels	  than	  the	  group	  without	  treatment	  or	  recurrence	  (U	  =	  3.00,	  p	  <	  0.01).	  All	   other	   comparisons	  were	  not	   significant.	   The	   graph	   in	  Figure	  4.6	   illustrates	  the	   significant	   difference	   in	   propionate	   levels	   between	   treatment	   and	   recurrence	  status.	   The	   median	   levels	   for	   propionate	   and	   succinate	   were	   higher	   in	   the	   post-­‐treatment	  group	  (Figure	  4.7).	  On	  the	  other	  hand,	   the	  median	   level	  of	  propionate	  was	  higher	   in	   the	   recurrence	   group	   while	   the	   levels	   of	   succinate	   were	   lower	   in	   the	  recurrence	  group	  compared	  with	  the	  non-­‐recurrence	  group	  (Figure	  4.8).	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Figure	  4.6	  Box	  plot	  illustrating	  the	  significantly	  higher	  propionate	  (mM)	  levels	  in	  the	  Treatment	  
and	  Recurrence	  group	  compared	  with	  the	  other	  three	  groups.	  The	  median	  value	  for	  propionate	  is	  
much	  higher	  in	  the	  Treatment-­‐Recurrence	  group	  than	  in	  the	  other	  three	  groups.	  	  	  	  
	  
Figure	  4.7	  Succinate	  levels	  in	  faecal	  water	  samples	  of	  patients	  with	  colonic	  adenomas.	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  Intensity	  (a.u)	  	  	  	  	  	  
Figure	   4.8	   A	   median	   NMR	   spectrum	   of	   faecal	   water	   extracts	   showing	   the	   visual	   difference	   in	  
succinate	   at	   δ2.41	   ppm	   between	   individuals	   with	   recurrent	   (red)	   adenomas	   and	   individuals	  
without	  recurrence	  (black).	  a.u	  –	  absorbance	  units	  	  	  
(iii)	  Effects	  of	  patient	  factors	  on	  metabolite	  concentrations	  and	  adenoma	  recurrence	  There	  was	  no	  significant	  effect	  of	  BMI	  on	  metabolite	  levels	  among	  participants	  for	  all	  of	  the	  comparison	  tests.	  	  There	  was	  also	  no	  significant	  difference	  observed	  in	  metabolite	  concentration	   between	   ex-­‐smokers	   and	   individuals	   who	   had	   never	   smoked.	   Gender	  showed	  no	  significant	  association	  with	  recurrence	  (χ2	  =	  1.16,	  p	  =	  0.28).	  Only	  8	  per	  cent	  recurrence	  occurred	  in	  females	  compared	  with	  28	  per	  cent	  in	  male	  participants	  in	  the	  
1H	  NMR	  study	   sample	   set.	  The	  patients’	  BMI	  did	  not	  have	  any	   significant	  association	  with	  recurrence	  (p	  =	  0.32).	  	  
ppm	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(iv)	  Association	  between	  age	  and	  adenoma	  recurrence	  There	  was	  no	  significant	  association	  between	  age	  and	  recurrence	  (χ2	  =	  7.07,	  p	  =	  0.07).	  Although	  not	  statistically	  significant,	  the	  p	  value	  is	  approaching	  the	  significance	  level	  of	  0.05.	   Thus,	   there	   is	   positive,	   but	   not	   significant,	   association	   between	   age	   and	  recurrence	  of	  colonic	  adenomas	  in	  faecal	  water	  samples.	  In	  this	  patient	  group	  subset,	  the	  70-­‐79	  age	  group	  had	  the	  highest	  percentage	  of	  recurrence	  (16%),	  followed	  by	  the	  50-­‐59	   age	   group	   (12%).	   The	   lowest	   level	   of	   recurrence	  was	   in	   the	   60-­‐69	   age	   group	  (8%)	  and	  the	  40-­‐49	  age	  group	  had	  no	  recurrence.	  	  	  	  
(v)	  Association	  between	  age	  and	  metabolite	  concentrations	  A	  Kruskal-­‐Wallis	   test	   examined	   the	   hypothesis	   that	   age	   (within	   the	   four	   age	   groups	  previously	  outlined)	  will	  have	  an	  effect	  on	  faecal	  water	  extract	  metabolite	  levels.	  Table	  4.4	   and	   Figure	   4.9	   show	   the	   significant	   effect	   of	   age	   on	   a	   number	   of	   metabolites.	  Alanine	  levels	  showed	  significant	  difference	  with	  age	  as	  a	  whole	  (p	  <	  0.05).	  However,	  these	  were	  not	  statistically	  significant	  differences	  between	  the	  age	  groups.	  The	  40-­‐49	  age	   group	   had	   comparatively	   higher	   levels	   of	   alanine	   than	   the	   other	   age	   groups.	   As	  there	  were	  only	  two	  individuals	   in	  the	  40-­‐49	  age	  group	  and	  thus	  possibly	  skewing	  of	  the	  results,	  removing	  them	  from	  the	  analysis	  showed	  a	  significant	  difference	  between	  the	  three	  groups	  with	  X2	  =	  8.10,	  p	  =	  0.02.	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Table	   4.4	   Results	   of	   the	   Kruskal-­‐Wallis	   test	   and	   medians	   of	   the	   metabolites	   that	   were	  




P-­‐value	   Age	  Groups	  of	  Participants	  40-­‐49	   50-­‐59	   60-­‐69	   70-­‐79	  Median	  
Alanine	   8.80	   <0.05	   3.60	   1.03	  (0.19)*	   1.95	   2.33	  (1.07)*	  
Glutamate	   9.30	   <0.05	   4.04	   1.90	   2.59	   3.09	  
Glycine	   10.63	   <0.05	   1.05	   0.60	   1.00	   1.26	  
Isoleucine	   12.01	   <0.01	   0.80	   0.45	   0.70	   1.27	  
Tyrosine	   8.48	   <0.05	   0.37	   0.22	   0.36	   0.37	  
Valine	   8.48	   <0.05	   1.15	   0.70	   1.10	   1.40	  	  *	  P	  =	  0.01,	  number	  in	  brackets	  is	  the	  standard	  deviation.	  	  Age	  had	  a	  significant	  effect	  on	  glutamate	  (χ2	  =	  9.30,	  p	  <	  0.05)	  and	  glycine	  levels	  (χ2	  =	  10.63,	  p	  <	  0.05).	  Nevertheless,	  the	  box	  plot	  in	  Figure	  4.9	  shows	  that	  the	  40-­‐49	  years	  age	  group	  had	  the	  highest	  glutamate	  levels	  (Median	  =	  4.04),	  compared	  with	  the	  50-­‐59	  age	  group	  (Median	  =	  1.90),	  60-­‐69	  age	  group	  (Median	  =	  2.59),	  and	  70-­‐79	  age	  group	  (Median	  =	  3.09).	  After	  excluding	   the	  40-­‐49	  age	  group,	   there	  was	  a	   significant	  effect	  of	   age	  on	  glycine	   (χ2	   =	   9.90,	  p	   =	   0.007)	   and	   glutamate	   levels	   (χ2	   =	   6.51,	  p	   =	   0.039).	   The	  70-­‐79	  group	  had	  higher	  glycine	  levels	  (Mean	  Rank	  =	  8.50)	  than	  the	  50-­‐59	  group	  (Mean	  Rank	  =	  2.50).	  	  	  There	   was	   also	   a	   significant	   difference	   between	   the	   50-­‐59	   and	   60-­‐69	   groups	   (p	   =	  0.013).	  The	  60-­‐69	  group	  had	  higher	  levels	  of	  glycine	  (Mean	  Rank	  =	  10.17)	  than	  the	  50-­‐59	  group	  (Mean	  Rank	  =	  3.50).	  Isoleucine	  levels	  were	  also	  significantly	  affected	  by	  age	  (χ2	  =	  12.01,	  p	  <	  0.01).	  Tyrosine	  and	  valine	  levels	  also	  showed	  significant	  effects	  on	  age	  (p	  <	  0.05).	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  c)	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  e)	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Figure	  4.9	  Box	  plots	   showing	   the	   levels	  of	  metabolites	   (mM)	   in	   faecal	  water	  samples	   that	  were	  
significant	  or	  close	  to	  significance	  in	  various	  age	  groups	  (n=26).	  The	  different	  plots	  represent	  (a)	  
Alanine,	  (b)	  Glutamate,	  (c)	  Glycine,	  (d)	  Valine,	  (e)	  Isoleucine,	  and	  (f)	  Tyrosine.	   	  
a)	   b)	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  (vi)	  Association	  between	  anatomical	  location	  and	  metabolite	  concentrations	  The	   levels	   of	   1,3-­‐dihydroxyacetone	   were	   significantly	   higher	   in	   the	   proximal	   colon	  (Median	  =	  0.49,	  SD	  =	  0.21)	  compared	  with	  the	  distal	  colon	  (Median	  =	  0.33,	  SD	  =	  0.06)	  (p	  <	  0.01)	  (Figure	  4.10).	  	  	  	  	  	  	  	  	  	  
Figure	  4.10	  Box	  plot	  illustrating	  the	  significant	  difference	  in	  1,	  3-­‐dihydroxyacetone	  levels	  based	  
on	  anatomical	  location	  in	  the	  faecal	  water	  extract	  samples.	  	  	  
(vii)	  Two–dimensional	  (2-­‐D)	  faecal	  water	  experiments	  The	   J-­‐resolved	   experiments	   allow	   the	   separation	   of	   overlapping	   peaks	   into	   a	   second	  dimension	   and	   thereby	   enable	   the	   specific	   identification	   of	   metabolites	   or	   their	  confirmation	  from	  1-­‐D	  data.	  	  
(i)	  Time	  course	  experiments	  Two-­‐dimensional	   1H	   NMR	   experiments	   were	   conducted	   to	   evaluate	   the	   changes	   in	  metabolites	  levels	  over	  time,	  due	  to	  the	  longer	  duration	  of	  2-­‐D	  experiments	  compared	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with	   1-­‐D	   experiments.	   The	   2-­‐D	   experiments	   were	   also	   used	   to	   confirm	   the	  identification	  of	  some	  metabolites	  with	  regards	  to	  their	  multiplicity	  and	  chemical	  shift	  (Figure	  4.11).	  The	  duration	  for	  each	  standard	  NOESY	  experiment	  was	  46	  seconds	  and	  that	  of	  a	  standard	  JRES	  experiment	  1	  hour	  3	  minutes	  and	  47	  seconds.	  Both	  Figure	  4.12	  and	   Table	   4.5	   illustrate	   the	   concentration	   of	   metabolites	   with	   time	   during	   2-­‐D	  experiments.	   The	   results	   show	   there	  was	   a	  minimal	   change	   in	   the	   concentrations	   of	  metabolites	   over	   a	   period	   of	   6	   hours.	   Thus,	   indicating	   the	   stability	   of	   the	  metabolite	  concentrations	  over	  time.	  The	  percentage	  difference	  of	  metabolites	  varied	  as	  minimum	  as	  less	  than	  one	  per	  cent	  to	  up	  to	  20	  per	  cent.	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Figure	  4.11	  Two-­‐dimensional	   JRES	  1H	  NMR	  spectra	  showing	  the	  spectra	   from	  the	  1.2	  –	  3.5	  ppm	  
region	   and	   the	   3.5	   –	   10	   ppm	   region	   with	   corresponding	   1D	   skyline	   projection	   above.	   The	  
metabolites	  succinate	  (s),	  formate	  (s),	  alanine	  (d),	  and	  acetate	  (s)	  are	  shown.	   	  
	  Succinate	   Acetate	   Alanine	  
Formate	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Table	  4.5	  Integral	  regions	  of	  some	  of	  the	  faecal	  water	  metabolites	  following	  2-­‐D	  JRES	  
experiments	  over	  time.	  Measurements	  are	  to	  3	  decimal	  places	  to	  display	  true	  values.	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  
Figure	  4.12	  Changes	  with	   time	   in	   formate,	   succinate,	  propionate	  and	  alanine	   concentrations	   in	  
arbitrary	  units	  of	  a	  faecal	  water	  samples	  following	  2-­‐D	  1H	  NMR	  experiments.	  	   	  
Time	  (hours)	  
Metabolites	  
Formate	   Acetate	   Succinate	   Propionate	   Alanine	  00:38:25	   0.020	   17.322	   0.777	   1.910	   1.234	  01:42:58	   0.022	   17.915	   0.773	   2.148	   1.240	  02:47:31	   0.022	   17.742	   0.757	   2.021	   1.207	  03:52:04	   0.023	   17.879	   0.760	   2.121	   1.234	  04:56:37	   0.030	   17.639	   0.753	   2.199	   1.215	  06:01:10	   0.025	   17.208	   0.750	   2.116	   1.233	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4.8	  Results	  of	  Urine	  Sample	  Tests	  Twenty-­‐seven	  metabolites	  were	  identified	  as	  being	  present	  in	  over	  80	  per	  cent	  of	  the	  urine	  samples	  (Table	  4.6).	  The	  principal	  component	  analysis	  (PCA)	  using	  binned	  data	  did	  not	  reveal	  a	  distinct	  separation	  between	  patient	  groups	  based	  on	  treatment	  (Figure	  4.13)	   or	   recurrence.	   PLS-­‐DA	   was	   not	   used	   for	   further	   analysis,	   as	   it	   would	   be	  unsuitable	  for	  a	  small	  sample	  size.	  The	  metabolites	  that	  showed	  significant	  differences	  with	   colorectal	   adenomas	   recurrence	   are	   shown	   in	   Table	   4.7.	   Spiking	   experiments	  were	  performed	  to	  confirm	  identified	  metabolites	  of	  significant	  change.	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Table	   4.6	   Descriptive	   Statistics	   of	   27	   metabolites	   from	   urine	   samples	   (n	   =	   26).	   The	   urine	  
metabolites	  identified	  were	  the	  metabolites	  present	  in	  greater	  than	  1mM	  being	  Urea,	  Creatinine,	  
Hippurate	   and	   Citrate.	   Metabolites	   were	   identified	   using	   Chenomx	   and	   assignments	   for	   the	  
literature	  (Claus	  et	  al.,	  2008).	  	  
Metabolite	   Chemical	   shift	  
and	  multiplicity	  
Mean±	  SD	   Median	  
Urea	   5.79(s)	   24.00	  ±	  8.98	   22.60	  Creatinine	   3.06(s),	  4.06(s)	   6.64±	  4.82	   5.43	  Hippurate	   3.97(d),	   7.55(t),	  7.64(t),	  7.83(d)	   1.78±	  3.15	   1.00	  Citrate	   2.55(d),	  2.65(d)	   1.76±	  1.21	   1.52	  Glycine	   3.56(s)	   0.84±	  0.76	   0.45	  Taurine	   3.27(t),	  3.43(t)	   0.53	  ±	  0.43	   0.39	  Trimethylamine	  N-­‐oxide	  (TMAO)	   3.26(s)	   0.42±	  0.42	   0.26	  Glycolate	   3.95(s)	   0.39	  ±	  0.24	   0.34	  Guanidoacetate	   3.80(s)	   0.34	  ±	  0.25	   0.26	  Dimethylamine	   2.72(s)	   0.29	  ±	  0.30	   0.19	  Alanine	   3.77(q),	  1.48(d)	   0.24±	  0.20	   0.16	  Creatine	   1.88(m)	   0.24±	  0.14	   0.25	  Lactate	   4.12(q),	  1.33(d)	   0.18±	  0.15	   0.14	  Acetoacetate	   2.28(s)	   0.13	  ±	  0.11	   0.08	  Formate	   8.46(s)	   0.12±	  0.10	   0.10	  Succinate	   2.41(s)	   0.11±	  0.18	   0.05	  Xanthine	   7.92(s)	   0.11±	  0.10	   0.09	  Acetate	   1.92(s)	   0.10±0.06	   0.08	  Trigonelline	   4.43(s),	   8.07(t),	  8.80-­‐8.85(m),	  9.11(s)	   0.10±0.06	   0.10	  Adenine	   8.17(s),	  8.19(s)	   0.08±0.09	   0.05	  Hypoxanthine	   8.11(s),	  8.10(s)	   0.07±0.04	   0.06	  2-­‐hydroxy-­‐isobutyrate	   1.35(s)	   0.05±0.04	   0.04	  3-­‐hydroxy-­‐isovalerate	   1.24(s)	   0.05±0.03	   0.05	  Methanol	   3.36(s)	   0.05±0.03	   0.04	  Pyruvate	   2.41(s)	   0.04±0.04	   0.02	  Acetone	   2.23(s)	   0.03±0.02	   0.03	  Trimethylamine	  (TMA)	   2.91(s)	   0.01±0.01	   0.01	  	  SD	  -­‐	  Standard	  deviation.	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Figure	  4.13	  PCA	  from	  urine	  samples	  using	  binned	  data.	  R2X	  [1]	  =	  0.605	  and	  R2X	  [2]	  =	  0.131.	  The	  
two	  outliers	  are:	  (1)	  the	  only	  female	  patient	  that	  was	  treated	  and	  had	  adenoma	  recurrence,	  and	  
(2)	  a	  male	  patient	  with	  no	  treatment	  or	  recurrence.	  	  
	  	  
Table	  4.7	  The	  metabolites	  that	  change	  with	  adenoma	  recurrence	  in	  urine	  samples.	  The	  values	  
represent	  the	  Median±	  SD	  (standard	  deviation).	  
Adenoma	  Recurrence	  
	  
Citrate	   Formate	  
	  Recurrence	  
	  No	  recurrence	  
	  
0.67	  ±	  0.44	  	  1.84	  ±	  2.35	  	  
0.06	  ±	  0.02	  	  0.13	  ±	  0.11	  	  
	  	   	  
1	  
2	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(n	  =	  9)	  
Female	  Median	  	  
(n	  =	  6)	  
Mann	  Whitney	  	  
U	  Test	  
Z-­‐score	  
3-­‐hydroxy-­‐isovalerate	   0.04	   0.06	   39.00	   -­‐2.02*	  Acetate	   0.07	   0.14	   30.00	   -­‐2.51**	  Acetoacetate	   0.06	   0.2	   30.00	   -­‐2.51**	  Acetone	   0.02	   0.04	   36.00	   -­‐2.18*	  Alanine	   0.12	   0.28	   36.00	   -­‐2.18*	  Glycolate	   0.23	   0.55	   40.00	   -­‐1.97*	  Hypoxanthine	   0.04	   0.09	   30.00	   -­‐2.38*	  Methanol	   0.04	   0.05	   37.00	   -­‐2.13*	  Succinate	   0.05	   0.11	   36.00	   -­‐2.18*	  Trimethylamine	  N-­‐oxide	   0.23	   0.57	   38.00	   -­‐2.06*	  *	  =	  Significant	  at	  the	  0.05	  level.	  	  	  **	  =	  Significant	  at	  the	  0.01	  level	  	  	  
(ii)	  Association	  between	  adenoma	  recurrence	  and	  metabolite	  concentrations	  Figure	  4.14	   illustrates	   the	  significant	  difference	   in	  citrate	   levels	  based	  on	  recurrence.	  Citrate	  levels	  were	  significantly	  higher	  in	  the	  no	  recurrence	  group	  than	  the	  recurrence	  group	  with	  U	  =	  36.00,	  p	  <	  0.05.	  Formate	  levels	  were	  also	  significantly	  higher	  in	  the	  no	  recurrence	   group	   compared	   to	   the	   recurrence	   group	   (U	   =	   33.00,	   p	   <	   0.05).	   The	  difference	  in	  formate	  levels	  based	  on	  recurrence	  and	  UDCA	  treatment	  indicates	  much	  higher	  levels	  in	  the	  adenoma	  non-­‐recurrence	  group	  compared	  to	  the	  group	  of	  patients	  with	  adenoma	  recurrence	  (Figure	  4.15).	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Figure	  4.14	   (a)	  Box	  plot	   showing	  citrate	   (δ2.55	  ppm)	   levels	   for	  colorectal	  adenoma	  recurrence	  
and	   no	   recurrence	   patient	   groups	   in	   urine	   samples.	   (b)	   Citrate	   level	   changes	   with	   UDCA	  
treatment	  and	  colorectal	  adenoma	  recurrence.	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(a)	  	  	  	  	  	  	  	  	  
(b)	  
	  
Figure	  4.15	  (a)	  Box	  plot	  illustrating	  the	  difference	  in	  formate	  levels	  for	  adenoma	  recurrence	  and	  
no	  recurrence	  groups,	   in	  urine	  samples.	   (b)	  Formate	   levels	   changes	  with	   treatment	  with	  UCDA	  
and	  recurrence.	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  (iii)	  Association	  between	  treatment	  and	  adenoma	  recurrence	  	  There	  was	  no	  significant	  association	  between	  treatment	  and	  adenoma	  recurrence	  (χ2	  =	  0.59,	   p	   =	   0.44).	   Nevertheless,	   the	   participants	   in	   this	   subset	   group	   from	   the	   original	  study	  who	  were	   treated	   had	   lower	   recurrence	   (16%)	   than	   those	   not	   treated	   (20%).	  The	  results	  of	  the	  test	  showed	  no	  significant	  effect	  of	  treatment	  and	  recurrent	  status	  on	  urine	  metabolite	  levels	  for	  all	  comparison	  tests.	  On	  average,	  urea	  and	  creatinine	  levels	  were	  higher	  in	  the	  placebo	  group	  of	  patients	  without	  colorectal	  adenoma	  (Figure	  4.16).	  Citrate	   levels	   were	   also	   higher	   in	   the	   non-­‐treated,	   no	   recurrence	   group.	   Hippurate	  levels	   were,	   however,	   in	   comparison,	   higher	   in	   the	   treated	   and	   recurrence	   groups.	  There	   was	   a	   positive	   correlation	   between	   urinary	   citrate	   and	   urinary	   formate	   (p	  <	  0.001)	   (see	   Appendix	   II).	   The	   results	   show	   that	   as	   urinary	   citrate	   levels	   increased,	  urinary	   formate	   levels	   increased.	   However,	   there	   was	   no	   significant	   correlation	  between	  urine	  and	  faecal	  water	  metabolites.	  In	  the	  faecal	  water	  samples,	  the	  levels	  of	  formate	  were	  similar	  in	  the	  non-­‐recurrence	  and	  recurrence	  groups.	  
(a)	   	   	   	   	   	   (b)	  	  	  	  	  	  	  	  
Figure	  4.16	  Means	  with	  Standard	  Errors	  Bars	  for	  the	  Treated	  versus	  Not	  Treated	  groups	  (a)	  Urea	  
and	  (b)	  Creatinine	  levels	  in	  urine	  samples.	  The	  centre	  of	  each	  line	  is	  the	  mean	  ±	  1	  SE,	  and	  error	  
bars	  represent	  the	  95%	  confidence	  interval.	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(iv)	  Effect	  of	  body	  mass	  index	  (BMI)	  and	  metabolite	  concentrations	  Figure	  4.17	  shows	  the	  hippurate	  levels	  differed	  significantly	  as	  a	  function	  of	  BMI	  (χ2	  =	  6.36,	  p	  <	  0.05).	  The	  median	  value	  is	  much	  higher	  in	  the	  normal	  group	  versus	  the	  obese	  group.	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  4.17	  Box	  plot	  illustrating	  the	  significant	  difference	  in	  hippurate	  levels	  for	  body	  mass	  index	  
(BMI)	  groups,	  in	  urine	  samples.	  	  	  	  	  
(v)	  Association	  between	  clinicopathological	  data	  and	  metabolite	  concentrations	  There	  was	  no	  significant	  effect	  of	  age,	  anatomic	   location	  (distal	  versus	  proximal)	  and	  smoking	  on	  urine	  metabolites.	  There	  was	  also	  no	  significant	  association	  between	  age	  and	  adenoma	  recurrence	  (χ2	  =	  6.50,	  p	  =	  0.09).	  Although	  not	  statistically	  significant,	  the	  
p	   value	   is	   approaching	   the	   significance	   level	   of	   0.05.	   Thus,	   there	   is	   positive,	   but	   not	  significant,	   association	   between	   age	   and	   recurrence	   in	   urine	   samples.	   From	   the	  analysed	   samples	   by	   1H	   NMR,	   the	   70-­‐79	   age	   group	   had	   the	   highest	   percentage	   of	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recurrence	   (15.38%)	   followed	  by	   the	  50-­‐59	  age	  group	   (11.54%).	  The	   lowest	   level	  of	  recurrence	  was	   in	  60-­‐69	  age	  group	  (7.69%),	   the	  40-­‐49	  age	  group	  had	  no	  recurrence.	  There	  was	  also	  no	  significant	  association	  between	  gender	  and	  recurrence	  (χ2	  =	  0.93,	  p	  =	  0.33).	  Recurrence	  occurred	  in	  7.69	  per	  cent	  of	  female	  participants	  and	  26.92	  per	  cent	  of	  male	  participants.	   	  There	  was	  no	  significant	  association	  between	  body	  mass	   index	  and	  recurrence	  (χ2	  =	  2.81,	  p	  =	  0.25).	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4.9	  Discussion	  The	  presence	   and	   recurrence	   of	   colorectal	   adenomas	   act	   as	   a	   risk	  markers	   of	   future	  CRC.	  The	  metabonomic	  profiles	  studied	  in	  this	  chapter	  is	  from	  the	  phase	  III	  RCT;	  found	  that	  UDCA	  was	  non-­‐statistically	   significantly	   associated	  with	   a	  decrease	   in	   colorectal	  adenomas	  (Alberts	  et	  al.,	  2005).	  However,	  there	  was	  a	  statistically	  significant	  (39	  per	  cent)	   reduction	   in	   adenoma	   recurrence	   of	   high-­‐grade	   dysplasia.	   The	   results	   of	   the	  metabolic	   profiling	   study	   carried	   out	   in	   this	   chapter	   show	   the	   metabolic	   changes	  related	  to	  treatment	  with	  UDCA	  and	  colorectal	  adenoma	  recurrence	  were	  identified	  in	  urine	  and	  faecal	  water	  extract	  metabolites	  from	  SCFAs	  and	  TCA	  cycle	  intermediates.	  	  Colonic	  bacteria	  play	  a	   large	  role	   in	   the	  metabolism	  of	  an	   individual.	  Colonocytes	  are	  known	  to	  have	  anaerobic	  bacteria	  that	  produce	  SCFAs	  such	  as	  acetate,	  propionate	  and	  butyrate	  (McNeil	  et	  al.,	  1978).	  SCFAs	  are	  organic	  fatty	  acids	  which	  are	  generated	  from	  the	  intestinal	  bacterial	  fermentation	  of	  carbohydrates	  and	  proteins	  (Cummings,	  1983).	  Bile	  acids	  at	  high	  concentrations	  can	  be	  toxic	  to	  mammalian	  cells	  (Amaral	  et	  al.,	  2009)	  but	  the	  fact	  that	  they	  are	  produced	  in	  the	  liver	  and	  then	  secreted	  in	  the	  intestine	  makes	  their	   interaction	  with	   gut	  microflora	   and	   disease	   pathogenesis	   crucial.	   The	   different	  proportions	  of	  microbes	  present	  may	  predispose	  an	  individual	  to	  colorectal	  adenomas	  and	  subsequently	  CRC.	  	  	  SCFAs	   play	   an	   important	   role	   here:	   acetate,	   for	   example,	   is	   essential	   for	  muscle	   and	  brain	  cells,	  propionate	   for	  gluconeogenesis	  and	  butyrate	   for	  enterocytes.	  Acetate	  and	  propionate	  are	  also	   thought	   to	  have	  an	  effect	  on	  cholesterol	  production	  (Wong	  et	  al.,	  2006,	   Hamer	   et	   al.,	   2008,	   Wolever	   et	   al.,	   1991,	   Noble,	   1995).	   Colonic	   cells	   utilise	  butyrate	  as	  an	  energy	  source	  and	  it	  is	  thought	  to	  cause	  colon	  cancer	  cell	  differentiation.	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Changes	  in	  acetate,	  butyrate	  and	  propionate	  have	  been	  identified	  following	  treatment	  with	   acarbose,	   an	   α-­‐glucosidase	   inhibitor,	   used	   for	   treating	   non-­‐insulin	   dependent	  diabetes,	  which	  inhibits	  starch	  digestion	  (Wolin	  et	  al.,	  1999).	  	  In	   the	  experiments	  presented	   in	   this	  chapter,	   the	   levels	  of	  propionate	  were	  higher	   in	  patients	   that	   had	   colorectal	   adenoma	   recurrence	   compared	   to	   no	   recurrence.	  Prominent	  metabolite	  signals	  of	   the	  SCFA	  have	  been	  reported	   in	   faecal	  water	  extract	  samples	   in	   CRC	   (Monleon	   et	   al.,	   2009)	   as	   in	   the	   present	   study.	   However,	   unlike	  previous	  studies	  there	  was	  no	  statistically	  significant	  difference	  in	  acetate	  or	  butyrate	  in	  CRC	  compared	  to	  controls.	  Other	  studies	  have	  shown	  that	   the	  addition	  of	  butyrate	  and	  propionate	  to	  HT-­‐29	  adenocarcinoma	  cell	  lines	  inhibited	  growth,	  hence	  suggesting	  a	   protective	   effect	   of	   these	  metabolites	   (Gamet	   et	   al.,	   1992,	   Scheppach	   et	   al.,	   1995).	  Conversely,	   in	   this	   metabolic	   profiling	   study,	   patients	   that	   had	   adenoma	   recurrence	  had	  higher	  levels	  of	  propionate	  than	  non-­‐recurrent	  patients.	  	  	  Changes	   in	   butyrate	   and	   taurine	   as	   discussed	   in	   chapter	   1	   are	   associated	   with	   CRC	  (Moreno,	  1996,	  Monleon	  et	  al.,	  2009).	   In	  this	  study,	  the	  level	  of	  butyrate	  and	  formate	  were	   higher	   in	   the	   patients	   that	   had	   adenoma	   recurrence	   compared	   with	   the	   non-­‐recurrence	   group.	   However,	   there	   were,	   lower	   levels	   of	   taurine	   in	   the	   recurrence	  group.	   Interestingly,	   succinate	   levels	  had	   the	  opposite	  effect	  on	  adenoma	  recurrence,	  with	  lower	  levels	  in	  faecal	  water	  extracts.	  There	  seems	  to	  be	  a	  down	  regulation	  of	  some	  TCA	   cycle	   intermediates	   in	   colorectal	   adenomas	   and	   potentially	   carcinoma.	   Lower	  levels	   of	   urinary	   succinate	   and	   citrate	   were	   also	   reported	   in	   the	   CRC	   compared	   to	  controls	   that	   have	   been	   associated	  with	   alteration	   in	   the	   structure	   of	   gut	  microflora	  (Qiu	  et	  al.,	  2010).	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Human	  colonocytes	  are	  known	  to	  produce	  ketone	  bodies	  such	  as	  acetoacetate	  from	  n-­‐butyrate	  which	  has	  been	  reported	  as	  the	  primary	  fuel	  for	  colonocytes	  in	  the	  presence	  of	   glucose	   (Roediger,	   1980).	   Nonetheless,	   in	   the	   faecal	   water	   extract	   samples;	   there	  was	  no	  difference	  in	  butyrate	  concentration	  levels	  with	  individuals	  that	  had	  adenoma	  recurrence.	   The	   accumulation	   of	   SCFAs	   has	   been	   associated	   with	   a	   decrease	   of	  potential	  tumour	  activity	  of	  secondary	  bile	  acids	  (Grubben	  et	  al.,	  2001).	  The	  profile	  of	  bile	  acids	  is	  heavily	  dependent	  on	  gut	  microbial	  activity,	  as	  they	  convert	  primary	  bile	  acids	   to	   secondary	   ones.	   Consequently,	   the	   suppression	   of	   gut	   microbes	   with	  antibiotics	   has	   been	   associated	  with	   an	   alteration	   in	   bile	   acids	   (Swann	   et	   al.,	   2010).	  Therefore,	   the	  manipulation	  of	  gut	  microbes	  may	  alter	   the	  pathogenesis	  of	  colorectal	  adenomas	  and	  subsequently	  carcinoma.	  	  	  A	  number	  of	  hypotheses	  have	  been	  made	  that	  distal	  and	  proximal	  colon	  tumours	  have	  different	   pathophysiologies,	   as	   their	   embryological	   origins	   are	   different.	   As	  embryological,	  the	  proximal	  colon	  develops	  from	  the	  midgut	  and	  the	  distal	  colon	  from	  the	  hindgut	  (Bufill,	  1990).	  The	  finding	  here	  of	  the	  difference	  in	  1,	  3-­‐dihydroxyacetone	  levels	  between	  proximal	  and	  distal	  adenomas	  may	  be	  related	  to	  this,	  with	  higher	  levels	  in	  the	  proximal	  than	  distal	  adenomas.	  	  	  A	  number	  of	  urinary	  metabolites	  from	  CRC	  patients	  have	  been	  identified	  from	  the	  TCA	  cycle	  as	  well	  as	  the	  gut	  flora	  metabolism	  (Qiu	  et	  al.,	  2010),	  as	  in	  the	  current	  study.	  TMA	  is	   derived	   from	   gut	   microbe	   degradation	   of	   food	   components	   such	   as	   choline	   and	  carnitine	   or	   fish-­‐based	  meals	   (Zuppi	   et	   al.,	   1997).	   Although	   no	   significant	   difference	  was	  found	  between	  age	  and	  recurrence	  in	  urine	  samples,	  a	  larger	  sample	  size	  in	  future	  research	  might	  detect	  a	  significant	  difference.	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The	  relationship	  between	  diet	  and	  cancer	  can	  be	  thought	  of	  as	  being	  analogous	  to	  the	  relationship	   of	   the	   reactants	   to	   the	   products,	   as	   the	   interaction	   between	   the	   dietary	  intake	  and	  the	  reaction	  of	  gut	  microbes	  on	  them	  has	  an	  effect	  on	  the	  bile	  acid	  products	  and	  consequently	  the	  metabolites	  produced	  (Figure	  4.18).	  Dietary	  factors	  are	  thought	  to	  be	  associated	  with	  the	  composition	  of	  bile	  acids	  and	  gut	  microbes	  as	  the	  diet	  of	  an	  individual	   will	   have	   an	   impact	   on	   the	   faecal	   pH	   and	   thus	   the	   intestinal	   bacteria	  (Cummings	  et	  al.,	  1978).	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  4.18	  The	  relationship	  between	  diet,	  gut	  microbes	  and	  metabolites.	  
	  Supportive	  data	  from	  mice	  studies	  have	  shown	  that	  the	  suppression	  of	  Fasting-­‐induced	  adipocyte	  factor	  (Fiaf)	  by	  gut	  microbes	  promotes	  adiposity,	  hence	  the	  influence	  of	  gut	  microbes	   on	   diet	   as	   part	   of	   their	   “environmental”	   effect	   (Backhed	   et	   al.,	   2004).	   In	  addition,	   changes	   have	   been	   reported	   in	   SCFAs	   such	   as	   acetate	   in	   faecal	   samples	   of	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leptin	  deficient	   and	   lean	  mice.	  Accordingly,	   suggesting	   a	   change	   in	   gut	  microbiota	   in	  relation	  to	  obesity	  (Murphy	  et	  al.,	  2010).	  	  	  The	  gut	  microbiota	  is	  heterogeneous	  and	  variable	  in	  humans.	  The	  hypothesis	  that	  the	  relationship	   between	   dietary	   fat	   and	   intestinal	   bacteria	   producing	   carcinogens	   that	  promote	  CRC	  development	  has	  been	  present	  since	  1970s;	  hence,	  keeping	  with	  the	  idea	  that	  diet	  has	  a	  significant	  impact	  on	  the	  aetiology	  of	  CRC,	  as	  does	  geographical	  location.	  	  Studies	   have	   shown	   difference	   in	   bacterial	   species	   based	   on	   location.	   British	   and	  American	   individuals	   have	   higher	   levels	   of	   gram-­‐negative	   anaerobes	   such	   as	  
Bacteroides	  spp	  compared	  to	  Indians	  and	  Ugandans	  (Berthod	  et	  al.,	  1995).	  	  Conversely,	  Indians	  had	  more	  aerobic	  species	  such	  as	  Streptococci	  and	  Enterobacteria	  and	  lower	  faecal	  steroid	  concentrations.	  These	  steroids	  are	  dehydroxylated	  extensively	  in	   individuals	   living	   in	   high-­‐risk	   areas	   for	   CRC.	   The	   enterohepatic	   circulation	   is	   the	  most	  efficient	  route	  for	  co-­‐metabolism	  of	  bile	  acids	  and	  drugs	  between	  gut	  microbome	  and	   the	  human	   colonic	  mucosa	   (Miller	   and	  Wolin,	   1996).	   The	   final	   direct	   link	   of	   the	  exact	  type	  of	  carcinogen	  produced	  by	  gut	  microbes	  in	  the	  development	  of	  CRC	  is	  yet	  to	  be	   elucidated.	   Moreover,	   this	   metabolic	   profiling	   study	   provides	   pilot	   data	   into	   the	  interactions	  between	  a	  chemopreventive	  agent	  such	  as	  UDCA	  and	  gut	  microbes.	  	  Males	   have	  been	   found	   to	   be	   at	   a	   greater	   risk	   of	   developing	   adenomas	   than	   females	  (Yamaji	  et	  al.,	  2004).	  Treatment	  with	  UDCA	  has,	  however,	  been	  shown	  to	  significantly	  reduce	   advanced	   lesions	   (OR	   =	   0.62,	   95%	   CI	   0.43-­‐0.80)	   in	   male	   but	   not	   in	   female	  participants.	   Conversely,	   an	   increase	  was	   observed	   in	   female	   participants	   under	   the	  age	  of	  65	  years	   (OR	  =	  3.24,	  95%	  CI	  1.10-­‐9.56)	   (Thompson	  et	   al.,	   2009).	  Therefore,	   a	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targeted	  approach	  in	  chemopreventive	  measures	  in	  high-­‐risk	  individuals	  may	  prove	  to	  be	  more	  beneficial.	  	  Faecal	   water-­‐based	   NMR	   metabonomics	   offers	   an	   enormous	   opportunity	   of	  understanding	   the	   intimate	   connections	   between	   human	   intestinal	   mucosa	   and	   gut	  microbes.	   The	   complex	   mechanistic	   relationship	   between	   the	   gut	   microflora	   and	  humans	   in	   terms	   of	   physiology	   and	   metabolism	   is	   yet	   to	   be	   fully	   explained.	   Hence,	  further	  understanding	  of	  these	  mechanisms	  and	  benefits	  are	  still	  to	  be	  explored.	  In	  the	  effort	   of	   identifying	   robust	   classifiers	   of	   treatment	   and	   recurrence,	   the	   fact	   that	   not	  many	   significant	   difference	   metabolic	   signatures	   were	   identified	   based	   on	   age	   and	  gender	  from	  both	  faecal	  water	  extracts	  and	  urine	  is	  encouraging.	  So,	  it	  may	  be	  possible	  to	  identify	  biomarker	  panels	  for	  monitoring	  of	  treatment	  response.	  	  The	   use	   of	   urine	   and	   faecal	   water	   extracts	   for	   diagnostics	   or	   monitoring	   of	   disease	  progression	   from	   colorectal	   adenomas	   to	   cancer	   offers	   huge	   potential	   to	   benefit	  patient	   management.	   With	   regards	   to	   CRC	   screening,	   studies	   such	   as	   these	   could	  complement	   current	   faecal	   occult	   blood	   screening	   methods	   to	   aid	   non-­‐invasive	  techniques.	   Additionally,	   the	   potential	   use	   of	   a	   waste	   product	   as	   a	   monitoring	   tool	  would	   be	   attractive	   in	   clinical	   practice	   as	   the	   use	   of	   sterile	   equipment	   would	   be	  minimised	  and	  be	  more	  cost	  effective.	  The	  challenge	  would	  be	   to	   find	  ways	   in	  which	  the	  gut	  microbiota	  could	  be	  coaxed	  into	  tilting	  the	  balance	  of	  cytotoxic	  secondary	  bile	  acids	  such	  as	  DCA	  to	  cytoprotective	  tertiary	  bile	  acids	  such	  as	  UDCA.	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4.10	  Conclusion	  The	   primary	   goal	   of	   current	   CRC	   screening	   strategies	   is	   to	   identify	   adenomas	   early	  before	   they	   progress	   to	   carcinomas.	   However,	   recurrence	   of	   adenomas	   causes	   a	  significant	   impact	   on	   CRC	   screening.	   Therefore,	   a	   chemopreventive	   agent	   would	   be	  complementary	   to	   the	   strategies	   towards	   preventing	   CRC.	   The	   future	   of	  chemoprevention	   in	   CRC	   may	   be	   as	   an	   adjuvant	   therapy	   to	   CRC	   screening	   and	  metabonomics	  playing	  a	  role	  in	  personalising	  novel	  chemopreventive	  strategies.	  	  A	  single	  drug	  for	  all	  may	  not	  be	  the	  key	  to	  chemoprevention	  due	  to	  the	  heterogeneous	  nature	  of	  CRC	  and	  therefore	  colorectal	  adenomas.	   It	   is	  of	  paramount	   importance	  also	  that	   chemopreventive	  measures	  do	  not	   affect	   healthy	   cells	   but	   to	   strategically	   target	  potential	  malignant	  precursor	  cells.	  The	  findings	  in	  this	  preliminary	  study	  indicate	  the	  role	  of	   the	  gut	  microbes	   in	   the	  metabolic	  profiling	  of	  an	  agent	   such	  as	  UDCA.	   Indeed	  studies	   have	   shown	   that	   the	   gut	   microbome	   strongly	   interacts	   with	   the	   host	   and	  therefore	  has	  an	  influence	  on	  the	  metabolic	  phenotypes.	  	  These	  metabolic	  phenotypes	  of	  an	  individual	  are	  important	  determinants	  of	  drug	  response	  outcomes,	  (Holmes	  and	  Nicholson,	   2005,	   Clayton	   et	   al.,	   2006)	   thereby	   allowing	   for	   the	   future	   direction	   of	  personalization	  of	  medicine.	  The	  use	  of	  chemoprevention	  lies	   in	  the	  ability	  to	  stratify	  patients	   into	   low	   and	   high	   risk	   so	   as	   to	   be	   able	   to	   offer	   personalized	   therapy.	   The	  ability	   to	  manipulate	   the	   gut	  microbes	   to	   tilt	   the	   balance	   towards	   the	   production	   of	  tertiary	   bile	   acids	   such	   as	  UDCA	  may	   enable	   cancer	   control.	  Metabolic	   profiling	  may	  offer	  the	  path	  towards	  personalized	  chemoprevention,	  as	  individual	  metabolic	  profiles	  are	  mapped	  thereby	  embracing	  the	  prevention	  is	  better	  than	  cure	  strategy.	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CHAPTER	  5	  
Effects	  of	  neo-­‐adjuvant	  chemotherapy	  and	  radiotherapy	  (CRT)	  on	  the	  metabolic	  
profiles	  of	  rectal	  cancer	  patients	  
5.1	  Abstract	  Neo-­‐adjuvant	   chemoradiotherapy	   is	  part	   of	   the	   standard	   treatment	  of	   care	   for	  down	  staging	   rectal	   cancers	   prior	   to	   surgery.	   However,	   the	   exact	   impact	   of	   treatment	  response	   is	   a	   challenge	   to	   predict,	   with	   toxicity	   of	   treatment	   being	   an	   added	  complication.	  The	  metabolic	  profiles	  of	  patients	  undergoing	  chemoradiotherapy	  were	  assessed	  at	  different	  time	  courses	  using	  serum	  and	  plasma	  samples.	   	  Control	  patients	  with	   no	   colorectal	   pathology	   and	   ones	   with	   colonic	   polyps	   were	   included	   in	   the	   1H	  NMR	   experiments.	   Pattern	   recognition	   analysis	   and	   statistical	   analysis	  were	   used	   to	  identify	  metabolic	  changes	  between	  the	  patient	  groups.	  	  The	  1H	  NMR	  analysis	  showed	  higher	   levels	   in	   lactate	   and	   choline	   metabolites	   in	   the	   patients	   with	   rectal	   cancer	  undergoing	  chemoradiotherapy	  compared	  to	  controls.	  	  Statistically	  significant	  changes	  between	  the	  groups	  were	  also	  observed	  in	  low-­‐density	  lipoproteins,	  glycoproteins	  and	  amino	   acids	   such	   as	   valine	   and	   glutamine.	   	   Lipids	   in	   the	   form	   of	   phospholipids	   and	  components	   of	   their	   synthesis	   were	   found	   to	   account	   for	   the	   distinct	   separation	   of	  sample	  sets	  using	  PCA	  and	  PLS-­‐DA	  analysis	  based	  on	  response	  to	  chemoradiotherapy.	  Therefore,	   using	   metabonomic	   techniques	   it	   may	   be	   possible	   to	   be	   able	   to	   monitor	  response	  to	  chemoradiotherapy	  early	  and	  hence	  potentially	  avoid	  toxicity	  effects	  and	  be	  able	  to	  individualise	  therapy.	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5.2	  Introduction	  Body	  fluids	  render	  themselves	  amenable	  to	  the	  monitoring	  of	  disease	  states	  as	  well	  as	  responses	  to	  drugs.	  Therefore,	  in	  addition	  to	  metabonomics	  being	  used	  for	  toxicology	  studies,	  it	  can	  reflect	  both	  intrinsic	  molecular	  and	  metabolic	  host	  activities.	  	  Being	  able	  to	   study	  biofluids	   could	  aid	   specific	   stratification	  of	   chemotherapy	  and	   radiotherapy.	  Thereby	   allowing	   the	   potential	   to	  make	   therapy	   individualised	  by	  matching	   the	   best	  drug	  for	  each	  patient.	  	  Chemotherapy	   and	   radiotherapy	   provide	   the	   mainstay	   of	   non-­‐surgical	   treatment	   of	  CRC.	   Patients	   with	   poor	   prognosis	   cancers	   are	   offered	   neo-­‐adjuvant	   therapy	   in	   the	  form	   of	   chemotherapy	   and	   radiotherapy	   in	   order	   to	   eradicate	   potential	   micro-­‐metastasis.	   	   The	   response	   to	   radiotherapy	   between	   patients	  with	   CRC	   is	   variable.	   It	  depends	   on	   cellular,	   proliferative	   and	   tumour	   physiology	   factors	   (Seierstad	   et	   al.,	  2007).	  The	  ability	  to	  be	  able	  to	  monitor	  and	  predict	  the	  response	  to	  treatment	  is	  key	  to	  individualized	   medicine.	   NMR	   is	   a	   non-­‐invasive	   tool	   has	   shown	   promise	   in	   the	  monitoring	  of	  response	  to	  therapy,	  both	  clinically	  and	  experimentally	  (Seierstad	  et	  al.,	  2007).	  	  Neo-­‐adjuvant	   chemotherapy	   and	   radiotherapy	   (chemoradiotherapy)	   are	   part	   of	   the	  standard	  clinical	  management	  of	  patients	  with	  rectal	  cancer	  to	  aid	  in	  down-­‐staging	  the	  tumour	  and	  improve	  local	  control	  prior	  to	  surgical	  management.	  	  However,	  the	  success	  of	   surgical	   outcome	   is	   inherently	   related	   to	   the	   patient’s	   response	   to	  chemoradiotherapy.	  Drug	  toxicity	  and	  hypersensitivity	  are	  costly	  by	  products	  of	  cancer	  treatment	   with	   CRC	   chemotherapeutic	   agents	   being	   no	   exception.	   As	   tumours	   are	  heterogeneous,	   so	   also	   is	   an	   individual’s	   response	   to	   the	   treatment.	   Metastasis	   of	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cancer	   cells	   makes	   management	   difficult.	   Understanding	   the	   pathogenesis	   of	   cancer	  metastasis	  will	  enable	  effective	  treatment	  targets	  to	  be	  identified.	  Local	  recurrence	  of	  rectal	   cancer	   has	   been	   shown	   to	   be	   lower	   after	   pre-­‐operative	   than	   post-­‐operative	  radiotherapy.	   In	   addition,	   the	   combination	   of	   radiotherapy	   and	   chemotherapy	   has	  shown	  to	  reduce	  local	  recurrence	  in	  rectal	  cancer	  patients.	  Thus,	  patients	  that	  respond	  to	   treatment	   have	   better	   cancer	   specific	   outcomes	   compared	   to	   non-­‐responders	  (Nicholls	   and	   Tekkis,	   2008).	   Though,	   there	   are	   a	   myriad	   of	   responses	   to	  chemoradiotherapy,	  there	  are	  no	  effective	  and	  efficient	  means	  of	  predicting	  these.	  The	  assessments	  of	   therapeutic	   response	  are	  usually	  based	  on	  radiological	   findings	  using	  magnetic	   resonance	   imaging	   (MRI)	   to	   measure	   tumour	   size	   reduction	   (Figure	   5.1).	  Without	  relating	  to	  patient	  factors,	  the	  benefit	  of	  chemoradiotherapy	  is	  related	  to	  the	  risk	   of	   cancer	   relapse	   either	   on	   a	   local	   or	   systemic	   level.	   Current	   chemotherapeutic	  agents	  have	  limitations	  in	  terms	  of	  response	  and	  adverse	  effects.	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  5.1	  An	  MRI	  image	  showing	  a	  rectal	  cancer	  (indicated	  by	  the	  arrow	  and	  asterisk).	  The	  
image	  kindly	  provided	  by	  Dr	  S.	  Abysina,	  Consultant	  Radiologist)	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The	  concept	  of	  combinational	   therapy	  has	  always	  been	   thought	  of	  as	  a	  better	  way	  of	  tackling	  a	  disease	   than	  a	  single	  agent.	   It	   is	  applied	   in	  a	  number	  of	  conditions	  such	  as	  HIV,	   tuberculosis	   and	   rheumatoid	   arthritis	   with	   cancer	   being	   no	   exception.	  Nevertheless,	   this	   methodology	   is	   not	   without	   its	   drawbacks;	   causing	   normally	  functioning	   pathways	   to	   be	   affected	   or	   creating	  multiple	   side	   effects.	   Chemotherapy	  involves	   a	   multimodal	   method	   of	   treatment	   in	   order	   to	   target	   different	   pathogenic	  pathways.	   This	   inevitably	   leads	   to	   the	  multiple	   adverse	   effects	   and	   potential	   lack	   of	  response	  with	  time.	  A	  combination	  of	  synergistic	  chemotherapy	  drugs	  are	  usually	  used	  in	   order	   to	   be	   able	   to	   destroy	   cancer	   cells.	   The	   lack	   of	   treatment	   response	   to	  chemotherapy	  or	  radiotherapy	  has	  been	  attributed	  on	  a	  molecular	  level	  to	  the	  hypoxic	  environment	  of	   tumour	  cells	  (Wyrwich	  et	  al.,	  1999).	  Therefore,	  exploring	  reasons	   for	  the	  lack	  of	  response	  on	  a	  metabolic	  level	  would	  be	  advantageous	  given	  that	  the	  way	  in	  which	  drugs	  are	  processed	  either	  in	  the	  liver	  or	  kidney	  is	  down	  to	  metabolism.	  	  	  The	   goals	   of	   chemotherapy	   in	   the	   treatment	   of	   CRC	   are	   changing	   from	   palliation	   to	  prolongation	  of	  survival	  in	  the	  adjuvant	  and	  metastatic	  setting.	  Also,	  chemotherapy	  is	  used	  in	  patients	  with	  locally	  advanced	  disease	  to	  reduce	  tumour	  bulk	  to	  enable	  surgical	  management	   (Alberts,	  2008).	  Therefore,	  being	  able	   to	  deliver	   the	  correct	  drug	  at	   the	  correct	  dose	  is	  essential.	   	  Molecular	  markers	  of	  response	  to	  radiotherapy	  in	  CRC	  have	  been	  explored.	  Predictive	  markers	  such	  as	  vascular	  endothelial	  growth	  factor	  (VEGF),	  which	   is	   a	   mediator	   of	   tumour	   angiogenesis	   has	   been	   identified	   following	   immune-­‐histochemical	   studies	   of	   pre-­‐irradiation	   rectal	   cancer	   biopsies	   (Zlobec	   et	   al.,	   2005,	  Ferrara	   et	   al.,	   2003).	   CEA	   on	   the	   other	   hand	   is	   used	   as	   a	   predictive	   marker	   to	   the	  response	   to	   chemoradiotherapy	   in	   CRC	   patients	   as	   well	   as	   a	   prognostic	   marker.	  	  However,	   its	   sensitivity	   is	   variable	   and	   additional	   measures	   such	   as	   radiological	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imaging	  techniques	  are	  needed.	  As	  the	  changes	  induced	  by	  drugs	  in	  the	  body	  have	  an	  effect	  on	  the	  concentrations	  of	  metabolites	  in	  bodily	  fluids	  commonly	  blood	  and	  urine,	  metabolic	   profiling	   of	   these	   perturbations	   to	   organ	   pathology	   is	   a	   major	   point	   of	  biochemical	  interest	  and	  research.	  	  	  	  ‘Pharmaco-­‐metabonomics’	   is	   a	   means	   of	   determining	   an	   individual’s	   response	   to	  certain	  drug	  treatments	  (Mondon	  and	  Reaven,	  1988),	  thus	  allowing	  the	  investigation	  of	  drug	  toxicity	  through	  metabolic	  aspects	  of	  the	  body’s	  biochemistry.	  In	  this	  chapter,	  the	  therapeutic	  effects	  of	   chemoradiotherapy	  on	  rectal	   cancer	  patients	  were	   investigated	  by	  1H	  NMR	  analysis.	  Metabonomic	  studies	  carried	  out	  in	  rats	  taking	  NSAIDs	  identified	  gastric	  damage	  caused	  by	  these	  drugs	  (Um	  et	  al.,	  2009).	  Thus,	  the	  notion	  of	  potentially	  using	  metabolic	  profiling	  as	  a	  screening	  tool	  to	  identify	  patients	  at	  high	  risk	  for	  upper	  gastrointestinal	   bleeds.	   This	   is	   the	   rationale	   for	   the	   experiments	   carried	   out	   in	   this	  chapter	   on	   patients	   undergoing	   chemoradiotherapy	   for	   CRC.	   The	   standard	   neo-­‐adjuvant	  chemoradiotherapy	  regime	  for	  rectal	  cancer	  includes	  5-­‐FU	  (Kornmann	  et	  al.,	  2010).	  Capecitabine	  (Xeloda®,	  Roche,	  Switzerland)	  is	  an	  oral	  pro-­‐drug	  of	  5-­‐FU.	  It	  gets	  converted	  to	  5-­‐FU	  in	  cancer	  cells	  which	  inhibits	  DNA	  synthesis	  (Hameed	  and	  Cassidy,	  2011).	   In	   the	   experiments	   performed	   in	   this	   chapter,	   the	   metabolic	   response	   to	  capecitabine	   chemotherapy	   and	   radiotherapy	   in	   CRC	   patients	   using	   1H	   NMR	   was	  investigated.	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5.3	  Materials	  and	  Methods	  
5.3.1	  Patient	  recruitment	  Ten	  patients	   in	  total	  were	  recruited	  for	  the	  study.	  Seven	  patients	  with	  biopsy	  proven	  rectal	   cancer	  were	   identified	   following	   investigations	   of	   their	   symptoms	   of	   bleeding	  per	  rectum,	  abdominal	  pain	  or	  change	   in	  bowel	  habit.	  Written	   informed	  consent	  was	  obtained	  from	  all	  patients	  prior	  to	  being	  recruited	  for	  the	  study.	  Tumours	  were	  staged	  using	   the	   tumour,	   node	   and	   metastases	   (TNM)	   classification	   of	   the	   American	   Joint	  Committee	  on	  Cancer	  (AJCC).	  The	  Common	  Toxicity	  Criteria	  for	  adverse	  events	  (CTCAE	  version	  4.0)	  from	  the	  National	  Cancer	  Institute	  (NCI)	  was	  used	  to	  score	  the	  treatment	  related	  toxicity	  (O'Connell	  et	  al.,	  2004).	  The	  response	  to	  treatment	  was	  evaluated	  using	  the	  Response	  Evaluation	  Criteria	  in	  Solid	  Tumours	  (RECIST)	  criteria	  (Eisenhauer	  et	  al.,	  2009)	   (see	  Appendix	   III).	   In	  addition	   three	  patients	   that	  underwent	   colonoscopy	  but	  had	  no	  colorectal	  pathology	  or	  had	  polyps	  were	  recruited	  as	  controls.	  	  	  
5.3.2	  Sample	  collection	  Blood	  was	  collected	  from	  patients	  undergoing	  chemoradiotherapy	  at	  the	  start	  of	  their	  treatment,	   two	   weeks	   into	   their	   treatment	   and	   at	   the	   end	   of	   their	   treatment.	   Both	  plasma	  and	  serum	  samples	  were	  collected	  and	  centrifuged	  from	  whole	  blood	  samples	  and	  stored	  at	  -­‐80°C	  prior	  to	  the	  1H	  NMR	  analysis	  as	  previously	  described	  in	  chapter	  2.	  	  
5.3.3	  1H	  NMR	  spectroscopy	  The	   1H	   NMR	   spectra	   of	   the	   samples	   were	   acquired	   using	   the	   CPMG	   and	   NOESY	  sequences.	   The	   number	   scans	   were	   64	   for	   the	   NOESY	   experiments	   and	   256	   for	   the	  CPMG	  experiments.	  The	  spectra	  were	  calibrated	  to	  glucose	  at	  5.23	  ppm.	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5.3.4	  Data	  Analysis	  The	   1H	  NMR	  spectra	  were	   visualised	   and	  analysed	  using	  MATLAB	   (Mathworks,	  MA).	  Integrations	   were	   calculated	   using	   an	   in-­‐house	   MATLAB	   script	   (Dr	   H.C.	   Keun).	  Metabolite	  assignments	  were	  made	  from	  the	  literature	  (Nicholson,	  1995,	  Tukiainen	  et	  al.,	   2008,	   Teresa	  W.-­‐M,	   1996).	   SPSS	   was	   used	   for	   statistical	   analysis.	   Kruskal-­‐Wallis	  analyses	  were	  used	  to	  identify	  changes	  in	  metabolites	  in	  the	  sample	  sets,	  as	  the	  sample	  size	  was	  small.	  P-­‐values	  that	  were	  ≤0.05	  considered	  as	  significant.	  	  	  	  The	   pattern	   recognition	   analysis	   was	   carried	   out	   in	   SIMCA	   P+	   (Umetrics,	   Sweden)	  using	   PCA	   and	   partial	   least	   squares	   discrimination	   analysis	   (PLS-­‐DA).	   Scores	   plots	  were	  used	  to	  identify	  any	  inherent	  sample	  separations	  and	  loadings	  plot	  to	  determine	  the	  metabolites	  that	  caused	  the	  separation.	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5.4	  Results	  	  Seven	   rectal	   cancer	   patients	   (4	   males	   and	   3	   females)	   and	   three	   control	   patients	   (2	  males	   and	  1	   female)	  were	   recruited.	  Twenty-­‐four	  blood	   samples	  were	   collected,	   two	  from	  healthy	  individuals,	  four	  from	  patients	  with	  adenomas	  and	  18	  from	  rectal	  cancer	  patients	  undergoing	  treatment.	  Two	  patients	  with	  colonic	  polyps	  and	  one	  patient	  with	  healthy	  colonic	  mucosa	  following	  histological	  analysis	  were	  included	  as	  controls	  in	  the	  experiments	  with	   a	  mean	   age	   of	   45	   (range	   28-­‐64).	   The	   control	   group	   consisted	   of	   2	  males	  and	  1	  female.	  In	  addition,	  one	  patient	  had	  a	  recurrent	  presentation	  of	  a	  previous	  sigmoid	  carcinoma.	  Only	  one	  patient	  used	  aspirin,	  which	  was	   for	   the	  management	  of	  rheumatoid	   arthritis.	   The	   performance	   status	   (PS)	   of	   the	   patients	   undergoing	  chemoradiotherapy	  was	  documented	   according	   to	   the	  Eastern	  Cooperative	  Oncology	  Group	  (ECOG)	  scale	  (Oken,	  1982).	  The	  patients’	  PS	  scores	  were	  between	  0	  and	  1.	  The	  patient	  characteristics	  are	  shown	  in	  Table	  5.1.	  The	  CEA	  levels	  as	  seen	  in	  Table	  5.1	  did	  not	  indicate	  a	  true	  correlation	  with	  disease	  severity.	  However,	  in	  the	  case	  of	  the	  patient	  with	  recurrent	  disease	  the	  CEA	  level	  was	  markedly	  raised.	  	  	  
5.4.1	  Treatment	  and	  Toxicity	  	  All	   patients	  were	   treated	   concurrently	  with	   oral	   capecitabine	   for	   chemotherapy	   and	  radiotherapy	  with	  54	  Gray	  (Gy)	  in	  30	  fractions	  for	  a	  period	  of	  six	  weeks.	  The	  CTCAE	  v	  4.0	  graded	  toxicities	  following	  chemoradiotherapy	  are	  shown	  in	  Table	  6.2.	  These	  toxic	  effects	  constituted	  mainly	  of	  grade	  1	  reactions.	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Table	  5.1	  Clinicopathological	  characteristics	  of	  the	  ten	  patients	  recruited	  for	  the	  study	  
	  The	  CEA	  level	  is	  at	  the	  time	  of	  diagnosis.	  Abbreviations:	  T	  -­‐	  Tumour,	  N	  -­‐	  Node,	  M	  -­‐	  Metastasis	  	  
Table	  5.	  2	  Toxicity	  grades	  using	  the	  CTCAE	  Version	  4	  system.	  


















Rectal	  Cancer	  Patients	  72	   None	   Poorly	  differentiated	   Good	   T3N0M0	   None	   1	  63	   Hypertension	   Moderately	  differentiated	   Good	  partial	   T4N1M0	   None	   2	  31	   None	   Moderately	  differentiated	   No	   T3bN0M0	   Smoker	   10	  56	   Hypertension	   Poorly	  differentiated	  (Recurrence)	   Partial	   T3N0M0	   None	   59	  61	   Rheumatoid	  arthritis,	  hypertension	   Moderately	  differentiated	   Partial	   T3N0M0	   Ex-­‐smoker	   3	  57	   None	   Moderately-­‐poorly	  differentiated	   Partial	   T3N0M0	   	   2	  56	   None	   Mucinous	   No	   T3N0M0	   None	   4	  
Control	  Patients	  28	   Bone	  marrow	  transplant	   Adenoma	   N/A	   N/A	   None	   N/A	  45	   None	   Healthy	   N/A	   N/A	   None	   N/A	  64	   None	   Adenoma	   N/A	   N/A	   None	   N/A	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Thirty-­‐three	  metabolites	  were	  identified	  from	  the	  plasma	  CPMG	  experiments.	  Table	  5.3	  shows	  the	  mean	  concentrations	  of	  the	  metabolites	  identified	  based	  on	  their	  integration	  values	  from	  both	  the	  plasma	  and	  the	  serum	  samples	  of	  all	  patients.	  The	  cancer	  and	  the	  polyp	  group	  of	  patients	  tended	  to	  have	  similar	  levels	  of	  metabolites	  as	  shown	  in	  the	  1H	  NMR	   spectra	   (Figure	   5.2).	   Following	   Kruskal-­‐Wallis	   analysis,	   significant	   differences	  between	   the	   four	   classes	   of	   samples:	   polyps,	   healthy,	   cancer	   patients	   undergoing	  chemoradiotherapy	   and	   a	   recurrent	   carcinoma	  were	   seen	   as	   displayed	   in	   Table	   5.4.	  Visual	  inspection	  of	  the	  plasma	  CPMG	  1H	  NMR	  spectra	  revealed	  higher	  levels	  of	  lactate	  (δ	  1.33),	  alanine	  (δ	  1.48),	  creatinine	  (δ	  3.04),	  choline	  metabolites	  (δ	  3.21-­‐3.24),	  proline	  (δ	  3.34)	  and	  β-­‐glucose	  (δ	  4.64)	  in	  the	  chemoradiotherapy	  group	  of	  patients	  compared	  with	  the	  healthy	  controls	  and	  polyp	  group	  of	  patients.	  The	  polyp	  group	  of	  patients	  had	  the	  highest	   levels	  of	  valine	  (δ	  1.04).	   In	  addition	  the	  patient	  with	  recurrent	  carcinoma	  showed	   more	   prominent	   levels	   of	   myoinositol	   (δ	   3.65)	   and	   choline	   metabolites	  compared	  to	  the	  other	  groups	  as	  demonstrated	  in	  Figure	  5.3.	  Though,	  the	  estimates	  in	  intensities	  of	  myoinositol	   in	  the	  recurrent	  cancer	  sample	  may	  be	  underestimated	  due	  to	  the	  presence	  of	  underlying	  molecules	  within	  the	  spectra.	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Mean	  (x108)	   	  Standard	  Error	  (x108)	  Lipid	  (LDL)	   2.33	   0.07	   Lipid	  (LDL)	   2.34	   0.05	  Leucine	   0.06	   0.03	   Valine	   0.09	   0.003	  Valine	   0.06	   0.04	   3-­‐	   hydroxy-­‐butyrate	   0.13	   0.02	  3-­‐hydroxybutyrate	   0.08	   0.010	   Lipid	  	   2.10	   0.16	  Lipid	  	   2.05	   0.160	   Lactate	   0.42	   0.06	  Alanine	   0.17	   0.110	   Alanine	   0.02	   0.010	  Arginine	   0.07	   0.005	   Adipic	  acid	   0.14	   0.012	  Acetate	   0.05	   0.006	   Arginine	   0.08	   0.005	  Acetyl	  glycoprotein	   0.17	   0.001	   Lysine	   0.06	   0.004	  Acetoacetate	   0.07	   0.007	   Acetate	   0.004	   0.0009	  Glutamine	   0.14	   0.006	   Acetyl-­‐glycoprotein	   0.17	   0.008	  Citrate	   0.04	   0.002	   Aceto-­‐acetate	   0.18	   0.020	  Creatine	   0.02	   0.002	   Pyruvate	   0.007	   0.001	  	  Unknown	   0.004	   0.0004	   Citrate	   0.05	   0.002	  Choline	   0.15	   0.010	   Malonate	   0.005	   0.0006	  PC	   0.04	   0.003	   Choline	   0.02	   0.004	  GPC	   0.22	   0.009	   PC	   0.003	   0.001	  Taurine	   0.15	   0.005	   GPC	   0.02	   0.010	  Betaine	   0.02	   0.0004	   Betaine	   0.14	   0.005	  Lactate	   0.18	   0.008	   α-­‐glucose	   0.82	   0.030	  β-­‐glucose	   0.35	   0.010	   Threonine	   0.00009	   0.00008	  α-­‐glucose	   0.36	   0.010	   β-­‐glucose	   0.08	   0.005	  Tyrosine	   0.02	   0.002	   Tyrosine	   0.014	   0.001	  Histidine	   0.09	   0.0009	   Histidine	   0.01	   0.003	  Phenyl-­‐alanine	   0.05	   0.0007	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Figure	   5.2	  Median	   plasma	   NOESY	   spectral	   regions	   of	   glucose	   (δ	   5.2-­‐5.35)	   and	   choline	   (δ	   3.18-­‐
3.22)	   respectively	   showing	   the	  visual	  differences	  between	   the	   cancer	   (red),	  healthy	   (blue)	   and	  
polyp	  (black)	  samples.	  	  	  The	  visual	  differences	  seen	  in	  the	  spectra	  in	  Figure	  5.2	  indicate	  that	  the	  patients	  with	  rectal	   cancer,	   even	   though	   they	   are	   undergoing	   chemoradiotherapy	   still	   have	   higher	  levels	   of	   choline	  metabolites	   than	   both	   the	   patients	  with	   polyps	   and	   healthy	   control	  individuals.	  	  	  	  	   	  
Glucose	   Choline	  metabolites	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Table	  5.4	  Statistically	  significant	  differences	  between	  the	  4	  classes	  of	  patients	  
Metabolite	   Integrated	  
regions	   of	   the	  
spectra	  (ppm)	  
Chi-­‐square	   P-­‐value	  
	  
Plasma	  CPMG	  
	  3-­‐hydroxybutyrate	   1.18-­‐1.20	   14.63	   0.01	  Alanine	   1.46-­‐1.49	   7.95	   0.05	  Acetyl	  glycoprotein	   2.02-­‐2.05	   7.92	   0.05	  Creatine	   3.03-­‐3.04	   7.92	   0.05	  GPC	   3.23-­‐3.24	   8.13	   0.05	  β-­‐glucose	   4.63-­‐4.66	   8.86	   0.03	  
	  
Plasma	  NOESY	  
	  3-­‐hydroxybutyrate	   1.19-­‐1.21	   7.69	   0.05	  Alanine	   1.46-­‐1.48	   9.82	   0.02	  Proline	   3.34-­‐3.36	   8.92	   0.03	  α-­‐glucose	   5.22-­‐5.24	   8.97	   0.03	  Unknown	   3.14-­‐3.17	   12.77	   0.01	  Glutamine	   2.41-­‐2.47	   8.46	   0.04	  
	  
Serum	  CPMG	  
	  Acetyl	  glycoprotein	   2.02-­‐2.05	   9.94	   0.02	  Acetoacetate	   2.20-­‐2.25	   12.39	   0.01	  PC	   3.219-­‐3.225	   13.96	   0.01	  Betaine	   3.25-­‐3.265	   8.72	   0.03	  	  	  	  	  	  	  	   	  






Primary	  cancer	   Polyp	   Normal	   Recurrent	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	   5.3	   Graph	   showing	   the	  mean	   intensities	   of	  myoinositol	   (δ	   3.64)	   in	   the	   different	   groups	  
with	   the	   median	   serum	   CPMG	   spectral	   region	   showing	   differences	   in	   recurrent	   carcinoma	  
(green),	   primary	   (red),	   healthy	   normal	   (blue)	   and	   polyp	   patient	   (black).	   The	   error	   bars	  
represent	  the	  standard	  error	  of	  the	  mean.	  	  	  
5.4.2	  Changes	  in	  metabolite	  levels	  with	  timeframe	  of	  radiotherapy	  treatments	  During	  the	  first	  two	  weeks	  of	  chemoradiotherapy,	  the	  changes	  in	  metabolites	  on	  visual	  inspection	  of	  the	  spectra	  were	  similar	  to	  the	  levels	  at	  the	  end	  of	  treatment	  (Figure	  5.4).	  
In the plasma samples, there were significant changes in citrate (p = 0.01), unknown 
metabolite (p = 0.05) and glucose (p = 0.05) during the 3 timelines of treatment (baseline, 
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choline (p = 0.08) were observed and statistically within the limits of the p-value being < 
0.1. The serum sample showed similar changes with treatment times but showed significant 
changes in the lipids (p = 0.05), alanine (p = 0.04), lysine (p = 0.01), acetoacetate (p = 0.02) 










Lactate      Lipid 
 
Figure	  5.4	  Plasma	  CPMG	  plot	  showing	  the	  changes	  in	  metabolite	  levels	  with	  treatment	  times.	  Red	  
–	  baseline	  (start	  of	  treatment),	  green	  –	  2	  weeks	  into	  treatment,	  Blue	  –	  end	  of	  treatment.	  	  	  	  
5.4.3	  Response	  to	  treatment	  Visual	   inspection	  of	   the	   spectra	   showed	  high	   levels	  of	   valine	   (δ	  1.02)	   in	   the	  patients	  that	  had	  a	  good	  response	  compared	  to	  the	  partial	  and	  non-­‐responders.	  The	  patient	  that	  did	   not	   respond	   to	   chemoradiotherapy	   had	   higher	   levels	   of	   lactate	   and	   acetyl	  glycoproteins	   compared	   to	   the	   good	   and	   partial	   responders.	   Partial	   responders	   had	  high	   levels	   of	   alanine	   and	   pyruvate	   but	   decreased	   levels	   of	   lipid	   (δ	   0.8-­‐0.9).	   Partial	  responders	   also	   had	   high	   levels	   of	   lactate,	   however	   lower	   than	   the	   non-­‐responder.	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There	   were	   no	   statistically	   significant	   differences	   in	   the	   levels	   of	   metabolites	   with	  regards	   to	   good,	   partial	   or	   no	   response	   to	   treatment.	   The	   correlations	   between	   the	  treatment	   responses	   and	   the	   metabolites	   are	   shown	   in	   Table	   5.5.	   Spectral	  representations	  of	  treatment	  response	  are	  shown	  in	  Figure	  5.5.	  	  	  
Table	  5.5	  Pearson	  correlations	  showing	  treatment	  responses	  and	  metabolites.	  	  	  	  	  	  	  	  	  	  	   	  *	  Correlation	  is	  significant	  at	  the	  0.05	  level	  (2-­‐tailed),	  **	  correlation	  is	  significant	  at	  the	  0.01	  level	  (2-­‐tailed).	  The	  ‘-­‐‘	  indicates	  a	  negative	  correlation	  as	  with	  lactate,	  there	  is	  a	  reduction	  in	  lactate	  levels	  with	  good	  treatment	  response.	  	  	  	  	  	  	   	  
Metabolite) Response)to)chemoradiotherapy)
No#vs.#Good# No#vs.#Partial#Pearson’s)correlation) P.value) Pearson’s)correlation) P.value)
Lactate&&(δ&1.33)& .0.66*) 0.03) 0.18) 0.59)
Valine&&&&(δ&1.03)& .0.15) 0.66) 0.68*) 0.02)
32hydroxybutyrate&(δ1.19)& 0.95**) 0.00) .0.17) 0.61)
Lipid&(δ&1.23)& 0.17) 0.62) .0.84**) 0.00)
Alanine&(δ&1.48)& .0.45) 0.17) 0.63*) 0.04)
Arginine&(δ&1.8621.93)& .0.22) 0.51) 0.75**) 0.01)
Acetyl&protein&(δ&2.04)&& .0.58) 0.06) 0.74**) 0.01)
Acetoacetate&(δ&2.23)& 0.40) 0.23) .0.78**) 0.00)
Glucose&(δ&5.24)& .0.13) 0.70) 0.69*) 0.02)
Tyrosine&(δ&7.18)& 0.19) 0.58) 0.66*) 0.03))
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Figure	  5.5	  Comparisons	  of	  the	  median	  plasma	  CPMG	  spectra	  with	  responses	  to	  treatment.	  	  	  	  
5.4.4	  Classification	  Analysis	  
The PCA analysis showed separation of the 4 groups (R2 = 0.71, Q2 = 0.60), with clustering 
according to adenomas, healthy patients without colorectal pathology and patients 
undergoing neo-adjuvant chemoradiotherapy (Figure 5.6). The scores plot also give some 
indication of clustering according to response and treatment times. Patient labeled ‘1’ in the 
scores plot had a good response to chemoradiotherapy and thus clustered with the polyp 
patient group (samples 2, 3). The corresponding loadings plot for the separation of the PCA 
scores plot indicated metabolites at δ1.3 (lactate), 1.26 (lipid), 0.88 (lipid: mainly VLDL) 
and 1.48 (alanine) as shown in Figure 5.7.   
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Figure	   5.6	   Principal	   component	   analysis	   (PCA)	   scores	   plot	   of	   the	   first	   2	   components	   showing	  
separation	  between	  the	  sample	  sets	  of	  chemoradiotherapy	  patients,	  polyp	  patients	  and	  healthy	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Figure	   5.8	   PCA	   scores	   plot	   of	   the	   rectal	   cancer	   and	   the	   polyp	   patients.	   The	   partial	   response	  
patients	   clustered	   together.	   The	  mucinous	   cancer	   patient	   did	   not	   change	  with	   treatment	   from	  
their	  baseline.	  The	  outlier	  in	  the	  analysis	  is	  the	  patient	  with	  a	  recurrent	  cancer	  failing	  previous	  
treatment.	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Figure	   5.9	   Partial	   least	   squares	   discrimination	   analysis	   (PLS-­‐DA)	   models	   with	   corresponding	  
loading	  plots	  of	  the	  principal	  components	  showing	  NMR	  spectral	  regions	  0-­‐8-­‐2.5ppm.	  The	  PLS-­‐DA	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5.5	  Discussion	  The	  key	  to	  the	  application	  of	  personalised	  medicine	  in	  oncology	  is	  the	  identification	  of	  patients	   that	   can	   benefit	   from	   chemoradiotherapy	   and	   spare	   toxicity	   for	   those	   who	  cannot.	  This	  may	  be	  facilitated	  by	  being	  able	  to	  extend	  the	  information	  obtained	  from	  animal	  models	  as	   the	  cell	   lines	  used	   in	  chapter	  3	  to	  the	  clinic	  setting.	   In	  this	  chapter,	  pattern	  recognition	  methods	  were	  applied	  and	  showed	  distinct	  separation	  of	  patients	  with	  regards	  to	  their	  response	  to	  chemoradiotherapy.	  Most	  chemotherapy	  drugs	  have	  a	   narrow	   therapeutic	   window;	   therefore	   it	   is	   vital	   to	   be	   able	   to	   tailor	   treatment	  specifically	   to	   patients	   to	   ensure	   a	   good	   outcome	  with	  minimal	   adverse	   effects.	   The	  identification	   and	   characterization	   of	   specific	   metabolites	   in	   recurrent	   CRC	   and	  response	   to	   chemoradiotherapy	  as	  outlined	  here	  has	   the	  potential	   to	   allow	   targeting	  therapy	  to	  individual	  tumours	  through	  the	  early	  identification	  of	  metabolic	  responses	  to	  therapy.	  	  Metabolic	  profiling	  is	  still	  at	  its	  early	  stages	  of	  being	  explored	  as	  a	  clinically	  applicable	  technique.	   The	   Consortium	   for	   Metabonomic	   Toxicology	   (COMET)	   was	   set	   up	   as	  collaboration	   between	   academia	   and	   industry	   in	   order	   to	   predict	   organ	   toxicity	   in	  rodent	  models	   using	   known	   substances	  with	   toxic	   effects	   (Lindon	   et	   al.,	   2005).	   The	  translation	  of	   this	   has	  been	   exemplified	   in	   an	  oncological	   study	  where	  high	   levels	   of	  LDLs	   and	   choline	  metabolites	   were	   associated	  with	   high-­‐grade	   capecitabine	   toxicity	  (Backshall	  et	  al.,	  2011).	  In	  the	  early	  1990s,	  using	  31P	  MRS,	  found	  a	  marked	  increase	  in	  inorganic	  phosphate	  and	  a	  decrease	  in	  the	  α-­‐	  and	  β-­‐	  nucleotide	  phosphate	  portions	  of	  the	  spectra	  were	  found	  during	  the	  first	  few	  hours	  after	  local	  chemotherapy	  or	  chemo-­‐embolization	  in	  patient	  with	  liver	  metastases	  from	  CRC	  (Schilling,	  1992).	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In	  breast	  cancer,	  gaining	  weight	  during	  chemotherapy	  has	  been	  shown	  to	  be	  associated	  with	   changes	   in	   lactate	   and	   alanine	   in	  metabonomic	   studies	   (Stebbing	   et	   al.,	   2011).	  This	   is	   thought	   to	   be	   mediated	   through	   the	   effects	   of	   a	   lipid	   second	   messenger,	  sphingosine-­‐1-­‐phosphate	  (Pchejetski	  et	  al.,	  2010).	  Higher	  lactate	  and	  choline	  levels	  in	  cervical	  cancer	  have	  also	  been	  associated	  with	  metastatic	  spread	  (Sitter	  et	  al.,	  2004).	  Metabolites	   that	   are	   increased	   in	   CRC	   tissue	   from	   NMR	   studies	   include	   choline	  metabolites	   (PC),	   phosphoethanolamine,	   polyethylene	   glycol,	   taurine,	   scyllo-­‐inositol,	  glycine,	   lactate	   aspartate	   and	   glutamate	   (Chan	   et	   al.,	   2009,	   Piotto	   et	   al.,	   2009).	   In	  serum,	   lactate	   and	   pyruvate	   were	   increased	   and	   tryptophan,	   tyrosine	   and	   uridine	  decreased	   in	   CRC	   patients	   (Qiu	   et	   al.,	   2009).	   Some	   of	   these	   metabolites	   have	   been	  found	  to	  be	  the	  plasma	  and	  serum	  samples	  used	  the	  experiments	  here.	  	  	  	  Fundamentally,	   response	   to	   chemoradiotherapy	   in	   the	   neo-­‐adjuvant	   treatment	   of	  rectal	   cancer	   patients	   showed	   significant	   changes	   in	   the	   lipids,	   lactate,	   glucose	   and	  essential	  amino	  acids	  between	  non-­‐responders	  and	  partial	  responders.	  Hypoxia	  within	  solid	   tumours	   has	   been	   shown	   to	   be	   a	   determining	   factor	   of	   response	   to	  chemoradiotherapy	   (Yao	   et	   al.,	   2005).	   This	   is	   in	   keeping	   with	   the	   findings	   of	   high	  lactate	  levels	  in	  the	  cancerous	  samples	  compared	  with	  the	  polyps	  and	  normal	  samples	  and	   in	  the	  non-­‐responders.	  The	  altered	  glycolysis	  of	  cancer	  cells	  may	  account	   for	   the	  high	   levels	   of	   lactate	   seen	   in	   the	   patients	   here	   as	   explained	   by	   the	   Warburg	   effect	  described	   previously	   in	   chapter	   1.	   Acetoacetate	   and	   3-­‐hydroxybutyrate,	   which	  were	  found	   to	   be	   the	   main	   drivers	   of	   response	   to	   treatment	   are	   both	   involved	   in	  phospholipid	   metabolism	   as	   substrates	   for	   synthesis.	   The	   spectral	   changes	   seen	  related	  with	  the	  time	  course	  of	  chemoradiotherapy	  at	  intervals	  of	  two	  week	  and	  at	  the	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end	  of	  treatment	  being	  similar,	  give	  the	  possibility	  of	  measuring	  response	  to	  therapy	  in	  real	  time	  rather	  than	  6	  weeks	  post	  treatment	  for	  scans.	  	  	  MRI	   has	   been	   used	   as	   a	   non-­‐invasive	   way	   to	   monitoring	   response	   to	  chemoradiotherapy.	  Therefore	  the	  use	  of	  a	  quantitative	  method	  would	  be	  of	  additional	  value	   as	   opposed	   to	   measuring	   only	   recurrence	   with	   CEA	   in	   CRC.	   The	   natural	  variability	   in	   the	   way	   individuals	   metabolise	   drugs,	   is	   highly	   dependent	   on	   a	  physiological,	   genetic	   and	   environmental	   effects.	   These	   make	   up	   the	   individual’s	  unique	  phenotype,	  which	  the	  PCA	  models	  here	  have	  been	  able	  to	  noticeably	  isolate	  the	  mucinous	   rectal	   cancer	   from	   recurrent	   cancer	  patient.	  This	   is	   likely	   to	  be	  due	   to	   the	  difference	   in	   biology	   of	   the	   cancers	   compared	  with	   the	   patients	  who	   had	   a	   good	   or	  partial	  response	  to	  chemoradiotherapy	  which	  were	  all	  adenocarcinomas.	  The	  response	  to	  both	  chemotherapy	  and	  radiotherapy	  depend	  on	  metabolic	  and	  physiological	  factors	  that	   are	   individual	   dependent.	   These	   factors	   include	   patient	   characteristics	   such	   as	  performance	  status	  and	  the	  presence	  of	  certain	  genetic	  biomarkers.	  	  	  Metabonomics	  has	  the	  potential	   to	  tailor	  bespoke	  therapy	  in	  order	  to	  have	  metabolic	  drug	   response	   or	   sensitivity	   signatures,	   which	   in	   the	   long	   term	   could	   provide	  more	  effective	  designs	  for	  clinical	  trials.	  This	  will	  save	  costs	  in	  terms	  of	  time,	  morbidity	  and	  even	   mortality.	   The	   ‘MATCH’	   (Merging	   genomic	   and	   pharmacologic	   Analyses	   for	  Therapy	  Choice)	   study	  was	  developed	   to	   evaluate	   the	   role	   of	   genomics	   in	  predicting	  drug	  sensitivity	  to	  tumours	  (Cohen	  et	  al.,	  2011).	  DNA	  microarray	  data	  has	  been	  used	  to	  predict	   the	   response	   to	   radiotherapy	   in	  patients	  with	   rectal	   cancer	   (Watanabe	   et	   al.,	  2006).	  This	   in	  combination	  with	  panels	  such	  as	   the	  NCI	  60	  could	  prove	   invaluable	   in	  future	   drug	   development	   strategies.	   The	   reasons	   for	   sensitivity	   and	   resistance	   are	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multifaceted.	  The	  growth	  suppressive	  function	  of	  p53	  may	  be	  partially	  accountable	  for	  its	  ability	  to	  grant	  chemo-­‐sensitivity	  and	  radio-­‐sensitivity	  upon	  tumour	  cells	  (El-­‐Deiry,	  2003).	   A	   combination	   of	   pharmaco-­‐genomics	   and	   pharmaco-­‐metabonomics	   may	   be	  crucial	   in	   the	   future	   in	   order	   to	   maximise	   the	   effect	   of	   drug	   therapy	   and	   safety.	  	  Combinational	   therapy	   involving	   multiple	   metabolic	   pathways	   may	   be	   the	   key	   to	  tackling	  chemo-­‐resistance	  as	  a	  better	  understanding	  of	  these	  pathways	  occurs.	  	  	  
5.6	  Conclusion	  The	  ability	  to	  be	  able	  to	  unravel	  the	  metabolic	  changes	  that	  are	  related	  to	  the	  patterns	  of	  biochemical	  drug	  and	  radiation	  response	  in	  cancer	  patients	  given	  the	  adverse	  effects	  patients	  can	  suffer	  following	  chemotherapy	  and	  radiotherapy	  would	  be	  revolutionary	  to	   personalized	   medicine.	   Tailoring	   the	   monitoring	   of	   metabolites	   that	   indicate	  response	  non-­‐invasively	  with	  MRS	  could	  be	   the	   translational	   link	  between	   the	  use	  of	  NMR	  and	   clinical	   practice	   rather	   than	   a	   blood	   or	   urine	   biomarker	   from	  a	   sample.	   In	  time,	   a	   library	   of	   drug	   metabolites	   used	   as	   chemotherapeutic	   agents	   could	   be	  established	  with	  the	  advantage	  of	  MRS	  being	  used	  repeatedly.	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CHAPTER	  6	  
Metabolic	  syndrome	  (MetS)	  and	  colorectal	  cancer	  
6.1	  Abstract	  Metabolic	   Syndrome	   (MetS)	   has	   traditionally	   been	   associated	   with	   cardiovascular	  disease	  and	  diabetes.	  It	  is	  a	  trilogy	  of	  factors	  that	  can	  be	  classified	  as	  elements	  such	  as	  obesity	   clinical	   consequences	   such	   as	   type	   II	   diabetes	   and	   hypertension	   as	   well	   as	  blood	   constituent	   measures	   of	   MetS	   including	   hypertriglyceridemia,	   hyperglycaemia	  and	   low	  HDL.	   The	   association	   of	  MetS	   and	   cancer	   is	   still	   being	   explored.	   A	   clinically	  translatable	  aspect	  of	  this	  thesis	  is	  the	  relationship	  between	  MetS	  and	  CRC.	  A	  literature	  search	   identified	   fourteen	   studies,	  which	   reported	   an	   association	   between	  MetS	   and	  CRC.	   This	   comprised	   of	   11,769	   cases	   of	   CRC	   in	   a	   total	   of	   739,231	   participants.	   The	  meta-­‐analysis	   of	   showed	   that	   MetS	   confers	   a	   significant	   increase	   in	   the	   risk	   of	   CRC	  incidence	  (OR	  1.51,	  95%	  CI	  1.32-­‐1.73)	  in	  both	  males	  and	  females.	  	  When	  studies,	  which	  did	  not	  adjust	  for	  confounders,	  were	  excluded	  the	  effect	  estimate	  remained	  similar	  (11	  studies,	  OR	  1.40,	  95%	  CI	  1.24-­‐1.57).	  The	  increase	  in	  risk	  was	  slightly	  higher	  in	  women	  (nine	  studies,	  OR	  1.47,	  95%	  CI	  1.17-­‐1.85)	  than	  men	  (10	  studies,	  OR	  1.35,	  95%	  CI	  1.19-­‐1.53).	   It	   may	   therefore	   be	   beneficial	   to	   identify	   MetS	   components	   as	   part	   of	   the	  screening	  or	  preventive	  measures	  to	  reduce	  the	  incidence	  of	  CRC.	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6.2	  Introduction	  Metabolic	   syndrome	   (MetS)	   is	   defined	   as	   a	   cluster	   of	   risk	   factors	   for	   cardiovascular	  disease	   and	   type	   II	   diabetes	   which	   occur	   together	   and	   include	   dysglycaemia,	  hypertension,	  raised	  triglyceride	  levels,	  low	  HDL	  levels	  and	  principally	  central	  obesity	  (Grundy	  et	  al.,	  2005,	  Alberti	  et	  al.,	  2009).	  In	  essence,	  MetS	  includes	  abdominal	  obesity,	  insulin	   resistance,	   hypertension	   and	   dyslipidaemia	   (Cornier	   et	   al.,	   2008).	   It	   is	  synonymous	  with	   the	   terms	   ‘syndrome	   X’,	   ‘insulin	   resistance	   syndrome’,	   the	   ‘deadly	  quartet’	   and	   ‘hypertriglyceridemic	   waist’	   (Reaven,	   1988,	   DeFronzo	   and	   Ferrannini,	  1991).	  Insulin	  resistance	  syndrome	  has	  been	  thought	  to	  be	  related	  to	  MetS	  comprising	  of	  increase	  in	  systolic	  blood	  pressure	  (BP),	  BMI	  and	  uric	  acid	  (Colangelo	  et	  al.,	  2002).	  Syndrome	  X,	  on	  the	  other	  hand,	  is	  the	  resistance	  to	  insulin	  stimulated	  glucose	  uptake	  which	  is	  associated	  with	  other	  factors	  that	  include	  hyperinsulinaemia,	  decreased	  HDL,	  increased	  LDL	  and	  triglycerides,	  hypertension	  and	  glucose	  intolerance	  (Reaven,	  1988).	  	  With	  the	  current	  pandemic	  of	  obesity,	  interests	  into	  the	  pathophysiology	  of	  MetS	  have	  been	   resurrected.	   It	   had	   previously	   been	   limited	   to	   its	   risk	   potential	   in	   medical	  conditions	   such	   as	   type	   II	   diabetes	   and	   coronary	   heart	   disease,	   however	   multiple	  studies	  and	  epidemiological	  data	  have	  suggested	  the	  risk	  of	  cancer	  in	  individuals	  with	  MetS	   (Russo	   et	   al.,	   2008).	   In	   particular,	  MetS	   has	   been	   associated	  with	   an	   increased	  risk	   of	   CRC	   (Chiu	   et	   al.,	   2007,	   Ahmed	   et	   al.,	   2006).	   MetS	   has	   both	   systemic	   and	  hormonal	  effects,	  which	  are	  also	  mediators	  in	  the	  pathogenesis	  of	  CRC.	  A	  translatable	  connection	  between	  metabonomics	  and	  clinical	  practice	   is	   the	   study	  of	  metabolically	  active	  conditions	  such	  as	  MetS.	  In	  this	  chapter,	  the	  association	  of	  the	  MetS	  and	  CRC	  is	  elucidated	   as	  metabolic	   profiling	   lends	   itself	  more	   amenable	   to	   research	   and	   clinical	  application.	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The	   inter-­‐relationship	   between	   insulin	   and	   glucose	   resistance	   in	   MetS	   is	   mediated	  though	   the	  changes	   in	  plasma	  concentrations	  of	   free	   fatty	  acids	   (Reaven,	  1988).	  This	  observation	  of	   changes	   in	   fatty	   acids	  has	  been	   shown	   in	   the	  previous	   chapters	   to	  be	  associated	  with	  the	  metabolic	  profiling	  of	  CRC.	  The	  mechanism	  by	  which	  insulin	  leads	  to	  an	  increase	  in	  CRC	  risk	  is	  by	  the	  stimulation	  of	  cell	  proliferation	  and	  the	  inhibition	  of	  apoptosis	  all	  mediated	  through	  the	  actions	  of	  IGF	  (Wu	  et	  al.,	  1995,	  Werner	  and	  LeRoith,	  1996).	   Hence,	   the	   use	   of	   insulin	   resistance	   as	   a	   biomarker	   for	   cancer	   is	   thought	   to	  predict	  mortality,	  with	  a	  HR	  of	  1.65	  and	  a	  95%	  CI	  of	  1.26-­‐2.17	  (Loh	  et	  al.,	  2010).	  This	  idea	  is	  part	  of	  the	  incentive	  to	  study	  CRC	  at	  a	  metabolic	  level.	  	  	  Our	   genetic	   predisposition,	   diet	   and	   lifestyle	   habits	   do	   have	   key	   roles	   to	   play	   in	   our	  BMI.	  As	  obesity	  becomes	  a	  chronic	  public	  health	  problem	  in	  developed	  countries	  today,	  MetS	   is	   increasing	   at	   epidemic	   proportions	   too.	   In	   Europe	   alone	   obesity	   and	   being	  overweight	  is	  thought	  to	  account	  for	  over	  15,	  000	  cases	  of	  CRC	  (Renehan	  et	  al.,	  2010).	  Thus,	   contributing	   to	   the	   corresponding	   increase	   in	   cardiovascular	   disease	   and	  diabetes.	  The	  risk	  of	  GI	  cancers	  with	  excess	  body	  weight	  is	  approximately	  twice	  that	  of	  individuals	  with	  normal	  body	  weight,	  with	  CRC	  as	  well	  as	  colorectal	  adenomas	  being	  no	   exception	   (Kant	   and	   Hull,	   2011).	   Epidemiological	   studies	   and	   previous	   meta-­‐analyses	  have	  shown	  that	  an	  increase	  in	  BMI	  is	  associated	  with	  a	  RR	  of	  between	  1.09-­‐1.4	  (Renehan	  et	  al.,	  2008,	  Dignam	  et	  al.,	  2006).	  Hence,	  both	  obesity	  and	  MetS	  have	  been	  shown	   to	  be	   related	   to	   the	  development	  of	  CRC	   (Pais	   et	   al.,	   2009,	  Moghaddam	  et	   al.,	  2007).	   The	   meta-­‐analysis	   performed	   in	   this	   chapter	   summarises	   the	   data	   across	  several	  studies	  that	  illustrate	  the	  association	  between	  MetS	  and	  CRC.	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6.3	  Methods	  MEDLINE,	  PubMed	  and	  Embase	  were	  searched	  for	  all	  studies	  in	  English	  related	  to	  MetS	  and	  CRC.	  A	  literature	  search	  was	  performed	  between	  1965	  and	  2011	  to	  identify	  studies	  (Figure	  6.1).	  However,	  the	  term	  ‘metabolic	  syndrome’	  itself	  was	  however	  not	  described	  until	  after	  Reaven’s	  paper	  in	  1988	  (Reaven,	  1988)	  and	  only	  properly	  defined	  in	  1998	  (WHO,	   1999).	   The	   search	   terms	   used	   alone	   or	   in	   combinations	   included	   “metabolic	  syndrome”,	  “colorectal	  cancer/	  tumour/neoplasm”,	  “colon	  cancer/tumour/neoplasm”,	  rectal	   cancer/tumour/neoplasm”,	   “insulin	   resistance	   syndrome”	   and	   “syndrome	   X”.	  Other	  articles	  were	  identified	  manually	  from	  searching	  reference	  lists.	  The	  last	  search	  date	   was	   April	   2012.	   Multiple	   definitions	   of	   MetS	   are	   used	   and	   these	   are	   shown	   in	  Table	  6.1.	  Studies	  were	  excluded	  if	   they	  were	  reviews,	  editorials,	  animal	  experiments	  or	  duplicate	  studies,	  with	  the	  most	  recent	  being	  selected.	  	  	  	  The	   information	   extracted	   from	   each	   study	   included	   the	   year	   of	   publication,	   study	  design,	  number	  of	  participants,	  gender,	  definition	  of	  MetS	  used,	  the	  OR	  and	  CIs	  of	  MetS	  components	   and	   studies	   assessing	  HR	  or	  RR	  were	   recorded.	   Studies	   that	   exclusively	  used	  insulin	  resistance	  syndrome	  rather	  than	  MetS	  were	  excluded	  as	  they	  comprised	  of	  parameters	   that	  are	  not	  currently	  measured	   in	  MetS	  such	  as	  uric	  acid	  and	  heart	   rate	  (Colangelo	   et	   al.,	   2002).	   Where	   articles	   mentioned	   only	   colon	   cancer,	   analysis	   was	  performed	  as	  per	  CRC.	  The	  data	  was	  analysed	  using	  Review	  Manager	  (RevMan)	  version	  5.1.	  The	  pooled	  estimates	  of	  the	  RR	  were	  calculated	  using	  OR	  and	  the	  HR	  from	  selected	  studies.	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Table	  6.1	  Definitions	  of	  Metabolic	  Syndrome	  	  
Group	   Definition	  criteria	  of	  Metabolic	  Syndrome	  
(a)	   National	  
Cholesterol	   Education	  
Program	  /	  Third	  Adults	  
Treatment	   Panel	  
(NCEP-­‐ATP	  III)	  (Grundy	  
et	  al.,	  2005).	  
• The	  presence	  of	  3	  or	  more	  of	  5	  components:	  	  
• Waist	  circumference:	  Male	  ≥40	  inches	  (101-­‐102cm),	  female	  ≥35	  inches	  (88cm)	  
• Serum	   glycerides	   ≥150mg/dl	   (1.7mmol/l)	   or	   taking	  medication	  for	  elevated	  triglyceride	  levels	  	  
• High	   density	   lipoprotein	   (HDL)	   <40mg/dl	  (1.03mmol/l)(male),	   <50mg/dl	   (1.29mmol/l)	   (female)	   or	  taking	  medication	  for	  low	  HDL	  levels	  	  
• High	  BP	   ≥130/85mmHg	   or	   taking	  medication	   for	   elevated	  blood	  pressure	  levels	  	  
• Fasting	   glucose	   ≥100-­‐110mg	   (5.6mmol/l)	   or	   taking	  medication	  for	  elevated	  blood	  glucose	  level	  	  
(b)	   World	   Health	  
Organisation	   (WHO)	  
definition	   of	   Metabolic	  
Syndrome	   factors	  
(WHO,	   1999,	   Alberti	  
and	  Zimmet,	  1998).	  
	  
• Hypertension	   ≥140mmHg	   (systolic),	   ≥90mmHg	   (diastolic)	  or	   use	   of	   anti-­‐hypertensives	   14	   days	   prior	   to	   blood	  sampling	  
• Impaired	   fasting	   glucose/tolerance:	   fasting	   glucose	  ≥6.1mmol/l,	  post-­‐load	  glucose	  ≥8.9mmol/l	  
• Raised	  TAGs	  ≥1.7mmol	  (150mg/dl)	  
o And/or	  
• Obesity:	   Waist:	   hip	   >0.90	   (male),	   >0.85	   (female)	   and/or	  BMI	  >30kg/m2	  	  
• HDL:	   Males	   <0.9mmol/l	   (35mg/dl),	   females	   <1.0mmol/l	  (39mg/dl)	  
• Microalbuminuria:	   Urinary	   albumin	   excretion	   rate	  >20μg/min	  or	  albumin:	  creatinine	  ratio	  ≥30mg/g	  	  
(c)	   International	  
Diabetes	   Federation	  
(IDF)	   (Alberti	   et	   al.,	  
2006,	   Alberti	   et	   al.,	  
2005).	  
• Waist	   circumference	   ≥94cm	   (European	   males),	   ≥80cm	  (European	  females)	  +	  any	  of	  the	  following:	  
• Raised	   triglycerides	   ≥1.7mmol/l	   or	   treatment	   for	   lipid	  abnormality	  
• Reduced	  HDL	  <1.03mmol/l	  (males),	  <1.29mmol/l	  (females)	  
• Raised	   BP:	   systolic	   ≥130mmHg	   or	   diastolic	   ≥85mmHg	   or	  treatment	  of	  hypertension	  
• Fasting	   plasma	   glucose	   ≥5.6mmol/l	   or	   previously	  diagnosed	  type	  II	  diabetes	  	  
(d)	   Japanese	   Ministry	  
of	   Health,	   Labour	   and	  
Welfare	   -­‐	   Modified	   IDF	  
(Kaneko	  R,	  2010).	  
• Increased	  waist	  circumference	  (male	  ≥85	  cm,	  female	  ≥85cm	  or	  ≥80cm)	  and	  at	  least	  two	  out	  of:	  
• Elevated	   BP	   (systolic	   BP	   ≥130mmHg	   and/or	   diastolic	  ≥85mmHg),	  	  
• Elevated	  fasting	  glucose	  level	  (≥110mg/dl),	  
• Dyslipidaemia	  (HDL	  <40mg/dl	  and/or	  TG	  ≥150mg/dl).	  	  	  
(e)	   Diabetic	   Society	   of	  
the	   Chinese	   Medical	  
Association	  (Shen	  et	  al.,	  
2010a).	  
• The	  presence	  of	  ≥3	  of	  the	  following:	  
• Central	  obesity:	  BMI	  ≥25kg/m2	  
• Hypertension:	   anti-­‐hypertensive	   drug	   treatment	   and/or	  systolic	  BP	  ≥140mmHg	  or	  diastolic	  BP	  ≥90mmHg	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• Abnormal	   lipids:	   high	   TG	   (≥1.7mmol/l)	   and/or	   low	   HDL	  (male:	  <0.9mmol/l,	  female:	  <1.0mmol/l)	  
• Fasting	  plasma	  glucose:	  ≥6.1mmol/l	  or	  2	  hour	  post-­‐prandial	  glucose	  ≥7.8mmol/l	  	  
(f)	   Modified	   NCEP-­‐ATP	  
III	   (Sturmer	   et	   al.,	  
2006).	  
• BMI	  ≥27kg/m2	  
• Total	   cholesterol	   ≥240mg/dl	   or	   the	   use	   of	   lipid	   lowering	  drugs	  
• BP	  ≥130/85mmHg	  or	  use	  of	  anti-­‐hypertensives	  
• Diagnosis	  of	  diabetes	  	  
(g)	   Insulin	   Resistance	  
Syndrome	   (Trevisan	   et	  
al.,	  2001).	  
• Abnormal	   levels	   of	   serum	   total	   triglycerides,	   HDL	  cholesterol,	  blood	  glucose	  and	  BP.	  	  
(h)	   Harmonized	  
definition	   (Alberti	   et	  
al.,	  2009).	  
• Any	  3	  of	  the	  following:	  
• Abdominal	   obesity:	   Males	   ≥94cm,	   females	   ≥80cm	   (for	   a	  European	  population)	  
• Elevated	   TAGs:	   ≥150	   mg/dl	   (1.7mmol/l)	   or	   treatment	   for	  lipid	  metabolism	  
• Reduced	   HDL:	   	  Males:	   <40mg/dl	   (1.03	  mmol/l),	   female:	   <	  50mg/dl	  (1.29	  mmol/l)	  or	  drug	  treatment	  
• Fasting	   glucose	   levels	   ≥100mg/dl	   (≥5.6	   mmol/l)	   or	   drug	  treatment	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Figure	  6.1	  Flowchart	  for	  the	  identification	  of	  eligible	  articles	  	  	   	  
The	  search	  terms	  used	  revealed	  	  	  	  445	  number	  of	  studies	  	  
71	  relevant	  articles	  and	  abstracts	  read	  
14	  studies	  were	  included	  in	  the	  meta-­‐analysis	  
57	  studies	  further	  excluded:	  adenoma	  studies,	  editorials,	  animal	  studies	  	  and	  reviews	  	  
	  	  Excluded	  based	  on	  titles:	  MetS	  and	  cancer	  in	  general,	  including	  1	  duplicate	  study	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6.4	  Results	  Fourteen	  articles	  in	  total	  were	  included	  in	  the	  meta-­‐analysis.	  The	  characteristics	  of	  the	  included	   studies	   are	   shown	   in	   Table	   6.2.	   Analyses	   examining	   the	   effect	   of	   3	  components	  of	  MetS	  on	  CRC	  based	  on	  reporting	  the	  effects	  as	  RRs	  revealed	  a	  pooled	  RR	  of	  1.50	  (95%	  CI	  1.12	  -­‐	  1.99)	  (Figure	  6.2).	  The	  associated	  p-­‐value	  was	  0.006,	  suggesting	  the	  occurrence	  of	  CRC	  to	  be	  higher	  in	  patients	  with	  MetS.	  The	  OR	  for	  the	  incidence	  and	  mortality	  CRC	  and	  MetS	  in	  both	  males	  and	  females	  was	  found	  to	  be	  1.51	  with	  a	  95%	  CI	  of	  1.32-­‐1.73	  (p<0.00001)	  (Figure	  6.3).	  	  
	  
The	  incidence	  and	  mortality	  for	  males	  and	  females	  were	  1.35	  (95%	  C.I	  1.19-­‐1.53)	  and	  1.47	  (95%	  C.I	  1.17-­‐1.85)	  respectively.	  These	  correspond	  to	  heterogeneity	  p-­‐values	  of	  0.05	  (I2	  =	  46%)	  for	  the	  males	  and	  0.002	  (I2	  =	  66%)	  for	  females	  (Figures	  6.4	  and	  6.5).	  Eleven	  studies	  made	  adjustments	  for	  their	  data	  analysis	  of	  confounding	  factors,	  which	  are	  shown	  in	  Table	  6.3.	  This	  showed	  an	  OR	  of	  1.40	  (95%	  C.I	  1.24-­‐1.57)	  in	  both	  males	  and	   females.	  The	  morality	   from	  CRC	   in	   the	  presence	  of	  MetS	  was	  1.90	  (95%	  CI	  1.00-­‐3.60).	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Table	  6.2	  Characteristics	  of	  included	  studies	  
Study	  	   Country	   Study	  
year(s)	  




Ahmed	  2006	   USA	   1987-­‐
2000	  
Prospective,	   Population	  








Case	   control	   (nested	   within	  
European	   Prospective	  
Investigation	   in	   Cancer	   and	  
Nutrition	  (EPIC)	  cohort)	  
CRC	  
incidence	  
	  a,	  c,	  h	  
Ashbeck	  2009	   USA	   1990-­‐
2000	  





Bowers	  2006	   Finland	   1985-­‐
2002	  












Prospective	  cohort	   CRC	  
mortality	  
g	  	  
Kabat	  2011	   USA	   1993-­‐
2010	  
Prospective,	  Multicenter	   CRC	  
incidence	  
a	  
Kaneko	  2010	   Japan	   2007-­‐8	   Prospective	   CRC	  
incidence	  
d	  




Case-­‐control	   CRC	  
incidence	  
c	  
Shen	  2009	   China	   2002-­‐
2007	  
Case-­‐control	   CRC	  
incidence	  
e	  
Stocks	  2008	   Sweden	   1985-­‐
1996	  





Stocks	  2011	   Europe	   1972-­‐
2006	  
Prospective	  cohort	   CRC	  
incidence	  
b	  
Sturmer	  2006	   USA	   1982-­‐
2003	  




a	   (and	   f	   in	  
the	   absence	  
of	   data	  
needed	   to	  
fulfill	   NCEP-­‐
ATP	   III	  
definition).	  
Trevisan	  2001	   Italy	   1978-­‐
1987	  
Prospective	  cohort	   CRC	  
mortality	  
g	  	  The	  studies	  used	  definitions	  of	  metabolic	  syndrome	  based	  on:	  a	  –	  NCEP-­‐ATP	  III,	  a*	  Modified	  Asian	  –	  HDL	  cholesterol	  <40mg/dl,	  waist	  circumference	  >90cm	  in	  males	  and	  >	  80cm	  in	  females	  (Tan,	  2004)	  b	  -­‐	  WHO,	  c	   –	   IDF,	   d	   -­‐	   Japanese	  Ministry	   of	   Labour,	   e	   -­‐	   Diabetic	   Society	   of	   the	   Chinese	  Medical	   Association,	   f	   –	  Modified	  NCEP-­‐ATP	  III,	  g	  -­‐	  Insulin	  Resistance	  Syndrome,	  h	  –	  Harmonized	  definition.	  The	  study	  by	  Ahmed	  et	  al	  used	  the	  NCEP-­‐ATP	  III	  definition	  with	   its	  updated	  criteria	  of	  a	   fasting	  glucose	  of	  >5.6mM	  in	  2005	  compared	  to	  ≥6.1mM	  in	  its	  2001	  definition	  (Grundy	  et	  al.,	  2005,	  Ahmed	  et	  al.,	  2006).	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Figure	  6.2	  Relative	   risks	  of	   colorectal	   cancer	  and	  ≥3	   components	  of	  metabolic	   syndrome	  using	  
random	  effects	  meta-­‐analysis	  suggested	  in	  two	  studies.	  	  
	  	  
Figure	  6.3	  Forest	  Plot	  of	  CRC	  and	  MetS	  in	  both	  males	  and	  females.	  The	  horizontal	  bars	  represents	  
the	   95%	   confidence	   intervals.	   The	   OR	   reported	   for	   the	   study	   by	   Sturmer	   et	   al	   is	   based	   on	  
calculated	  crude	  RR	  (Sturmer	  et	  al.,	  2006).	  	   	  
Relative Risk
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Figure	  6.4	  Forest	  plot	  of	  colorectal	  cancer	  and	  metabolic	  syndrome	  in	  males.	  	  	  
	  	  
Figure	  6.5	  Forest	  plot	  of	  colorectal	  cancer	  and	  metabolic	  syndrome	  in	  females.	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Table	   6.3	   Adjustments	   of	   variables	   in	   eleven	   studies	   of	   metabolic	   syndrome	   and	   colorectal	  
cancer.	  
	  NSAID-­‐	  non-­‐steroidal	  anti-­‐inflammatory	  drugs	  *	  Pooled	  values	  	  	  	  	  	  	   	  
Study	  	   Adjusted	  
OR	   of	   CRC	  







Ahmed	  2006	   1.26	   0.9	   1.7	   Age,	  gender,	  family	  history	  of	  CRC,	  
physical	   activity,	   NSAID	   use,	  
aspirin	   use,	   smoking	   history,	  
alcohol	  intake	  
Aleksandrova*	  
2011	   1.70	  	   1.40	   2.06	   Smoking	  status,	  education,	  alcohol	  consumption,	   physical	   activity,	  
fibre	  intake	  
Bowers	  2006	   1.40	   1.12	   1.74	   Age,	   smoking	   history,	   total	  
cholesterol	  
Chiu	  2007	   1.35	   1.05	   1.73	   Age,	   gender,	   BMI,	   smoking,	  




1.5	   1.03	   2.19	   Age,	   race,	   education	   category,	  
height,	  gender	  
Kabat	  2011	   2.15	   1.3	   3.53	   Age,	   ethnicity,	   alcohol	   pw,	   family	  
history	  of	  CRC,	  physical	  activity	  
Pelucci	  2010	   1.58	   1.14	   2.19	   Age,	   gender,	   study	   centre,	  
education,	   smoking	   habit,	   alcohol	  
intake,	   occupational	   physical	  
activity,	  non-­‐alcohol	  energy	  intake	  
Stocks	  2011	   1.20	   1.16	   1.26	   Age,	  birth	  year,	  smoking	  status	  
Trevisan	  2001	   2.99	   1.27	   7.02	   Age,	   smoking,	   alcohol	   intake,	  
gender	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6.5	  Discussion	  The	  main	   finding	   from	  this	  meta-­‐analysis	   is	   that	  MetS	   is	   significantly	  associated	  with	  increased	   risk	   of	   CRC	   (OR	   1·51,	   95%	   CI	   1·32	   to	   1·73).	   This	   indicated	   that	   CRC	   risk	  might	  be	  greater	  among	  females	  with	  MetS	  (OR	  1·47,	  95%	  CI	  1·17	  to	  1·85)	  than	  males	  (OR	   1.35,	   95%	   CI	   1·19	   to	   1·53),	   however	   as	   the	   confidence	   intervals	   overlap	   this	  gender	   difference	   is	   not	   significant.	   Reports	   have	   been	   made	   of	   the	   association	  between	  MetS	  increasing	  the	  risk	  of	  CRC	  in	  males	  but	  not	  females	  (Ahmed	  et	  al.,	  2006,	  Pelucchi	  et	  al.,	  2010,	  Trevisan	  et	  al.,	  2001).	  In	  particular,	  association	  of	  MetS	  have	  been	  made	   with	   aggressive	   phenotypes	   of	   CRC	   in	   males	   (Healy	   et	   al.,	   2011).	   This	  relationship	   between	  MetS	   and	   CRC	  may	   have	   significant	   implications	   for	   screening	  tactics	  as	  the	  early	  diagnosis	  of	  CRC	  is	  fundamental	  to	  long	  term	  survival,	  therefore	  if	  managing	   the	   components	   of	   MetS	   may	   be	   of	   benefit	   to	   patients	   with	   adenomas.	  Chemopreventive	  strategies	  using	  NSAIDS	  in	  CRC	  may	  be	  related	  to	  the	  association	  of	  CRC	  and	  MetS	  with	  hypertension	  being	  part	  of	  the	  syndrome	  and	  the	  use	  of	  aspirin	  in	  the	  management	  of	   ischemic	  heart	  disease.	  Nonetheless,	   both	  hypertension	  and	  high	  cholesterol	   have	   been	   observed	   to	   be	  more	   associated	  with	  male	   colon	   cancer	   than	  rectal	  cancer	  (Pelucchi	  et	  al.,	  2010).	  Hypertension	  is	  thought	  to	  increase	  cancer	  risk	  by	  affecting	  apoptosis	  and	  cell	  turnover	  (Mason,	  1999).	  	  In	  relation	  to	  metabonomic	  studies,	  MetS	  offers	  a	  translatable	  link	  between	  laboratory	  studies	  and	  clinical	   scenarios.	  A	  recent	  metabonomic	  study	   in	  breast	  cancer	  patients,	  showed	  high	  glucose	  a	   component	  of	  MetS	  was	  associated	  with	  a	  poorer	  outcome	   in	  response	  to	  chemotherapy	  (Stebbing	  et	  al.,	  2011).	  Studies	  are	  yet	  to	  be	  carried	  on	  CRC	  patients.	   The	   European	   cohort	   study	   of	   the	  Metabolic	   Syndrome	   and	   Cancer	   Project	  (Me-­‐Can)	  reported	  a	  RR	  of	  1.25	  (95%	  C.I.	  1.18-­‐1.32)	  in	  males	  and	  1.14	  (95%	  C.I.	  1.06-­‐
	  	   200	  
1.22)	   in	   females	   for	   CRC	   in	   a	   population	   of	   over	   4000	   (Stocks	   et	   al.,	   2011).	   Some	  studies	  have	  reported	  an	  association	  between	  colorectal	  adenomas	  and	  MetS	  (Kim	  et	  al.,	  2007,	  Wang	  et	  al.,	  2005).	  With	  regards	  to	  colorectal	  adenomas,	  the	  association	  with	  MetS	  has	  been	  reported	  with	  an	  OR	  of	  1.61	  for	  three	  or	  more	  components	  of	  MetS	  (Hu	  et	   al.,	   2011).	   Conversely,	   the	   CLUE	   II	   study	   did	   not	   find	   a	   statistically	   significant	  association	   between	   the	   components	   of	   MetS	   apart	   from	   diabetes	   with	   the	   risk	   of	  colorectal	  adenomas	  (Tsilidis	  et	  al.,	  2010).	   It	   is	  possible	  that	  the	  components	  of	  MetS	  become	   more	   prominent	   in	   the	   risk	   assessment	   of	   CRC	   in	   the	   state	   of	   malignancy.	  There	   may	   be	   a	   complementary	   relationship	   between	   MetS	   factors	   that	   coalesce	   to	  drive	  the	  cancer	  cascade.	  	  A	  high	  fasting	  glucose	  is	  also	  associated	  with	  CRC	  risk	  (RR	  1.8,	  95%	  CI	  1.0-­‐3.1)	  (Schoen	  et	  al.,	  1999).	  There	  is	   furthermore	  an	  inter-­‐relationship	  between	  the	  rise	  in	  free	  fatty	  acids	   and	   insulin	   resistance	   (Cornier	   et	   al.,	   2008).	   This	   has	   been	   established	   with	  studies	   that	  have	   shown	   that	  being	  overweight	   and	  having	  diabetes	   to	  be	   associated	  with	   increased	   risk	   of	   CRC	   (Sturmer	   et	   al.,	   2006,	   Aleksandrova	   et	   al.,	   2011).	  Hyperglycaemia	  in	  particular	  was	  associated	  with	  a	  two-­‐fold	  increase	  in	  CRC	  (Stocks	  et	  al.,	  2008).	  A	  meta-­‐analysis	  assessing	  the	  risk	  of	  CRC	  and	  diabetes	  showed	  a	  RR	  of	  1.30	  (95%	  CI	  1.20-­‐1.40)	  and	  a	  mortality	  RR	  of	  1.26	  (95%	  CI	  1.05-­‐1.50)(Larsson	  et	  al.,	  2005).	  	  	  The	  rationale	   for	  studying	  diabetes	  as	  an	  association	  with	  CRC	  has	  been	   following	   in	  vitro	   studies	   that	   insulin	   can	   stimulate	   tumour	   growth	   (Lawlor	   and	   Alessi,	   2001).	  Insulin	   resistance	   specifically	   has	   been	   thought	   to	   be	   one	   of	   the	   main	   players	   in	  accounting	  for	  cancer	  risk	  in	  MetS.	  This	  is	  due	  to	  the	  increase	  in	  insulin	  secretion	  and	  the	  subsequent	  hyperinsulinaemia	  activating	  the	  insulin	  receptor,	  IGF-­‐1	  (Giovannucci,	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2007,	   Chiu	   et	   al.,	   2007).	   Hyperinsulinaemia	   involves	   IGF-­‐1	   increase,	   which	   in	   turn	  increases	   cell	   differentiation,	   proliferation	   and	   inhibits	   apoptosis	   as	  well	   as	   increase	  the	  production	  of	  VEGF,	  which	  play	  a	  major	   role	   in	   tumour	  angiogenesis	   (Kaaks	  and	  Lukanova,	  2001).	  Hence,	  the	  reasoning	  behind	  the	  use	  of	  anti-­‐VEGF	  chemotherapeutic	  drugs	  in	  CRC	  treatment.	  	  Visceral	  obesity	  is	  correlated	  with	  a	  high	  prevalence	  of	  MetS	  in	  CRC	  patients	  (Healy	  et	  al.,	   2011).	  A	  meta-­‐analysis	   of	   obesity	   and	   the	   risk	   of	   CRC,	   showed	   the	  RR	   to	  be	  1.19	  (95%CI	  1.11-­‐1.29)	  (Moghaddam	  et	  al.,	  2007).	  A	  BMI	  of	  ≥	  27	  kg/m2	  and	  diabetes	  have	  been	  shown	  to	  be	   independently	  associated	  with	  an	  increased	  risk	  of	  CRC	  (Schoen	  et	  al.,	  1999).	  Interestingly,	  high	  cholesterol	  was	  associated	  with	  a	  slightly	  decreased	  risk	  (HR	   0.9	   (95%	  CI	   0.7-­‐1.1)	   (Sturmer	   et	   al.,	   2006).	   On	   the	   other	   hand,	  weight	   loss	   has	  been	  associated	  with	  a	  decrease	  in	  incidence	  of	  CRC	  in	  large	  cohort	  studies	  (Parker	  and	  Folsom,	   2003,	   Rapp	   et	   al.,	   2008).	   Interestingly,	   other	   authors	   have	   reported	   no	  association	   between	   BMI	   and	   CRC	   risk	   (Nilsen	   and	   Vatten,	   2001).	   The	   consensus	  behind	  increased	  visceral	  adipose	  tissue	  and	  CRC	  risk	  have	  been	  due	  to	  the	  association	  with	   insulin	   like	   growth	   factors,	   triglycerides	   and	   hyperinsulinaemia	   (Giovannucci,	  1995,	  Bjorntorp,	  1990).	  	  Although	  not	  exclusively	  investigated	  in	  this	  study,	  observations	  have	  been	  made	  of	  a	  stronger	  effect	  of	  MetS	  on	  proximal	  rather	  than	  distal	  tumours	  (Chiu	  et	  al.,	  2007).	  MetS	  is	  thought	  of	  as	  an	  independent	  factor	  of	  influencing	  survival,	  however	  only	  one	  study	  has	   looked	   into	   its	   relation	   with	   prognostic	   outcomes.	   Having	   MetS	   likewise	   has	   a	  higher	  rate	  of	  post-­‐operative	  complications	  after	  CRC	  surgery	  (Lohsiriwat	  et	  al.,	  2010).	  The	  HR	  for	  recurrence	  of	  colon	  cancer	  in	  patients	  that	  have	  MetS	  is	  4.77	  (95%CI	  1.58-­‐
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14.35).	   Furthermore,	   the	   rates	   of	   liver	   metastasis	   and	   CRC	   recurrence	   have	   been	  reported	  as	  higher	  in	  patients	  with	  MetS	  (Shen	  et	  al.,	  2010b).	  	  	  Again	   the	   gut	   microflora	   referred	   to	   as	   a	   “microbial	   organ”	   has	   changes	   in	   its	  population	  that	  have	  been	  associated	  with	  obesity	  in	  animal	  models	  (Ley	  et	  al.,	  2005).	  Differences	  in	  gut	  microbes	  occur	  between	  normal	  and	  obese	  individuals	  such	  as	  in	  the	  decrease	   in	   Bacteroides	   species	   in	   obese	   individuals	   (Ley	   et	   al.,	   2006).	   Thus	   their	  probable	  role	  in	  the	  pathophysiology	  of	  MetS	  and	  CRC	  (Cani	  and	  Delzenne,	  2009).	  This	  relationship	  is	  shown	  in	  Figure	  6.6.	  	  	  
	  	  
Figure	   6.6	   Inter-­‐relationship	   of	   the	   metabolic	   syndrome	   components	   and	   the	   gut	  
microenvironment.	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There	  are	  however	  limitations	  to	  this	  systematic	  review.	  The	  multiple	  definitions	  used	  in	  various	  studies	  make	  comparisons	  of	  study	  populations	  difficult.	  In	  addition,	  various	  definitions	   of	   MetS	   place	   different	   importance	   on	   certain	   components.	   Other	  confounding	   factors	  are	   the	  different	  populations,	   even	   though	   the	  outcomes	  may	  be	  the	   same.	   The	   biochemical	   measurements	   may	   not	   be	   necessarily	   comparable,	   as	  different	  methods	   have	   been	  used	   in	   different	   countries.	   Also	   the	   lack	   of	   universally	  acceptable	   cut	  offs	   for	  measurements	   such	  as	  waist-­‐hip	   ratios.	  What	   lies	  beyond	   this	  meta-­‐analysis	  is	  the	  aetiology	  of	  MetS	  in	  the	  first	  place	  before	  it	  begins	  to	  place	  a	  role	  in	  the	  manifestation	  of	  other	  diseases	  such	  as	  cancer.	  	  	  
6.6	  Conclusion	  This	  meta-­‐analysis	  suggests	  a	  significant	  effect	  of	  MetS	  on	  CRC.	  The	  likelihood	  of	  CRC	  was	   almost	   fifty	   percent	   higher	   for	   patients	  with	   at	   least	   three	   components	   of	  MetS.	  Apart	   from	   the	   syndrome,	   multiple	   metabolic	   pathways	   may	   be	   involved	   in	   the	  pathogenesis	  of	  CRC.	  Malignancy	   itself	  may	  be	   the	   factor	   causing	  effects	  on	   lipids,	   so	  further	  baffling	  the	  influence	  of	  MetS	  in	  cancer.	  This	  chapter	  demonstrates	  the	  aspects	  of	  the	  cause	  or	  link	  of	  CRC	  as	  a	  modifiable	  disease	  as	  a	  hypothesis	  that	  MetS	  precedes	  the	   development	   of	   CRC.	   The	   exact	   mechanism	   whereby	   MetS	   relates	   to	   CRC	  pathophysiology	  is	  yet	  to	  be	  clarified.	  However,	  understanding	  the	  pathophysiology	  of	  disease	   aids	   the	   development	   of	   therapeutic	   and	   preventative	   measures,	   so	   the	  components	  of	  MetS	   could	  potentially	  be	  part	  of	   the	  preventable	   causes	  of	   cancer	  as	  whole,	  through	  lifestyle	  and	  dietary	  changes.	   	  
	  	   204	  
CHAPTER	  7	  
DISCUSSION	  The	  exact	  cause	  of	  CRC	  is	  unknown,	  like	  most	  cancers,	  a	  number	  of	  associations	  have	  been	  made	  with	  certain	  lifestyles,	  diets	  and	  clinical	  conditions.	  Cancer	  is	  continuously	  being	   thought	   of	   as	   a	   systems	   biology	   disease	   (Hornberg	   et	   al.,	   2006).	   The	   ‘omic’	  sciences	   are	   increasing	   gaining	   popularity	   in	   the	   scientific	   and	  medical	   communities	  for	  the	  identification	  of	  diagnostic	  and	  prognostic	  biomarkers	  as	  applied	  in	  this	  thesis.	  An	   initial	   untargeted	   exploratory	   approach	   was	   used	   at	   the	   start	   of	   this	   thesis	   to	  identify	   potential	   metabolites	   involved	   CRC	   using	   cell	   lines.	   Discovering	   these	  metabolites	   led	   to	   the	   more	   strategic	   metabolite	   identification	   in	   the	   subsequent	  chapters.	  	  Knowing	   the	  metabolic	   status	   of	   patients	   in	   relation	   to	   a	   state	   of	   disease	   and	  health	  could	   offer	   additional	   personal	   signatures	   for	   individual	   health	   management.	   The	  ability	   to	   combine	   information	   from	   the	   building	   blocks	   of	   the	   organism	   by	  incorporating	  genomics,	  proteomics	  and	  metabonomics	  offers	  huge	  potential	   into	  the	  development	  of	   individualised	  therapeutic	  measures.	  Even	  saliva	   is	  being	  explored	   in	  metabonomic	   studies	   as	   a	   readily	   accessible	  biofluid.	   It	   has	  been	  used	   to	  distinguish	  between	  smoking	  and	  non-­‐smoking	  individuals	  (Takeda	  et	  al.,	  2009).	  	  	  Since	   the	   discovery	   of	   NMR	   in	   1940s,	   its	   development,	   uses	   and	   applications	   have	  evolved.	   NMR	   technology	   has	   progressed	  with	   developmental	   speed	  with	   the	   use	   of	  cryoprobes	   that	  significantly	   increase	   the	  signal	   to	  noise	  ratio	   (Bezabeh	  et	  al.,	  2009).	  The	  NMR	  measurements	  are	  an	  average	  of	  the	  cellular	  types	  and	  extracellular	  space	  for	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a	  given	  tissue	  type,	  hence	  the	  heterogeneity	  (Tofts	  and	  Wray,	  1988).	  Metabonomics	  has	  been	   used	   as	   a	   potential	   investigative	   tool,	   though	   conflicting	   evidence	   has	   been	  presented	  in	  the	  past	  about	  water	  suppression	  1H	  NMR	  for	  plasma	  could	  not	  be	  used	  for	  screening	  (Okunieff	  et	  al.,	  1990).	  	  	  The	   hallmark	   of	   cancer	  metabolism	   has	   been	   based	   on	   the	  work	   by	  Warburg	   in	   the	  1920s	   and	   hence	   the	   evolution	   of	   science	   of	   metabonomics.	   The	   use	   of	   NMR	   in	  discriminating	   tumours	   from	   normal	   tissue	   has	   come	   a	   long	   way	   since	   the	   use	   of	  different	  relaxation	  times.	  The	  biochemical	  principles	  behind	  the	  justification	  for	  using	  metabonomics	  to	  investigate	  diagnostic	  possibilities	  are	  shown	  in	  this	  thesis.	  	  The	  development	  of	  personalised	  medicine	  is	  an	  essential	  component	  for	  patient	  risk	  stratification.	  The	  aim	  of	  this	  thesis	  was	  to	  identify	  biomarkers	  of	  CRC	  using	  1H	  NMR	  to	  identify	   a	   repertoire	   of	  metabolites	  using	   animal	  models,	   colonic	   adenomas	   and	  CRC	  samples	  of	  various	  biofluids	  and	  tissue.	  	  Following	  the	  preliminary	  studies	  on	  CRC	  cell	  lines	   a	   candidate	   approach	   to	  metabolic	   profiling	  was	   undertaken,	   having	   identified	  choline	  metabolites	  as	  potential	  biomarkers.	  The	  use	  of	  xenografts	  allowed	  controlled	  experimental	   conditions;	   hence	   the	   confounding	   effects	   that	   could	   otherwise	   affect	  results	   are	   minimized.	   Thus	   providing	   a	   more	   robust	   starting	   point	   prior	   to	   the	  analysis	  of	  tissue	  samples.	  This	  enabled	  the	  focus	  on	  specific	  metabolites	  and	  ratios	  of	  metabolites	  using	  1H	  MAS	  NMR.	  	  	  Endogenous	   metabolites	   identified	   as	   possible	   biomarkers	   or	   part	   of	   biomarker	  complexes	  of	  CRC,	  from	  this	  research	  study	  include	  amino	  acids	  (increases	  in	  taurine,	  glutamate),	   fatty	   acids	   and	   carbohydrates.	   Other	   compounds	   identified	  were	   nucleic	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acid	   metabolites	   (e.g.	   adenine,	   uracil),	   glycolytic	   intermediates	   and	   decreased	   TCA	  cycle	   intermediates	   such	   as	   succinate	   and	   citrate	   as	   in	   the	   colonic	   adenoma	  chemoprevention	  study	  in	  chapter	  4.	  	  Several	   studies	   have	   since	   shown	   metabonomics	   to	   be	   used	   to	   provide	   a	   holistic	  picture	  of	  the	  body’s	  metabolism	  on	  a	  pathological	  level.	  Unprecedented	  progress	  has	  been	  made	  in	  NMR	  since	  the	  suggestion	  that	  cancer	  patients	  can	  be	  distinguished	  from	  healthy	   individuals	  by	  assessing	   the	   changes	   in	  methyl	   and	  methylene	   line	  widths	  of	  plasma	   lipoproteins	   (Fossel	   et	   al.,	   1986).	   It	   is	   interesting	   that	   decades	   after,	   lipid	  components	  still	  seem	  to	  be	  the	  players	  in	  cancer	  metabolism.	  	  As	   a	   slowly	   progressing	   disease,	   CRC	   outcome	   is	   closely	   related	   to	   the	   stage	   of	   the	  disease.	  Detecting	  cancer	  early	  could	  result	  in	  a	  decrease	  in	  mortality.	  Metabolism	  is	  an	  integral	  part	  of	  tumourigenesis	  as	  it	  provides	  the	  energy	  requirements	  of	  cancer	  cells.	  Metabolites,	  which	  are	  the	  outcome	  of	  regulatory	  processes	  in	  the	  body,	  are	  therefore	  integral	  to	  cancer	  pathogenesis.	  NMR-­‐based	  metabonomics	  has	  the	  potential	  to	  identify	  biomarkers	  and	  also	  provide	  assessment	  tools	  for	  patients	  at	  different	  stages	  of	  disease	  progression.	  	  	  The	  architectural	  heterogeneity	  of	  CRC	  makes	  the	  immortality	  of	  cancer	  cells	  difficult	  to	   exploit.	   The	   premise	   of	   a	   non-­‐invasive	   method	   of	   diagnosis	   and	   prognostic	  management	   of	   CRC	   is	   encouraging,	   in	   addition	   to	   the	   development	   of	   planning	  schemes	  for	  cancer	  prevention.	  Metabolic	  profiling	  of	  cancers	  such	  as	  CRC	  will	  have	  a	  broad	  range	  of	  utility	  for	  delineating	  the	  pathways	  of	  its	  pathogenesis.	  The	  essence	  of	  metabolic	  profiling	  may	  not	  be	  able	  to	  reflect	  all	   the	  alterations	  in	  biology	  to	  account	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for	  a	  one-­‐test	  approach	  for	  CRC.	  It	  may	  be	  a	  multiple	  panel	  of	  tests	  would	  be	  required.	  These	  would	  have	  to	  be	  robust	  analytical	  stands	  in	  order	  to	  be	  used	  in	  clinical	  practice.	  	  	  The	  ultimate	  goal	  would	  be	  to	  conflate	  a	  metabolic	  data	  network	  as	  the	  human	  genome	  project,	  which	  provides	  a	  vast	   source	  of	   information	   for	   research.	  The	   science	  of	   the	  relationship	   between	   metabolism	   and	   disease	   has	   been	   ongoing	   for	   centuries.	  Metabonomics	  offers	  a	  novel	  approach	  to	  the	  use	  of	  identifying	  signature	  pathways	  of	  CRC	  that	  can	  be	  translated	  into	  the	  clinical	  working	  environment.	  	  	  Metabolic	   profiling	   combined	   with	   histology	   could	   be	   a	   more	   sensitive	   predictor	   to	  determine	  the	  risk	  of	  tumour	  recurrence	  in	  CRC	  patients.	  This	  may	  help	  identify	  which	  patients	  should	  undergo	  initial	  extensive	  radical	  resections	  and	  thus	  reduce	  the	  rate	  of	  recurrence	   and	   the	   need	   for	   intensive	   surveillance,	   that	   are	   not	   without	   their	   own	  risks.	   Using	   biofluids	   such	   as	   urine	   and	   faeces	   in	   metabonomic	   profiling	   offers	   the	  obvious	   advantage	   of	   being	  minimally	   intrusive	   and	  more	   likely	   to	   be	   acceptable	   to	  patients	  in	  terms	  of	  investigative	  mechanisms.	  In	  this	  thesis,	  I	  have	  demonstrated	  the	  Warburg	   effect	   of	   CRC	   cells	   in	   chapter	   3,	   generating	   high	   levels	   of	   lactate	   in	   the	  presence	  of	  oxygen.	  Lactate	  production	  in	  cancer	  cells	  has	  been	  associated	  with	  KRAS	  mutations	   (Yun	   et	   al.,	   2009).	   The	   membrane	   metabolites	   choline,	   PC	   and	   GPC	   have	  been	  indicated	  in	  chapter	  3	  (and	  the	  supplementary	  chapter)	  to	  be	  key	  players	  in	  the	  metabonomics	  of	  CRC.	  	  	  In	  addition,	  biomarkers	  that	  are	  indicators	  of	  pathology	  and	  pharmacological	  effects	  of	  chemoradiotherapy	   for	   CRC	   that	   could	   potentially	   have	   an	   impact	   on	   the	   clinical	  outcome	  of	  CRC	  management	  were	   investigated,	   indicating	  changes	   in	   lipids,	  alanine,	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glycoproteins,	   glucose	   and	   lactate	   (chapter	   5).	   Similar	   findings	   with	   HR-­‐MAS	   NMR	  studies	  have	  shown	  increases	  in	  taurine,	  glutamate,	  aspartate	  and	  lactate	  were	  seen	  in	  CRC	  patients	  (Piotto	  et	  al.,	  2009).	  HR-­‐MAS	  NMR	  has	  also	  been	  successfully	  applied	  to	  determine	  field	  ‘cancerization’	  in	  non-­‐dysplastic	  tissue	  in	  oesophageal	  cancer	  patients	  with	  changes	  in	  metabolites	  such	  as	  lactate	  and	  myoinositol	  (Yakoub	  et	  al.,	  2010).	  	  The	  biochemical	  morphology	  of	  CRC	  cells	  depicted	  in	  the	  studies	  here,	  are	  not	  specific	  for	   CRC,	   some	   of	   the	   findings	   associated	   with	   metabolites	   such	   as	   choline,	   lactate,	  alanine	   and	   taurine	   are	   perhaps	   a	   ‘cancer	   phenomenon’.	   For	   example,	   renal	   cell	  carcinoma	  has	  also	  been	  distinguished	  from	  controls	  groups	  due	  to	  alterations	  in	  levels	  of	  LDL/VLDL,	  lactate	  and	  choline	  (Zira	  et	  al.,	  2010).	  Therefore,	  for	  these	  metabolites	  to	  be	  used	  clinically	  as	  biomarkers	  further	  evaluation	  is	  necessary.	  	  	  
The	   dietary	   habits	   of	   individuals	   are	   bound	   to	   have	   an	   impact	   on	   their	  metabolism.	  Current	   global	   pandemics	   such	   as	   obesity,	   diabetes	   and	   other	   liver	   disorders	   are	  intimately	  connected	  pathophysiologically	  with	  the	  metabolism.	  The	  risk	  of	  recurrence	  and	   morality	   from	   CRC	   has	   been	   reported	   as	   higher	   in	   very	   obese	   individuals	  compared	  to	  normal	  (Dignam	  et	  al.,	  2006).	  In	  accordance	  with	  this,	  the	  focus	  of	  chapter	  6	  was	  on	  MetS	  and	  the	  revelation	  that	  there	  is	  an	  increased	  risk	  of	  CRC	  with	  MetS.	  Lipid	  and	   enzymatic	   assays	   of	   colonic	   tissue	   have	   shown	   elevated	   levels	   of	   membrane	  phospholipids	   including	   PC	   in	  malignant	   tissue	   compared	  with	   normal	   (Dueck	   et	   al.,	  1996).	   This	   further	   supports	   the	   metabolic	   findings	   of	   increased	   levels	   of	   specific	  phospholipids	  that	  are	  associated	  with	  tumorigenicity.	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The	  alterations	  in	  these	  phospholipids	  with	  malignancy	  may	  be	  due	  to	  the	  fluctuations	  in	   the	   rate	   of	   synthesis	   and	   degradation	   of	   these	   lipids	   (Dueck	   et	   al.,	   1996).	   The	  metabolite,	  3-­‐hydroxybutyrate	  is	  formed	  during	  fatty	  acid	  oxidation	  (Havel	  et	  al.,	  1970)	  and	  thus	  present	  in	  high	  levels	  in	  CRC	  patients	  due	  to	  increase	  metabolic	  demands	  as	  seen	   in	   the	   study	   in	   chapter	   5.	   The	   over-­‐expression	   of	   fatty	   acid	   synthase,	   which	   is	  responsible	  for	  the	  synthesis	  of	  fatty	  acids	  has	  been	  associated	  with	  poor	  prognosis	  in	  breast	  and	  prostate	  cancers.	  The	  mediation	  of	  this	  process	  is	  through	  the	  MAP	  kinase	  and	  P13K	  pathways	  (Yang	  et	  al.,	  2002,	  Van	  de	  Sande	  et	  al.,	  2002).	  Thus	  in	  keeping	  with	  the	  observations	  in	  chapters	  4	  and	  5,	  where	  fatty	  acids	  have	  been	  the	  main	  metabolic	  markers.	   Therefore,	   serum	   fatty	   acid	   analysis	   may	   be	   beneficial	   as	   part	   of	   the	  biomarker	  profiling	  for	  CRC.	  The	  multiple	  metabolic	  nonentities	  involved	  in	  metastatic	  CRC	   remains	   to	   be	   illuminated.	   Studies	   have	   shown	   that	   the	   diverse	   interaction	  between	   tumour	   and	   host	   determines	   the	   probability	   and	   potential	   location	   of	  metastatic	   disease.	   The	   presence	   of	   unsaturated	   fats	   and	   compound	   lipids	   have	   also	  been	   found	   in	   metastasizing	   tissue	   (Chen,	   1987)	   reflecting	   the	   effect	   of	   lipid	  metabolism	  and	  diet	  on	  the	  pathology	  of	  CRC.	  	  	  The	   gut	   bacteria	   could	   be	   critical	   to	   the	   metabolic	   profiles	   of	   individuals	   in	   health,	  disease	   and	   bio-­‐therapeutics.	   They	   are	   necessary	   for	   colonic	   haemostasis,	   assisting	  with	  functions	  such	  as	  digestion	  and	  immunity	  (Dethlefsen,	  2007,	  Cani	  and	  Delzenne,	  2009).	  The	  gut	  microbiota	  varies	  on	  an	  individual	  level	  (Turnbaugh	  and	  Gordon,	  2009).	  The	   colon	   is	   predominantly	   anaerobic	   due	   to	   the	   presence	   of	   gut	   microbiota	   and	  contains	  more	  organisms	  than	  the	  rest	  of	  the	  gastrointestinal	  tract	  (GIT).	  This	  is	  due	  to	  the	  more	  conducive	  environment	  the	  colon	  creates	  for	  the	  gut	  microbes	  than	  the	  rest	  of	  the	  GIT,	  with	  low	  acid	  and	  bile	  levels	  (Prakash	  et	  al.,	  2011).	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The	  type	  of	  gut	  microbes	  we	  possess	  may	  have	  a	  role	  not	  only	  in	  our	  colonic	  metabolic	  behaviour	   but	   also	   our	   disease	   phenotype.	   This	   has	   been	   observed	   in	   the	  chemoprevention	  study	  in	  chapter	  4,	  where	  metabolic	  changes	  seen	  in	  individuals	  with	  colonic	   adenoma	   could	   be	   related	   to	   the	   gut	   microflora,	   as	   SCFAs	   are	   produced	   by	  bacterial	   fermentation	   in	   the	  colonic	   lumen	  (Scheppach,	  1994,	  Blumberg	  and	  Powrie,	  2012).	   There	   are	   always	   commensal	   or	   symbiotic	   relationships	   between	   organisms	  and	   their	   environment,	   as	   cancer	   is	   multifactorial	   involving	   the	   environment	   and	  genetics.	  CRC	  has	  been	  thought	   to	  be	   induced	  by	  environmental	   factors	  such	  as	   food,	  based	  on	  ingestion	  of	  carcinogens	  and	  the	  production	  of	  agents	  by	  gut	  microflora	  such	  as	  mycotoxin	  (Weisburger,	  1971).	  Gut	  dysbiosis	  which	  involves	  the	  disruption	  of	  the	  of	  the	  normal	  biology	  of	  the	  gut	  microbiota	  is	  associated	  with	  CRC	  (Prakash	  et	  al.,	  2011).	  Gut	   microbes	   have	   also	   been	   implicated	   in	   drug	   metabolism	   such	   as	   L-­‐3,4-­‐dihydroxyphenylalanine	  (L-­‐DOPA),	  digoxin	  and	  glyceryl	  trinitrate	  (Sousa	  et	  al.,	  2008).	  Therefore	  with	  biomarker	  discovery	  all	  these	  factors	  have	  to	  be	  put	  into	  consideration,	  so	  as	  to	  enable	  bespoke	  therapy	  and	  care.	  	  	  Nutrition	  has	  been	  linked	  as	  a	  risk	  factor	  in	  different	  types	  of	  cancer.	  The	  fact	  that	  plant	  polysaccharides	  are	  not	  digestible	  by	  humans	  and	   constitute	   the	  main	   substrates	   for	  the	  microbes	   in	   the	   colon,	  which	  are	   the	  most	  abundant	  and	  diverse	   communities	   in	  the	   human	   body	   make	   gut	   microflora	   potential	   key	   players	   in	   therapeutics	   for	   the	  management	   of	   CRC	   (Dethlefsen,	   2007,	   Nicholson	   et	   al.,	   2002b).	   The	   Embden-­‐Meyerhof-­‐Parnas	   (EMP)	   pathway	   is	   a	   major	   metabolic	   pathway	   for	   colonic	   glucose	  catabolism,	   while	   the	   Wood-­‐Ljungdahl	   pathway	   is	   responsible	   for	   the	   formation	   of	  acetate	   by	   the	   gut	  microflora	   (Miller	   and	  Wolin,	   1996).	   Changes	   in	  metabolite	   levels	  involving	  both	  pathways	  have	  been	  shown	  in	  chapter	  5.	  Acetate	  is	  a	  major	  SCFA	  in	  the	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colon	   that	   is	   involved	   in	   cholesterol	   synthesis	   (Prakash	   et	   al.,	   2011).	   Studies	   have	  shown	   that	   the	   ratio	   of	   acetate	   to	   propionate	   in	   human	   colonic	   contents	   to	   be	  approximately	   3:1	   (Wolever	   et	   al.,	   1991).	   Again	   in	   keeping	   with	   the	   findings	   of	   the	  faecal	  water	  studies	  in	  chapter	  4.	  	  	  Cancer	   cells	   have	   high	   proliferation	   rates	   in	   keeping	  with	   their	   high	   demand	   for	   the	  synthesis	  of	  molecules	  such	  as	  glucose.	  The	  preliminary	  studies	  on	  both	   the	  aqueous	  tumour	   tissue	   extracts	   and	   the	   polypoid	   colonic	   tissue	   showed	   changes	   in	   choline	  metabolites.	  The	  PCA	  plot	  showed	  a	  separation	  of	  the	  four	  cell	   line	  genotypes,	  due	  to	  the	  choline	  metabolites,	  which	  are	  related	  to	  the	  poor	  levels	  of	  tumour	  differentiation.	  It	   is	  well	  established	   that	  membrane	  phospholipid	  metabolism	  plays	  a	  crucial	   role	   in	  cancer	  pathogenesis.	  	  	  Choline	   containing	   compounds	   in	   particular	   have	   been	   found	   to	   be	   present	   in	   CRC	  following	  a	  number	  of	  studies	  (Ende,	  1996,	  Chan,	  2009,	  Mori,	  2004,	  Jordan,	  2009).	  High	  choline	   intake	   has	   moreover	   been	   associated	   with	   increased	   risk	   of	   colorectal	  adenomas	  (Griffin	  et	  al.,	  2007).	  This	  increase	  in	  choline	  levels	  in	  cancer	  cells	  is	  thought	  to	   be	   related	   to	   the	   increase	   in	   phospholipid	   synthesis	   that	   these	   cells	   require	   for	  membrane	   turnover	  and	  growth	  (Bezabeh,	  1996).	  This	  would	  explain	   the	   increase	   in	  phospholipids	  seen	  in	  the	  cell	  lines	  and	  colonic	  polyps,	  as	  their	  growth	  rate	  is	  increased	  compared	  to	  normal	  tissue.	  With	  the	  identification	  of	  changes	  in	  choline	  metabolites	  as	  potential	  drug	  targets,	  the	  challenge	  would	  be	  to	  make	  drugs	  that	  are	  able	  to	  target	  the	  rapid	  proliferation	   in	  tumour	  cells	  and	  not	  normally	  replicating	  cells	  as	  the	  epithelial	  lining	  of	  the	  GIT	  has	  one	  of	  the	  most	  rapid	  turnovers	  than	  any	  other	  tissue	  in	  the	  body	  (Lipkin,	  1988).	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NMR	   can	   be	   used	   as	   a	   tool	   for	   looking	   at	   drug	   sensitivity	   and	   toxicity.	   Even	   though	  animal	  models	   and	   humans	  may	   not	   have	   the	   same	   responses,	   due	   to	   differences	   in	  baseline	  metabolism.	  Understanding	  their	  metabonomic	  profiles	  could	  allow	  informed	  decisions	  to	  be	  made	  as	  to	  the	  choices	  of	  drugs	  used.	  Thereby,	  allowing	  the	  translation	  of	  animal	  studies	  to	  human	  applications	  and	  in	  essence	  to	  link	  CRC	  metabolic	  profiles	  and	  biochemical	  phenotypes	  to	  diagnosis,	  prognosis	  and	  treatments.	  
	  
Apart	   from	   the	   clinical,	   radiological	   and	   endoscopic	   findings	   of	   CRC,	   the	   diagnosis	   is	  confirmed	   using	   histopathological	   techniques,	   which	   are	   invasive	   and	   sometimes	  inconclusive	  at	  a	  microscopic	  scale.	  CRC	  is	  a	  cancer	  with	  an	  identifiable	  pre-­‐cancerous	  lesion,	   therefore	   being	   able	   to	   target	   the	   development	   of	   the	   lesion	   would	   be	   ideal.	  Endoscopic	   polypectomy	   following	   the	   identification	   of	   adenomas	   offers	   invasive	  treatments	   but	   still	   lags	   behind	   in	   the	   management	   of	   flat	   adenomas.	   Therefore,	  biomarkers	  that	  can	  be	  used	  to	  identify	  these	  lesions	  in	  blood,	  urine	  and	  faeces	  would	  offer	   more	   rapid	   management	   and	   screening	   tactics.	   From	   the	   results	   in	   the	  supplementary	  chapter	  on	  colonic	  polyps,	  magic	  angle	  metabolic	  profiling	  could	  solve	  the	   issues	   of	   inter-­‐observer	   variability	   in	   histological	   diagnoses	   of	   colorectal	   polyps	  and	  cancer.	  	  The	  ability	  to	  combine	  the	  information	  acquired	  from	  metabonomics	  and	  genomics	  and	  use	   computational	   biology	   methods	   to	   individually	   stratify	   patients	   for	   their	  chemoradiotherapy	   from	   the	   point	   of	   clinical	   trials	   to	   clinical	   use	   would	   add	   to	   the	  radiological	   information	   routinely	   used.	   This	   union	   of	   pharmacology	   and	  bioinformatics	   may	   shorten	   the	   timescale	   of	   drugs	   reaching	   clinical	   practice	   and	   so	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may	  change	  the	  current	  trend	  of	  drug	  development	  and	  trials.	  Moreover,	  the	  benefits	  of	  positive	  drug	   response	   for	  patients	   and	  avoiding	  unwanted	  adverse	   reactions,	  which	  are	   a	   major	   cause	   of	   morbidity	   but	   also	   additional	   costs	   to	   health	   care	   services.	  Controlled	  specificity	  with	  multiple	  targets	  could	  possibly	  be	  the	  key	  to	  the	  success	  of	  management	   of	   adverse	   effects	   of	   chemoradiotherapy.	   The	   rational	   behind	   this	   is	   to	  avoid	  too	  much	  specificity	  that	  would	  lead	  to	  resistance	  as	  is	  well	  known	  in	  healthcare	  with	  antibiotic	  and	  antiretroviral	  drug	  resistance.	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7.1	  Conclusion	  Generically,	   cancer	   cells	   are	   known	   to	   have	   alterations	   in	   carbohydrates,	   proteins,	  nucleic	  acids	  and	   lipids	  (Cairns	  et	  al.,	  2011)	  which	  has	  been	  the	   finding	   in	   this	   thesis	  (Figure	  8.1).	  Metabonomics	  relies	  on	  a	  systems	  biology	  approach,	  which	  encompasses	  the	   integration	   of	   experimental	   data	   from	   biological	   systems	   with	   computational	  research.	  The	  reproducibility	  of	  1H	  NMR	  metabonomics	  has	  been	  tried	  and	  tested	  with	  positive	  results	  (Keun	  et	  al.,	  2002).	  The	  scenario	  of	  using	  NMR	  in	  clinical	  practice	  may	  be	  eminently	  possible.	  The	  ability	  to	  obtain	   instant	  results	  using	  tissue	  NMR	  can	  also	  guide	   surgical	   resection	   margins	   and	   anastomotic	   sites	   by	   providing	   quantitative	  results	  of	  tumour	  tissue	  (Bhattacharya,	  2009).	  This	  could	  potentially	  allow	  the	  surgeon	  to	   be	   able	   to	   make	   precise,	   qualitative	   decisions	   about	   the	   tumour	   tissue	   that	   is	  removed	  and	  the	  healthy	  tissue	  left	  behind	  during	  cancer	  surgery.	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  7.1	  Schematic	  diagram	  illustrating	  the	  main	  metabolic	  pathways	  identified	  in	  colorectal	  
cancer	  biomarker	  complexes.	  Adapted	  from	  (Munoz-­‐Pinedo	  et	  al.,	  2012).	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Cancer	   is	   a	   complex	   evolving	   disease	   and	   being	   a	   step	   ahead	   in	   understanding	   the	  metabolism	   is	   of	   paramount	   importance	   in	   order	   to	   use	   the	   biological	   information	  advantageously	   for	  screening	  and	  preventative	  actions.	  The	  manipulation	  of	  gut	   flora	  may	  well	  be	  in	  the	  future	  of	  drug	  therapeutics,	  as	  the	  aetiology	  of	  CRC	  encased	  in	  the	  metabolic	  pathways	  is	  deciphered.	  The	  anatomical	  locations	  of	  the	  tumours	  may	  have	  an	   impact	   on	   the	  metabolites	   identified,	   as	   CRCs	   are	   known	   to	   be	  more	   common	   in	  certain	   anatomical	   sites	   than	   others.	   CRC	   metabonomics	   using	   faeces	   sampling,	  proposes	  insights	  into	  the	  disease	  due	  to	  its	  intimate	  nature	  with	  the	  colon.	  	  	  The	  complicated	  nature	  of	  cancer,	  means	  an	  integrated	  approach	  is	  needed	  to	  improve	  care	   standards	  using	   scientific	   information	   from	  a	  host	  of	  masteries	   including	  genes,	  metabolites	  and	  proteins.	  There	  are	  up	  to	  tens	  of	  thousands	  of	  metabolites	  in	  the	  body,	  which	  make	   them	  an	  attractive	  research	  point	   for	  pathophysiology.	   	  Here	   in	  also	   lies	  the	  challenge	  due	  to	  their	  various	  types	  and	  numbers.	  However,	  the	  future	  application	  of	  NMR	  in	  the	  context	  of	  metabonomics	  partly	  lies	  with	  NMR	  spectrometers	  becoming	  more	   technically	   sophisticated.	   Presently,	   there	   are	   now	   one	   Giga	   Hz	   (GHz)	   NMR	  spectrometers	  that	  will	  enable	  more	  detailed	  study	  of	  biofuilds	  (Bhattacharya,	  2010).	  To	   this	   end,	   NMR	   does	   show	   promising	   results	   into	   the	   further	   understanding	   and	  development	  of	  biomarkers	  and	  therapy	  for	  CRC.	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7.2	  Limitations	  of	  metabolic	  profiling	  using	  1H	  NMR	  	  There	  is	  wide	  scope	  potential	  for	  the	  application	  of	  NMR	  metabonomics,	  however	  like	  any	   approach	   it	   is	   not	   without	   its	   strengths	   and	   weaknesses.	   As	   the	   experiments	  performed	   were	   exploratory,	   the	   small	   number	   of	   samples	   may	   not	   have	   been	  sufficient	  to	  make	  absolute	  conclusions.	  Experiments	  with	  a	  larger	  number	  of	  samples	  would	  show	  if	  the	  effects	  are	  definite.	  	  	  Some	  of	  the	  limitations	  in	  the	  analysis	  of	  biofluids	  are	  the	  day-­‐to-­‐day	  variations.	  There	  would	   also	   be	   heterogeneity	   between	   individual	   samples	   and	   within	   an	   individual’s	  sample	  based	  on	  diet	  thus	  accounting	  for	  differences	   in	  transit	   time,	   faecal	  pH,	  water	  content,	  stool	  homogeneity	  and	  bulk.	  The	  natural	  variability	  between	  individuals	  such	  as	  blood	  pH	  and	  diet	  could	  account	  for	  the	  slight	  variability	  seen	  in	  chemical	  shifts	  and	  potentially	  in	  the	  variability	  of	  metabolites	  identified.	  	  	  Additionally,	   specific	   factors	   such	   as	   smoking	   and	   intake	   of	   drug	   supplements	   by	  participants	   could	   confound	   matters	   further.	   Therefore,	   quantified	   differences	  encountered	  in	  metabolic	  profiling	  using	  1H	  NMR	  is	  not	  always	  directly	  related	  to	  the	  biological	  significance.	  There	  is	  also	  a	  lack	  of	  age	  matched	  participants	  and	  genders	  and	  the	   confounding	   effects	   of	   demographic	   data	   when	   making	   comparisons	   between	  groups.	  In	  addition	  to	  not	  having	  external	  datasets	  to	  cross	  validate	  findings.	  	  The	  biochemical	  effects	  of	  bowel	  preparations	  on	  NMR	  have	  not	  been	   fully	  explored.	  Patients	  need	   to	  have	  bowel	  preparation	  prior	   to	  having	  colorectal	  biopsies	   for	   their	  tumours.	  These	  pathological	  specimens	  are	  washed	  and	  practically	  made	  bacteria-­‐free	  may	   remove	   the	   possibility	   of	  making	   the	   bacterial	   link	  with	   CRC	  biopsy	   specimens.	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Perhaps	   metabonomic	   comparative	   studies	   using	   blood	   samples	   from	   CRC	   patients	  diagnosed	   via	   CT	   colonography	   and	   endoscopically	   could	   provide	   identifiable	  metabolic	  changes	  associated	  with	  the	  use	  of	  bowel	  preparations.	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7.3	  Future	  work	  Metabonomics	   is	   a	  marriage	  of	   experimental	   and	  computerized	   statistical	   analysis	  of	  cancer	   biology.	   The	   use	   of	   metabonomics	   is	   still	   in	   its	   infancy	   with	   regards	   to	  application	  in	  clinical	  practice.	  The	  multi-­‐faceted	  pathological	  basis	  of	  cancer	  means	  a	  multidimensional	  approach	  to	  its	  management	  is	  required.	  So,	  using	  metabonomics	  to	  complement	  genomic	  and	  proteomic	  findings	  would	  be	  the	  direction	  of	  the	  future.	  
	  
Having	  used	  an	  untargeted	  approach	  at	  the	  start	  of	  this	  research	  project	  using	  CRC	  cell	  lines	   (chapter	   3)	   to	   identify	   potential	   biomarkers	   and	   subsequently	   structuring	   the	  experiments	   in	   the	   following	   chapters	   with	   a	   targeted	   approach	   allowed	   the	  identification	   of	   lactate	   and	   choline	   as	   associated	   with	   CRC	   and	   colonic	   adenomas.	  These	   studies	   imparted	   likely	   candidate	   biomarkers	   for	   clinical	   prospective	   studies.	  Therefore,	   the	   future	  direction	   I	   intend	   to	   take	  with	   this	   thesis,	   is	  with	   collaborative	  work	   at	   the	   National	   registry	   for	   colorectal	   polyps	   at	   St	   Marks	   Hospital,	   Northwick	  Park,	  measuring	   choline	  and	   lactate	   as	   an	   initial	  project	   in	   colonic	   adenoma	  patients	  with	  matched	  controls	  and	  then	  making	  comparisons	  with	  CRC	  patients.	  	  
	  
The	  sophistication	  of	  instruments	  and	  the	  development	  of	  mathematical	  and	  statistical	  methodology	   will	   continue	   to	   enhance	   NMR	   technology.	   Studies	   have	   shown	   that	  alterations	   in	   the	   microstructure	   and	   metabolism	   of	   colorectal	   tumours	   can	   be	  detected	  by	  in	  vivo	  diffusion-­‐weighted	  MRI	  and	  1H	  MRS	  were	  found	  to	  correlate	  with	  histological	  changes	  observed	  in	   irradiated	  HT-­‐29	  xenografts	   in	  nude	  mice	  (Seierstad	  et	   al.,	   2007).	   The	   prospect	   of	   metabonomic	   profiling	   may	   in	   the	   ability	   to	   combine	  visual	  information	  in	  the	  form	  MRI	  with	  quantitative	  data	  from	  NMR	  studies.	  The	  use	  of	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metabolic	   tumour	   identification	   using	   imaging	   techniques	   such	   as	   MRI	   and	   a	  multi-­‐modality	   approach	   using	   different	   identified	   metabonomic	   techniques	   may	   be	   more	  specific	  for	  the	  diagnosis	  or	  prognosis	  of	  a	  particular	  cancer	  type.	  	  As	  the	  cause	  of	  MetS	  itself	  is	  unclear,	  metabolic	  studies	  on	  patients	  with	  the	  syndrome	  using	  multiple	  metabonomic	   techniques	  could	  prove	  more	   informative.	  Furthermore,	  understanding	   the	   microbiology	   of	   CRC	   with	   an	   in	   depth	   exploration	   of	   the	  biomolecular	   links	   between	   CRC	   risk	   and	   gut	   microbe	   ecology	   using	   metabonomics	  would	  be	  beneficial	  for	  medical	  practice.	  	  The	   optimum	   biomarker	   is	   one	   that	   is	   sensitive	   and	   specific	   to	   CRC.	   The	   clinical	  application	  of	  metabonomics	   lies	  not	  only	   in	  the	  positive	   identification	  of	  biomarkers	  but	  also	  the	  validation	  of	  the	  findings	  in	  this	  thesis	  in	  large	  epidemiological	  studies.	  The	  unique	   metabolism	   of	   cancer	   as	   a	   whole	   makes	   it	   amenable	   to	   the	   study	   of	   its	  metabolites	  for	  diagnosis	  and	  therapy.	  As	  the	  use	  of	  metabonomics	  becomes	  part	  of	  the	  patient	  pathway,	  NMR	  may	  be	  introduced	  to	  individualise	  patient	  care.	  
	  The	  detection	  of	  change	   in	   the	  cellular	  chemistry	  of	  CRC	  using	  stem	  cells	  with	  poly	  –	  ‘omic’	   platforms	   may	   harness	   the	   transformations	   of	   cancer	   cells	   particularly	   their	  inefficient	  method	  of	  energy	  production	  which	  is	  an	  appealing	  difference	  from	  normal	  cells.	   Distinguishing	   metabolic	   profiles	   of	   CRC	   patients	   with	   primary	   disease,	  metastatic	   and	   recurrent	  with	  matched	   normal	   controls,	   could	   hypothetically	   enable	  more	  specific	  biomarkers	  of	  disease	  states.	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The	  clinical	  application	  of	  metabonomics	  is	  yet	  to	  start,	  however,	  the	  excitement	  of	  its	  potential	  is	  cultivating	  at	  a	  fast	  rate	  in	  clinicians	  of	  different	  specialties	  from	  surgery	  to	  critical	   care.	   The	   direction	   of	  metabonomics	   following	   the	   completion	   of	   the	   human	  metabolome	  project	  with	  the	  combination	  of	  the	  information	  from	  the	  human	  genome	  project	  offers	  great	  promise.	  The	  identification	  of	  individually	  unambiguous	  metabolic	  pathways	  linked	  to	  apoptosis	  or	  proliferation	  could	  remedy	  the	  as	  yet	  unrealised	  need	  for	  personalised	  therapy,	  yet	  to	  be	  solved	  in	  medicine.	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SUPPLEMENTARY	  CHAPTER	  	  
Metabonomic	  profiling	  of	  colonic	  tissue	  using	  high-­‐resolution	  magic	  angle	  
spinning	  proton	  NMR	  (HR-­‐MAS1H	  NMR)	  spectroscopy	  
S.1	  Abstract	  The	  diagnosis	  of	  colonic	  pathology	  following	  endoscopic	  biopsies	  relies	  on	  histological	  examination.	   High-­‐resolution	   ‘magic	   angle	   spinning’	   (MAS)	   proton	   nuclear	   magnetic	  resonance	  (HR-­‐MAS	  1H	  NMR)	  spectroscopy	  analyses	  solid	  substances	  such	  as	  tissue.	  It	  offers	  a	  quantitative	  method	  of	  analysing	  colonic	   tissue	  and	  aiding	  diagnoses.	  Animal	  studies	  on	  mice	  have	  shown	  that	  there	  are	  significant	  differences	  between	  metabolites	  produced	   from	   benign	   and	   malignant	   colonic	   tissue.	   The	   aim	   of	   this	   study	   was	   to	  investigate	  the	  metabolic	  alterations	  of	  colonic	  polyps	  compared	  with	  normal	  colonic	  tissue	  using	  HR-­‐MAS	  1H	  NMR.	  Fourteen	  colonic	  biopsy	  specimens	  were	  obtained	  from	  patients	   with	   colonic	   polyps.	   The	   specimens	   were	   inserted	   in	   a	   MAS	   rotor	   with	  deuterium	   (D20).	   All	   NMR	   spectra	   were	   acquired	   using	   a	   Bruker	   DRX600C	  spectrometer	   (Bruker	   Biospin,	   Rheinstetten,	   Germany).	   The	   obtained	   spectra	   were	  reviewed	   using	   software	   Topsin™	   and	   then	   transferred	   to	   MATLAB.	   A	   number	   of	  metabolites	   such	   as	   lactate,	   choline	   and	   alanine	   were	   identified.	   Higher	   levels	   of	  choline	  metabolites	  were	  seen	  in	  the	  colonic	  polyp	  samples	  compared	  to	  normal.	  This	  investigation	   suggests	   that	   HR-­‐MAS	   1H	   NMR	   could	   be	   used	   for	   the	   quantitative	  metabolic	   analysis	   of	   biopsied	   tissue	   in	   synergy	   with	   histological	   examination	   for	  diagnostic	  and	  potentially	  prognostic	  purposes.	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S.2	  Introduction	  The	   histological	   examination	   of	   tissue	   in	   the	   clinical	   setting	   is	   the	   gold	   standard	   for	  making	  diagnosis	  and	  in	  some	  cases	  providing	  prognostic	  indicators	  following	  surgery.	  However,	   these	   processes	   take	   time,	   with	   the	   average	   histology	   report	   following	  excision	  biopsies,	  surgery	  or	  diagnostic	  biopsies	  taking	  up	  to	  a	  week	  or	  more.	  Several	  steps	   are	   involved	   in	   the	   preparation	   of	   a	   histological	   specimen,	   from	   staining,	   and	  sectioning	  to	  fixation,	  which	  takes	  several	  hours.	  After	  such	  a	  period	  of	  time,	  additional	  staining	   procedures	   or	   immune-­‐histochemical	   processes	   are	   sometimes	   required.	  Furthermore,	   the	   reports	   are	   purely	   qualitative	   and	   as	   such	   could	   be	   reporter-­‐dependent,	  with	   the	   potential	   for	   subjective	   interpretations	   of	   results.	   The	   ability	   to	  distinguish	  an	  adenoma	  from	  a	  carcinoma	  from	  a	  histopathological	  specimen	  is	  based	  on	  certain	  visual	  characteristics	  (Figure	  S.1).	  Clearly,	  there	  is	  a	  need	  for	  a	  more	  reliable,	  rapid	   and	  qualitative	   approach	   to	  histological	   examinations,	   as	   these	   findings	  have	  a	  significant	  impact	  on	  patient	  management	  and	  outcome.	  	  	  (a)	   	   	   	   	   	   	   (b)	  	   	   	   	   	   	   	  	  	  	  	  	  
Figure	   S.1	   (a)	   Macroscopic	   slices	   of	   a	   rectal	   cancer	   specimen	   as	   part	   of	   the	   histological	  
examination	  (b)	  High	  power	  haematoxylin	  and	  eosin	  stain	  microscopic	  section	  of	  a	  rectal	  cancer.	  
Image	  kindly	  provided	  by	  Dr	  Andrew	  Wotherspoon,	  The	  Royal	  Marsden	  NHS	  Foundation	  Trust.	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Metabonomics	   using	   the	   technique	   of	   HR–MAS	   1H	   NMR	   offers	   the	   advantage	   of	  providing	  metabolic	  maps	  of	  intact	  tissue	  samples	  with	  a	  rapid	  acquisition	  time	  (Righi,	  2009).	  A	   sample	   can	  be	   run	   to	  acquire	   spectral	  data	   in	  approximately	  10	  minutes	  as	  well	   as	   maintaining	   the	   integrity	   of	   the	   tissue	   for	   subsequent	   histological	   analysis	  (Beckonert	  et	  al.,	  2010).	   It	   involves	  spinning	  a	  sample	   in	  magnetic	   field	  enclosed	  in	  a	  rotor	  device	  (Figure	  S.2).	  Therefore	  it	  offers	  the	  likely	  benefit	  for	  having	  dual	  methods	  of	  the	  translation	  of	  tissue	  pathology	  on	  a	  quantitative	  and	  qualitative	  scale.	  	  	  	  (a)	   	   	   	   	   	   (b)	  	  	  	  	  	  
Figure	  S.2	  A	  schematic	  diagram	  of	  the	  MAS	  rotor	  with	  a	  tissue	  sample	  (a)	  and	  a	  picture	  of	  a	  rotor,	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additional	   benefit	   of	   tissue	   over	   blood	   as	   a	   biofluid,	   is	   its	   provision	   of	   site	   specific	  anatomical	  information	  and	  therefore	  less	  variation	  (Mal	  et	  al.,	  2012).	  	  	  In	   this	   chapter	   the	   metabolic	   profiling	   of	   colonic	   polyps	   and	   normal	   tissue	   was	  evaluated	   using	   HR-­‐MAS	   NMR	   so	   as	   to	   decipher	   biomarkers	   involved	   in	   the	  development	  of	  colorectal	  adenomas	  to	  carcinoma.	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S.3	  Materials	  and	  methods	  
S.3.1	  Patient	  recruitment	  Patients	  were	   recruited	   from	   Chelsea	   and	  Westminster	   and	   the	   Royal	  Marsden	  NHS	  Foundation	   Trust	   Hospitals.	   Ethical	   approval	   for	   the	   study	   was	   obtained	   from	   the	  Royal	   Marsden	   Research	   Ethics	   Committee	   (REC	   No.	   08/H0801/180).	   Patients	   that	  were	  recruited	  gave	  written	  informed	  consent.	  
	  
S.3.2	  Sample	  collection	  Biopsy	   samples	   were	   collected	   from	   patients	   undergoing	   elective	   colonoscopies	   for	  change	   in	   bowel	   habit,	   anaemia	   or	   bleeding	  per	   rectum.	   Six	   patients	  were	   recruited:	  four	  male	  and	  two	  female	  patients,	  with	  an	  age	  range	  between	  28	  to	  69	  years.	  	  	  The	  colonic	  biopsies	  were	  collected	  in	  the	  morning	  to	  reduce	  possible	  variation	  effects	  in	  the	  NMR	  data	  obtained.	  Furthermore,	  to	  minimize	  confounding	  factors	  by	  a	  number	  of	   variables	   that	   could	   have	   effects	   on	   the	   interpretation	   of	   the	   metabolic	   profiling	  data,	  certain	  patients	  were	  excluded	  from	  the	  study	  as	  described	  below.	  The	  exclusion	  criteria	  were	  as	  follows:	  	  
• Present	  or	  previous	  diagnosis	  of	  CRC	  
• Recent	  blood	  transfusions	  or	  surgery	  within	  two	  months	  
• Patients	  requiring	  TPN	  
• Pregnant	  women	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• Professional	  athletes	  (due	  to	  high	  creatinine	  in	  their	  biofluids	  as	  this	  can	  affect	  data	  interpretation)	  
• Patients	   with	   urinary	   tract	   infections	   or	   frank	   haematuria	   (these	   affect	   data	  interpretation)	  
• Patients	  who	  have	  FAP,	  Crohn’s	  disease,	  ulcerative	  colitis	  or	  a	  family	  history	  of	  HNPCC	  
	  
Two	  to	   four	  endoscopic	  biopsy	  specimens	  were	   taken	   from	  each	  patient.	  These	  were	  then	  placed	  into	  cryogenic	  vials	  (Nalgene,	  Fisher	  Scientific,	  UK)	  and	  kept	  on	  dry	  ice	  in	  order	   to	   minimize	   enzymatic	   activity	   before	   freezing	   at	   -­‐80°C	   prior	   to	   NMR	  preparation	  and	  analysis.	  Fourteen	  colonic	  biopsy	  specimens	  were	  obtained	   from	  six	  patients.	  Multiple	  biopsies	  were	  taken	  from	  macroscopically	  normal	  tissue	  as	  controls	  and	  from	  colonic	  polyps	  prior	  to	  sending	  other	  specimens	  for	  histological	  examination.	  Samples	   weights	   ranged	   from	   4	   -­‐	   18mg.	   Three	   patients	   with	   polyps	   and	   three	   with	  macroscopically	  normal	  tissue	  were	  analysed.	  
	  
S.3.3	  Sample	  preparation	  A	   heterogeneous	   tissue	   sample	   from	   the	   colon	   of	   each	   patient	   was	   analysed.	   Each	  tissue	  sample	  was	  temporarily	  stored	  on	  dry	  ice	  at	  the	  time	  of	  preparation.	  The	  tissue	  samples	  were	  weighed	   (Table	   S.1)	   and	   rinsed	   in	   deuterated	  water	   (D20)	   in	   order	   to	  remove	   any	   residual	   blood	   or	   organic	  matter,	  which	   could	   have	   effects	   on	   the	   NMR	  signals	  obtained.	  Each	  sample	  had	  10μl	  of	  D20	  added	  to	  it	  and	  then	  transferred	  into	  a	  4mm	  diameter	  zirconium	  MAS	  rotor	  (Bruker,	  Rheinstetten,	  Germany)	  with	  a	  spherical	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insert.	  The	  tissue	  samples	  were	  small	  enough	  in	  size	  to	  fit	  into	  the	  rotor	  without	  being	  cut.	  The	  D20	  added	  was	  to	  provide	  a	  frequency	  lock	  for	  the	  NMR	  spectrometer	  and	  also	  to	  displace	  any	  air	  bubbles.	  A	  black	  marker	  pen	  was	  used	  to	  make	  a	  semi-­‐circle	  pattern	  as	  in	  Figure	  S.2,	  at	  the	  bottom	  of	  the	  rotor	  so	  that	  the	  spectrometer	  can	  detect	  the	  spin	  rate.	  
	  
Table	  S.1	  Patient	  demographics,	  histology,	  past	  medical	  history	  (PMH),	  histology	  and	  weights	  of	  
colonic	  tissue	  biopsies.	  The	  abbreviations	  in	  the	  table	  represent	  the	  parts	  of	  the	  colon	  the	  tissue	  
was	   obtained	   from:	   dc-­‐	   descending	   colon,	   ac-­‐	   ascending	   colon,	   sf-­‐	   splenic	   flexure,	   hf-­‐	   hepatic	  





Gender	   Histology	   PMH	   Number	   of	  
specimens	   and	  
parts	   of	   the	   colon	  
samples	  taken	  from	  
P3	   69	   Male	   Adenoma	  +	   low	  grade	  dysplasia	  
Previous	   polyps,	  Hypertension,	  High	  cholesterol	   2	  (tc,	  dc)	  
P14	   28	   Male	   Adenoma	   Bone	   marrow	  transplant	   1	  (sf)	  
P15	   64	   Female	   Adenoma	   Nil	   1	  (r)	  
N5	   41	   Male	   Normal	  tissue	   Nil	   2	  (dc)	  
N13	   63	   Male	   Normal	  tissue	   Nil	   4	  (dc,	  tc)	  
N12	   67	   Female	   Normal	  tissue	   Diverticular	  disease	   4	  (hf,	  sf,	  ac,	  dc)	  	  
	  
S.3.4	  HR-­‐MAS	  1H	  NMR	  analysis	  All	   experiments	   were	   carried	   out	   using	   a	   Bruker	   DRX-­‐600C	   spectrometer	   (Bruker	  Biospin,	  Rheinstetten,	  Germany),	  with	  a	  high-­‐resolution	  (600.13MHz)	  MAS	  probe.	  The	  temperature	  was	  set	  at	  283K	  with	  a	  sample	  spin	  rate	  of	  5kHz	  and	  at	  the	  magic	  angle	  of	  54.7°.	  Tuning,	  matching	  and	  manual	  shimming	  were	  performed	  for	  each	  sample	  prior	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to	   acquisition	   of	   spectra,	   thereby	   allowing	   optimum	   spectral	   information	   to	   be	  acquired	   from	   each	   sample.	   The	   90°	   pulse	   length	   was	   adjusted	   for	   each	   individual	  sample.	  A	   total	   of	  128	   transients	  were	   collected	   in	  16k	  data	  points.	  All	   spectra	  were	  acquired	  using	  a	  standard	  1D	  1H	  NMR	  NOESY	  experiment	  with	  a	  pulse	  sequence	  of	  RD-­‐90°-­‐t1-­‐90°-­‐τm-­‐90°-­‐acquire,	  where	  t1	  =	  3μs	  and	  the	  mixing	  time,	  τm	  =	  100ms.	  	  
S.3.5	  Data	  analysis	  The	   MAS	   spectra	   were	   manually	   phased,	   baseline	   corrected	   and	   calibrated	   to	   the	  amino	  acid,	  alanine	  (δ	  1.48ppm)	  using	  Topspin™	  (Bruker,	  Rheinstetten,	  Germany).	  The	  data	   was	   then	   transferred	   to	   MATLAB	   (MathWorks™,	   MA)	   using	   in-­‐house	   software.	  The	   spectra	   were	   then	   normalized	   by	   median	   fold	   change	   (mfc)	   using	   in-­‐house	  software	   in	  MATLAB	  as	   per	   previous	   chapters.	   The	  NMR	   spectra	  were	   labelled	   from	  assignments	  in	  the	  literature	  (Tugnoli	  et	  al.,	  2004,	  Wang,	  2007).	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Figure	   S.3	   Enlarged	   600MHz	  NMR	   spectral	   region	   (δ2.8-­‐4.2ppm)	   from	   human	   biopsies	   of	   both	  
colonic	  polyps	  (above)	  and	  normal	  tissue	  (below).	  	  
Choline	  PC	  
GPC	  Myoinositol	   Creatine	  Lactate	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The	   choline	   metabolites	   identified	   were	   as	   per	   chapter	   3	   these	   consisted	   of	  phosphocholine	  (PC)	  and	  glycerophosphocholine	  (GPC).	  The	  patients	  with	  the	  colonic	  polyps	  compared	  with	  normal	   tissue	  had	  higher	  PC:	  GPC	  ratios,	  although	   the	  p-­‐value	  was	  only	  at	  0.30	  (Figure	  S.4).	  The	  levels	  of	  PC	  were	  also	  slightly	  higher	  in	  the	  adenoma	  tissue	  samples	  (p	  =	  0.99).	  The	  levels	  of	  GPC	  on	  the	  other	  hand	  were	  slightly	  higher	  in	  the	  polyp	  samples	  than	  the	  normal	  samples	  (p	  =	  0.76).	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  S.4	  The	  PC:	  GPC	  ratios	  of	  normal	  and	  polypoid	  colonic	  tissue.	  The	  error	  bars	  represent	  the	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S.5	  Discussion	  Scientific	  thinking	  changes	  with	  time	  as	  it	  was	  once	  thought	  that	  “neither	  NMR	  nor	  any	  other	  method	  requiring	  surgical	  biopsy	  is	  likely	  to	  replace	  or	  supplement	  the	  standard	  histopathological	   techniques”	   (Hollis,	   1979).	   However,	   the	   developments	   in	   NMR	  technology	   with	   HR-­‐MAS	   as	   used	   in	   the	   experiments	   in	   this	   chapter	   also	   provide	  further	   evidence	   that	   this	   is	   not	   the	   case.	   Being	   able	   to	   map	   out	   pathological	  phenotypes	   that	  provide	   further	   information	   into	   the	  biochemical	  nature	  of	  patient’s	  tumour	  using	  HR-­‐MAS	  NMR	  would	  be	  beneficial.	  	  	  The	   results	   of	   the	   HR-­‐MAS	   NMR	   experiments	   in	   this	   chapter	   reveal	   changes	   in	   the	  levels	   of	   choline	   metabolites	   seen	   in	   colonic	   adenomas	   are	   the	   same	   as	   the	   CRC	  xenografts	  in	  chapter	  3	  and	  in	  studies	  performed	  in	  the	  APC	  mouse	  model	  (Backshall,	  2011).	   These	   changes	   are	   in	   keeping	   with	   elevated	   levels	   of	   choline	   metabolites	   in	  colonic	  tumours	  both	  in	  the	  case	  of	  malignancy	  and	  adenomas	  compared	  with	  normal	  tissue.	   The	   levels	   of	   GPC	  were	   higher	   in	   the	   polyps	   than	   in	   normal	   tissue.	   This	  was	  different	   from	   the	   previously	   described	   CRC	   xenograft	   study	   where	   higher	   levels	   of	  GPC	  were	  found	  in	  the	  cell	  lines	  that	  had	  well	  differentiated	  tumours.	  	  	  Tessem	  et	  al.	  also	  observed	  high	  PC	  and	  choline	  levels,	  though	  the	  levels	  of	  GPC	  were	  lower	  in	  adenomas	  compared	  to	  normal	  tissue	  in	  three	  out	  of	  four	  samples	  but	  not	  in	  one	   out	   of	   four	   colonic	   adenoma	   samples	   (Tessem	   et	   al.,	   2010).	   The	   reason	   for	   this	  could	  probably	  be	  due	  to	  the	  higher	  cell	   turnover	  of	  the	  polypoid	  tissue	  compared	  to	  the	  normal	  colonic	  tissue,	  reflecting	  a	  region	  of	  increased	  mitosis.	  	  It	  may	  also	  be	  due	  to	  the	   high	   lipid	   content	   in	   the	   samples,	   which	   subsequently	   altered	   the	   integral	  calculations	  of	  the	  GPC	  peak.	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Histological	  examination	  is	  purely	  descriptive	  and	  histopathologists	  have	  to	  rely	  on	  the	  identification	  of	  certain	  cells	  and	  their	  aggregation	  to	  be	  able	  to	  make	  a	  diagnosis.	  NMR	  offers	  the	  advantage	  of	  being	  a	  quantifiable	  chemical	  measurement	  of	  histopathological	  diagnosis	   rather	   than	   a	   qualitative	   measurement,	   which	   can	   have	   a	   subjective	  component	  to	  it.	  	  	  The	   importance	   of	   these	   changes	   in	   metabolites	   identified	   using	   HR-­‐MAS	   NMR	   in	  patients	  with	   adenomas	   is	   the	   potential	   value	   of	   providing	   information	   into	   the	   risk	  assessment	   of	   developing	   CRC.	   Therefore,	   having	   identifiable	   biomarkers	   as	  biochemically	   related	   factors	   to	   the	   pathological	   specimen,	   HR-­‐MAS	   could	   also	   be	  applied	   to	   situations	   of	   real	   time	   surgery	   and	   thus	   avoid	   the	   delays	   and	   sometimes	  equivocal	   results	   associated	   with	   frozen	   sections	   that	   can	   affect	   surgical	   decision-­‐making.	  	  Tissue	  is	  naturally	  heterogeneous,	  consisting	  of	  different	  cell	  types.	  The	  use	  of	  different	  sizes	  of	  tissue	  may	  have	  increased	  the	  heterogeneity	  of	  the	  colonic	  tissue	  samples.	  The	  number	  of	  samples	  used	  was	  however	  small	  in	  order	  to	  be	  able	  to	  extract	  meaningful	  principal	  component	  analysis	  data.	   	  Therefore,	   further	  studies	  need	   to	  be	  carried	  out	  with	   a	   larger	   number	   of	   samples.	   The	   inter-­‐segmental	   variation	   seen	   in	   the	   NMR	  spectra	  of	  the	  different	  samples	  may	  be	  due	  to	  the	  different	   intestinal	  segments	  from	  which	  the	  biopsies	  were	  taken.	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S.6	  Conclusion	  The	   clinical	   relevance	  of	   this	   exploratory	   study	  using	   a	   small	   number	  of	   samples	   for	  tissue-­‐based	  metabonomics	  is	  the	  potential	  influence	  on	  the	  measurements	  of	  choline	  metabolites	   as	   previously	   identified	   from	   blood	   into	   the	   understanding	   of	   colonic	  adenoma	   biology.	   The	   identification	   of	   choline	   metabolites	   being	   differentially	  expressed	   in	   colonic	   adenoma	   patients	   compared	   to	   histologically	   normal	   colonic	  tissue,	  may	   have	   relevance	   into	   the	   pathological	   process	   of	   CRC.	  With	   larger	   studies	  using	  more	   samples	   from	  matched	   samples	  of	   colonic	   adenomas	  and	  healthy	   colonic	  tissue,	  the	  true	  impact	  of	  the	  use	  of	  tissue	  NMR	  could	  be	  elucidated.	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APPENDICES	  
Appendix	  I	  Cell	  lines	  	  (Chapter	  3)	  	  
STOCSY	  Analysis	  of	  the	  4	  cell	  lines	  in	  chapter	  3	  A	   STOCSY	   investigates	   the	  multiple	   co-­‐linearity	   of	   spectral	   variables	  within	   an	  NMR	  spectrum.	   It	   indicates	   the	  correlation	  among	   individual	   spectral	  peaks	   in	   the	  sample.	  	  Thus,	   providing	   information	   about	   the	   relations	   of	   the	   protons	   in	   a	   molecule	  (Beckonert,	  2007).	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  One	   -­‐	   dimensional	   STOCSY	   analysis	   for	   the	   choline	   (δ3.22)	   peak.	   The	   degree	   of	  correlation	   is	   related	   to	   the	   colour	   scale.	   The	   correlation	   coefficient	   towards	   the	   red	  indicates	  high	  correlation	  whereas	  towards	  the	  blue	  means	  low	  correlation.	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O-­‐PLS	  analysis	  of	  the	  cell	  lines	  	  	  
Models	  	   Cell	  lines	   R2	   Q2	  
M1	   SW620:	  HCT116	   1	   0.89	  
M2	   SW620:	  COLO205	   1	   0.81	  
M3	   HCT116:	  COLO205	   0.99	   0.81	  	  Y	  =	  covariance,	  R2	  =	  correlation	  to	  Y	  variable	  	  	  	  
Metabolites	  used	  from	  the	  NCI60	  panel	  for	  the	  data	  processing	  of	  the	  MSEA	  and	  
pathway	  analysis	  using	  MetaboAnalyst	  
	  	   1. Xanthosine	  2. Valine	  3. Uracil	  4. Tyrosine	  5. Tyramine	  6. Sn-­‐Glycerol-­‐3-­‐phosphate	  7. Serine	  8. Ribulose-­‐5-­‐phosphate	  9. Phenylalanine	  10. Octopamine	  11. Ornihine	  12. N(‘6)-­‐trimethyl-­‐1-­‐lysine	  13. N-­‐acetylneuraminic	  acid	  14. Methionine	  15. Mannose-­‐6-­‐phosphate	  16. Leucine	  17. Betaine	  
18. D-­‐arabinose-­‐5-­‐phosphate/	  D-­‐ribulose-­‐5-­‐phosphate/alpha-­‐D-­‐ribose-­‐5-­‐phosphate	  19. Inositol-­‐1-­‐phosphate/Mannose-­‐6-­‐phosphate/Glucose-­‐6-­‐phosphate/D-­‐mannose	  -­‐1-­‐phosphate/alpha-­‐D-­‐glucose-­‐1-­‐phosphate	  20. Inositol-­‐1-­‐phosphate	  21. Gulono-­‐1,4-­‐lactone	  22. Gluconic	  acid	  23. D-­‐ribose	  24. Anthranilic	  acid	  25. 6-­‐phosphogluconic	  acid	  26. 5’-­‐s-­‐methyl-­‐5’-­‐thioadenosine	  27. 2’-­‐deoxyuridine	  28. (p-­‐Hydroxyphenyl)lactic	  acid	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Lopes	  genes	  from	  gene	  analysis	  data	  
Gene	  Symbol	   Gene	  Title	   Gene	  function	   Reference	  to	  CRC	  
RBP1	  
	  
	  	   Retinol	  binding	  protein	  1,	  cellular	   Intracellular	  transport	  of	  retinol	  	  
Antiproliferative	  activity	  of	  retinoic	  acid	  
and	  some	  novel	  retinoid	  derivatives	  in	  


















silenced	  in	  cancer	  
Inhibition	  of	  the	  growth	  and	  metastasis	  
of	  human	  colon	  cancer	  by	  restoration	  of	  

















siRNA	  directed	  against	  c-­‐Myc	  inhibits	  
proliferation	  and	  downregulates	  human	  
telomerase	  reverse	  transcriptase	  in	  
human	  colon	  cancer	  Colo	  320	  cells.	  	  
BDNF	  
	  	   Brain-­‐derived	  neurotrophic	  factor	   Nerve	  growth	  factor	  	   -­‐	  




	  	   Cyclin-­‐dependent	  kinase	  inhibitor	  1C	  (p57,	  Kip2)	  
Negative	  regulator	  of	  
cell	  proliferation	  
	  	  
Loss	  of	  p57KIP2	  is	  associated	  with	  























that	  binds	  to	  
glucocorticoid	  
response	  elements	  
(GRE)	  and	  as	  a	  
modulator	  of	  other	  
transcription	  factors	  
FKBP51	  expressed	  by	  both	  normal	  
epithelial	  cells	  and	  adenocarcinoma	  of	  















MLH1	  germline	  epimutations	  as	  a	  factor	  













to	  yield	  AMP	  and	  
ADP.	  Possible	  tumor	  
suppressor	  for	  
specific	  tissues	  
Fhit	  protein	  inhibits	  cell	  growth	  by	  
attenuating	  the	  signaling	  mediated	  by	  
nuclear	  factor-­‐kappaB	  in	  colon	  cancer	  
cell	  lines.	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McGarvey	  genes	  







homology	  to	  L1CAM	  





cell	  death	  	  
Coding	  sequences	  of	  human	  









Inhibits	  secretion	  of	  
follitropin,	  a	  follicle-­‐
stimulating	  





related	  protein	  5	  
	  	  
Modulators	  of	  Wnt	  
signalling	  
	  	   Silencing	  of	  secreted	  frizzled-­‐related	  protein	  genes	  in	  MSI	  colorectal	  carcinogenesis.	  
FOXL2	  
	  	   Forkhead	  box	  L2	  	  	   Ovarian	  development	  and	  function	   -­‐	  
DDX43	  













Expression	  of	  an	  ASCL2	  
related	  stem	  cell	  signature	  
and	  IGF2	  in	  CRC	  liver	  














Acts	  as	  an	  A-­‐kinase	  
anchoring	  protein	  by	  
binding	  to	  the	  type	  II	  
regulatory	  subunit	  of	  
protein	  kinase	  A	  and	  
anchoring	  it	  to	  the	  
mitochondrion	  
Identification	  of	  genes	  
uniquely	  involved	  in	  frequent	  
microsatellite	  instability	  colon	  
carcinogenesis	  by	  expression	  
profiling	  combined	  with	  
epigenetic	  scanning.	  
FBLN2	  















Polymorphisms	  in	  the	  
glutathione	  S-­‐transferase	  mu	  
cluster	  are	  associated	  with	  
tumour	  progression	  and	  





SRY	  (sex	  determining	  
region	  Y)-­‐box	  17	  
	  	  
Transcription	  
regulator	  that	  binds	  
target	  promoter	  DNA	  
and	  bends	  the	  DNA	  
Epigenetic	  inactivation	  of	  the	  
canonical	  Wnt	  antagonist	  
SRY-­‐box	  containing	  gene	  17	  in	  
CRC	  
LEF1	   Lymphoid	  enhancer-­‐ Participates	  in	  the	   Lymphoid	  enhancer	  factor/T	  




binding	  factor	  1	  
	  	   Wnt	  signaling	  pathway.	  Activates	  transcription	  of	  
target	  genes	  







	  	   -­‐	  
Expression	  profile	  of	  cancer-­‐
testis	  genes	  in	  121	  human	  
CRC	  tissue	  and	  adjacent	  










hypermethylation	  in	  colon	  










	  	   -­‐	  
Neuralized1	  causes	  apoptosis	  
and	  downregulates	  Notch	  







molecule	  3	  	  
May	  participate	  in	  
cell-­‐cell	  adhesion	  
distinct	  from	  tight	  
junctions	  
Antibody	  against	  junctional	  
adhesion	  molecule-­‐C	  inhibits	  






pathway	  inhibitor	  2	  
	  	  
May	  play	  a	  role	  in	  
the	  regulation	  of	  
plasmin-­‐mediated	  
matrix	  remodeling	  
Methylation	  of	  TFPI2	  gene	  is	  
frequently	  detected	  in	  
advanced	  well-­‐differentiated	  
CRC.	  
INHA	  	   Inhibin,	  alpha	  	   Inhibits	  secretion	  of	  follitropin	   -­‐	  	  	  	  
Gene	  enrichment	  analysis	  Genes	  are	  ranked	  based	  on	  their	  correlation	  between	  expression	  and	  the	  distinction	  of	  classes,	  which	  are	  shown	  below:	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Creatine	  levels	  in	  the	  different	  cell	  lines	  
	  	   241	  
	  	  









SW620 HCT116 HT29 COLO205 
CREATINE 
	  	   242	  
Appendix	  II	  Colonic	  adenoma	  chemoprevention	  study	  (Chapter	  4)	  	  
Association	  between	  Age	  and	  Metabolite	  concentrations	  	  The	   associations	   between	   age	   and	   various	   metabolites	   that	   showed	   significant	  differences	  following	  univariate	  analysis	  are	  shown	  below:	  	  
Alanine	  Alanine	  levels	  did	  not	  significantly	  differ	  between	  (i)	  40-­‐49	  and	  50-­‐59	  years,	  (ii)	  40-­‐49	  and	  60-­‐69	  years,	  (iii)	  40-­‐49	  and	  70-­‐79	  years,	  or	  (iv)	  50-­‐59	  or	  60-­‐69	  years.	   	  However,	  alanine	   levels	  were	   significantly	   lower	   in	   the	   50-­‐59	   age	   group	   (Median	   =	   1.03,	   SD	   =	  0.19),	  than	  the	  70-­‐79	  age	  group	  (Median	  =	  2.33,	  SD	  =	  1.07),	  (U	  =	  1.00,	  Z	  =	  -­‐2.548,	  n1	  =	  4,	  n2	  =	  8,	  p	  <	  0.01).	  	  Comparing	  the	  50-­‐59,	  60-­‐69	  and	  70-­‐79	  age	  groups,	  similar	  low	  values	  were	   seen	   in	   alanine	   but	   in	   the	   40-­‐49	   age	   group	   the	   values	   were	   higher.	   	   The	   two	  individuals	   in	   the	   40-­‐49	   age	   group	   were	   removed	   from	   the	   analysis	   to	   see	   if	   they	  caused	  skewering	  of	   the	  results.	   	  A	  post	  hoc	  Mann	  Whitney	  U	   test	   found	   there	  was	  a	  significant	  difference	  between	   the	  50-­‐59	  group	  and	  70-­‐79	  group,	  with	  U	  =	  1.00,	  z	  =	   -­‐2.55,	  p	  =	  0.008.	  	  The	  70-­‐79	  group	  had	  higher	  alanine	  levels	  (Mean	  Rank	  =	  8.38)	  than	  the	  50-­‐59	  group	  (Mean	  Rank	  =	  2.75).	  	  
Glutamate	  Post	  hoc	  Mann-­‐Whitney	  U	  tests	  found	  no	  significant	  effect	  of	  age	  at	  the	  p	  <	  0.0125	  level,	  between	  (i)	  40-­‐49	  and	  50-­‐59	  years,	   (ii)	  40-­‐49	  and	  60-­‐69	  years,	   (iii)	  40-­‐49	  and	  70-­‐79	  years,	  (iv)	  50-­‐59	  or	  60-­‐69	  years,	  (v)	  50-­‐59	  or	  70-­‐79	  years,	  or	  (vi)	  60-­‐69	  or	  70-­‐79	  years	  for	  glutamate.	   	  Following	  exclusion	  of	   the	  40-­‐49	  age	  group	  from	  the	  analysis,	  none	  of	  the	  post	  hoc	  Mann	  Whitney	  U	  tests	  were	  significant	  at	  the	  Bonferroni	  significance	  level	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set	  at	  p	  =	  0.017.	  	  The	  difference	  between	  the	  50-­‐59	  and	  70-­‐79	  group	  was	  approaching	  significance	  with	  U	  =	  3.00,	  z	  =	  -­‐2.21,	  p	  =	  0.028).	  	  
Glycine	  In	   the	   case	  of	   glycine,	   post	  hoc	  Mann-­‐Whitney	   tests	   showed	  no	   significant	  difference	  between	  (i)	  40-­‐49	  and	  50-­‐59	  years,	   (ii)	  40-­‐49	  and	  60-­‐69	  years,	   (iii)	  40-­‐49	  and	  70-­‐79	  years,	   and	   (iv)	   50-­‐59	   or	   60-­‐69	   years.	   	   Following	   exclusion	   of	   the	   404-­‐49	   age	   group,	  there	  was	  also	  a	  significant	  difference	  between	  the	  50-­‐59	  and	  60-­‐69	  groups	  with	  U	  =	  4.000,	  z	  =	  -­‐2.425,	  p	  =	  0.013,	  two	  tailed.	  	  	  
Isoleucine	  Analysis	  without	   the	  40-­‐49	  group,	   also	   found	   there	  was	  a	   significant	   effect	  of	   age	  on	  isoleucine	  with	  χ2	  =	  11.43,	  df	  =	  2,	  p	  =	  0.003.	  	  There	  was	  a	  significant	  difference	  between	  the	  50-­‐59	  and	  60-­‐69	  groups	  with	  U	  =	  4.00,	  z	  =	  -­‐2.43,	  p	  =	  0.013.	  	  The	  60-­‐69	  group	  had	  higher	  isoleucine	  levels	  (Mean	  Rank	  =	  9.64)	  than	  the	  50-­‐59	  group	  (Mean	  Rank	  =	  3.50).	  	  There	  was	  also	  a	  significant	  difference	  between	  the	  50-­‐59	  and	  70-­‐79	  groups	  with	  U=	  1.00,	   z	   =	   -­‐2.55,	  p	   =	   0.008.	   	   The	   70-­‐79	   group	   had	   higher	   isoleucine	  metabolite	   levels	  (Mean	  Rank	  =	  8.38)	  than	  the	  50-­‐59	  group	  (Mean	  Rank	  =	  2.75).	  	  	  
	  
Tyrosine	  A	  Kruskal	  Wallis	  analysis,	  without	  the	  40-­‐49	  group,	  also	  found	  there	  was	  a	  significant	  effect	  of	  age	  on	  tyrosine	  with	  χ2	  =	  8.14,	  df	  =	  2,	  p	  =	  0.017.	  	  The	  post	  hoc	  Mann	  Whitney	  U	  tests	  found	  there	  was	  a	  significant	  difference	  between	  the	  50-­‐59	  and	  70-­‐79	  groups	  with	  a	  p	  value	  of	  0.004.	  	  The	  70-­‐79	  group	  had	  higher	  tyrosine	  levels	  (Mean	  Rank	  =	  8.50)	  than	  the	  50-­‐59	  group	  (Mean	  Rank	  =	  2.50).	  	  There	  was	  also	  a	  significant	  difference	  between	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the	  50-­‐59	  and	  60-­‐69	  groups	  with	  U	  =	  4.00,	  z	  =	  -­‐2.35,	  p	  =	  0.018.	  	  The	  60-­‐69	  group	  had	  higher	  tyrosine	  levels	  (Mean	  Rank	  =	  9.64)	  than	  the	  50-­‐59	  group	  (Mean	  Rank	  =	  3.50).	  
	  
Valine	  Despite	   excluding	   the	   40-­‐49	   group,	   in	   assessing	   valine	   levels	   there	   was	   again	   a	  significant	   effect	   of	   age	   on	   valine	   (χ2	   =	   8.67,	  df	   =	   2,	  p	   =	   0.013).	   	   The	   post	   hoc	  Mann	  Whitney	  U	  tests	  found	  there	  was	  a	  significant	  difference	  between	  the	  50-­‐59	  and	  70-­‐79	  groups	  with	  U	  =	  1.00,	  z	  =	  -­‐2.548,	  p	  =	  0.008.	  The	  70-­‐79	  group	  had	  higher	  valine	   levels	  (Mean	  Rank	  =	  8.38)	  than	  the	  50-­‐59	  group	  (Mean	  Rank	  =	  2.75).	  	  	  	  	  	  
Pearson’s	  correlation	  of	  urine	  metabolites	  	  
Correlations 
 Urinary_Formate Urinary_Citrate 
Urinary_Formate Pearson Correlation 1 .803** 
Sig. (2-tailed)  .000 
N 26 26 
Urinary_Citrate Pearson Correlation .803** 1 
Sig. (2-tailed) .000  
N 26 26 
**. Correlation is significant at the 0.01 level (2-tailed). 	  
	   	  
	  	   245	  
Appendix	  III	  RECIST	  Criteria	  (Chapter	  5)	  	  
Response	  Evaluation	  Criteria	  in	  Solid	  Tumors	  (RECIST)(Eisenhauer	  et	  al.,	  2009)	  Evaluation	  of	  target	  lesions	  Complete	  Response	  (CR):	  Disappearance	  of	  all	  target	  lesions.	  Any	  pathological	   lymph	  nodes	  (whether	  target	  or	  non-­‐target)	  must	  have	  reduction	   in	  short	  axis	  to	  <	  10	  mm.	  	  Partial	  Response	  (PR):	  At	  least	  a	  30%	  decrease	  in	  the	  sum	  of	  diameters	  of	  target	  lesions,	  taking	  as	  reference	  the	  baseline	  sum	  diameters.	  	  Progressive	  Disease	   (PD):	   At	   least	   a	   20%	   increase	   in	   the	   sum	   of	   diameters	   of	   target	  lesions,	  taking	  as	  reference	  the	  smallest	  sum	  on	  study	  (this	  includes	  the	  baseline	  sum	  if	  that	  is	  the	  smallest	  on	  study).	  In	  addition	  to	  the	  relative	  increase	  of	  20%,	  the	  sum	  must	  also	  demonstrate	  an	  absolute	  increase	  of	  at	  least	  5	  mm.	  (Note:	  the	  appearance	  of	  one	  or	  more	  new	  lesions	  is	  also	  considered	  progression).	  	  Stable	   Disease	   (SD):	   Neither	   sufficient	   shrinkage	   to	   qualify	   for	   PR	   nor	   sufficient	  increase	   to	   qualify	   for	   PD,	   taking	   as	   reference	   the	   smallest	   sum	   diameters	   while	   on	  study	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